*********** PTASSAMj00 ******** FILEIN user.vek ../../CSA/PIK_SPRITE/ ULMN 4 13pk_c00 3-PHOSPHOGLYCERATE KINASE user 1 4 # 1 A 39 ARG D 134 ARG~? 13.66 CL CL D 145 A 219 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 376 GLY B 35 GLY.? 12.52 CL CL D 145 A 399 GLY D 137 GLY.? -3.82 C5 EPE D 146s coo -12.38 76.96 90.60 -12.31 75.41 87.97 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -15.03 67.62 79.35 -16.01 71.68 83.38 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -9.88 73.08 89.49 -9.40 72.65 89.00 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo -11.12 75.93 79.79 -10.82 76.54 80.30 -2.63 -4.20 -22.88 -2.56 -4.40 -23.65 ULMN 4 13pk_c00 3-PHOSPHOGLYCERATE KINASE user 2 4 # 2 A 39 ARG D 134 ARG~? 13.66 CL CL D 145 A 219 LYS D 7 LYS.? 12.04 O8 EPE D 146 A 376 GLY B 35 GLY.? 12.52 CL CL D 145 A 399 GLY D 137 GLY.? -3.82 C5 EPE D 146s coo -12.38 76.96 90.60 -12.31 75.41 87.97 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -15.03 67.62 79.35 -16.01 71.68 83.38 4.11 -10.06 -22.93 10.31 -9.82 -22.91 coo -9.88 73.08 89.49 -9.40 72.65 89.00 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo -11.12 75.93 79.79 -10.82 76.54 80.30 -2.63 -4.20 -22.88 -2.56 -4.40 -23.65 13pk_c00 source 13pk 3-PHOSPHOGLYCERATE KINASE : 2 hits 13pk_c00 naa= 4 ULMN 4 13pk_c01 3-PHOSPHOGLYCERATE KINASE user 1 4 # 1 B 39 ARG D 134 ARG~? 13.66 CL CL D 145 B 219 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 376 GLY B 35 GLY.? 12.52 CL CL D 145 B 399 GLY D 137 GLY.? -3.82 C5 EPE D 146s coo -2.66 39.94 47.71 -4.08 39.67 44.99 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -12.62 42.34 36.27 -8.73 43.54 40.31 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -6.85 37.45 46.42 -7.20 36.92 45.92 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo -4.26 38.64 36.66 -3.61 38.69 37.17 -2.63 -4.20 -22.88 -2.56 -4.40 -23.65 13pk_c01 source 13pk 3-PHOSPHOGLYCERATE KINASE : 1 hits 13pk_c01 naa= 4 ULMN 4 13pk_c02 3-PHOSPHOGLYCERATE KINASE user 1 4 # 1 C 39 ARG D 134 ARG~? 13.66 CL CL D 145 C 219 LYS D 6 LYS.? 14.92 O8 EPE D 146 C 376 GLY B 35 GLY.? 12.52 CL CL D 145 C 399 GLY D 137 GLY.? -3.82 C5 EPE D 146s coo -3.47 26.80 67.67 -1.24 26.00 69.62 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 5.22 26.79 80.32 0.48 26.84 77.06 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 1.35 28.76 68.50 2.09 28.66 68.61 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 2.85 20.10 73.72 2.25 20.01 73.15 -2.63 -4.20 -22.88 -2.56 -4.40 -23.65 13pk_c02 source 13pk 3-PHOSPHOGLYCERATE KINASE : 1 hits 13pk_c02 naa= 4 ULMN 4 1am5_c02 PEPSIN user 1 4 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 218 THR A 130 THR~? 5.01 CL CL D 145 coo -7.18 8.92 145.10 -8.77 8.81 143.59 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -12.30 10.35 145.24 -10.75 8.55 145.88 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -8.20 12.64 138.30 -8.86 10.97 139.38 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -6.03 8.73 136.74 -7.80 9.12 135.47 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1am5_c02 source 1am5 PEPSIN : 1 hits 1am5_c02 naa= 4 ULMN 4 1apt_c02 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 1 4 # 1 E 33 ASP D 133 ASP~? 7.85 CL CL D 145 E 36 SER B 34 SER~? 6.65 CL CL D 145 E 213 ASP A 133 ASP~? 7.97 CL CL D 145 E 216 THR A 130 THR~? 5.01 CL CL D 145 coo 26.30 12.96 16.78 25.46 12.99 18.72 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 28.33 15.15 21.27 28.70 13.12 19.97 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 20.15 16.04 19.79 21.65 14.49 19.86 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 18.77 11.27 18.60 18.17 11.74 20.64 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1apt_c02 source 1apt ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET (LYSTA IS : 1 hits 1apt_c02 naa= 4 ULMN 4 1apt_c06 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 1 4 # 1 E 33 ASP D 133 ASP~? 7.85 CL CL D 145 E 36 SER B 34 SER~? 6.65 CL CL D 145 E 75 TYR B 36 TYR.? 11.13 O3S EPE A 145 E 213 ASP A 133 ASP~? 7.97 CL CL D 145 coo 26.30 12.96 16.78 25.46 12.99 18.72 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 28.33 15.15 21.27 28.70 13.12 19.97 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 26.74 7.85 22.76 28.93 8.53 21.17 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 20.15 16.04 19.79 21.65 14.49 19.86 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1apt_c06 source 1apt ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET (LYSTA IS : 1 hits 1apt_c06 naa= 4 ULMN 4 1avf_c00 GASTRICSIN user 1 4 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 217 ASP A 133 ASP~? 7.97 CL CL D 145 A 220 THR A 130 THR~? 5.01 CL CL D 145 coo -10.06 2.54 49.69 -8.83 3.73 50.96 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -11.96 5.74 52.90 -10.55 6.74 51.22 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -5.22 1.43 56.08 -5.36 2.84 54.49 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -1.48 1.48 52.34 -0.65 2.04 54.29 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1avf_c00 source 1avf GASTRICSIN : 1 hits 1avf_c00 naa= 4 ULMN 4 1avf_c01 GASTRICSIN user 1 4 # 1 J 32 ASP D 133 ASP~? 7.85 CL CL D 145 J 35 SER B 34 SER~? 6.65 CL CL D 145 J 217 ASP A 133 ASP~? 7.97 CL CL D 145 J 220 THR A 130 THR~? 5.01 CL CL D 145 coo -37.57 -17.54 20.53 -38.55 -18.66 19.00 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -40.93 -20.91 21.81 -38.85 -21.36 20.65 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -43.00 -16.46 14.92 -41.37 -17.71 15.28 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -38.56 -16.44 11.85 -40.37 -16.72 10.69 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1avf_c01 source 1avf GASTRICSIN : 1 hits 1avf_c01 naa= 4 ULMN 4 1bbs_c08 RENIN user 1 4 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 75 TYR B 36 TYR.? 11.13 O3S EPE A 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 61.19 45.85 78.73 62.86 45.48 77.48 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 66.00 46.17 80.29 64.31 47.92 79.91 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 65.68 50.76 74.77 64.63 51.40 77.28 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 63.61 40.10 74.06 64.05 42.07 74.70 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1bbs_c08 source 1bbs RENIN : 1 hits 1bbs_c08 naa= 4 ULMN 4 1bbs_c09 RENIN user 1 4 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 75 TYR B 36 TYR.? 11.13 O3S EPE A 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 61.19 45.85 78.73 62.86 45.48 77.48 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 66.00 46.17 80.29 64.31 47.92 79.91 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 65.68 50.76 74.77 64.63 51.40 77.28 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 63.61 40.10 74.06 64.05 42.07 74.70 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1bbs_c09 source 1bbs RENIN : 1 hits 1bbs_c09 naa= 4 ULMN 4 1cms_c02 CHYMOSIN B (FORMERLY KNOWN AS RENNINuser 1 4 # 1 34 ASP D 133 ASP~? 7.85 CL CL D 145 37 SER B 34 SER~? 6.65 CL CL D 145 216 ASP A 133 ASP~? 7.97 CL CL D 145 219 THR A 130 THR~? 5.01 CL CL D 145 coo 16.90 26.20 29.49 16.22 24.50 28.41 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.23 24.31 30.40 14.55 23.96 31.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 13.93 25.52 22.10 14.75 24.44 23.75 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 18.26 23.14 21.54 16.59 21.96 20.68 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1cms_c02 source 1cms CHYMOSIN B (FORMERLY KNOWN AS RENNIN) (E.C.3.4: 1 hits 1cms_c02 naa= 4 ULMN 4 1d1q_c00 TYROSINE PHOSPHATASE (E.C.3.1.3.48) user 1 4 # 1 A 13 ALA D 135 ALA~? 7.33 O2S EPE D 146 A 19 ARG D 134 ARG~? 13.66 CL CL D 145 A 20 SER D 10 SER^? 8.71 O3S EPE D 146 A 132 ASP D 133 ASP~? 7.85 CL CL D 145 coo 4.53 4.32 26.47 3.96 3.36 27.51 -5.15 -7.14 -27.91 -5.30 -6.27 -29.15 coo 2.60 -1.55 27.54 1.76 0.32 25.25 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 6.18 2.66 31.27 5.30 4.91 30.67 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -1.40 -1.52 24.89 -2.64 -0.24 26.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 1d1q_c00 source 1d1q TYROSINE PHOSPHATASE (E.C.3.1.3.48) : 1 hits 1d1q_c00 naa= 4 ULMN 4 1d3g_c01 DIHYDROOROTATE DEHYDROGENASE user 1 4 # 1 A 149 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 215 SER A 10 SER^? 8.69 O1S EPE A 145 A 218 THR A 140 THR^? -4.46 O3S EPE A 145s A 255 LYS A 100 LYS^? 18.99 CL CL D 145 coo 44.60 28.41 9.39 42.46 29.45 10.83 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 38.32 30.82 8.35 40.14 29.77 7.21 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 39.65 24.77 7.41 41.19 24.89 8.93 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 36.63 36.86 14.86 40.52 38.40 10.14 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 4 1d3g_c01 DIHYDROOROTATE DEHYDROGENASE user 2 4 # 2 A 149 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 215 SER D 10 SER^? 8.71 O3S EPE D 146 A 218 THR D 140 THR^? -4.35 O2S EPE D 146s A 255 LYS D 100 LYS^? 18.85 CL CL D 145 coo 44.60 28.41 9.39 42.46 29.45 10.83 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 38.32 30.82 8.35 40.14 29.77 7.21 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 39.65 24.77 7.41 41.19 24.89 8.93 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 36.63 36.86 14.86 40.52 38.40 10.14 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1d3g_c01 source 1d3g DIHYDROOROTATE DEHYDROGENASE : 2 hits 1d3g_c01 naa= 4 ULMN 4 1db3_c00 GDP-MANNOSE 4,6-DEHYDRATASE user 1 4 # 1 A 132 THR A 139 THR^? -4.08 O1S EPE A 145s A 134 GLU C 136 GLU~? 8.02 O8 EPE A 145 A 156 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 160 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 14.05 56.93 22.25 14.86 58.63 23.18 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 11.64 63.07 23.95 11.76 62.47 21.20 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 5.78 61.30 21.65 8.04 62.89 17.54 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 4 1db3_c00 GDP-MANNOSE 4,6-DEHYDRATASE user 2 4 # 2 A 132 THR B 139 THR^? -4.10 O3S EPE A 145s A 134 GLU A 136 GLU~? 8.92 C6 EPE A 145 A 156 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 160 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 14.05 56.93 22.25 14.86 58.63 23.18 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 11.64 63.07 23.95 11.76 62.47 21.20 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 5.78 61.30 21.65 8.04 62.89 17.54 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 1db3_c00 source 1db3 GDP-MANNOSE 4,6-DEHYDRATASE : 2 hits 1db3_c00 naa= 4 ULMN 4 1doo_c00 HEAT SHOCK LOCUS U user 1 4 # 1 A 1 THR A 28 THR~? 15.27 CL CL A 144 A 33 LYS A 100 LYS^? 18.99 CL CL D 145 A 48 GLY A 97 GLY.? 20.25 O1S EPE A 145 A 124 SER A 29 SER~? 20.16 O1S EPE A 145 coo 20.60 80.81 78.25 19.93 81.48 80.23 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 24.21 79.63 86.31 23.19 81.94 80.55 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 18.07 85.03 84.32 18.49 84.59 84.79 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 15.73 80.26 75.45 17.95 80.97 75.03 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1doo_c00 HEAT SHOCK LOCUS U user 2 4 # 2 A 1 THR A 107 THR~? 14.10 CL CL D 145 A 33 LYS B 77 LYS.? 21.17 CL CL D 145 A 48 GLY A 112 GLY.? 18.91 CL CL D 145 A 124 SER A 105 SER~? 6.77 CL CL D 145 coo 20.60 80.81 78.25 19.93 81.48 80.23 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 24.21 79.63 86.31 23.19 81.94 80.55 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 18.07 85.03 84.32 18.49 84.59 84.79 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 15.73 80.26 75.45 17.95 80.97 75.03 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1doo_c00 HEAT SHOCK LOCUS U user 3 4 # 3 A 1 THR B 28 THR~? 14.99 CL CL D 145 A 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 48 GLY B 97 GLY.? 16.18 CL CL D 145 A 124 SER B 29 SER~? 11.10 CL CL D 145 coo 20.60 80.81 78.25 19.93 81.48 80.23 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 24.21 79.63 86.31 23.19 81.94 80.55 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 18.07 85.03 84.32 18.49 84.59 84.79 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 15.73 80.26 75.45 17.95 80.97 75.03 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1doo_c00 HEAT SHOCK LOCUS U user 4 4 # 4 A 1 THR C 28 THR~? 15.27 CL CL A 144 A 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 A 48 GLY C 97 GLY.? 20.31 O2S EPE A 145 A 124 SER C 29 SER~? 20.03 O2S EPE A 145 coo 20.60 80.81 78.25 19.93 81.48 80.23 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 24.21 79.63 86.31 23.19 81.94 80.55 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 18.07 85.03 84.32 18.49 84.59 84.79 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 15.73 80.26 75.45 17.95 80.97 75.03 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1doo_c00 HEAT SHOCK LOCUS U user 5 4 # 5 A 1 THR D 28 THR~? 15.29 CL CL D 144 A 33 LYS D 100 LYS^? 18.85 CL CL D 145 A 48 GLY D 97 GLY.? 19.88 O8 EPE D 146 A 124 SER D 29 SER~? 20.03 O3S EPE D 146 coo 20.60 80.81 78.25 19.93 81.48 80.23 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 24.21 79.63 86.31 23.19 81.94 80.55 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 18.07 85.03 84.32 18.49 84.59 84.79 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 15.73 80.26 75.45 17.95 80.97 75.03 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1doo_c00 source 1doo HEAT SHOCK LOCUS U : 5 hits 1doo_c00 naa= 4 ULMN 4 1doo_c01 HEAT SHOCK LOCUS U user 1 4 # 1 B 1 THR A 28 THR~? 15.27 CL CL A 144 B 33 LYS A 100 LYS^? 18.99 CL CL D 145 B 48 GLY A 97 GLY.? 20.25 O1S EPE A 145 B 124 SER A 29 SER~? 20.16 O1S EPE A 145 coo 26.69 108.13 78.57 25.70 107.69 80.43 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 30.17 110.91 86.31 27.32 111.03 80.63 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 22.32 108.46 85.29 22.91 108.64 85.71 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 24.65 103.43 76.04 24.59 105.78 75.60 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1doo_c01 HEAT SHOCK LOCUS U user 2 4 # 2 B 1 THR A 107 THR~? 14.10 CL CL D 145 B 33 LYS B 77 LYS.? 21.17 CL CL D 145 B 48 GLY A 112 GLY.? 18.91 CL CL D 145 B 124 SER A 105 SER~? 6.77 CL CL D 145 coo 26.69 108.13 78.57 25.70 107.69 80.43 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 30.17 110.91 86.31 27.32 111.03 80.63 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 22.32 108.46 85.29 22.91 108.64 85.71 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 24.65 103.43 76.04 24.59 105.78 75.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1doo_c01 HEAT SHOCK LOCUS U user 3 4 # 3 B 1 THR C 28 THR~? 15.27 CL CL A 144 B 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 B 48 GLY C 97 GLY.? 20.31 O2S EPE A 145 B 124 SER C 29 SER~? 20.03 O2S EPE A 145 coo 26.69 108.13 78.57 25.70 107.69 80.43 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 30.17 110.91 86.31 27.32 111.03 80.63 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 22.32 108.46 85.29 22.91 108.64 85.71 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 24.65 103.43 76.04 24.59 105.78 75.60 -28.39 -21.41 2.10 -28.58 -23.61 3.07 1doo_c01 source 1doo HEAT SHOCK LOCUS U : 3 hits 1doo_c01 naa= 4 ULMN 4 1doo_c02 HEAT SHOCK LOCUS U user 1 4 # 1 C 1 THR A 28 THR~? 15.27 CL CL A 144 C 33 LYS A 100 LYS^? 18.99 CL CL D 145 C 48 GLY A 97 GLY.? 20.25 O1S EPE A 145 C 124 SER A 29 SER~? 20.16 O1S EPE A 145 coo -5.30 26.59 199.66 -4.98 26.05 197.57 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo -4.62 30.60 191.94 -3.32 28.83 197.07 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo -3.44 22.13 193.22 -3.30 22.85 192.94 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo -8.31 23.03 202.48 -6.18 24.15 202.80 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1doo_c02 HEAT SHOCK LOCUS U user 2 4 # 2 C 1 THR A 107 THR~? 14.10 CL CL D 145 C 33 LYS B 77 LYS.? 21.17 CL CL D 145 C 48 GLY A 112 GLY.? 18.91 CL CL D 145 C 124 SER A 105 SER~? 6.77 CL CL D 145 coo -5.30 26.59 199.66 -4.98 26.05 197.57 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo -4.62 30.60 191.94 -3.32 28.83 197.07 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo -3.44 22.13 193.22 -3.30 22.85 192.94 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo -8.31 23.03 202.48 -6.18 24.15 202.80 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1doo_c02 HEAT SHOCK LOCUS U user 3 4 # 3 C 1 THR B 28 THR~? 14.99 CL CL D 145 C 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 C 48 GLY B 97 GLY.? 16.18 CL CL D 145 C 124 SER B 29 SER~? 11.10 CL CL D 145 coo -5.30 26.59 199.66 -4.98 26.05 197.57 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo -4.62 30.60 191.94 -3.32 28.83 197.07 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo -3.44 22.13 193.22 -3.30 22.85 192.94 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo -8.31 23.03 202.48 -6.18 24.15 202.80 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1doo_c02 HEAT SHOCK LOCUS U user 4 4 # 4 C 1 THR C 28 THR~? 15.27 CL CL A 144 C 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 C 48 GLY C 97 GLY.? 20.31 O2S EPE A 145 C 124 SER C 29 SER~? 20.03 O2S EPE A 145 coo -5.30 26.59 199.66 -4.98 26.05 197.57 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo -4.62 30.60 191.94 -3.32 28.83 197.07 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo -3.44 22.13 193.22 -3.30 22.85 192.94 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo -8.31 23.03 202.48 -6.18 24.15 202.80 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1doo_c02 HEAT SHOCK LOCUS U user 5 4 # 5 C 1 THR D 28 THR~? 15.29 CL CL D 144 C 33 LYS D 100 LYS^? 18.85 CL CL D 145 C 48 GLY D 97 GLY.? 19.88 O8 EPE D 146 C 124 SER D 29 SER~? 20.03 O3S EPE D 146 coo -5.30 26.59 199.66 -4.98 26.05 197.57 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo -4.62 30.60 191.94 -3.32 28.83 197.07 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo -3.44 22.13 193.22 -3.30 22.85 192.94 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo -8.31 23.03 202.48 -6.18 24.15 202.80 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1doo_c02 source 1doo HEAT SHOCK LOCUS U : 5 hits 1doo_c02 naa= 4 ULMN 4 1doo_c03 HEAT SHOCK LOCUS U user 1 4 # 1 D 1 THR A 28 THR~? 15.27 CL CL A 144 D 33 LYS A 100 LYS^? 18.99 CL CL D 145 D 48 GLY A 97 GLY.? 20.25 O1S EPE A 145 D 124 SER A 29 SER~? 20.16 O1S EPE A 145 coo 21.09 18.28 199.42 20.72 17.74 197.38 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 25.54 20.08 191.91 24.21 17.77 197.54 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 18.82 14.75 192.32 19.54 14.99 192.16 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 16.26 18.98 201.87 18.32 18.00 202.67 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1doo_c03 HEAT SHOCK LOCUS U user 2 4 # 2 D 1 THR A 107 THR~? 14.10 CL CL D 145 D 33 LYS B 77 LYS.? 21.17 CL CL D 145 D 48 GLY A 112 GLY.? 18.91 CL CL D 145 D 124 SER A 105 SER~? 6.77 CL CL D 145 coo 21.09 18.28 199.42 20.72 17.74 197.38 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 25.54 20.08 191.91 24.21 17.77 197.54 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 18.82 14.75 192.32 19.54 14.99 192.16 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 16.26 18.98 201.87 18.32 18.00 202.67 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1doo_c03 HEAT SHOCK LOCUS U user 3 4 # 3 D 1 THR C 28 THR~? 15.27 CL CL A 144 D 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 D 48 GLY C 97 GLY.? 20.31 O2S EPE A 145 D 124 SER C 29 SER~? 20.03 O2S EPE A 145 coo 21.09 18.28 199.42 20.72 17.74 197.38 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 25.54 20.08 191.91 24.21 17.77 197.54 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 18.82 14.75 192.32 19.54 14.99 192.16 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 16.26 18.98 201.87 18.32 18.00 202.67 -28.39 -21.41 2.10 -28.58 -23.61 3.07 1doo_c03 source 1doo HEAT SHOCK LOCUS U : 3 hits 1doo_c03 naa= 4 ULMN 4 1eag_c02 PEPTIDE INHIBITOR user 1 4 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 218 ASP A 133 ASP~? 7.97 CL CL D 145 A 221 THR A 130 THR~? 5.01 CL CL D 145 coo 47.22 22.34 8.57 45.16 22.02 9.13 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 43.58 20.85 5.15 44.62 23.01 5.76 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 44.05 16.99 12.67 44.05 18.89 11.74 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 44.42 20.57 16.06 42.37 19.87 16.06 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1eag_c02 source 1eag PEPTIDE INHIBITOR : 1 hits 1eag_c02 naa= 4 ULMN 4 1eag_c05 PEPTIDE INHIBITOR user 1 4 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 84 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 218 ASP A 133 ASP~? 7.97 CL CL D 145 coo 47.22 22.34 8.57 45.16 22.02 9.13 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 43.58 20.85 5.15 44.62 23.01 5.76 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 40.49 26.39 8.83 42.48 26.82 6.92 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 44.05 16.99 12.67 44.05 18.89 11.74 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1eag_c05 source 1eag PEPTIDE INHIBITOR : 1 hits 1eag_c05 naa= 4 ULMN 4 1eed_c02 ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLuser 1 4 # 1 P 32 ASP D 133 ASP~? 7.85 CL CL D 145 P 35 SER B 34 SER~? 6.65 CL CL D 145 P 215 ASP A 133 ASP~? 7.97 CL CL D 145 P 218 THR A 130 THR~? 5.01 CL CL D 145 coo 10.15 33.41 11.98 7.98 33.66 12.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 7.57 37.60 10.00 8.86 37.02 12.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 4.04 29.97 8.82 4.78 31.15 10.46 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 4.25 27.93 13.40 2.30 28.73 12.88 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1eed_c02 source 1eed ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLEX WITH TH: 1 hits 1eed_c02 naa= 4 ULMN 4 1mpp_c02 PEPSIN (RENIN) (E.C.3.4.23.23) user 1 4 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 218 THR A 130 THR~? 5.01 CL CL D 145 coo 20.97 14.47 32.28 19.66 15.96 31.62 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 16.04 14.72 33.82 17.27 13.71 31.95 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 20.65 22.00 33.80 20.06 20.56 32.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 22.99 21.66 29.34 21.36 23.06 29.40 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1mpp_c02 source 1mpp PEPSIN (RENIN) (E.C.3.4.23.23) : 1 hits 1mpp_c02 naa= 4 ULMN 4 1oh9_c00 ACETYLGLUTAMATE KINASE user 1 4 # 1 A 8 LYS A 8 LYS^? 8.24 C6 EPE A 145 A 11 GLY A 35 GLY.? 16.89 C5 EPE A 145 A 45 GLY A 30 GLY~? 16.60 O1S EPE A 145 A 217 LYS A 100 LYS^? 18.99 CL CL D 145 coo 23.95 20.41 42.64 25.99 15.22 44.13 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 21.78 10.35 42.81 21.85 10.58 42.04 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 27.49 8.11 39.28 26.75 8.17 38.90 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 29.45 15.15 50.79 25.80 14.13 47.92 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 4 1oh9_c00 ACETYLGLUTAMATE KINASE user 2 4 # 2 A 8 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 11 GLY B 35 GLY.? 12.52 CL CL D 145 A 45 GLY B 30 GLY~? 7.61 CL CL D 145 A 217 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 23.95 20.41 42.64 25.99 15.22 44.13 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 21.78 10.35 42.81 21.85 10.58 42.04 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 27.49 8.11 39.28 26.75 8.17 38.90 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 29.45 15.15 50.79 25.80 14.13 47.92 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 4 1oh9_c00 ACETYLGLUTAMATE KINASE user 3 4 # 3 A 8 LYS C 8 LYS^? 8.33 O8 EPE A 145 A 11 GLY C 35 GLY.? 16.82 C2 EPE A 145 A 45 GLY C 30 GLY~? 16.61 O2S EPE A 145 A 217 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 23.95 20.41 42.64 25.99 15.22 44.13 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 21.78 10.35 42.81 21.85 10.58 42.04 -20.52 -15.68 4.99 -20.85 -15.81 4.28 coo 27.49 8.11 39.28 26.75 8.17 38.90 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 29.45 15.15 50.79 25.80 14.13 47.92 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 4 1oh9_c00 ACETYLGLUTAMATE KINASE user 4 4 # 4 A 8 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 11 GLY D 35 GLY.? 15.58 O8 EPE D 146 A 45 GLY D 30 GLY~? 16.53 O3S EPE D 146 A 217 LYS D 100 LYS^? 18.85 CL CL D 145 coo 23.95 20.41 42.64 25.99 15.22 44.13 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 21.78 10.35 42.81 21.85 10.58 42.04 7.77 -16.22 -24.79 7.63 -15.64 -25.34 coo 27.49 8.11 39.28 26.75 8.17 38.90 10.38 -14.18 -33.00 9.58 -14.37 -32.83 coo 29.45 15.15 50.79 25.80 14.13 47.92 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1oh9_c00 source 1oh9 ACETYLGLUTAMATE KINASE : 4 hits 1oh9_c00 naa= 4 ULMN 4 1pix_c00 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 151 VAL A 90 VAL.? 18.62 CL CL A 144 A 194 GLY A 25 GLY~? 16.04 CL CL A 144 A 417 ILE D 50 ILE~? 19.07 CL CL D 145 A 457 ALA D 103 ALA^? 13.10 CL CL D 145 coo 60.43 93.31 8.03 62.16 94.30 8.93 -38.21 1.15 -22.82 -37.11 -0.58 -23.47 coo 59.34 89.99 13.88 59.24 89.18 13.73 -39.61 -2.76 -19.24 -39.33 -3.08 -18.55 coo 39.61 128.90 22.54 40.04 128.24 23.80 -5.17 -17.77 -43.89 -5.31 -17.14 -42.73 coo 43.27 124.32 20.47 43.79 125.29 21.53 -10.21 -15.10 -39.10 -10.65 -16.28 -39.96 ULMN 4 1pix_c00 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 2 4 # 2 A 151 VAL D 90 VAL.? 18.63 CL CL D 144 A 194 GLY D 25 GLY~? 15.96 CL CL D 144 A 417 ILE A 50 ILE~? 19.14 CL CL D 145 A 457 ALA A 103 ALA^? 13.16 CL CL D 145 coo 60.43 93.31 8.03 62.16 94.30 8.93 3.30 -19.06 -38.19 1.62 -17.72 -38.54 coo 59.34 89.99 13.88 59.24 89.18 13.73 5.71 -14.52 -40.01 6.02 -13.78 -39.77 coo 39.61 128.90 22.54 40.04 128.24 23.80 -37.19 -5.63 -30.69 -35.97 -5.62 -29.99 coo 43.27 124.32 20.47 43.79 125.29 21.53 -29.80 -6.42 -31.41 -30.56 -6.09 -32.76 1pix_c00 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 2 hits 1pix_c00 naa= 4 ULMN 4 1pix_c02 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 457 ALA A 31 ALA~? 12.58 O1S EPE A 145 A 458 ALA C 129 ALA~? 15.24 O1S EPE A 145 B 193 ALA A 33 ALA~? 19.79 O1S EPE A 145 B 194 GLY A 35 GLY.? 16.89 C5 EPE A 145 coo 43.27 124.32 20.47 43.79 125.29 21.53 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo 39.57 123.53 20.89 38.42 124.25 20.20 -34.15 0.77 -8.09 -34.39 2.21 -8.42 coo 47.95 129.15 20.31 47.81 128.95 18.79 -35.26 7.02 -13.65 -36.69 6.75 -13.22 coo 50.40 126.23 20.48 50.46 127.00 20.75 -29.80 7.53 -12.97 -29.98 6.77 -13.01 1pix_c02 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 1 hits 1pix_c02 naa= 4 ULMN 4 1pix_c03 GLUTACONYL-COA DECARBOXYLASE A SUBUNuser 1 4 # 1 A 193 ALA A 33 ALA~? 19.79 O1S EPE A 145 A 194 GLY A 35 GLY.? 16.89 C5 EPE A 145 B 457 ALA A 31 ALA~? 12.58 O1S EPE A 145 B 458 ALA C 129 ALA~? 15.24 O1S EPE A 145 coo 61.89 87.20 13.50 62.59 88.00 12.38 -35.26 7.02 -13.65 -36.69 6.75 -13.22 coo 59.34 89.99 13.88 59.24 89.18 13.73 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 65.50 91.13 17.77 64.65 89.88 18.00 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo 68.56 91.15 20.03 69.95 90.68 19.64 -34.15 0.77 -8.09 -34.39 2.21 -8.42 1pix_c03 source 1pix GLUTACONYL-COA DECARBOXYLASE A SUBUNIT : 1 hits 1pix_c03 naa= 4 ULMN 4 1pma_c00 PROTEASOME user 1 4 # 1 B 1 THR A 28 THR~? 15.27 CL CL A 144 B 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 B 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 B 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 136.79 102.27 111.59 142.67 100.98 109.47 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 140.77 93.29 113.52 140.45 93.77 112.93 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 148.45 97.25 114.98 149.72 97.25 112.90 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c00 PROTEASOME user 2 4 # 2 B 1 THR A 28 THR~? 15.27 CL CL A 144 B 33 LYS A 100 LYS^? 18.99 CL CL D 145 B 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 B 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 136.79 102.27 111.59 142.67 100.98 109.47 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 140.77 93.29 113.52 140.45 93.77 112.93 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 148.45 97.25 114.98 149.72 97.25 112.90 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c00 PROTEASOME user 3 4 # 3 B 1 THR A 107 THR~? 14.10 CL CL D 145 B 33 LYS B 77 LYS.? 21.17 CL CL D 145 B 47 GLY A 112 GLY.? 18.91 CL CL D 145 B 129 SER A 105 SER~? 6.77 CL CL D 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 136.79 102.27 111.59 142.67 100.98 109.47 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 140.77 93.29 113.52 140.45 93.77 112.93 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 148.45 97.25 114.98 149.72 97.25 112.90 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c00 PROTEASOME user 4 4 # 4 B 1 THR B 28 THR~? 14.99 CL CL D 145 B 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 47 GLY B 97 GLY.? 16.18 CL CL D 145 B 129 SER B 29 SER~? 11.10 CL CL D 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 136.79 102.27 111.59 142.67 100.98 109.47 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 140.77 93.29 113.52 140.45 93.77 112.93 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 148.45 97.25 114.98 149.72 97.25 112.90 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c00 PROTEASOME user 5 4 # 5 B 1 THR B 28 THR~? 14.99 CL CL D 145 B 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 47 GLY B 97 GLY.? 16.18 CL CL D 145 B 129 SER B 29 SER~? 11.10 CL CL D 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 136.79 102.27 111.59 142.67 100.98 109.47 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 140.77 93.29 113.52 140.45 93.77 112.93 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 148.45 97.25 114.98 149.72 97.25 112.90 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c00 PROTEASOME user 6 4 # 6 B 1 THR C 28 THR~? 15.27 CL CL A 144 B 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 B 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 B 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 136.79 102.27 111.59 142.67 100.98 109.47 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 140.77 93.29 113.52 140.45 93.77 112.93 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 148.45 97.25 114.98 149.72 97.25 112.90 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c00 PROTEASOME user 7 4 # 7 B 1 THR C 28 THR~? 15.27 CL CL A 144 B 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 B 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 B 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 145.45 99.84 111.72 143.76 98.56 112.07 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 136.79 102.27 111.59 142.67 100.98 109.47 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 140.77 93.29 113.52 140.45 93.77 112.93 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 148.45 97.25 114.98 149.72 97.25 112.90 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c00 PROTEASOME user 8 4 # 8 B 1 THR D 28 THR~? 15.29 CL CL D 144 B 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 B 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 145.45 99.84 111.72 143.76 98.56 112.07 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 136.79 102.27 111.59 142.67 100.98 109.47 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 140.77 93.29 113.52 140.45 93.77 112.93 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 148.45 97.25 114.98 149.72 97.25 112.90 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c00 PROTEASOME user 9 4 # 9 B 1 THR D 28 THR~? 15.29 CL CL D 144 B 33 LYS D 100 LYS^? 18.85 CL CL D 145 B 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 B 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 145.45 99.84 111.72 143.76 98.56 112.07 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 136.79 102.27 111.59 142.67 100.98 109.47 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 140.77 93.29 113.52 140.45 93.77 112.93 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 148.45 97.25 114.98 149.72 97.25 112.90 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c00 source 1pma PROTEASOME : 9 hits 1pma_c00 naa= 4 ULMN 4 1pma_c01 PROTEASOME user 1 4 # 1 P 1 THR A 28 THR~? 15.27 CL CL A 144 P 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 P 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 P 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 133.38 85.70 85.38 139.26 83.66 84.60 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 138.10 81.91 93.37 137.75 81.71 92.63 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 145.29 86.16 90.67 146.68 84.74 89.28 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c01 PROTEASOME user 2 4 # 2 P 1 THR A 28 THR~? 15.27 CL CL A 144 P 33 LYS A 100 LYS^? 18.99 CL CL D 145 P 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 P 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 133.38 85.70 85.38 139.26 83.66 84.60 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 138.10 81.91 93.37 137.75 81.71 92.63 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 145.29 86.16 90.67 146.68 84.74 89.28 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c01 PROTEASOME user 3 4 # 3 P 1 THR A 107 THR~? 14.10 CL CL D 145 P 33 LYS B 77 LYS.? 21.17 CL CL D 145 P 47 GLY A 112 GLY.? 18.91 CL CL D 145 P 129 SER A 105 SER~? 6.77 CL CL D 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 133.38 85.70 85.38 139.26 83.66 84.60 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 138.10 81.91 93.37 137.75 81.71 92.63 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 145.29 86.16 90.67 146.68 84.74 89.28 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c01 PROTEASOME user 4 4 # 4 P 1 THR B 28 THR~? 14.99 CL CL D 145 P 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 P 47 GLY B 97 GLY.? 16.18 CL CL D 145 P 129 SER B 29 SER~? 11.10 CL CL D 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 133.38 85.70 85.38 139.26 83.66 84.60 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 138.10 81.91 93.37 137.75 81.71 92.63 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 145.29 86.16 90.67 146.68 84.74 89.28 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c01 PROTEASOME user 5 4 # 5 P 1 THR B 28 THR~? 14.99 CL CL D 145 P 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 P 47 GLY B 97 GLY.? 16.18 CL CL D 145 P 129 SER B 29 SER~? 11.10 CL CL D 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 133.38 85.70 85.38 139.26 83.66 84.60 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 138.10 81.91 93.37 137.75 81.71 92.63 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 145.29 86.16 90.67 146.68 84.74 89.28 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c01 PROTEASOME user 6 4 # 6 P 1 THR C 28 THR~? 15.27 CL CL A 144 P 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 P 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 P 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 133.38 85.70 85.38 139.26 83.66 84.60 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 138.10 81.91 93.37 137.75 81.71 92.63 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 145.29 86.16 90.67 146.68 84.74 89.28 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c01 PROTEASOME user 7 4 # 7 P 1 THR C 28 THR~? 15.27 CL CL A 144 P 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 P 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 P 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 142.15 84.99 86.79 140.56 84.37 88.13 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 133.38 85.70 85.38 139.26 83.66 84.60 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 138.10 81.91 93.37 137.75 81.71 92.63 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 145.29 86.16 90.67 146.68 84.74 89.28 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c01 PROTEASOME user 8 4 # 8 P 1 THR D 28 THR~? 15.29 CL CL D 144 P 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 P 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 P 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 142.15 84.99 86.79 140.56 84.37 88.13 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 133.38 85.70 85.38 139.26 83.66 84.60 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 138.10 81.91 93.37 137.75 81.71 92.63 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 145.29 86.16 90.67 146.68 84.74 89.28 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c01 PROTEASOME user 9 4 # 9 P 1 THR D 28 THR~? 15.29 CL CL D 144 P 33 LYS D 100 LYS^? 18.85 CL CL D 145 P 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 P 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 142.15 84.99 86.79 140.56 84.37 88.13 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 133.38 85.70 85.38 139.26 83.66 84.60 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 138.10 81.91 93.37 137.75 81.71 92.63 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 145.29 86.16 90.67 146.68 84.74 89.28 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c01 source 1pma PROTEASOME : 9 hits 1pma_c01 naa= 4 ULMN 4 1pma_c02 PROTEASOME user 1 4 # 1 Q 1 THR A 28 THR~? 15.27 CL CL A 144 Q 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 Q 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Q 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 131.97 54.44 81.72 138.04 53.15 82.45 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 136.89 58.65 89.43 136.55 57.93 89.18 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 143.72 59.85 83.98 145.20 57.91 84.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c02 PROTEASOME user 2 4 # 2 Q 1 THR A 28 THR~? 15.27 CL CL A 144 Q 33 LYS A 100 LYS^? 18.99 CL CL D 145 Q 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Q 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 131.97 54.44 81.72 138.04 53.15 82.45 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 136.89 58.65 89.43 136.55 57.93 89.18 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 143.72 59.85 83.98 145.20 57.91 84.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c02 PROTEASOME user 3 4 # 3 Q 1 THR A 107 THR~? 14.10 CL CL D 145 Q 33 LYS B 77 LYS.? 21.17 CL CL D 145 Q 47 GLY A 112 GLY.? 18.91 CL CL D 145 Q 129 SER A 105 SER~? 6.77 CL CL D 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 131.97 54.44 81.72 138.04 53.15 82.45 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 136.89 58.65 89.43 136.55 57.93 89.18 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 143.72 59.85 83.98 145.20 57.91 84.07 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c02 PROTEASOME user 4 4 # 4 Q 1 THR B 28 THR~? 14.99 CL CL D 145 Q 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 Q 47 GLY B 97 GLY.? 16.18 CL CL D 145 Q 129 SER B 29 SER~? 11.10 CL CL D 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 131.97 54.44 81.72 138.04 53.15 82.45 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 136.89 58.65 89.43 136.55 57.93 89.18 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 143.72 59.85 83.98 145.20 57.91 84.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c02 PROTEASOME user 5 4 # 5 Q 1 THR B 28 THR~? 14.99 CL CL D 145 Q 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 Q 47 GLY B 97 GLY.? 16.18 CL CL D 145 Q 129 SER B 29 SER~? 11.10 CL CL D 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 131.97 54.44 81.72 138.04 53.15 82.45 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 136.89 58.65 89.43 136.55 57.93 89.18 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 143.72 59.85 83.98 145.20 57.91 84.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c02 PROTEASOME user 6 4 # 6 Q 1 THR C 28 THR~? 15.27 CL CL A 144 Q 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 Q 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Q 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 131.97 54.44 81.72 138.04 53.15 82.45 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 136.89 58.65 89.43 136.55 57.93 89.18 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 143.72 59.85 83.98 145.20 57.91 84.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c02 PROTEASOME user 7 4 # 7 Q 1 THR C 28 THR~? 15.27 CL CL A 144 Q 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 Q 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Q 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 140.73 55.93 82.67 139.31 56.56 84.17 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 131.97 54.44 81.72 138.04 53.15 82.45 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 136.89 58.65 89.43 136.55 57.93 89.18 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 143.72 59.85 83.98 145.20 57.91 84.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c02 PROTEASOME user 8 4 # 8 Q 1 THR D 28 THR~? 15.29 CL CL D 144 Q 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 Q 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Q 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 140.73 55.93 82.67 139.31 56.56 84.17 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 131.97 54.44 81.72 138.04 53.15 82.45 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 136.89 58.65 89.43 136.55 57.93 89.18 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 143.72 59.85 83.98 145.20 57.91 84.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c02 PROTEASOME user 9 4 # 9 Q 1 THR D 28 THR~? 15.29 CL CL D 144 Q 33 LYS D 100 LYS^? 18.85 CL CL D 145 Q 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Q 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 140.73 55.93 82.67 139.31 56.56 84.17 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 131.97 54.44 81.72 138.04 53.15 82.45 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 136.89 58.65 89.43 136.55 57.93 89.18 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 143.72 59.85 83.98 145.20 57.91 84.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c02 source 1pma PROTEASOME : 9 hits 1pma_c02 naa= 4 ULMN 4 1pma_c03 PROTEASOME user 1 4 # 1 R 1 THR A 28 THR~? 15.27 CL CL A 144 R 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 R 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 R 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 133.82 32.17 103.65 140.06 32.45 104.82 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 137.84 41.34 104.86 137.70 40.63 105.29 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 144.81 38.28 100.19 146.44 37.17 101.53 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c03 PROTEASOME user 2 4 # 2 R 1 THR A 28 THR~? 15.27 CL CL A 144 R 33 LYS A 100 LYS^? 18.99 CL CL D 145 R 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 R 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 133.82 32.17 103.65 140.06 32.45 104.82 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 137.84 41.34 104.86 137.70 40.63 105.29 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 144.81 38.28 100.19 146.44 37.17 101.53 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c03 PROTEASOME user 3 4 # 3 R 1 THR A 107 THR~? 14.10 CL CL D 145 R 33 LYS B 77 LYS.? 21.17 CL CL D 145 R 47 GLY A 112 GLY.? 18.91 CL CL D 145 R 129 SER A 105 SER~? 6.77 CL CL D 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 133.82 32.17 103.65 140.06 32.45 104.82 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 137.84 41.34 104.86 137.70 40.63 105.29 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 144.81 38.28 100.19 146.44 37.17 101.53 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c03 PROTEASOME user 4 4 # 4 R 1 THR B 28 THR~? 14.99 CL CL D 145 R 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 R 47 GLY B 97 GLY.? 16.18 CL CL D 145 R 129 SER B 29 SER~? 11.10 CL CL D 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 133.82 32.17 103.65 140.06 32.45 104.82 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 137.84 41.34 104.86 137.70 40.63 105.29 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 144.81 38.28 100.19 146.44 37.17 101.53 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c03 PROTEASOME user 5 4 # 5 R 1 THR B 28 THR~? 14.99 CL CL D 145 R 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 R 47 GLY B 97 GLY.? 16.18 CL CL D 145 R 129 SER B 29 SER~? 11.10 CL CL D 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 133.82 32.17 103.65 140.06 32.45 104.82 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 137.84 41.34 104.86 137.70 40.63 105.29 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 144.81 38.28 100.19 146.44 37.17 101.53 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c03 PROTEASOME user 6 4 # 6 R 1 THR C 28 THR~? 15.27 CL CL A 144 R 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 R 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 R 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 133.82 32.17 103.65 140.06 32.45 104.82 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 137.84 41.34 104.86 137.70 40.63 105.29 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 144.81 38.28 100.19 146.44 37.17 101.53 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c03 PROTEASOME user 7 4 # 7 R 1 THR C 28 THR~? 15.27 CL CL A 144 R 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 R 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 R 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 142.38 34.41 102.60 140.86 35.75 103.29 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 133.82 32.17 103.65 140.06 32.45 104.82 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 137.84 41.34 104.86 137.70 40.63 105.29 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 144.81 38.28 100.19 146.44 37.17 101.53 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c03 PROTEASOME user 8 4 # 8 R 1 THR D 28 THR~? 15.29 CL CL D 144 R 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 R 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 R 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 142.38 34.41 102.60 140.86 35.75 103.29 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 133.82 32.17 103.65 140.06 32.45 104.82 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 137.84 41.34 104.86 137.70 40.63 105.29 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 144.81 38.28 100.19 146.44 37.17 101.53 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c03 PROTEASOME user 9 4 # 9 R 1 THR D 28 THR~? 15.29 CL CL D 144 R 33 LYS D 100 LYS^? 18.85 CL CL D 145 R 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 R 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 142.38 34.41 102.60 140.86 35.75 103.29 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 133.82 32.17 103.65 140.06 32.45 104.82 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 137.84 41.34 104.86 137.70 40.63 105.29 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 144.81 38.28 100.19 146.44 37.17 101.53 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c03 source 1pma PROTEASOME : 9 hits 1pma_c03 naa= 4 ULMN 4 1pma_c04 PROTEASOME user 1 4 # 1 S 1 THR A 28 THR~? 15.27 CL CL A 144 S 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 S 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 S 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 137.54 35.66 134.42 143.74 36.95 134.69 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 140.84 42.46 127.91 140.66 42.32 128.74 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 148.11 37.39 126.83 149.93 38.14 128.30 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c04 PROTEASOME user 2 4 # 2 S 1 THR A 28 THR~? 15.27 CL CL A 144 S 33 LYS A 100 LYS^? 18.99 CL CL D 145 S 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 S 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 137.54 35.66 134.42 143.74 36.95 134.69 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 140.84 42.46 127.91 140.66 42.32 128.74 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 148.11 37.39 126.83 149.93 38.14 128.30 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c04 PROTEASOME user 3 4 # 3 S 1 THR A 107 THR~? 14.10 CL CL D 145 S 33 LYS B 77 LYS.? 21.17 CL CL D 145 S 47 GLY A 112 GLY.? 18.91 CL CL D 145 S 129 SER A 105 SER~? 6.77 CL CL D 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 137.54 35.66 134.42 143.74 36.95 134.69 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 140.84 42.46 127.91 140.66 42.32 128.74 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 148.11 37.39 126.83 149.93 38.14 128.30 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c04 PROTEASOME user 4 4 # 4 S 1 THR B 28 THR~? 14.99 CL CL D 145 S 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 S 47 GLY B 97 GLY.? 16.18 CL CL D 145 S 129 SER B 29 SER~? 11.10 CL CL D 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 137.54 35.66 134.42 143.74 36.95 134.69 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 140.84 42.46 127.91 140.66 42.32 128.74 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 148.11 37.39 126.83 149.93 38.14 128.30 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c04 PROTEASOME user 5 4 # 5 S 1 THR B 28 THR~? 14.99 CL CL D 145 S 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 S 47 GLY B 97 GLY.? 16.18 CL CL D 145 S 129 SER B 29 SER~? 11.10 CL CL D 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 137.54 35.66 134.42 143.74 36.95 134.69 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 140.84 42.46 127.91 140.66 42.32 128.74 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 148.11 37.39 126.83 149.93 38.14 128.30 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c04 PROTEASOME user 6 4 # 6 S 1 THR C 28 THR~? 15.27 CL CL A 144 S 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 S 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 S 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 137.54 35.66 134.42 143.74 36.95 134.69 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 140.84 42.46 127.91 140.66 42.32 128.74 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 148.11 37.39 126.83 149.93 38.14 128.30 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c04 PROTEASOME user 7 4 # 7 S 1 THR C 28 THR~? 15.27 CL CL A 144 S 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 S 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 S 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 145.99 36.73 131.50 144.29 37.93 131.05 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 137.54 35.66 134.42 143.74 36.95 134.69 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 140.84 42.46 127.91 140.66 42.32 128.74 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 148.11 37.39 126.83 149.93 38.14 128.30 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c04 PROTEASOME user 8 4 # 8 S 1 THR D 28 THR~? 15.29 CL CL D 144 S 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 S 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 S 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 145.99 36.73 131.50 144.29 37.93 131.05 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 137.54 35.66 134.42 143.74 36.95 134.69 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 140.84 42.46 127.91 140.66 42.32 128.74 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 148.11 37.39 126.83 149.93 38.14 128.30 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c04 PROTEASOME user 9 4 # 9 S 1 THR D 28 THR~? 15.29 CL CL D 144 S 33 LYS D 100 LYS^? 18.85 CL CL D 145 S 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 S 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 145.99 36.73 131.50 144.29 37.93 131.05 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 137.54 35.66 134.42 143.74 36.95 134.69 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 140.84 42.46 127.91 140.66 42.32 128.74 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 148.11 37.39 126.83 149.93 38.14 128.30 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c04 source 1pma PROTEASOME : 9 hits 1pma_c04 naa= 4 ULMN 4 1pma_c05 PROTEASOME user 1 4 # 1 T 1 THR A 28 THR~? 15.27 CL CL A 144 T 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 T 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 T 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 140.35 62.12 151.02 146.27 63.46 149.54 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 142.85 61.51 141.28 142.70 62.06 141.93 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 150.80 57.97 144.10 152.46 59.79 144.30 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c05 PROTEASOME user 2 4 # 2 T 1 THR A 28 THR~? 15.27 CL CL A 144 T 33 LYS A 100 LYS^? 18.99 CL CL D 145 T 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 T 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 140.35 62.12 151.02 146.27 63.46 149.54 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 142.85 61.51 141.28 142.70 62.06 141.93 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 150.80 57.97 144.10 152.46 59.79 144.30 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c05 PROTEASOME user 3 4 # 3 T 1 THR A 107 THR~? 14.10 CL CL D 145 T 33 LYS B 77 LYS.? 21.17 CL CL D 145 T 47 GLY A 112 GLY.? 18.91 CL CL D 145 T 129 SER A 105 SER~? 6.77 CL CL D 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 140.35 62.12 151.02 146.27 63.46 149.54 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 142.85 61.51 141.28 142.70 62.06 141.93 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 150.80 57.97 144.10 152.46 59.79 144.30 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c05 PROTEASOME user 4 4 # 4 T 1 THR B 28 THR~? 14.99 CL CL D 145 T 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 T 47 GLY B 97 GLY.? 16.18 CL CL D 145 T 129 SER B 29 SER~? 11.10 CL CL D 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 140.35 62.12 151.02 146.27 63.46 149.54 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 142.85 61.51 141.28 142.70 62.06 141.93 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 150.80 57.97 144.10 152.46 59.79 144.30 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c05 PROTEASOME user 5 4 # 5 T 1 THR B 28 THR~? 14.99 CL CL D 145 T 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 T 47 GLY B 97 GLY.? 16.18 CL CL D 145 T 129 SER B 29 SER~? 11.10 CL CL D 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 140.35 62.12 151.02 146.27 63.46 149.54 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 142.85 61.51 141.28 142.70 62.06 141.93 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 150.80 57.97 144.10 152.46 59.79 144.30 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c05 PROTEASOME user 6 4 # 6 T 1 THR C 28 THR~? 15.27 CL CL A 144 T 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 T 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 T 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 140.35 62.12 151.02 146.27 63.46 149.54 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 142.85 61.51 141.28 142.70 62.06 141.93 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 150.80 57.97 144.10 152.46 59.79 144.30 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c05 PROTEASOME user 7 4 # 7 T 1 THR C 28 THR~? 15.27 CL CL A 144 T 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 T 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 T 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 148.59 61.06 147.60 146.72 61.19 146.49 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 140.35 62.12 151.02 146.27 63.46 149.54 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 142.85 61.51 141.28 142.70 62.06 141.93 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 150.80 57.97 144.10 152.46 59.79 144.30 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c05 PROTEASOME user 8 4 # 8 T 1 THR D 28 THR~? 15.29 CL CL D 144 T 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 T 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 T 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 148.59 61.06 147.60 146.72 61.19 146.49 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 140.35 62.12 151.02 146.27 63.46 149.54 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 142.85 61.51 141.28 142.70 62.06 141.93 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 150.80 57.97 144.10 152.46 59.79 144.30 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c05 PROTEASOME user 9 4 # 9 T 1 THR D 28 THR~? 15.29 CL CL D 144 T 33 LYS D 100 LYS^? 18.85 CL CL D 145 T 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 T 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 148.59 61.06 147.60 146.72 61.19 146.49 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 140.35 62.12 151.02 146.27 63.46 149.54 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 142.85 61.51 141.28 142.70 62.06 141.93 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 150.80 57.97 144.10 152.46 59.79 144.30 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c05 source 1pma PROTEASOME : 9 hits 1pma_c05 naa= 4 ULMN 4 1pma_c06 PROTEASOME user 1 4 # 1 U 1 THR A 28 THR~? 15.27 CL CL A 144 U 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 U 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 U 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 140.15 91.82 140.86 145.77 92.05 138.33 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 143.01 84.16 135.00 142.77 84.96 134.97 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 150.85 84.74 138.83 152.35 86.20 137.62 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c06 PROTEASOME user 2 4 # 2 U 1 THR A 28 THR~? 15.27 CL CL A 144 U 33 LYS A 100 LYS^? 18.99 CL CL D 145 U 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 U 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 140.15 91.82 140.86 145.77 92.05 138.33 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 143.01 84.16 135.00 142.77 84.96 134.97 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 150.85 84.74 138.83 152.35 86.20 137.62 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c06 PROTEASOME user 3 4 # 3 U 1 THR A 107 THR~? 14.10 CL CL D 145 U 33 LYS B 77 LYS.? 21.17 CL CL D 145 U 47 GLY A 112 GLY.? 18.91 CL CL D 145 U 129 SER A 105 SER~? 6.77 CL CL D 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 140.15 91.82 140.86 145.77 92.05 138.33 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 143.01 84.16 135.00 142.77 84.96 134.97 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 150.85 84.74 138.83 152.35 86.20 137.62 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c06 PROTEASOME user 4 4 # 4 U 1 THR B 28 THR~? 14.99 CL CL D 145 U 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 U 47 GLY B 97 GLY.? 16.18 CL CL D 145 U 129 SER B 29 SER~? 11.10 CL CL D 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 140.15 91.82 140.86 145.77 92.05 138.33 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 143.01 84.16 135.00 142.77 84.96 134.97 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 150.85 84.74 138.83 152.35 86.20 137.62 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c06 PROTEASOME user 5 4 # 5 U 1 THR B 28 THR~? 14.99 CL CL D 145 U 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 U 47 GLY B 97 GLY.? 16.18 CL CL D 145 U 129 SER B 29 SER~? 11.10 CL CL D 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 140.15 91.82 140.86 145.77 92.05 138.33 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 143.01 84.16 135.00 142.77 84.96 134.97 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 150.85 84.74 138.83 152.35 86.20 137.62 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c06 PROTEASOME user 6 4 # 6 U 1 THR C 28 THR~? 15.27 CL CL A 144 U 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 U 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 U 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 140.15 91.82 140.86 145.77 92.05 138.33 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 143.01 84.16 135.00 142.77 84.96 134.97 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 150.85 84.74 138.83 152.35 86.20 137.62 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c06 PROTEASOME user 7 4 # 7 U 1 THR C 28 THR~? 15.27 CL CL A 144 U 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 U 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 U 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 148.42 89.29 138.93 146.59 88.50 138.15 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 140.15 91.82 140.86 145.77 92.05 138.33 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 143.01 84.16 135.00 142.77 84.96 134.97 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 150.85 84.74 138.83 152.35 86.20 137.62 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c06 PROTEASOME user 8 4 # 8 U 1 THR D 28 THR~? 15.29 CL CL D 144 U 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 U 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 U 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 148.42 89.29 138.93 146.59 88.50 138.15 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 140.15 91.82 140.86 145.77 92.05 138.33 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 143.01 84.16 135.00 142.77 84.96 134.97 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 150.85 84.74 138.83 152.35 86.20 137.62 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c06 PROTEASOME user 9 4 # 9 U 1 THR D 28 THR~? 15.29 CL CL D 144 U 33 LYS D 100 LYS^? 18.85 CL CL D 145 U 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 U 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 148.42 89.29 138.93 146.59 88.50 138.15 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 140.15 91.82 140.86 145.77 92.05 138.33 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 143.01 84.16 135.00 142.77 84.96 134.97 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 150.85 84.74 138.83 152.35 86.20 137.62 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c06 source 1pma PROTEASOME : 9 hits 1pma_c06 naa= 4 ULMN 4 1pma_c07 PROTEASOME user 1 4 # 1 V 1 THR A 28 THR~? 15.27 CL CL A 144 V 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 V 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 V 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 168.58 29.07 108.83 162.49 30.41 108.07 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 165.30 38.28 111.45 165.51 37.78 110.79 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 158.15 34.28 114.77 156.42 34.20 113.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c07 PROTEASOME user 2 4 # 2 V 1 THR A 28 THR~? 15.27 CL CL A 144 V 33 LYS A 100 LYS^? 18.99 CL CL D 145 V 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 V 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 168.58 29.07 108.83 162.49 30.41 108.07 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 165.30 38.28 111.45 165.51 37.78 110.79 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 158.15 34.28 114.77 156.42 34.20 113.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c07 PROTEASOME user 3 4 # 3 V 1 THR A 107 THR~? 14.10 CL CL D 145 V 33 LYS B 77 LYS.? 21.17 CL CL D 145 V 47 GLY A 112 GLY.? 18.91 CL CL D 145 V 129 SER A 105 SER~? 6.77 CL CL D 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 168.58 29.07 108.83 162.49 30.41 108.07 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 165.30 38.28 111.45 165.51 37.78 110.79 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 158.15 34.28 114.77 156.42 34.20 113.07 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c07 PROTEASOME user 4 4 # 4 V 1 THR B 28 THR~? 14.99 CL CL D 145 V 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 V 47 GLY B 97 GLY.? 16.18 CL CL D 145 V 129 SER B 29 SER~? 11.10 CL CL D 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 168.58 29.07 108.83 162.49 30.41 108.07 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 165.30 38.28 111.45 165.51 37.78 110.79 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 158.15 34.28 114.77 156.42 34.20 113.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c07 PROTEASOME user 5 4 # 5 V 1 THR B 28 THR~? 14.99 CL CL D 145 V 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 V 47 GLY B 97 GLY.? 16.18 CL CL D 145 V 129 SER B 29 SER~? 11.10 CL CL D 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 168.58 29.07 108.83 162.49 30.41 108.07 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 165.30 38.28 111.45 165.51 37.78 110.79 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 158.15 34.28 114.77 156.42 34.20 113.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c07 PROTEASOME user 6 4 # 6 V 1 THR C 28 THR~? 15.27 CL CL A 144 V 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 V 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 V 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 168.58 29.07 108.83 162.49 30.41 108.07 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 165.30 38.28 111.45 165.51 37.78 110.79 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 158.15 34.28 114.77 156.42 34.20 113.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c07 PROTEASOME user 7 4 # 7 V 1 THR C 28 THR~? 15.27 CL CL A 144 V 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 V 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 V 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 160.31 31.63 111.03 162.05 32.90 110.99 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 168.58 29.07 108.83 162.49 30.41 108.07 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 165.30 38.28 111.45 165.51 37.78 110.79 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 158.15 34.28 114.77 156.42 34.20 113.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c07 PROTEASOME user 8 4 # 8 V 1 THR D 28 THR~? 15.29 CL CL D 144 V 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 V 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 V 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 160.31 31.63 111.03 162.05 32.90 110.99 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 168.58 29.07 108.83 162.49 30.41 108.07 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 165.30 38.28 111.45 165.51 37.78 110.79 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 158.15 34.28 114.77 156.42 34.20 113.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c07 PROTEASOME user 9 4 # 9 V 1 THR D 28 THR~? 15.29 CL CL D 144 V 33 LYS D 100 LYS^? 18.85 CL CL D 145 V 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 V 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 160.31 31.63 111.03 162.05 32.90 110.99 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 168.58 29.07 108.83 162.49 30.41 108.07 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 165.30 38.28 111.45 165.51 37.78 110.79 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 158.15 34.28 114.77 156.42 34.20 113.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c07 source 1pma PROTEASOME : 9 hits 1pma_c07 naa= 4 ULMN 4 1pma_c08 PROTEASOME user 1 4 # 1 W 1 THR A 28 THR~? 15.27 CL CL A 144 W 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 W 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 W 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 166.07 44.81 82.01 160.13 46.94 82.57 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 163.23 48.87 90.83 163.39 49.06 90.01 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 155.60 44.58 89.97 153.89 45.98 88.92 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c08 PROTEASOME user 2 4 # 2 W 1 THR A 28 THR~? 15.27 CL CL A 144 W 33 LYS A 100 LYS^? 18.99 CL CL D 145 W 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 W 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 166.07 44.81 82.01 160.13 46.94 82.57 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 163.23 48.87 90.83 163.39 49.06 90.01 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 155.60 44.58 89.97 153.89 45.98 88.92 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c08 PROTEASOME user 3 4 # 3 W 1 THR A 107 THR~? 14.10 CL CL D 145 W 33 LYS B 77 LYS.? 21.17 CL CL D 145 W 47 GLY A 112 GLY.? 18.91 CL CL D 145 W 129 SER A 105 SER~? 6.77 CL CL D 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 166.07 44.81 82.01 160.13 46.94 82.57 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 163.23 48.87 90.83 163.39 49.06 90.01 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 155.60 44.58 89.97 153.89 45.98 88.92 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c08 PROTEASOME user 4 4 # 4 W 1 THR B 28 THR~? 14.99 CL CL D 145 W 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 W 47 GLY B 97 GLY.? 16.18 CL CL D 145 W 129 SER B 29 SER~? 11.10 CL CL D 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 166.07 44.81 82.01 160.13 46.94 82.57 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 163.23 48.87 90.83 163.39 49.06 90.01 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 155.60 44.58 89.97 153.89 45.98 88.92 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c08 PROTEASOME user 5 4 # 5 W 1 THR B 28 THR~? 14.99 CL CL D 145 W 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 W 47 GLY B 97 GLY.? 16.18 CL CL D 145 W 129 SER B 29 SER~? 11.10 CL CL D 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 166.07 44.81 82.01 160.13 46.94 82.57 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 163.23 48.87 90.83 163.39 49.06 90.01 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 155.60 44.58 89.97 153.89 45.98 88.92 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c08 PROTEASOME user 6 4 # 6 W 1 THR C 28 THR~? 15.27 CL CL A 144 W 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 W 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 W 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 166.07 44.81 82.01 160.13 46.94 82.57 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 163.23 48.87 90.83 163.39 49.06 90.01 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 155.60 44.58 89.97 153.89 45.98 88.92 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c08 PROTEASOME user 7 4 # 7 W 1 THR C 28 THR~? 15.27 CL CL A 144 W 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 W 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 W 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 157.95 45.66 85.32 159.70 46.33 86.38 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 166.07 44.81 82.01 160.13 46.94 82.57 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 163.23 48.87 90.83 163.39 49.06 90.01 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 155.60 44.58 89.97 153.89 45.98 88.92 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c08 PROTEASOME user 8 4 # 8 W 1 THR D 28 THR~? 15.29 CL CL D 144 W 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 W 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 W 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 157.95 45.66 85.32 159.70 46.33 86.38 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 166.07 44.81 82.01 160.13 46.94 82.57 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 163.23 48.87 90.83 163.39 49.06 90.01 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 155.60 44.58 89.97 153.89 45.98 88.92 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c08 PROTEASOME user 9 4 # 9 W 1 THR D 28 THR~? 15.29 CL CL D 144 W 33 LYS D 100 LYS^? 18.85 CL CL D 145 W 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 W 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 157.95 45.66 85.32 159.70 46.33 86.38 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 166.07 44.81 82.01 160.13 46.94 82.57 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 163.23 48.87 90.83 163.39 49.06 90.01 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 155.60 44.58 89.97 153.89 45.98 88.92 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c08 source 1pma PROTEASOME : 9 hits 1pma_c08 naa= 4 ULMN 4 1pma_c09 PROTEASOME user 1 4 # 1 X 1 THR A 28 THR~? 15.27 CL CL A 144 X 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 X 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 X 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 166.53 76.03 77.46 160.69 77.43 79.50 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 163.43 71.87 86.14 163.64 72.61 85.77 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 155.48 70.66 82.49 154.03 72.56 83.11 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c09 PROTEASOME user 2 4 # 2 X 1 THR A 28 THR~? 15.27 CL CL A 144 X 33 LYS A 100 LYS^? 18.99 CL CL D 145 X 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 X 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 166.53 76.03 77.46 160.69 77.43 79.50 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 163.43 71.87 86.14 163.64 72.61 85.77 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 155.48 70.66 82.49 154.03 72.56 83.11 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c09 PROTEASOME user 3 4 # 3 X 1 THR A 107 THR~? 14.10 CL CL D 145 X 33 LYS B 77 LYS.? 21.17 CL CL D 145 X 47 GLY A 112 GLY.? 18.91 CL CL D 145 X 129 SER A 105 SER~? 6.77 CL CL D 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 166.53 76.03 77.46 160.69 77.43 79.50 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 163.43 71.87 86.14 163.64 72.61 85.77 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 155.48 70.66 82.49 154.03 72.56 83.11 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c09 PROTEASOME user 4 4 # 4 X 1 THR B 28 THR~? 14.99 CL CL D 145 X 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 X 47 GLY B 97 GLY.? 16.18 CL CL D 145 X 129 SER B 29 SER~? 11.10 CL CL D 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 166.53 76.03 77.46 160.69 77.43 79.50 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 163.43 71.87 86.14 163.64 72.61 85.77 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 155.48 70.66 82.49 154.03 72.56 83.11 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c09 PROTEASOME user 5 4 # 5 X 1 THR B 28 THR~? 14.99 CL CL D 145 X 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 X 47 GLY B 97 GLY.? 16.18 CL CL D 145 X 129 SER B 29 SER~? 11.10 CL CL D 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 166.53 76.03 77.46 160.69 77.43 79.50 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 163.43 71.87 86.14 163.64 72.61 85.77 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 155.48 70.66 82.49 154.03 72.56 83.11 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c09 PROTEASOME user 6 4 # 6 X 1 THR C 28 THR~? 15.27 CL CL A 144 X 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 X 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 X 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 166.53 76.03 77.46 160.69 77.43 79.50 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 163.43 71.87 86.14 163.64 72.61 85.77 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 155.48 70.66 82.49 154.03 72.56 83.11 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c09 PROTEASOME user 7 4 # 7 X 1 THR C 28 THR~? 15.27 CL CL A 144 X 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 X 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 X 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 158.06 74.74 80.29 159.87 74.24 81.32 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 166.53 76.03 77.46 160.69 77.43 79.50 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 163.43 71.87 86.14 163.64 72.61 85.77 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 155.48 70.66 82.49 154.03 72.56 83.11 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c09 PROTEASOME user 8 4 # 8 X 1 THR D 28 THR~? 15.29 CL CL D 144 X 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 X 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 X 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 158.06 74.74 80.29 159.87 74.24 81.32 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 166.53 76.03 77.46 160.69 77.43 79.50 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 163.43 71.87 86.14 163.64 72.61 85.77 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 155.48 70.66 82.49 154.03 72.56 83.11 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c09 PROTEASOME user 9 4 # 9 X 1 THR D 28 THR~? 15.29 CL CL D 144 X 33 LYS D 100 LYS^? 18.85 CL CL D 145 X 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 X 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 158.06 74.74 80.29 159.87 74.24 81.32 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 166.53 76.03 77.46 160.69 77.43 79.50 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 163.43 71.87 86.14 163.64 72.61 85.77 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 155.48 70.66 82.49 154.03 72.56 83.11 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c09 source 1pma PROTEASOME : 9 hits 1pma_c09 naa= 4 ULMN 4 1pma_c10 PROTEASOME user 1 4 # 1 Y 1 THR A 28 THR~? 15.27 CL CL A 144 Y 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 Y 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Y 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 169.59 99.02 98.57 163.79 98.75 101.06 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 165.73 89.82 100.87 166.04 90.54 101.24 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 157.98 92.90 97.78 156.61 93.86 99.58 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c10 PROTEASOME user 2 4 # 2 Y 1 THR A 28 THR~? 15.27 CL CL A 144 Y 33 LYS A 100 LYS^? 18.99 CL CL D 145 Y 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Y 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 169.59 99.02 98.57 163.79 98.75 101.06 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 165.73 89.82 100.87 166.04 90.54 101.24 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 157.98 92.90 97.78 156.61 93.86 99.58 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c10 PROTEASOME user 3 4 # 3 Y 1 THR A 107 THR~? 14.10 CL CL D 145 Y 33 LYS B 77 LYS.? 21.17 CL CL D 145 Y 47 GLY A 112 GLY.? 18.91 CL CL D 145 Y 129 SER A 105 SER~? 6.77 CL CL D 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 169.59 99.02 98.57 163.79 98.75 101.06 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 165.73 89.82 100.87 166.04 90.54 101.24 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 157.98 92.90 97.78 156.61 93.86 99.58 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c10 PROTEASOME user 4 4 # 4 Y 1 THR B 28 THR~? 14.99 CL CL D 145 Y 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 Y 47 GLY B 97 GLY.? 16.18 CL CL D 145 Y 129 SER B 29 SER~? 11.10 CL CL D 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 169.59 99.02 98.57 163.79 98.75 101.06 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 165.73 89.82 100.87 166.04 90.54 101.24 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 157.98 92.90 97.78 156.61 93.86 99.58 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c10 PROTEASOME user 5 4 # 5 Y 1 THR B 28 THR~? 14.99 CL CL D 145 Y 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 Y 47 GLY B 97 GLY.? 16.18 CL CL D 145 Y 129 SER B 29 SER~? 11.10 CL CL D 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 169.59 99.02 98.57 163.79 98.75 101.06 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 165.73 89.82 100.87 166.04 90.54 101.24 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 157.98 92.90 97.78 156.61 93.86 99.58 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c10 PROTEASOME user 6 4 # 6 Y 1 THR C 28 THR~? 15.27 CL CL A 144 Y 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 Y 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Y 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 169.59 99.02 98.57 163.79 98.75 101.06 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 165.73 89.82 100.87 166.04 90.54 101.24 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 157.98 92.90 97.78 156.61 93.86 99.58 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c10 PROTEASOME user 7 4 # 7 Y 1 THR C 28 THR~? 15.27 CL CL A 144 Y 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 Y 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Y 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 161.01 96.61 99.53 162.71 95.26 99.85 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 169.59 99.02 98.57 163.79 98.75 101.06 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 165.73 89.82 100.87 166.04 90.54 101.24 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 157.98 92.90 97.78 156.61 93.86 99.58 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c10 PROTEASOME user 8 4 # 8 Y 1 THR D 28 THR~? 15.29 CL CL D 144 Y 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 Y 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Y 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 161.01 96.61 99.53 162.71 95.26 99.85 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 169.59 99.02 98.57 163.79 98.75 101.06 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 165.73 89.82 100.87 166.04 90.54 101.24 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 157.98 92.90 97.78 156.61 93.86 99.58 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c10 PROTEASOME user 9 4 # 9 Y 1 THR D 28 THR~? 15.29 CL CL D 144 Y 33 LYS D 100 LYS^? 18.85 CL CL D 145 Y 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Y 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 161.01 96.61 99.53 162.71 95.26 99.85 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 169.59 99.02 98.57 163.79 98.75 101.06 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 165.73 89.82 100.87 166.04 90.54 101.24 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 157.98 92.90 97.78 156.61 93.86 99.58 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c10 source 1pma PROTEASOME : 9 hits 1pma_c10 naa= 4 ULMN 4 1pma_c11 PROTEASOME user 1 4 # 1 Z 1 THR A 28 THR~? 15.27 CL CL A 144 Z 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 Z 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Z 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 173.04 96.56 129.40 167.10 95.22 131.11 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 168.59 89.38 123.90 168.88 89.54 124.70 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 161.09 94.40 124.50 159.85 93.81 126.51 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c11 PROTEASOME user 2 4 # 2 Z 1 THR A 28 THR~? 15.27 CL CL A 144 Z 33 LYS A 100 LYS^? 18.99 CL CL D 145 Z 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 Z 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 173.04 96.56 129.40 167.10 95.22 131.11 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 168.59 89.38 123.90 168.88 89.54 124.70 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 161.09 94.40 124.50 159.85 93.81 126.51 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c11 PROTEASOME user 3 4 # 3 Z 1 THR A 107 THR~? 14.10 CL CL D 145 Z 33 LYS B 77 LYS.? 21.17 CL CL D 145 Z 47 GLY A 112 GLY.? 18.91 CL CL D 145 Z 129 SER A 105 SER~? 6.77 CL CL D 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 173.04 96.56 129.40 167.10 95.22 131.11 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 168.59 89.38 123.90 168.88 89.54 124.70 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 161.09 94.40 124.50 159.85 93.81 126.51 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c11 PROTEASOME user 4 4 # 4 Z 1 THR B 28 THR~? 14.99 CL CL D 145 Z 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 Z 47 GLY B 97 GLY.? 16.18 CL CL D 145 Z 129 SER B 29 SER~? 11.10 CL CL D 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 173.04 96.56 129.40 167.10 95.22 131.11 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 168.59 89.38 123.90 168.88 89.54 124.70 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 161.09 94.40 124.50 159.85 93.81 126.51 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c11 PROTEASOME user 5 4 # 5 Z 1 THR B 28 THR~? 14.99 CL CL D 145 Z 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 Z 47 GLY B 97 GLY.? 16.18 CL CL D 145 Z 129 SER B 29 SER~? 11.10 CL CL D 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 173.04 96.56 129.40 167.10 95.22 131.11 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 168.59 89.38 123.90 168.88 89.54 124.70 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 161.09 94.40 124.50 159.85 93.81 126.51 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c11 PROTEASOME user 6 4 # 6 Z 1 THR C 28 THR~? 15.27 CL CL A 144 Z 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 Z 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Z 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 173.04 96.56 129.40 167.10 95.22 131.11 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 168.59 89.38 123.90 168.88 89.54 124.70 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 161.09 94.40 124.50 159.85 93.81 126.51 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c11 PROTEASOME user 7 4 # 7 Z 1 THR C 28 THR~? 15.27 CL CL A 144 Z 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 Z 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 Z 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 164.44 95.20 128.49 165.90 93.95 127.46 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 173.04 96.56 129.40 167.10 95.22 131.11 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 168.59 89.38 123.90 168.88 89.54 124.70 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 161.09 94.40 124.50 159.85 93.81 126.51 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c11 PROTEASOME user 8 4 # 8 Z 1 THR D 28 THR~? 15.29 CL CL D 144 Z 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 Z 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Z 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 164.44 95.20 128.49 165.90 93.95 127.46 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 173.04 96.56 129.40 167.10 95.22 131.11 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 168.59 89.38 123.90 168.88 89.54 124.70 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 161.09 94.40 124.50 159.85 93.81 126.51 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c11 PROTEASOME user 9 4 # 9 Z 1 THR D 28 THR~? 15.29 CL CL D 144 Z 33 LYS D 100 LYS^? 18.85 CL CL D 145 Z 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 Z 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 164.44 95.20 128.49 165.90 93.95 127.46 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 173.04 96.56 129.40 167.10 95.22 131.11 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 168.59 89.38 123.90 168.88 89.54 124.70 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 161.09 94.40 124.50 159.85 93.81 126.51 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c11 source 1pma PROTEASOME : 9 hits 1pma_c11 naa= 4 ULMN 4 1pma_c12 PROTEASOME user 1 4 # 1 1 1 THR A 28 THR~? 15.27 CL CL A 144 1 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 1 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 1 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 174.42 70.53 146.91 168.32 69.05 146.87 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 169.45 70.72 138.12 169.78 70.22 138.68 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 162.75 74.36 142.49 161.13 72.65 143.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c12 PROTEASOME user 2 4 # 2 1 1 THR A 28 THR~? 15.27 CL CL A 144 1 33 LYS A 100 LYS^? 18.99 CL CL D 145 1 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 1 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 174.42 70.53 146.91 168.32 69.05 146.87 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 169.45 70.72 138.12 169.78 70.22 138.68 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 162.75 74.36 142.49 161.13 72.65 143.07 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c12 PROTEASOME user 3 4 # 3 1 1 THR A 107 THR~? 14.10 CL CL D 145 1 33 LYS B 77 LYS.? 21.17 CL CL D 145 1 47 GLY A 112 GLY.? 18.91 CL CL D 145 1 129 SER A 105 SER~? 6.77 CL CL D 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 174.42 70.53 146.91 168.32 69.05 146.87 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 169.45 70.72 138.12 169.78 70.22 138.68 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 162.75 74.36 142.49 161.13 72.65 143.07 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c12 PROTEASOME user 4 4 # 4 1 1 THR B 28 THR~? 14.99 CL CL D 145 1 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 1 47 GLY B 97 GLY.? 16.18 CL CL D 145 1 129 SER B 29 SER~? 11.10 CL CL D 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 174.42 70.53 146.91 168.32 69.05 146.87 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 169.45 70.72 138.12 169.78 70.22 138.68 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 162.75 74.36 142.49 161.13 72.65 143.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c12 PROTEASOME user 5 4 # 5 1 1 THR B 28 THR~? 14.99 CL CL D 145 1 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 1 47 GLY B 97 GLY.? 16.18 CL CL D 145 1 129 SER B 29 SER~? 11.10 CL CL D 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 174.42 70.53 146.91 168.32 69.05 146.87 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 169.45 70.72 138.12 169.78 70.22 138.68 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 162.75 74.36 142.49 161.13 72.65 143.07 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c12 PROTEASOME user 6 4 # 6 1 1 THR C 28 THR~? 15.27 CL CL A 144 1 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 1 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 1 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 174.42 70.53 146.91 168.32 69.05 146.87 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 169.45 70.72 138.12 169.78 70.22 138.68 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 162.75 74.36 142.49 161.13 72.65 143.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c12 PROTEASOME user 7 4 # 7 1 1 THR C 28 THR~? 15.27 CL CL A 144 1 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 1 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 1 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 165.64 71.38 145.38 167.12 71.04 143.87 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 174.42 70.53 146.91 168.32 69.05 146.87 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 169.45 70.72 138.12 169.78 70.22 138.68 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 162.75 74.36 142.49 161.13 72.65 143.07 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c12 PROTEASOME user 8 4 # 8 1 1 THR D 28 THR~? 15.29 CL CL D 144 1 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 1 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 1 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 165.64 71.38 145.38 167.12 71.04 143.87 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 174.42 70.53 146.91 168.32 69.05 146.87 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 169.45 70.72 138.12 169.78 70.22 138.68 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 162.75 74.36 142.49 161.13 72.65 143.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c12 PROTEASOME user 9 4 # 9 1 1 THR D 28 THR~? 15.29 CL CL D 144 1 33 LYS D 100 LYS^? 18.85 CL CL D 145 1 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 1 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 165.64 71.38 145.38 167.12 71.04 143.87 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 174.42 70.53 146.91 168.32 69.05 146.87 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 169.45 70.72 138.12 169.78 70.22 138.68 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 162.75 74.36 142.49 161.13 72.65 143.07 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c12 source 1pma PROTEASOME : 9 hits 1pma_c12 naa= 4 ULMN 4 1pma_c13 PROTEASOME user 1 4 # 1 2 1 THR A 28 THR~? 15.27 CL CL A 144 2 33 LYS A 8 LYS^? 8.24 C6 EPE A 145 2 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 2 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 172.39 40.52 137.60 166.18 40.30 136.65 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 168.22 48.11 132.44 168.40 47.27 132.39 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 161.33 47.56 138.08 159.59 46.11 137.23 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c13 PROTEASOME user 2 4 # 2 2 1 THR A 28 THR~? 15.27 CL CL A 144 2 33 LYS A 100 LYS^? 18.99 CL CL D 145 2 47 GLY A 97 GLY.? 20.25 O1S EPE A 145 2 129 SER A 29 SER~? 20.16 O1S EPE A 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 172.39 40.52 137.60 166.18 40.30 136.65 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 168.22 48.11 132.44 168.40 47.27 132.39 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo 161.33 47.56 138.08 159.59 46.11 137.23 -37.74 2.28 -16.63 -39.96 3.28 -16.58 ULMN 4 1pma_c13 PROTEASOME user 3 4 # 3 2 1 THR A 107 THR~? 14.10 CL CL D 145 2 33 LYS B 77 LYS.? 21.17 CL CL D 145 2 47 GLY A 112 GLY.? 18.91 CL CL D 145 2 129 SER A 105 SER~? 6.77 CL CL D 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 172.39 40.52 137.60 166.18 40.30 136.65 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 168.22 48.11 132.44 168.40 47.27 132.39 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo 161.33 47.56 138.08 159.59 46.11 137.23 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 ULMN 4 1pma_c13 PROTEASOME user 4 4 # 4 2 1 THR B 28 THR~? 14.99 CL CL D 145 2 33 LYS B 8 LYS^? 8.74 C3 EPE A 145 2 47 GLY B 97 GLY.? 16.18 CL CL D 145 2 129 SER B 29 SER~? 11.10 CL CL D 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 172.39 40.52 137.60 166.18 40.30 136.65 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 168.22 48.11 132.44 168.40 47.27 132.39 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 161.33 47.56 138.08 159.59 46.11 137.23 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c13 PROTEASOME user 5 4 # 5 2 1 THR B 28 THR~? 14.99 CL CL D 145 2 33 LYS B 100 LYS^? 21.03 O3S EPE A 145 2 47 GLY B 97 GLY.? 16.18 CL CL D 145 2 129 SER B 29 SER~? 11.10 CL CL D 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 172.39 40.52 137.60 166.18 40.30 136.65 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 168.22 48.11 132.44 168.40 47.27 132.39 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 161.33 47.56 138.08 159.59 46.11 137.23 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 4 1pma_c13 PROTEASOME user 6 4 # 6 2 1 THR C 28 THR~? 15.27 CL CL A 144 2 33 LYS C 8 LYS^? 8.33 O8 EPE A 145 2 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 2 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 172.39 40.52 137.60 166.18 40.30 136.65 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 168.22 48.11 132.44 168.40 47.27 132.39 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 161.33 47.56 138.08 159.59 46.11 137.23 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c13 PROTEASOME user 7 4 # 7 2 1 THR C 28 THR~? 15.27 CL CL A 144 2 33 LYS C 100 LYS^? 20.71 O2S EPE A 145 2 47 GLY C 97 GLY.? 20.31 O2S EPE A 145 2 129 SER C 29 SER~? 20.03 O2S EPE A 145 coo 163.80 43.09 137.65 165.35 44.06 136.49 -29.24 -18.71 -0.40 -31.00 -17.58 0.03 coo 172.39 40.52 137.60 166.18 40.30 136.65 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 168.22 48.11 132.44 168.40 47.27 132.39 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo 161.33 47.56 138.08 159.59 46.11 137.23 -28.39 -21.41 2.10 -28.58 -23.61 3.07 ULMN 4 1pma_c13 PROTEASOME user 8 4 # 8 2 1 THR D 28 THR~? 15.29 CL CL D 144 2 33 LYS D 8 LYS^? 8.17 O8 EPE D 146 2 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 2 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 163.80 43.09 137.65 165.35 44.06 136.49 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 172.39 40.52 137.60 166.18 40.30 136.65 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 168.22 48.11 132.44 168.40 47.27 132.39 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 161.33 47.56 138.08 159.59 46.11 137.23 8.08 -16.49 -34.93 9.82 -17.78 -36.00 ULMN 4 1pma_c13 PROTEASOME user 9 4 # 9 2 1 THR D 28 THR~? 15.29 CL CL D 144 2 33 LYS D 100 LYS^? 18.85 CL CL D 145 2 47 GLY D 97 GLY.? 19.88 O8 EPE D 146 2 129 SER D 29 SER~? 20.03 O3S EPE D 146 coo 163.80 43.09 137.65 165.35 44.06 136.49 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 172.39 40.52 137.60 166.18 40.30 136.65 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 168.22 48.11 132.44 168.40 47.27 132.39 4.73 -20.88 -28.20 4.26 -21.26 -28.73 coo 161.33 47.56 138.08 159.59 46.11 137.23 8.08 -16.49 -34.93 9.82 -17.78 -36.00 1pma_c13 source 1pma PROTEASOME : 9 hits 1pma_c13 naa= 4 ULMN 4 1rne_c05 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 1 4 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 75 TYR B 36 TYR.? 11.13 O3S EPE A 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 11.85 17.24 72.81 11.09 15.37 72.36 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.20 12.71 75.45 13.69 13.84 74.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 15.08 11.29 68.68 16.45 12.70 70.65 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 5.22 15.03 71.43 7.19 14.88 70.83 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1rne_c05 source 1rne RENIN (ACTIVATED, GLYCOSYLATED, INHIBITED) (E.: 1 hits 1rne_c05 naa= 4 ULMN 4 1sme_c00 PLASMEPSIN II user 1 4 # 1 A 34 ASP D 133 ASP~? 7.85 CL CL D 145 A 37 SER B 34 SER~? 6.65 CL CL D 145 A 214 ASP A 133 ASP~? 7.97 CL CL D 145 A 217 THR A 130 THR~? 5.01 CL CL D 145 coo 51.75 60.57 19.10 52.05 60.90 21.19 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 51.10 65.11 20.73 52.62 63.74 19.42 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 48.59 58.89 25.78 50.13 59.74 24.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 52.57 55.68 25.62 52.26 56.53 27.63 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1sme_c00 source 1sme PLASMEPSIN II : 1 hits 1sme_c00 naa= 4 ULMN 4 1sme_c01 PLASMEPSIN II user 1 4 # 1 B 34 ASP D 133 ASP~? 7.85 CL CL D 145 B 37 SER B 34 SER~? 6.65 CL CL D 145 B 214 ASP A 133 ASP~? 7.97 CL CL D 145 B 217 THR A 130 THR~? 5.01 CL CL D 145 coo 17.69 97.58 52.73 17.33 97.19 54.77 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 20.67 100.44 55.84 20.21 98.51 54.45 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 12.41 98.71 58.47 14.37 98.17 58.05 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.08 94.10 57.29 12.50 94.74 59.28 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1sme_c01 source 1sme PLASMEPSIN II : 1 hits 1sme_c01 naa= 4 ULMN 4 1sme_c06 PLASMEPSIN II user 1 4 # 1 A 34 ASP D 133 ASP~? 7.85 CL CL D 145 A 37 SER B 34 SER~? 6.65 CL CL D 145 A 77 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 214 ASP A 133 ASP~? 7.97 CL CL D 145 coo 51.75 60.57 19.10 52.05 60.90 21.19 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 51.10 65.11 20.73 52.62 63.74 19.42 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 58.03 63.52 22.21 57.19 63.97 19.60 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 48.59 58.89 25.78 50.13 59.74 24.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1sme_c06 source 1sme PLASMEPSIN II : 1 hits 1sme_c06 naa= 4 ULMN 4 1sme_c07 PLASMEPSIN II user 1 4 # 1 B 34 ASP D 133 ASP~? 7.85 CL CL D 145 B 37 SER B 34 SER~? 6.65 CL CL D 145 B 77 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 214 ASP A 133 ASP~? 7.97 CL CL D 145 coo 17.69 97.58 52.73 17.33 97.19 54.77 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 20.67 100.44 55.84 20.21 98.51 54.45 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 21.97 93.33 56.91 23.11 94.24 54.54 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 12.41 98.71 58.47 14.37 98.17 58.05 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1sme_c07 source 1sme PLASMEPSIN II : 1 hits 1sme_c07 naa= 4 ULMN 4 2apr_c02 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 1 4 # 1 35 ASP D 133 ASP~? 7.85 CL CL D 145 38 SER B 34 SER~? 6.65 CL CL D 145 218 ASP A 133 ASP~? 7.97 CL CL D 145 221 THR A 130 THR~? 5.01 CL CL D 145 coo 41.14 58.72 105.19 42.39 59.85 103.92 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 46.04 57.35 103.96 44.97 58.52 105.78 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 41.33 60.20 97.63 42.00 60.96 99.49 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 39.43 64.47 99.56 41.07 64.93 98.18 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 2apr_c02 source 2apr ACID PROTEINASE (RHIZOPUSPEPSIN) (E.C.3.4.23.6: 1 hits 2apr_c02 naa= 4 ULMN 4 2apr_c05 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 1 4 # 1 35 ASP D 133 ASP~? 7.85 CL CL D 145 38 SER B 34 SER~? 6.65 CL CL D 145 77 TYR B 36 TYR.? 11.13 O3S EPE A 145 218 ASP A 133 ASP~? 7.97 CL CL D 145 coo 41.14 58.72 105.19 42.39 59.85 103.92 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 46.04 57.35 103.96 44.97 58.52 105.78 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 47.21 64.36 106.26 46.67 62.33 108.12 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 41.33 60.20 97.63 42.00 60.96 99.49 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 2apr_c05 source 2apr ACID PROTEINASE (RHIZOPUSPEPSIN) (E.C.3.4.23.6: 1 hits 2apr_c05 naa= 4 ULMN 4 2jxr_c02 LIGAND CP-081282 user 1 4 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 215 ASP A 133 ASP~? 7.97 CL CL D 145 A 218 THR A 130 THR~? 5.01 CL CL D 145 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -15.15 62.13 36.13 -14.92 64.23 35.68 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 2jxr_c02 source 2jxr LIGAND CP-081282 : 1 hits 2jxr_c02 naa= 4 ULMN 4 2jxr_c05 LIGAND CP-081282 user 1 4 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 75 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -20.05 66.65 43.47 -19.36 65.65 45.97 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 2jxr_c05 source 2jxr LIGAND CP-081282 : 1 hits 2jxr_c05 naa= 4 ULMN 3 12as_c00 ASPARAGINE SYNTHETASE user 1 3 # 1 A 46 ASP B 117 ASP~? 29.07 CL CL A 144 A 100 ARG B 53 ARG~? 32.64 CL CL A 144 A 116 GLN B 48 GLN~? 22.63 CL CL A 144 coo 32.24 20.09 5.34 30.38 19.04 5.27 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo 26.40 25.34 6.28 26.15 22.33 7.25 -27.69 -43.43 -19.78 -28.54 -45.56 -21.87 coo 26.74 21.94 13.78 27.57 20.97 12.08 -30.94 -34.83 -17.34 -30.84 -36.26 -15.73 ULMN 3 12as_c00 ASPARAGINE SYNTHETASE user 2 3 # 2 A 46 ASP D 124 ASP^? 11.01 CL CL D 145 A 100 ARG D 115 ARG~? 12.45 CL CL D 145 A 116 GLN B 92 GLN.? 16.90 CL CL D 145 coo 32.24 20.09 5.34 30.38 19.04 5.27 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 26.40 25.34 6.28 26.15 22.33 7.25 -16.99 -21.67 -39.03 -18.83 -20.42 -36.87 coo 26.74 21.94 13.78 27.57 20.97 12.08 -14.29 -26.44 -30.92 -15.44 -25.87 -32.67 12as_c00 source 12as ASPARAGINE SYNTHETASE : 2 hits 12as_c00 naa= 3 ULMN 3 12as_c01 ASPARAGINE SYNTHETASE user 1 3 # 1 B 46 ASP B 117 ASP~? 29.07 CL CL A 144 B 100 ARG B 53 ARG~? 32.64 CL CL A 144 B 116 GLN B 48 GLN~? 22.63 CL CL A 144 coo 32.18 48.37 12.48 33.96 49.46 12.97 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo 39.04 43.25 11.37 38.30 45.35 13.56 -27.69 -43.43 -19.78 -28.54 -45.56 -21.87 coo 37.43 42.63 19.41 36.76 44.08 17.97 -30.94 -34.83 -17.34 -30.84 -36.26 -15.73 12as_c01 source 12as ASPARAGINE SYNTHETASE : 1 hits 12as_c01 naa= 3 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 1 3 # 1 A 140 TYR B 67 TYR~? 16.82 CL CL A 144 B 190 LYS A 65 LYS~? 24.48 CL CL A 144 B 222 ASP A 19 ASP~? 15.97 CL CL A 144 coo 7.17 16.59 41.26 8.01 19.20 40.73 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 13.38 20.00 35.06 11.43 22.49 39.53 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 9.76 26.58 38.10 11.63 25.78 38.76 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 ULMN 3 1a05_c00 3-ISOPROPYLMALATE DEHYDROGENASE user 2 3 # 2 A 140 TYR C 67 TYR~? 16.92 CL CL A 144 B 190 LYS B 65 LYS~? 24.78 CL CL A 144 B 222 ASP B 19 ASP~? 15.75 CL CL A 144 coo 7.17 16.59 41.26 8.01 19.20 40.73 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo 13.38 20.00 35.06 11.43 22.49 39.53 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 9.76 26.58 38.10 11.63 25.78 38.76 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 1a05_c00 source 1a05 3-ISOPROPYLMALATE DEHYDROGENASE : 2 hits 1a05_c00 naa= 3 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 1 3 # 1 A 190 LYS A 65 LYS~? 24.48 CL CL A 144 A 222 ASP A 19 ASP~? 15.97 CL CL A 144 B 140 TYR B 67 TYR~? 16.82 CL CL A 144 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 1.51 16.60 24.17 0.82 19.23 24.79 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1a05_c01 3-ISOPROPYLMALATE DEHYDROGENASE user 2 3 # 2 A 190 LYS B 65 LYS~? 24.78 CL CL A 144 A 222 ASP B 19 ASP~? 15.75 CL CL A 144 B 140 TYR C 67 TYR~? 16.92 CL CL A 144 coo -4.61 20.12 30.34 -2.74 22.65 25.95 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -1.04 26.60 27.37 -2.94 25.93 26.69 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 1.51 16.60 24.17 0.82 19.23 24.79 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 1a05_c01 source 1a05 3-ISOPROPYLMALATE DEHYDROGENASE : 2 hits 1a05_c01 naa= 3 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 1 3 # 1 A 49 GLU A 68 GLU~? 25.44 CL CL A 144 A 60 ASP B 64 ASP~? 15.96 CL CL A 144 A 175 TYR A 67 TYR~? 16.80 CL CL A 144 coo 46.10 28.27 19.27 45.48 26.99 20.84 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 56.42 28.06 12.93 55.01 27.92 14.50 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 45.02 22.04 15.38 46.16 24.00 13.76 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 2 3 # 2 A 49 GLU B 68 GLU~? 25.19 CL CL A 144 A 60 ASP C 64 ASP~? 15.91 CL CL A 144 A 175 TYR B 67 TYR~? 16.82 CL CL A 144 coo 46.10 28.27 19.27 45.48 26.99 20.84 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 56.42 28.06 12.93 55.01 27.92 14.50 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 45.02 22.04 15.38 46.16 24.00 13.76 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1a50_c03 TRYPTOPHAN SYNTHASE user 3 3 # 3 A 49 GLU C 68 GLU~? 25.33 CL CL A 144 A 60 ASP A 64 ASP~? 16.08 CL CL A 144 A 175 TYR C 67 TYR~? 16.92 CL CL A 144 coo 46.10 28.27 19.27 45.48 26.99 20.84 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 56.42 28.06 12.93 55.01 27.92 14.50 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 45.02 22.04 15.38 46.16 24.00 13.76 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 1a50_c03 source 1a50 TRYPTOPHAN SYNTHASE : 3 hits 1a50_c03 naa= 3 ULMN 3 1akd_c01 CYTOCHROME P450CAM user 1 3 # 1 252 THR C 130 THR~? 17.24 O1S EPE A 145 350 PHE C 41 PHE^? 13.95 CL CL A 144 357 CYH C 104 CYH^? 16.50 CL CL A 144 coo 17.85 20.47 14.62 16.85 19.84 12.80 -33.96 0.15 -4.28 -35.19 0.92 -2.69 coo 7.92 21.96 13.27 8.57 20.30 15.42 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 8.82 20.77 7.90 10.59 19.75 9.80 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 1akd_c01 source 1akd CYTOCHROME P450CAM : 1 hits 1akd_c01 naa= 3 ULMN 3 1ald_c00 ALDOLASE A (E.C.4.1.2.13) user 1 3 # 1 33 ASP A 133 ASP~? 7.97 CL CL D 145 187 GLU A 37 GLU^? 12.50 C6 EPE A 145 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -52.57 56.60 47.75 -51.52 54.87 46.95 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -45.08 48.37 46.81 -46.53 49.74 45.96 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo -47.40 44.36 48.48 -50.80 49.18 46.20 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1ald_c00 ALDOLASE A (E.C.4.1.2.13) user 2 3 # 2 33 ASP B 133 ASP~? 13.85 C2 EPE A 145 187 GLU B 37 GLU^? 13.18 C3 EPE A 145 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -52.57 56.60 47.75 -51.52 54.87 46.95 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -45.08 48.37 46.81 -46.53 49.74 45.96 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo -47.40 44.36 48.48 -50.80 49.18 46.20 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ald_c00 ALDOLASE A (E.C.4.1.2.13) user 3 3 # 3 33 ASP C 133 ASP~? 13.97 O1S EPE A 145 187 GLU C 37 GLU^? 12.70 O8 EPE A 145 229 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -52.57 56.60 47.75 -51.52 54.87 46.95 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -45.08 48.37 46.81 -46.53 49.74 45.96 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo -47.40 44.36 48.48 -50.80 49.18 46.20 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ald_c00 ALDOLASE A (E.C.4.1.2.13) user 4 3 # 4 33 ASP D 133 ASP~? 7.85 CL CL D 145 187 GLU D 37 GLU^? 11.78 O8 EPE D 146 229 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -52.57 56.60 47.75 -51.52 54.87 46.95 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -45.08 48.37 46.81 -46.53 49.74 45.96 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo -47.40 44.36 48.48 -50.80 49.18 46.20 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1ald_c00 source 1ald ALDOLASE A (E.C.4.1.2.13) : 4 hits 1ald_c00 naa= 3 ULMN 3 1am5_c04 PEPSIN user 1 3 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo -7.18 8.92 145.10 -8.77 8.81 143.59 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -12.30 10.35 145.24 -10.75 8.55 145.88 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -8.20 12.64 138.30 -8.86 10.97 139.38 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1am5_c04 source 1am5 PEPSIN : 1 hits 1am5_c04 naa= 3 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 1 3 # 1 179 ASP A 64 ASP~? 16.08 CL CL A 144 214 ASP B 117 ASP~? 29.07 CL CL A 144 289 ASP B 64 ASP~? 15.96 CL CL A 144 coo -0.62 65.95 29.97 0.31 67.47 31.05 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 26.86 59.76 46.36 25.42 58.23 45.92 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 2 3 # 2 179 ASP B 64 ASP~? 15.96 CL CL A 144 214 ASP C 117 ASP~? 29.23 CL CL A 144 289 ASP C 64 ASP~? 15.91 CL CL A 144 coo -0.62 65.95 29.97 0.31 67.47 31.05 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 26.86 59.76 46.36 25.42 58.23 45.92 -51.47 -11.37 0.99 -53.36 -10.39 1.01 coo 9.42 68.07 30.27 7.35 68.27 30.10 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 3 3 # 3 179 ASP C 64 ASP~? 15.91 CL CL A 144 214 ASP A 117 ASP~? 21.56 CL CL D 145 289 ASP A 64 ASP~? 16.08 CL CL A 144 coo -0.62 65.95 29.97 0.31 67.47 31.05 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 26.86 59.76 46.36 25.42 58.23 45.92 -36.85 -7.00 -40.01 -36.64 -7.71 -42.00 coo 9.42 68.07 30.27 7.35 68.27 30.10 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1amy_c01 ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE user 4 3 # 4 179 ASP C 64 ASP~? 15.91 CL CL A 144 214 ASP A 124 ASP^? 10.83 CL CL D 145 289 ASP B 64 ASP~? 15.96 CL CL A 144 coo -0.62 65.95 29.97 0.31 67.47 31.05 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 26.86 59.76 46.36 25.42 58.23 45.92 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 9.42 68.07 30.27 7.35 68.27 30.10 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 1amy_c01 source 1amy ALPHA-1,4 GLYCAN-4-GLUCANOHYDROLASE (ALPHA-AMY: 4 hits 1amy_c01 naa= 3 ULMN 3 1apt_c04 ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET user 1 3 # 1 E 33 ASP D 133 ASP~? 7.85 CL CL D 145 E 36 SER B 34 SER~? 6.65 CL CL D 145 E 213 ASP A 133 ASP~? 7.97 CL CL D 145 coo 26.30 12.96 16.78 25.46 12.99 18.72 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 28.33 15.15 21.27 28.70 13.12 19.97 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 20.15 16.04 19.79 21.65 14.49 19.86 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1apt_c04 source 1apt ISOVALERYL (IVA)-VAL-VAL-LYSTA-O-ET (LYSTA IS : 1 hits 1apt_c04 naa= 3 ULMN 3 1avf_c04 GASTRICSIN user 1 3 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 217 ASP A 133 ASP~? 7.97 CL CL D 145 coo -10.06 2.54 49.69 -8.83 3.73 50.96 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -11.96 5.74 52.90 -10.55 6.74 51.22 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -5.22 1.43 56.08 -5.36 2.84 54.49 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1avf_c04 source 1avf GASTRICSIN : 1 hits 1avf_c04 naa= 3 ULMN 3 1avf_c05 GASTRICSIN user 1 3 # 1 J 32 ASP D 133 ASP~? 7.85 CL CL D 145 J 35 SER B 34 SER~? 6.65 CL CL D 145 J 217 ASP A 133 ASP~? 7.97 CL CL D 145 coo -37.57 -17.54 20.53 -38.55 -18.66 19.00 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -40.93 -20.91 21.81 -38.85 -21.36 20.65 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -43.00 -16.46 14.92 -41.37 -17.71 15.28 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1avf_c05 source 1avf GASTRICSIN : 1 hits 1avf_c05 naa= 3 ULMN 3 1ax4_c04 TRYPTOPHANASE user 1 3 # 1 A 130 PHE A 41 PHE^? 11.09 CL CL D 145 A 223 ASP A 133 ASP~? 7.97 CL CL D 145 A 265 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 39.74 52.86 65.74 41.15 55.14 66.52 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 30.70 47.50 67.53 29.83 49.47 67.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 19.99 54.53 64.11 20.55 58.78 68.33 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1ax4_c04 TRYPTOPHANASE user 2 3 # 2 A 130 PHE A 44 PHE~? 15.48 CL CL A 144 A 223 ASP B 64 ASP~? 15.96 CL CL A 144 A 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 30.70 47.50 67.53 29.83 49.47 67.39 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 19.99 54.53 64.11 20.55 58.78 68.33 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c04 TRYPTOPHANASE user 3 3 # 3 A 130 PHE A 102 PHE^? 11.63 CL CL D 145 A 223 ASP A 133 ASP~? 7.97 CL CL D 145 A 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 30.70 47.50 67.53 29.83 49.47 67.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 19.99 54.53 64.11 20.55 58.78 68.33 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c04 TRYPTOPHANASE user 4 3 # 4 A 130 PHE A 110 PHE~? 14.69 CL CL D 145 A 223 ASP B 19 ASP~? 15.75 CL CL A 144 A 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -29.27 -18.72 -35.30 -26.96 -19.68 -34.02 coo 30.70 47.50 67.53 29.83 49.47 67.39 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c04 TRYPTOPHANASE user 5 3 # 5 A 130 PHE A 111 PHE~? 19.07 CL CL D 145 A 223 ASP B 19 ASP~? 15.75 CL CL A 144 A 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo 30.70 47.50 67.53 29.83 49.47 67.39 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c04 TRYPTOPHANASE user 6 3 # 6 A 130 PHE A 111 PHE~? 19.07 CL CL D 145 A 223 ASP B 19 ASP~? 15.75 CL CL A 144 A 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo 30.70 47.50 67.53 29.83 49.47 67.39 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c04 TRYPTOPHANASE user 7 3 # 7 A 130 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 223 ASP A 124 ASP^? 10.83 CL CL D 145 A 265 LYS A 94 LYS.? 20.29 CL CL D 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 30.70 47.50 67.53 29.83 49.47 67.39 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 19.99 54.53 64.11 20.55 58.78 68.33 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1ax4_c04 TRYPTOPHANASE user 8 3 # 8 A 130 PHE A 142 PHE^? -6.60 CL CL A 144s A 223 ASP B 19 ASP~? 15.75 CL CL A 144 A 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo 30.70 47.50 67.53 29.83 49.47 67.39 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c04 TRYPTOPHANASE user 9 3 # 9 A 130 PHE B 44 PHE~? 15.63 CL CL A 144 A 223 ASP C 64 ASP~? 15.91 CL CL A 144 A 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 30.70 47.50 67.53 29.83 49.47 67.39 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 19.99 54.53 64.11 20.55 58.78 68.33 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c04 TRYPTOPHANASE user 10 3 # 10 A 130 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 223 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 265 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 30.70 47.50 67.53 29.83 49.47 67.39 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ax4_c04 TRYPTOPHANASE user 11 3 # 11 A 130 PHE B 110 PHE~? 21.03 CL CL A 144 A 223 ASP C 19 ASP~? 15.67 CL CL A 144 A 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 coo 30.70 47.50 67.53 29.83 49.47 67.39 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c04 TRYPTOPHANASE user 12 3 # 12 A 130 PHE B 111 PHE~? 20.82 CL CL A 144 A 223 ASP C 19 ASP~? 15.67 CL CL A 144 A 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo 30.70 47.50 67.53 29.83 49.47 67.39 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c04 TRYPTOPHANASE user 13 3 # 13 A 130 PHE B 111 PHE~? 20.82 CL CL A 144 A 223 ASP C 19 ASP~? 15.67 CL CL A 144 A 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo 30.70 47.50 67.53 29.83 49.47 67.39 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c04 TRYPTOPHANASE user 14 3 # 14 A 130 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 223 ASP B 124 ASP^? 22.45 O2S EPE A 145 A 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 30.70 47.50 67.53 29.83 49.47 67.39 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 19.99 54.53 64.11 20.55 58.78 68.33 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c04 TRYPTOPHANASE user 15 3 # 15 A 130 PHE B 142 PHE^? -6.58 CL CL A 144s A 223 ASP C 19 ASP~? 15.67 CL CL A 144 A 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 30.70 47.50 67.53 29.83 49.47 67.39 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c04 TRYPTOPHANASE user 16 3 # 16 A 130 PHE B 142 PHE^? -6.58 CL CL A 144s A 223 ASP C 19 ASP~? 15.67 CL CL A 144 A 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 30.70 47.50 67.53 29.83 49.47 67.39 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 19.99 54.53 64.11 20.55 58.78 68.33 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c04 TRYPTOPHANASE user 17 3 # 17 A 130 PHE C 41 PHE^? 13.95 CL CL A 144 A 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 265 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 30.70 47.50 67.53 29.83 49.47 67.39 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 19.99 54.53 64.11 20.55 58.78 68.33 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1ax4_c04 TRYPTOPHANASE user 18 3 # 18 A 130 PHE C 44 PHE~? 15.66 CL CL A 144 A 223 ASP A 64 ASP~? 16.08 CL CL A 144 A 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 30.70 47.50 67.53 29.83 49.47 67.39 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 19.99 54.53 64.11 20.55 58.78 68.33 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c04 TRYPTOPHANASE user 19 3 # 19 A 130 PHE C 110 PHE~? 21.09 CL CL A 144 A 223 ASP A 19 ASP~? 15.97 CL CL A 144 A 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -48.65 -5.68 -12.24 -47.16 -3.89 -13.77 coo 30.70 47.50 67.53 29.83 49.47 67.39 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 19.99 54.53 64.11 20.55 58.78 68.33 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c04 TRYPTOPHANASE user 20 3 # 20 A 130 PHE C 111 PHE~? 21.07 CL CL A 144 A 223 ASP A 19 ASP~? 15.97 CL CL A 144 A 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -50.06 -10.80 -9.50 -48.81 -11.85 -11.73 coo 30.70 47.50 67.53 29.83 49.47 67.39 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 19.99 54.53 64.11 20.55 58.78 68.33 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c04 TRYPTOPHANASE user 21 3 # 21 A 130 PHE C 142 PHE^? -6.66 CL CL A 144s A 223 ASP A 19 ASP~? 15.97 CL CL A 144 A 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 39.74 52.86 65.74 41.15 55.14 66.52 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo 30.70 47.50 67.53 29.83 49.47 67.39 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 19.99 54.53 64.11 20.55 58.78 68.33 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c04 TRYPTOPHANASE user 22 3 # 22 A 130 PHE D 41 PHE^? 10.83 CL CL D 145 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c04 TRYPTOPHANASE user 23 3 # 23 A 130 PHE D 42 PHE^? 15.36 CL CL D 144 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c04 TRYPTOPHANASE user 24 3 # 24 A 130 PHE D 111 PHE~? 18.80 CL CL D 145 A 223 ASP D 117 ASP~? 21.71 CL CL D 145 A 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -13.55 -11.13 -49.68 -12.29 -8.64 -49.81 coo 30.70 47.50 67.53 29.83 49.47 67.39 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo 19.99 54.53 64.11 20.55 58.78 68.33 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c04 TRYPTOPHANASE user 25 3 # 25 A 130 PHE D 121 PHE.? 21.38 CL CL D 145 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c04 TRYPTOPHANASE user 26 3 # 26 A 130 PHE D 121 PHE.? 21.38 CL CL D 145 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c04 TRYPTOPHANASE user 27 3 # 27 A 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 223 ASP A 133 ASP~? 7.97 CL CL D 145 A 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 30.70 47.50 67.53 29.83 49.47 67.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 19.99 54.53 64.11 20.55 58.78 68.33 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c04 TRYPTOPHANASE user 28 3 # 28 A 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c04 TRYPTOPHANASE user 29 3 # 29 A 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 223 ASP D 124 ASP^? 11.01 CL CL D 145 A 265 LYS D 94 LYS.? 20.13 CL CL D 145 coo 39.74 52.86 65.74 41.15 55.14 66.52 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 30.70 47.50 67.53 29.83 49.47 67.39 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 19.99 54.53 64.11 20.55 58.78 68.33 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1ax4_c04 source 1ax4 TRYPTOPHANASE : 29 hits 1ax4_c04 naa= 3 ULMN 3 1ax4_c05 TRYPTOPHANASE user 1 3 # 1 B 130 PHE A 41 PHE^? 11.09 CL CL D 145 B 223 ASP A 133 ASP~? 7.97 CL CL D 145 B 265 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 7.48 54.94 99.62 7.67 52.27 100.42 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 10.43 61.66 91.81 9.80 60.04 90.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 5.43 58.06 80.08 8.57 53.00 79.37 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1ax4_c05 TRYPTOPHANASE user 2 3 # 2 B 130 PHE A 44 PHE~? 15.48 CL CL A 144 B 223 ASP B 64 ASP~? 15.96 CL CL A 144 B 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 10.43 61.66 91.81 9.80 60.04 90.61 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 5.43 58.06 80.08 8.57 53.00 79.37 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c05 TRYPTOPHANASE user 3 3 # 3 B 130 PHE A 102 PHE^? 11.63 CL CL D 145 B 223 ASP A 133 ASP~? 7.97 CL CL D 145 B 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 10.43 61.66 91.81 9.80 60.04 90.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 5.43 58.06 80.08 8.57 53.00 79.37 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c05 TRYPTOPHANASE user 4 3 # 4 B 130 PHE A 110 PHE~? 14.69 CL CL D 145 B 223 ASP B 19 ASP~? 15.75 CL CL A 144 B 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -29.27 -18.72 -35.30 -26.96 -19.68 -34.02 coo 10.43 61.66 91.81 9.80 60.04 90.61 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c05 TRYPTOPHANASE user 5 3 # 5 B 130 PHE A 111 PHE~? 19.07 CL CL D 145 B 223 ASP B 19 ASP~? 15.75 CL CL A 144 B 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo 10.43 61.66 91.81 9.80 60.04 90.61 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c05 TRYPTOPHANASE user 6 3 # 6 B 130 PHE A 111 PHE~? 19.07 CL CL D 145 B 223 ASP B 19 ASP~? 15.75 CL CL A 144 B 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo 10.43 61.66 91.81 9.80 60.04 90.61 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c05 TRYPTOPHANASE user 7 3 # 7 B 130 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 223 ASP A 124 ASP^? 10.83 CL CL D 145 B 265 LYS A 94 LYS.? 20.29 CL CL D 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 10.43 61.66 91.81 9.80 60.04 90.61 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 5.43 58.06 80.08 8.57 53.00 79.37 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1ax4_c05 TRYPTOPHANASE user 8 3 # 8 B 130 PHE A 142 PHE^? -6.60 CL CL A 144s B 223 ASP B 19 ASP~? 15.75 CL CL A 144 B 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo 10.43 61.66 91.81 9.80 60.04 90.61 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c05 TRYPTOPHANASE user 9 3 # 9 B 130 PHE B 44 PHE~? 15.63 CL CL A 144 B 223 ASP C 64 ASP~? 15.91 CL CL A 144 B 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 10.43 61.66 91.81 9.80 60.04 90.61 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 5.43 58.06 80.08 8.57 53.00 79.37 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c05 TRYPTOPHANASE user 10 3 # 10 B 130 PHE B 102 PHE^? 16.45 O2S EPE A 145 B 223 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 265 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 10.43 61.66 91.81 9.80 60.04 90.61 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ax4_c05 TRYPTOPHANASE user 11 3 # 11 B 130 PHE B 110 PHE~? 21.03 CL CL A 144 B 223 ASP C 19 ASP~? 15.67 CL CL A 144 B 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 coo 10.43 61.66 91.81 9.80 60.04 90.61 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c05 TRYPTOPHANASE user 12 3 # 12 B 130 PHE B 111 PHE~? 20.82 CL CL A 144 B 223 ASP C 19 ASP~? 15.67 CL CL A 144 B 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo 10.43 61.66 91.81 9.80 60.04 90.61 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c05 TRYPTOPHANASE user 13 3 # 13 B 130 PHE B 111 PHE~? 20.82 CL CL A 144 B 223 ASP C 19 ASP~? 15.67 CL CL A 144 B 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo 10.43 61.66 91.81 9.80 60.04 90.61 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c05 TRYPTOPHANASE user 14 3 # 14 B 130 PHE B 131 PHE~? 9.25 O2S EPE A 145 B 223 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 10.43 61.66 91.81 9.80 60.04 90.61 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 5.43 58.06 80.08 8.57 53.00 79.37 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c05 TRYPTOPHANASE user 15 3 # 15 B 130 PHE B 142 PHE^? -6.58 CL CL A 144s B 223 ASP C 19 ASP~? 15.67 CL CL A 144 B 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 10.43 61.66 91.81 9.80 60.04 90.61 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c05 TRYPTOPHANASE user 16 3 # 16 B 130 PHE B 142 PHE^? -6.58 CL CL A 144s B 223 ASP C 19 ASP~? 15.67 CL CL A 144 B 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 10.43 61.66 91.81 9.80 60.04 90.61 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 5.43 58.06 80.08 8.57 53.00 79.37 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c05 TRYPTOPHANASE user 17 3 # 17 B 130 PHE C 41 PHE^? 13.95 CL CL A 144 B 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 265 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 10.43 61.66 91.81 9.80 60.04 90.61 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 5.43 58.06 80.08 8.57 53.00 79.37 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1ax4_c05 TRYPTOPHANASE user 18 3 # 18 B 130 PHE C 44 PHE~? 15.66 CL CL A 144 B 223 ASP A 64 ASP~? 16.08 CL CL A 144 B 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 10.43 61.66 91.81 9.80 60.04 90.61 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 5.43 58.06 80.08 8.57 53.00 79.37 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c05 TRYPTOPHANASE user 19 3 # 19 B 130 PHE C 110 PHE~? 21.09 CL CL A 144 B 223 ASP A 19 ASP~? 15.97 CL CL A 144 B 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -48.65 -5.68 -12.24 -47.16 -3.89 -13.77 coo 10.43 61.66 91.81 9.80 60.04 90.61 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 5.43 58.06 80.08 8.57 53.00 79.37 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c05 TRYPTOPHANASE user 20 3 # 20 B 130 PHE C 111 PHE~? 21.07 CL CL A 144 B 223 ASP A 19 ASP~? 15.97 CL CL A 144 B 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -50.06 -10.80 -9.50 -48.81 -11.85 -11.73 coo 10.43 61.66 91.81 9.80 60.04 90.61 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 5.43 58.06 80.08 8.57 53.00 79.37 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c05 TRYPTOPHANASE user 21 3 # 21 B 130 PHE C 142 PHE^? -6.66 CL CL A 144s B 223 ASP A 19 ASP~? 15.97 CL CL A 144 B 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo 7.48 54.94 99.62 7.67 52.27 100.42 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo 10.43 61.66 91.81 9.80 60.04 90.61 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 5.43 58.06 80.08 8.57 53.00 79.37 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c05 TRYPTOPHANASE user 22 3 # 22 B 130 PHE D 41 PHE^? 10.83 CL CL D 145 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c05 TRYPTOPHANASE user 23 3 # 23 B 130 PHE D 42 PHE^? 15.36 CL CL D 144 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c05 TRYPTOPHANASE user 24 3 # 24 B 130 PHE D 111 PHE~? 18.80 CL CL D 145 B 223 ASP D 117 ASP~? 21.71 CL CL D 145 B 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -13.55 -11.13 -49.68 -12.29 -8.64 -49.81 coo 10.43 61.66 91.81 9.80 60.04 90.61 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo 5.43 58.06 80.08 8.57 53.00 79.37 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c05 TRYPTOPHANASE user 25 3 # 25 B 130 PHE D 121 PHE.? 21.38 CL CL D 145 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c05 TRYPTOPHANASE user 26 3 # 26 B 130 PHE D 121 PHE.? 21.38 CL CL D 145 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c05 TRYPTOPHANASE user 27 3 # 27 B 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 223 ASP A 133 ASP~? 7.97 CL CL D 145 B 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 10.43 61.66 91.81 9.80 60.04 90.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 5.43 58.06 80.08 8.57 53.00 79.37 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c05 TRYPTOPHANASE user 28 3 # 28 B 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c05 TRYPTOPHANASE user 29 3 # 29 B 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 223 ASP D 124 ASP^? 11.01 CL CL D 145 B 265 LYS D 94 LYS.? 20.13 CL CL D 145 coo 7.48 54.94 99.62 7.67 52.27 100.42 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 10.43 61.66 91.81 9.80 60.04 90.61 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 5.43 58.06 80.08 8.57 53.00 79.37 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1ax4_c05 source 1ax4 TRYPTOPHANASE : 29 hits 1ax4_c05 naa= 3 ULMN 3 1ax4_c06 TRYPTOPHANASE user 1 3 # 1 C 130 PHE A 41 PHE^? 11.09 CL CL D 145 C 223 ASP A 133 ASP~? 7.97 CL CL D 145 C 265 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1ax4_c06 TRYPTOPHANASE user 2 3 # 2 C 130 PHE A 44 PHE~? 15.48 CL CL A 144 C 223 ASP B 64 ASP~? 15.96 CL CL A 144 C 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c06 TRYPTOPHANASE user 3 3 # 3 C 130 PHE A 102 PHE^? 11.63 CL CL D 145 C 223 ASP A 133 ASP~? 7.97 CL CL D 145 C 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c06 TRYPTOPHANASE user 4 3 # 4 C 130 PHE A 110 PHE~? 14.69 CL CL D 145 C 223 ASP B 19 ASP~? 15.75 CL CL A 144 C 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -29.27 -18.72 -35.30 -26.96 -19.68 -34.02 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c06 TRYPTOPHANASE user 5 3 # 5 C 130 PHE A 111 PHE~? 19.07 CL CL D 145 C 223 ASP B 19 ASP~? 15.75 CL CL A 144 C 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c06 TRYPTOPHANASE user 6 3 # 6 C 130 PHE A 111 PHE~? 19.07 CL CL D 145 C 223 ASP B 19 ASP~? 15.75 CL CL A 144 C 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c06 TRYPTOPHANASE user 7 3 # 7 C 130 PHE A 131 PHE~? 8.85 O3S EPE A 145 C 223 ASP A 124 ASP^? 10.83 CL CL D 145 C 265 LYS A 94 LYS.? 20.29 CL CL D 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1ax4_c06 TRYPTOPHANASE user 8 3 # 8 C 130 PHE A 142 PHE^? -6.60 CL CL A 144s C 223 ASP B 19 ASP~? 15.75 CL CL A 144 C 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c06 TRYPTOPHANASE user 9 3 # 9 C 130 PHE B 44 PHE~? 15.63 CL CL A 144 C 223 ASP C 64 ASP~? 15.91 CL CL A 144 C 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c06 TRYPTOPHANASE user 10 3 # 10 C 130 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 223 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 265 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ax4_c06 TRYPTOPHANASE user 11 3 # 11 C 130 PHE B 110 PHE~? 21.03 CL CL A 144 C 223 ASP C 19 ASP~? 15.67 CL CL A 144 C 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c06 TRYPTOPHANASE user 12 3 # 12 C 130 PHE B 111 PHE~? 20.82 CL CL A 144 C 223 ASP C 19 ASP~? 15.67 CL CL A 144 C 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c06 TRYPTOPHANASE user 13 3 # 13 C 130 PHE B 111 PHE~? 20.82 CL CL A 144 C 223 ASP C 19 ASP~? 15.67 CL CL A 144 C 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c06 TRYPTOPHANASE user 14 3 # 14 C 130 PHE B 131 PHE~? 9.25 O2S EPE A 145 C 223 ASP B 124 ASP^? 22.45 O2S EPE A 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 15 3 # 15 C 130 PHE B 142 PHE^? -6.58 CL CL A 144s C 223 ASP C 19 ASP~? 15.67 CL CL A 144 C 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c06 TRYPTOPHANASE user 16 3 # 16 C 130 PHE B 142 PHE^? -6.58 CL CL A 144s C 223 ASP C 19 ASP~? 15.67 CL CL A 144 C 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c06 TRYPTOPHANASE user 17 3 # 17 C 130 PHE C 41 PHE^? 13.95 CL CL A 144 C 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 265 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1ax4_c06 TRYPTOPHANASE user 18 3 # 18 C 130 PHE C 44 PHE~? 15.66 CL CL A 144 C 223 ASP A 64 ASP~? 16.08 CL CL A 144 C 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c06 TRYPTOPHANASE user 19 3 # 19 C 130 PHE C 102 PHE^? 16.65 O1S EPE A 145 C 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 265 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1ax4_c06 TRYPTOPHANASE user 20 3 # 20 C 130 PHE C 110 PHE~? 21.09 CL CL A 144 C 223 ASP A 19 ASP~? 15.97 CL CL A 144 C 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -48.65 -5.68 -12.24 -47.16 -3.89 -13.77 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c06 TRYPTOPHANASE user 21 3 # 21 C 130 PHE C 111 PHE~? 21.07 CL CL A 144 C 223 ASP A 19 ASP~? 15.97 CL CL A 144 C 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -50.06 -10.80 -9.50 -48.81 -11.85 -11.73 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c06 TRYPTOPHANASE user 22 3 # 22 C 130 PHE C 142 PHE^? -6.66 CL CL A 144s C 223 ASP A 19 ASP~? 15.97 CL CL A 144 C 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c06 TRYPTOPHANASE user 23 3 # 23 C 130 PHE D 41 PHE^? 10.83 CL CL D 145 C 223 ASP D 123 ASP.? 17.57 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 24 3 # 24 C 130 PHE D 41 PHE^? 10.83 CL CL D 145 C 223 ASP D 124 ASP^? 11.01 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 25 3 # 25 C 130 PHE D 42 PHE^? 15.36 CL CL D 144 C 223 ASP D 123 ASP.? 17.57 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 26 3 # 26 C 130 PHE D 42 PHE^? 15.36 CL CL D 144 C 223 ASP D 124 ASP^? 11.01 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 27 3 # 27 C 130 PHE D 111 PHE~? 18.80 CL CL D 145 C 223 ASP D 117 ASP~? 21.71 CL CL D 145 C 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -13.55 -11.13 -49.68 -12.29 -8.64 -49.81 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c06 TRYPTOPHANASE user 28 3 # 28 C 130 PHE D 121 PHE.? 21.38 CL CL D 145 C 223 ASP D 124 ASP^? 11.01 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 29 3 # 29 C 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 223 ASP A 133 ASP~? 7.97 CL CL D 145 C 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c06 TRYPTOPHANASE user 30 3 # 30 C 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 223 ASP D 124 ASP^? 11.01 CL CL D 145 C 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -4.44 67.20 42.32 -7.50 62.41 40.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c06 TRYPTOPHANASE user 31 3 # 31 C 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 223 ASP D 124 ASP^? 11.01 CL CL D 145 C 265 LYS D 94 LYS.? 20.13 CL CL D 145 coo -6.55 73.45 23.60 -6.77 71.48 21.66 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -9.52 75.74 33.62 -8.85 73.74 33.93 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -4.44 67.20 42.32 -7.50 62.41 40.49 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1ax4_c06 source 1ax4 TRYPTOPHANASE : 31 hits 1ax4_c06 naa= 3 ULMN 3 1ax4_c07 TRYPTOPHANASE user 1 3 # 1 D 130 PHE A 41 PHE^? 11.09 CL CL D 145 D 223 ASP A 133 ASP~? 7.97 CL CL D 145 D 265 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1ax4_c07 TRYPTOPHANASE user 2 3 # 2 D 130 PHE A 44 PHE~? 15.48 CL CL A 144 D 223 ASP B 64 ASP~? 15.96 CL CL A 144 D 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c07 TRYPTOPHANASE user 3 3 # 3 D 130 PHE A 102 PHE^? 11.63 CL CL D 145 D 223 ASP A 133 ASP~? 7.97 CL CL D 145 D 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c07 TRYPTOPHANASE user 4 3 # 4 D 130 PHE A 110 PHE~? 14.69 CL CL D 145 D 223 ASP B 19 ASP~? 15.75 CL CL A 144 D 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -29.27 -18.72 -35.30 -26.96 -19.68 -34.02 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c07 TRYPTOPHANASE user 5 3 # 5 D 130 PHE A 111 PHE~? 19.07 CL CL D 145 D 223 ASP B 19 ASP~? 15.75 CL CL A 144 D 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c07 TRYPTOPHANASE user 6 3 # 6 D 130 PHE A 111 PHE~? 19.07 CL CL D 145 D 223 ASP B 19 ASP~? 15.75 CL CL A 144 D 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -34.68 -16.61 -35.56 -34.77 -18.40 -33.40 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c07 TRYPTOPHANASE user 7 3 # 7 D 130 PHE A 131 PHE~? 8.85 O3S EPE A 145 D 223 ASP A 124 ASP^? 10.83 CL CL D 145 D 265 LYS A 94 LYS.? 20.29 CL CL D 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1ax4_c07 TRYPTOPHANASE user 8 3 # 8 D 130 PHE A 142 PHE^? -6.60 CL CL A 144s D 223 ASP B 19 ASP~? 15.75 CL CL A 144 D 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c07 TRYPTOPHANASE user 9 3 # 9 D 130 PHE B 44 PHE~? 15.63 CL CL A 144 D 223 ASP C 64 ASP~? 15.91 CL CL A 144 D 265 LYS A 20 LYS~? 9.88 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1ax4_c07 TRYPTOPHANASE user 10 3 # 10 D 130 PHE B 102 PHE^? 16.45 O2S EPE A 145 D 223 ASP B 133 ASP~? 13.85 C2 EPE A 145 D 265 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ax4_c07 TRYPTOPHANASE user 11 3 # 11 D 130 PHE B 110 PHE~? 21.03 CL CL A 144 D 223 ASP C 19 ASP~? 15.67 CL CL A 144 D 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c07 TRYPTOPHANASE user 12 3 # 12 D 130 PHE B 111 PHE~? 20.82 CL CL A 144 D 223 ASP C 19 ASP~? 15.67 CL CL A 144 D 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c07 TRYPTOPHANASE user 13 3 # 13 D 130 PHE B 111 PHE~? 20.82 CL CL A 144 D 223 ASP C 19 ASP~? 15.67 CL CL A 144 D 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c07 TRYPTOPHANASE user 14 3 # 14 D 130 PHE B 131 PHE~? 9.25 O2S EPE A 145 D 223 ASP B 124 ASP^? 22.45 O2S EPE A 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 15 3 # 15 D 130 PHE B 142 PHE^? -6.58 CL CL A 144s D 223 ASP C 19 ASP~? 15.67 CL CL A 144 D 265 LYS A 65 LYS~? 24.48 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1ax4_c07 TRYPTOPHANASE user 16 3 # 16 D 130 PHE B 142 PHE^? -6.58 CL CL A 144s D 223 ASP C 19 ASP~? 15.67 CL CL A 144 D 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c07 TRYPTOPHANASE user 17 3 # 17 D 130 PHE C 41 PHE^? 13.95 CL CL A 144 D 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 D 265 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1ax4_c07 TRYPTOPHANASE user 18 3 # 18 D 130 PHE C 44 PHE~? 15.66 CL CL A 144 D 223 ASP A 64 ASP~? 16.08 CL CL A 144 D 265 LYS B 20 LYS~? 9.95 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1ax4_c07 TRYPTOPHANASE user 19 3 # 19 D 130 PHE C 102 PHE^? 16.65 O1S EPE A 145 D 223 ASP C 133 ASP~? 13.97 O1S EPE A 145 D 265 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1ax4_c07 TRYPTOPHANASE user 20 3 # 20 D 130 PHE C 110 PHE~? 21.09 CL CL A 144 D 223 ASP A 19 ASP~? 15.97 CL CL A 144 D 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -48.65 -5.68 -12.24 -47.16 -3.89 -13.77 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c07 TRYPTOPHANASE user 21 3 # 21 D 130 PHE C 111 PHE~? 21.07 CL CL A 144 D 223 ASP A 19 ASP~? 15.97 CL CL A 144 D 265 LYS C 20 LYS~? 9.96 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -50.06 -10.80 -9.50 -48.81 -11.85 -11.73 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1ax4_c07 TRYPTOPHANASE user 22 3 # 22 D 130 PHE C 142 PHE^? -6.66 CL CL A 144s D 223 ASP A 19 ASP~? 15.97 CL CL A 144 D 265 LYS B 65 LYS~? 24.78 CL CL A 144 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1ax4_c07 TRYPTOPHANASE user 23 3 # 23 D 130 PHE D 41 PHE^? 10.83 CL CL D 145 D 223 ASP D 123 ASP.? 17.57 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 24 3 # 24 D 130 PHE D 41 PHE^? 10.83 CL CL D 145 D 223 ASP D 124 ASP^? 11.01 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 25 3 # 25 D 130 PHE D 42 PHE^? 15.36 CL CL D 144 D 223 ASP D 123 ASP.? 17.57 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 26 3 # 26 D 130 PHE D 42 PHE^? 15.36 CL CL D 144 D 223 ASP D 124 ASP^? 11.01 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 27 3 # 27 D 130 PHE D 111 PHE~? 18.80 CL CL D 145 D 223 ASP D 117 ASP~? 21.71 CL CL D 145 D 265 LYS B 82 LYS.? 24.10 CL CL D 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -13.55 -11.13 -49.68 -12.29 -8.64 -49.81 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1ax4_c07 TRYPTOPHANASE user 28 3 # 28 D 130 PHE D 121 PHE.? 21.38 CL CL D 145 D 223 ASP D 124 ASP^? 11.01 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 29 3 # 29 D 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 D 223 ASP A 133 ASP~? 7.97 CL CL D 145 D 265 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ax4_c07 TRYPTOPHANASE user 30 3 # 30 D 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 D 223 ASP D 124 ASP^? 11.01 CL CL D 145 D 265 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -18.87 56.53 54.79 -19.47 62.22 53.03 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1ax4_c07 TRYPTOPHANASE user 31 3 # 31 D 130 PHE D 131 PHE~? 8.86 O2S EPE D 146 D 223 ASP D 124 ASP^? 11.01 CL CL D 145 D 265 LYS D 94 LYS.? 20.13 CL CL D 145 coo -38.60 55.38 52.70 -40.06 57.72 53.04 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo -29.46 51.67 48.51 -28.63 53.31 49.56 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -18.87 56.53 54.79 -19.47 62.22 53.03 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1ax4_c07 source 1ax4 TRYPTOPHANASE : 31 hits 1ax4_c07 naa= 3 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 1 3 # 1 A 88 PHE A 14 PHE.? 11.46 CL CL A 144 A 159 ASP B 64 ASP~? 15.96 CL CL A 144 A 188 LYS A 20 LYS~? 9.88 CL CL A 144 coo 13.91 34.58 14.67 12.95 36.00 12.47 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 20.97 28.40 16.26 20.19 30.15 15.34 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 22.55 41.65 15.60 18.92 37.20 14.63 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 2 3 # 2 A 88 PHE A 41 PHE^? 11.09 CL CL D 145 A 159 ASP A 133 ASP~? 7.97 CL CL D 145 A 188 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 20.97 28.40 16.26 20.19 30.15 15.34 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 3 3 # 3 A 88 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 159 ASP A 133 ASP~? 7.97 CL CL D 145 A 188 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 20.97 28.40 16.26 20.19 30.15 15.34 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 4 3 # 4 A 88 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 159 ASP A 133 ASP~? 7.97 CL CL D 145 A 188 LYS A 100 LYS^? 18.99 CL CL D 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 20.97 28.40 16.26 20.19 30.15 15.34 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 5 3 # 5 A 88 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 159 ASP A 133 ASP~? 7.97 CL CL D 145 A 188 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 20.97 28.40 16.26 20.19 30.15 15.34 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 6 3 # 6 A 88 PHE A 142 PHE^? -6.60 CL CL A 144s A 159 ASP B 19 ASP~? 15.75 CL CL A 144 A 188 LYS A 20 LYS~? 9.88 CL CL A 144 coo 13.91 34.58 14.67 12.95 36.00 12.47 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo 20.97 28.40 16.26 20.19 30.15 15.34 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 22.55 41.65 15.60 18.92 37.20 14.63 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 7 3 # 7 A 88 PHE B 14 PHE.? 11.43 CL CL A 144 A 159 ASP C 64 ASP~? 15.91 CL CL A 144 A 188 LYS B 20 LYS~? 9.95 CL CL A 144 coo 13.91 34.58 14.67 12.95 36.00 12.47 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 coo 20.97 28.40 16.26 20.19 30.15 15.34 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 22.55 41.65 15.60 18.92 37.20 14.63 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 8 3 # 8 A 88 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 159 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 188 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 20.97 28.40 16.26 20.19 30.15 15.34 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 22.55 41.65 15.60 18.92 37.20 14.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 9 3 # 9 A 88 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 159 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 188 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 20.97 28.40 16.26 20.19 30.15 15.34 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 22.55 41.65 15.60 18.92 37.20 14.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 10 3 # 10 A 88 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 159 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 188 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 20.97 28.40 16.26 20.19 30.15 15.34 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 22.55 41.65 15.60 18.92 37.20 14.63 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 11 3 # 11 A 88 PHE C 14 PHE.? 11.62 CL CL A 144 A 159 ASP A 64 ASP~? 16.08 CL CL A 144 A 188 LYS C 20 LYS~? 9.96 CL CL A 144 coo 13.91 34.58 14.67 12.95 36.00 12.47 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 coo 20.97 28.40 16.26 20.19 30.15 15.34 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 22.55 41.65 15.60 18.92 37.20 14.63 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 12 3 # 12 A 88 PHE C 41 PHE^? 13.95 CL CL A 144 A 159 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 188 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 20.97 28.40 16.26 20.19 30.15 15.34 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 13 3 # 13 A 88 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 159 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 188 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 20.97 28.40 16.26 20.19 30.15 15.34 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 14 3 # 14 A 88 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 159 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 188 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 20.97 28.40 16.26 20.19 30.15 15.34 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 22.55 41.65 15.60 18.92 37.20 14.63 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 15 3 # 15 A 88 PHE D 41 PHE^? 10.83 CL CL D 145 A 159 ASP D 133 ASP~? 7.85 CL CL D 145 A 188 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 13.91 34.58 14.67 12.95 36.00 12.47 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 20.97 28.40 16.26 20.19 30.15 15.34 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 22.55 41.65 15.60 18.92 37.20 14.63 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 16 3 # 16 A 88 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 159 ASP D 133 ASP~? 7.85 CL CL D 145 A 188 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 13.91 34.58 14.67 12.95 36.00 12.47 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 20.97 28.40 16.26 20.19 30.15 15.34 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 22.55 41.65 15.60 18.92 37.20 14.63 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1b9h_c02 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHAuser 17 3 # 17 A 88 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 159 ASP D 133 ASP~? 7.85 CL CL D 145 A 188 LYS D 100 LYS^? 18.85 CL CL D 145 coo 13.91 34.58 14.67 12.95 36.00 12.47 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 20.97 28.40 16.26 20.19 30.15 15.34 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 22.55 41.65 15.60 18.92 37.20 14.63 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1b9h_c02 source 1b9h 3-AMINO-5-HYDROXYBENZOIC ACID SYNTHASE : 17 hits 1b9h_c02 naa= 3 ULMN 3 1bbs_c06 RENIN user 1 3 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 61.19 45.85 78.73 62.86 45.48 77.48 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 66.00 46.17 80.29 64.31 47.92 79.91 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 63.61 40.10 74.06 64.05 42.07 74.70 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1bbs_c06 source 1bbs RENIN : 1 hits 1bbs_c06 naa= 3 ULMN 3 1bbs_c07 RENIN user 1 3 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 61.19 45.85 78.73 62.86 45.48 77.48 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 66.00 46.17 80.29 64.31 47.92 79.91 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 63.61 40.10 74.06 64.05 42.07 74.70 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1bbs_c07 source 1bbs RENIN : 1 hits 1bbs_c07 naa= 3 ULMN 3 1bib_c00 BIRA BIFUNCTIONAL PROTEIN (ACTS AS Buser 1 3 # 1 118 ARG D 134 ARG~? 13.66 CL CL D 145 183 LYS B 6 LYS.? 15.05 O8 EPE D 146 317 ARG A 134 ARG~? 13.60 CL CL D 145 coo 76.57 109.19 73.41 73.86 110.26 72.16 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 82.09 117.51 66.37 80.60 114.32 71.44 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 65.21 120.62 58.76 63.62 123.14 59.66 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1bib_c00 BIRA BIFUNCTIONAL PROTEIN (ACTS AS Buser 2 3 # 2 118 ARG D 134 ARG~? 13.66 CL CL D 145 183 LYS B 8 LYS^? 8.74 C3 EPE A 145 317 ARG A 134 ARG~? 13.60 CL CL D 145 coo 76.57 109.19 73.41 73.86 110.26 72.16 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 82.09 117.51 66.37 80.60 114.32 71.44 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 65.21 120.62 58.76 63.62 123.14 59.66 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 1bib_c00 source 1bib BIRA BIFUNCTIONAL PROTEIN (ACTS AS BIOTIN OPER: 2 hits 1bib_c00 naa= 3 ULMN 3 1bjo_c00 PHOSPHOSERINE AMINOTRANSFERASE user 1 3 # 1 A 102 TRP A 45 TRP~? 16.76 CL CL A 144 A 174 ASP B 64 ASP~? 15.96 CL CL A 144 A 198 LYS A 20 LYS~? 9.88 CL CL A 144 coo 21.59 67.76 35.19 19.10 64.95 36.34 -36.53 -17.86 -26.77 -37.06 -19.54 -30.28 coo 19.39 73.14 39.98 19.70 71.07 40.14 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 27.94 65.10 43.55 24.20 64.94 40.01 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1bjo_c00 PHOSPHOSERINE AMINOTRANSFERASE user 2 3 # 2 A 102 TRP B 45 TRP~? 16.74 CL CL A 144 A 174 ASP C 64 ASP~? 15.91 CL CL A 144 A 198 LYS B 20 LYS~? 9.95 CL CL A 144 coo 21.59 67.76 35.19 19.10 64.95 36.34 -34.37 -27.58 -15.49 -35.93 -30.94 -14.23 coo 19.39 73.14 39.98 19.70 71.07 40.14 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 27.94 65.10 43.55 24.20 64.94 40.01 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1bjo_c00 PHOSPHOSERINE AMINOTRANSFERASE user 3 3 # 3 A 102 TRP C 45 TRP~? 17.05 CL CL A 144 A 174 ASP A 64 ASP~? 16.08 CL CL A 144 A 198 LYS C 20 LYS~? 9.96 CL CL A 144 coo 21.59 67.76 35.19 19.10 64.95 36.34 -43.91 -15.76 -13.57 -47.74 -15.00 -13.94 coo 19.39 73.14 39.98 19.70 71.07 40.14 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 27.94 65.10 43.55 24.20 64.94 40.01 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 1bjo_c00 source 1bjo PHOSPHOSERINE AMINOTRANSFERASE : 3 hits 1bjo_c00 naa= 3 ULMN 3 1bqc_c01 BETA-MANNANASE user 1 3 # 1 A 50 ARG D 134 ARG~? 13.66 CL CL D 145 A 128 GLU D 98 GLU^? 15.40 O8 EPE D 146 A 225 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 38.56 19.11 14.83 37.12 21.00 16.76 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 36.48 24.43 22.02 36.86 26.34 21.13 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 40.16 23.71 17.01 38.52 24.96 17.40 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 1bqc_c01 source 1bqc BETA-MANNANASE : 1 hits 1bqc_c01 naa= 3 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 1 3 # 1 A 109 PHE A 14 PHE.? 11.46 CL CL A 144 A 205 ASP A 19 ASP~? 15.97 CL CL A 144 A 236 LYS A 65 LYS~? 24.48 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 2 3 # 2 A 109 PHE A 14 PHE.? 11.46 CL CL A 144 A 205 ASP C 64 ASP~? 15.91 CL CL A 144 A 236 LYS A 65 LYS~? 24.48 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 3 3 # 3 A 109 PHE A 14 PHE.? 11.46 CL CL A 144 A 205 ASP C 64 ASP~? 15.91 CL CL A 144 A 236 LYS B 65 LYS~? 24.78 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 4 3 # 4 A 109 PHE A 44 PHE~? 15.48 CL CL A 144 A 205 ASP A 64 ASP~? 16.08 CL CL A 144 A 236 LYS B 65 LYS~? 24.78 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 5 3 # 5 A 109 PHE A 142 PHE^? -6.60 CL CL A 144s A 205 ASP A 64 ASP~? 16.08 CL CL A 144 A 236 LYS C 20 LYS~? 9.96 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 6 3 # 6 A 109 PHE A 142 PHE^? -6.60 CL CL A 144s A 205 ASP A 133 ASP~? 7.97 CL CL D 145 A 236 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 4.14 2.10 36.34 6.69 3.08 36.92 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 7 3 # 7 A 109 PHE B 14 PHE.? 11.43 CL CL A 144 A 205 ASP A 64 ASP~? 16.08 CL CL A 144 A 236 LYS B 65 LYS~? 24.78 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 8 3 # 8 A 109 PHE B 14 PHE.? 11.43 CL CL A 144 A 205 ASP B 19 ASP~? 15.75 CL CL A 144 A 236 LYS B 65 LYS~? 24.78 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 9 3 # 9 A 109 PHE B 142 PHE^? -6.58 CL CL A 144s A 205 ASP B 64 ASP~? 15.96 CL CL A 144 A 236 LYS A 20 LYS~? 9.88 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 10 3 # 10 A 109 PHE B 142 PHE^? -6.58 CL CL A 144s A 205 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 236 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 4.14 2.10 36.34 6.69 3.08 36.92 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 11 3 # 11 A 109 PHE C 14 PHE.? 11.62 CL CL A 144 A 205 ASP B 64 ASP~? 15.96 CL CL A 144 A 236 LYS A 65 LYS~? 24.48 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 12 3 # 12 A 109 PHE C 44 PHE~? 15.66 CL CL A 144 A 205 ASP C 64 ASP~? 15.91 CL CL A 144 A 236 LYS A 65 LYS~? 24.48 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 13 3 # 13 A 109 PHE C 142 PHE^? -6.66 CL CL A 144s A 205 ASP C 64 ASP~? 15.91 CL CL A 144 A 236 LYS B 20 LYS~? 9.95 CL CL A 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 14 3 # 14 A 109 PHE C 142 PHE^? -6.66 CL CL A 144s A 205 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 236 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 4.14 2.10 36.34 6.69 3.08 36.92 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1bs0_c01 8-AMINO-7-OXONANOATE SYNTHASE user 15 3 # 15 A 109 PHE D 14 PHE.? 11.55 CL CL D 144 A 205 ASP D 19 ASP~? 15.85 CL CL D 144 A 236 LYS D 65 LYS~? 24.46 CL CL D 144 coo 4.14 2.10 36.34 6.69 3.08 36.92 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 coo 0.29 -1.62 50.50 1.21 -2.50 52.18 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 6.34 -8.87 44.53 6.49 -3.84 42.65 3.33 -3.03 -56.97 -1.82 -3.51 -60.81 1bs0_c01 source 1bs0 8-AMINO-7-OXONANOATE SYNTHASE : 15 hits 1bs0_c01 naa= 3 ULMN 3 1bs4_c00 PEPTIDE DEFORMYLASE user 1 3 # 1 A 50 GLN C 92 GLN.? 26.01 CL CL A 144 A 91 LEU C 89 LEU.? 20.13 CL CL A 144 A 133 GLU C 95 GLU.? 27.59 O2S EPE A 145 coo 43.58 43.67 66.73 42.32 42.78 68.15 -33.66 -23.58 8.52 -33.71 -25.68 8.00 coo 38.58 45.09 70.44 38.28 45.21 72.59 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo 44.05 36.87 70.65 43.15 38.64 69.97 -33.39 -18.53 11.57 -34.39 -20.35 12.06 1bs4_c00 source 1bs4 PEPTIDE DEFORMYLASE : 1 hits 1bs4_c00 naa= 3 ULMN 3 1bs4_c01 PEPTIDE DEFORMYLASE user 1 3 # 1 B 550 GLN C 92 GLN.? 26.01 CL CL A 144 B 591 LEU C 89 LEU.? 20.13 CL CL A 144 B 633 GLU C 95 GLU.? 27.59 O2S EPE A 145 coo 88.06 44.34 57.19 89.06 45.53 55.74 -33.66 -23.58 8.52 -33.71 -25.68 8.00 coo 86.70 48.66 52.61 87.15 48.69 50.51 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo 95.42 44.52 54.43 93.46 45.31 54.70 -33.39 -18.53 11.57 -34.39 -20.35 12.06 1bs4_c01 source 1bs4 PEPTIDE DEFORMYLASE : 1 hits 1bs4_c01 naa= 3 ULMN 3 1bs4_c02 PEPTIDE DEFORMYLASE user 1 3 # 1 C1050 GLN C 92 GLN.? 26.01 CL CL A 144 C1091 LEU C 89 LEU.? 20.13 CL CL A 144 C1133 GLU C 95 GLU.? 27.59 O2S EPE A 145 coo 68.29 34.44 43.03 66.67 34.74 44.37 -33.66 -23.58 8.52 -33.71 -25.68 8.00 coo 65.83 38.95 47.05 65.46 38.90 49.20 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo 63.14 29.39 46.25 63.84 31.31 45.74 -33.39 -18.53 11.57 -34.39 -20.35 12.06 1bs4_c02 source 1bs4 PEPTIDE DEFORMYLASE : 1 hits 1bs4_c02 naa= 3 ULMN 3 1bu7_c02 CYTOCHROME P450 user 1 3 # 1 A 268 THR B 130 THR~? 17.10 O2S EPE A 145 A 393 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 400 CYH B 104 CYH^? 16.50 CL CL A 144 coo 45.81 71.19 43.26 47.70 70.19 43.25 -17.23 -22.87 -4.50 -16.07 -24.66 -4.52 coo 48.54 63.17 48.16 46.74 64.99 49.22 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 53.76 64.39 46.87 52.06 66.55 47.33 -23.20 -29.24 -9.27 -25.51 -28.44 -7.91 ULMN 3 1bu7_c02 CYTOCHROME P450 user 2 3 # 2 A 268 THR C 130 THR~? 17.24 O1S EPE A 145 A 393 PHE C 41 PHE^? 13.95 CL CL A 144 A 400 CYH C 104 CYH^? 16.50 CL CL A 144 coo 45.81 71.19 43.26 47.70 70.19 43.25 -33.96 0.15 -4.28 -35.19 0.92 -2.69 coo 48.54 63.17 48.16 46.74 64.99 49.22 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 53.76 64.39 46.87 52.06 66.55 47.33 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 1bu7_c02 source 1bu7 CYTOCHROME P450 : 2 hits 1bu7_c02 naa= 3 ULMN 3 1bu7_c03 CYTOCHROME P450 user 1 3 # 1 B 268 THR A 130 THR~? 5.01 CL CL D 145 B 393 PHE A 41 PHE^? 11.09 CL CL D 145 B 400 CYH A 104 CYH^? 10.13 CL CL D 145 coo 37.20 116.32 52.00 35.18 117.07 52.13 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 coo 33.81 121.65 59.26 35.49 119.55 59.81 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 28.79 121.15 57.00 30.51 118.99 56.70 -27.84 -9.67 -31.52 -27.40 -12.40 -31.03 ULMN 3 1bu7_c03 CYTOCHROME P450 user 2 3 # 2 B 268 THR B 130 THR~? 17.10 O2S EPE A 145 B 393 PHE B 41 PHE^? 12.26 O2S EPE A 145 B 400 CYH B 104 CYH^? 16.50 CL CL A 144 coo 37.20 116.32 52.00 35.18 117.07 52.13 -17.23 -22.87 -4.50 -16.07 -24.66 -4.52 coo 33.81 121.65 59.26 35.49 119.55 59.81 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 28.79 121.15 57.00 30.51 118.99 56.70 -23.20 -29.24 -9.27 -25.51 -28.44 -7.91 ULMN 3 1bu7_c03 CYTOCHROME P450 user 3 3 # 3 B 268 THR C 130 THR~? 17.24 O1S EPE A 145 B 393 PHE C 41 PHE^? 13.95 CL CL A 144 B 400 CYH C 104 CYH^? 16.50 CL CL A 144 coo 37.20 116.32 52.00 35.18 117.07 52.13 -33.96 0.15 -4.28 -35.19 0.92 -2.69 coo 33.81 121.65 59.26 35.49 119.55 59.81 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 28.79 121.15 57.00 30.51 118.99 56.70 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 ULMN 3 1bu7_c03 CYTOCHROME P450 user 4 3 # 4 B 268 THR D 130 THR~? 5.00 CL CL D 145 B 393 PHE D 41 PHE^? 10.83 CL CL D 145 B 400 CYH D 104 CYH^? 9.92 CL CL D 145 coo 37.20 116.32 52.00 35.18 117.07 52.13 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 33.81 121.65 59.26 35.49 119.55 59.81 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 28.79 121.15 57.00 30.51 118.99 56.70 -12.42 -12.02 -39.45 -13.14 -9.45 -40.35 1bu7_c03 source 1bu7 CYTOCHROME P450 : 4 hits 1bu7_c03 naa= 3 ULMN 3 1cjy_c00 CYTOSOLIC PHOSPHOLIPASE A2 user 1 3 # 1 A 198 GLY B 30 GLY~? 7.61 CL CL D 145 A 228 SER B 34 SER~? 6.65 CL CL D 145 A 549 ASP D 133 ASP~? 7.85 CL CL D 145 coo 43.62 -9.31 54.06 43.04 -9.29 54.58 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 45.99 -4.81 58.63 47.02 -6.84 57.75 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 51.69 -5.84 58.91 49.67 -6.52 58.93 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 1cjy_c00 source 1cjy CYTOSOLIC PHOSPHOLIPASE A2 : 1 hits 1cjy_c00 naa= 3 ULMN 3 1cjy_c01 CYTOSOLIC PHOSPHOLIPASE A2 user 1 3 # 1 B1198 GLY B 97 GLY.? 16.18 CL CL D 145 B1228 SER B 29 SER~? 11.10 CL CL D 145 B1549 ASP D 124 ASP^? 11.01 CL CL D 145 coo 126.34 72.75 125.66 125.95 73.27 126.11 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 131.65 74.68 129.41 130.31 72.73 128.82 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 coo 134.72 69.43 130.42 133.03 70.65 130.08 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 1cjy_c01 source 1cjy CYTOSOLIC PHOSPHOLIPASE A2 : 1 hits 1cjy_c01 naa= 3 ULMN 3 1cms_c04 CHYMOSIN B (FORMERLY KNOWN AS RENNINuser 1 3 # 1 34 ASP D 133 ASP~? 7.85 CL CL D 145 37 SER B 34 SER~? 6.65 CL CL D 145 216 ASP A 133 ASP~? 7.97 CL CL D 145 coo 16.90 26.20 29.49 16.22 24.50 28.41 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.23 24.31 30.40 14.55 23.96 31.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 13.93 25.52 22.10 14.75 24.44 23.75 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1cms_c04 source 1cms CHYMOSIN B (FORMERLY KNOWN AS RENNIN) (E.C.3.4: 1 hits 1cms_c04 naa= 3 ULMN 3 1cns_c00 CHITINASE user 1 3 # 1 A 67 GLU B 136 GLU~? 6.67 C2 EPE A 145 A 89 GLU B 37 GLU^? 13.18 C3 EPE A 145 A 120 SER B 10 SER^? 8.49 O2S EPE A 145 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 ULMN 3 1cns_c00 CHITINASE user 2 3 # 2 A 67 GLU C 136 GLU~? 8.02 O8 EPE A 145 A 89 GLU A 37 GLU^? 12.50 C6 EPE A 145 A 120 SER A 10 SER^? 8.69 O1S EPE A 145 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 ULMN 3 1cns_c00 CHITINASE user 3 3 # 3 A 67 GLU D 136 GLU~? 8.82 C5 EPE D 146 A 89 GLU D 37 GLU^? 11.78 O8 EPE D 146 A 120 SER D 10 SER^? 8.71 O3S EPE D 146 coo -24.35 9.53 67.64 -25.07 11.29 68.60 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo -31.18 6.91 75.60 -32.39 8.51 74.91 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo -34.73 8.57 68.21 -33.63 9.08 70.28 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 1cns_c00 source 1cns CHITINASE : 3 hits 1cns_c00 naa= 3 ULMN 3 1cns_c01 CHITINASE user 1 3 # 1 B 67 GLU A 136 GLU~? 8.92 C6 EPE A 145 B 89 GLU A 37 GLU^? 12.50 C6 EPE A 145 B 120 SER A 10 SER^? 8.69 O1S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 ULMN 3 1cns_c01 CHITINASE user 2 3 # 2 B 67 GLU A 136 GLU~? 8.92 C6 EPE A 145 B 89 GLU B 37 GLU^? 13.18 C3 EPE A 145 B 120 SER B 10 SER^? 8.49 O2S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 ULMN 3 1cns_c01 CHITINASE user 3 3 # 3 B 67 GLU A 136 GLU~? 8.92 C6 EPE A 145 B 89 GLU D 136 GLU~? 8.82 C5 EPE D 146 B 120 SER B 34 SER~? 6.65 CL CL D 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 1cns_c01 CHITINASE user 4 3 # 4 B 67 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 89 GLU D 37 GLU^? 11.78 O8 EPE D 146 B 120 SER B 34 SER~? 6.65 CL CL D 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 1cns_c01 CHITINASE user 5 3 # 5 B 67 GLU B 136 GLU~? 6.67 C2 EPE A 145 B 89 GLU B 37 GLU^? 13.18 C3 EPE A 145 B 120 SER B 10 SER^? 8.49 O2S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 ULMN 3 1cns_c01 CHITINASE user 6 3 # 6 B 67 GLU B 136 GLU~? 6.67 C2 EPE A 145 B 89 GLU C 37 GLU^? 12.70 O8 EPE A 145 B 120 SER C 10 SER^? 8.67 O1S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 ULMN 3 1cns_c01 CHITINASE user 7 3 # 7 B 67 GLU C 136 GLU~? 8.02 O8 EPE A 145 B 89 GLU A 37 GLU^? 12.50 C6 EPE A 145 B 120 SER A 10 SER^? 8.69 O1S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 ULMN 3 1cns_c01 CHITINASE user 8 3 # 8 B 67 GLU C 136 GLU~? 8.02 O8 EPE A 145 B 89 GLU C 37 GLU^? 12.70 O8 EPE A 145 B 120 SER C 10 SER^? 8.67 O1S EPE A 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 ULMN 3 1cns_c01 CHITINASE user 9 3 # 9 B 67 GLU D 37 GLU^? 11.78 O8 EPE D 146 B 89 GLU D 136 GLU~? 8.82 C5 EPE D 146 B 120 SER B 34 SER~? 6.65 CL CL D 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 1cns_c01 CHITINASE user 10 3 # 10 B 67 GLU D 136 GLU~? 8.82 C5 EPE D 146 B 89 GLU D 37 GLU^? 11.78 O8 EPE D 146 B 120 SER B 34 SER~? 6.65 CL CL D 145 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 1cns_c01 CHITINASE user 11 3 # 11 B 67 GLU D 136 GLU~? 8.82 C5 EPE D 146 B 89 GLU D 37 GLU^? 11.78 O8 EPE D 146 B 120 SER D 10 SER^? 8.71 O3S EPE D 146 coo 9.89 -17.65 45.79 9.28 -17.39 43.77 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 19.53 -19.89 39.46 19.21 -18.09 38.37 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 18.32 -11.51 42.26 16.65 -12.32 40.69 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 1cns_c01 source 1cns CHITINASE : 11 hits 1cns_c01 naa= 3 ULMN 3 1cs1_c00 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 101 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 173 ASP A 133 ASP~? 7.97 CL CL D 145 C 48 ARG D 134 ARG~? 13.66 CL CL D 145 coo 25.00 -3.03 25.68 27.14 -4.51 26.75 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 24.35 4.55 25.11 25.94 3.23 25.53 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 29.84 -5.31 33.83 28.87 -5.97 30.97 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1cs1_c00 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c00 naa= 3 ULMN 3 1cs1_c01 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 48 ARG D 134 ARG~? 13.66 CL CL D 145 C 101 TYR B 36 TYR.? 11.13 O3S EPE A 145 C 173 ASP A 133 ASP~? 7.97 CL CL D 145 coo 32.27 5.62 48.15 31.93 6.48 51.06 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 29.64 3.64 57.39 31.22 5.14 55.65 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 28.89 -3.78 58.23 30.38 -2.57 57.33 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1cs1_c01 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c01 naa= 3 ULMN 3 1cs1_c02 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 48 ARG D 134 ARG~? 13.66 CL CL D 145 D 101 TYR B 36 TYR.? 11.13 O3S EPE A 145 D 173 ASP A 133 ASP~? 7.97 CL CL D 145 coo 69.08 8.58 32.60 69.70 10.81 30.58 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 71.77 11.86 24.26 70.23 12.22 26.56 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 71.60 6.14 19.25 70.26 6.87 20.69 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1cs1_c02 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c02 naa= 3 ULMN 3 1cs1_c03 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 101 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 173 ASP A 133 ASP~? 7.97 CL CL D 145 D 48 ARG D 134 ARG~? 13.66 CL CL D 145 coo 74.59 -12.57 45.75 72.37 -12.96 44.12 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 76.00 -6.96 50.63 74.29 -7.61 49.57 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 69.39 -8.90 38.17 70.70 -11.19 39.77 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1cs1_c03 source 1cs1 CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1cs1_c03 naa= 3 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 1 3 # 1 A 173 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 243 ASP C 123 ASP.? 21.65 O2S EPE A 145 A 272 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 16.93 55.67 9.65 17.16 54.23 11.19 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 14.13 45.79 13.40 14.25 49.41 18.30 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 2 3 # 2 A 173 TYR A 67 TYR~? 16.80 CL CL A 144 A 243 ASP C 123 ASP.? 21.65 O2S EPE A 145 A 272 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 16.93 55.67 9.65 17.16 54.23 11.19 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 14.13 45.79 13.40 14.25 49.41 18.30 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 3 3 # 3 A 173 TYR A 83 TYR.? 22.53 CL CL A 144 A 243 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 272 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -48.44 -0.89 -15.75 -46.04 -0.50 -14.38 coo 16.93 55.67 9.65 17.16 54.23 11.19 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 14.13 45.79 13.40 14.25 49.41 18.30 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 4 3 # 4 A 173 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 243 ASP A 123 ASP.? 17.71 CL CL D 145 A 272 LYS A 94 LYS.? 20.29 CL CL D 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 16.93 55.67 9.65 17.16 54.23 11.19 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 14.13 45.79 13.40 14.25 49.41 18.30 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 5 3 # 5 A 173 TYR B 67 TYR~? 16.82 CL CL A 144 A 243 ASP A 123 ASP.? 17.71 CL CL D 145 A 272 LYS A 94 LYS.? 20.29 CL CL D 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 16.93 55.67 9.65 17.16 54.23 11.19 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 14.13 45.79 13.40 14.25 49.41 18.30 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 6 3 # 6 A 173 TYR B 83 TYR.? 13.54 CL CL D 145 A 243 ASP D 133 ASP~? 7.85 CL CL D 145 A 272 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 2.03 68.31 21.46 0.66 68.36 23.90 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo 16.93 55.67 9.65 17.16 54.23 11.19 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 14.13 45.79 13.40 14.25 49.41 18.30 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 7 3 # 7 A 173 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 243 ASP B 123 ASP.? 21.73 O3S EPE A 145 A 272 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 16.93 55.67 9.65 17.16 54.23 11.19 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 14.13 45.79 13.40 14.25 49.41 18.30 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1d7r_c02 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYuser 8 3 # 8 A 173 TYR C 67 TYR~? 16.92 CL CL A 144 A 243 ASP B 123 ASP.? 21.73 O3S EPE A 145 A 272 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 2.03 68.31 21.46 0.66 68.36 23.90 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo 16.93 55.67 9.65 17.16 54.23 11.19 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 14.13 45.79 13.40 14.25 49.41 18.30 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 1d7r_c02 source 1d7r 2,2-DIALKYLGLYCINE DECARBOXYLASE (PYRUVATE) : 8 hits 1d7r_c02 naa= 3 ULMN 3 1daa_c00 D-AMINO ACID AMINOTRANSFERASE user 1 3 # 1 A 145 LYS B 52 LYS~? 30.62 CL CL A 144 A 177 GLU B 116 GLU~? 31.41 CL CL A 144 A 201 LEU B 118 LEU~? 23.36 CL CL A 144 coo 46.63 -7.12 50.78 48.41 -11.39 47.79 -22.88 -38.98 -21.49 -17.51 -41.75 -19.48 coo 47.18 -4.46 40.10 47.54 -4.70 42.20 -19.55 -43.74 -13.26 -19.51 -43.52 -11.15 coo 49.45 -5.57 45.73 49.73 -6.78 47.47 -20.21 -36.15 -15.71 -21.61 -35.25 -14.31 ULMN 3 1daa_c00 D-AMINO ACID AMINOTRANSFERASE user 2 3 # 2 A 145 LYS C 52 LYS~? 30.57 CL CL A 144 A 177 GLU C 116 GLU~? 31.54 CL CL A 144 A 201 LEU C 118 LEU~? 23.44 CL CL A 144 coo 46.63 -7.12 50.78 48.41 -11.39 47.79 -49.26 -17.15 2.71 -49.73 -13.44 7.75 coo 47.18 -4.46 40.10 47.54 -4.70 42.20 -52.13 -7.01 5.97 -52.83 -5.84 4.34 coo 49.45 -5.57 45.73 49.73 -6.78 47.47 -46.12 -10.92 2.06 -45.88 -9.99 0.09 1daa_c00 source 1daa D-AMINO ACID AMINOTRANSFERASE : 2 hits 1daa_c00 naa= 3 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 1 3 # 1 A 132 THR A 17 THR~? 16.13 CL CL A 144 A 156 TYR A 67 TYR~? 16.80 CL CL A 144 A 160 LYS A 65 LYS~? 24.48 CL CL A 144 coo 10.50 56.87 17.73 11.24 57.93 19.43 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 coo 11.64 63.07 23.95 11.76 62.47 21.20 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 5.78 61.30 21.65 8.04 62.89 17.54 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 2 3 # 2 A 132 THR A 139 THR^? -4.08 O1S EPE A 145s A 156 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 160 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 11.64 63.07 23.95 11.76 62.47 21.20 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 5.78 61.30 21.65 8.04 62.89 17.54 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 3 3 # 3 A 132 THR A 139 THR^? -4.08 O1S EPE A 145s A 156 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 160 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 11.64 63.07 23.95 11.76 62.47 21.20 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 5.78 61.30 21.65 8.04 62.89 17.54 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 4 3 # 4 A 132 THR B 17 THR~? 16.02 CL CL A 144 A 156 TYR B 67 TYR~? 16.82 CL CL A 144 A 160 LYS B 65 LYS~? 24.78 CL CL A 144 coo 10.50 56.87 17.73 11.24 57.93 19.43 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 coo 11.64 63.07 23.95 11.76 62.47 21.20 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 5.78 61.30 21.65 8.04 62.89 17.54 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 5 3 # 5 A 132 THR B 139 THR^? -4.10 O3S EPE A 145s A 156 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 160 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 11.64 63.07 23.95 11.76 62.47 21.20 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 5.78 61.30 21.65 8.04 62.89 17.54 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 6 3 # 6 A 132 THR C 139 THR^? -4.20 O2S EPE A 145s A 156 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 160 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 10.50 56.87 17.73 11.24 57.93 19.43 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 11.64 63.07 23.95 11.76 62.47 21.20 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 5.78 61.30 21.65 8.04 62.89 17.54 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 7 3 # 7 A 132 THR D 17 THR~? 16.46 CL CL D 144 A 156 TYR D 67 TYR~? 16.83 CL CL D 144 A 160 LYS D 65 LYS~? 24.46 CL CL D 144 coo 10.50 56.87 17.73 11.24 57.93 19.43 1.11 -9.25 -50.49 1.81 -7.39 -51.27 coo 11.64 63.07 23.95 11.76 62.47 21.20 8.02 -1.60 -52.64 7.08 0.27 -50.76 coo 5.78 61.30 21.65 8.04 62.89 17.54 3.33 -3.03 -56.97 -1.82 -3.51 -60.81 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 8 3 # 8 A 132 THR D 139 THR^? -4.08 O3S EPE D 146s A 156 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 160 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo 10.50 56.87 17.73 11.24 57.93 19.43 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 11.64 63.07 23.95 11.76 62.47 21.20 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 5.78 61.30 21.65 8.04 62.89 17.54 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1db3_c01 GDP-MANNOSE 4,6-DEHYDRATASE user 9 3 # 9 A 132 THR D 139 THR^? -4.08 O3S EPE D 146s A 156 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 160 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 10.50 56.87 17.73 11.24 57.93 19.43 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 11.64 63.07 23.95 11.76 62.47 21.20 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 5.78 61.30 21.65 8.04 62.89 17.54 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1db3_c01 source 1db3 GDP-MANNOSE 4,6-DEHYDRATASE : 9 hits 1db3_c01 naa= 3 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 A 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 226 THR A 139 THR^? -4.08 O1S EPE A 145s A 229 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 7.24 97.46 49.60 8.11 95.69 48.80 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 10.53 97.56 43.71 9.33 93.71 47.17 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 A 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 226 THR A 139 THR^? -4.08 O1S EPE A 145s A 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 7.24 97.46 49.60 8.11 95.69 48.80 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 10.53 97.56 43.71 9.33 93.71 47.17 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 3 3 # 3 A 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 226 THR A 140 THR^? -4.46 O3S EPE A 145s A 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 7.24 97.46 49.60 8.11 95.69 48.80 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 10.53 97.56 43.71 9.33 93.71 47.17 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 4 3 # 4 A 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 A 226 THR B 139 THR^? -4.10 O3S EPE A 145s A 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 7.24 97.46 49.60 8.11 95.69 48.80 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 10.53 97.56 43.71 9.33 93.71 47.17 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 5 3 # 5 A 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 A 226 THR B 140 THR^? -4.33 O2S EPE A 145s A 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 7.24 97.46 49.60 8.11 95.69 48.80 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 10.53 97.56 43.71 9.33 93.71 47.17 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 6 3 # 6 A 57 GLU D 109 GLU~? 11.50 CL CL D 145 A 226 THR D 17 THR~? 16.46 CL CL D 144 A 229 LYS D 20 LYS~? 10.12 CL CL D 144 coo 9.66 102.78 70.07 9.79 101.18 71.42 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 coo 7.24 97.46 49.60 8.11 95.69 48.80 1.11 -9.25 -50.49 1.81 -7.39 -51.27 coo 10.53 97.56 43.71 9.33 93.71 47.17 3.77 -7.84 -45.94 1.16 -2.20 -46.49 ULMN 3 1dfo_c04 SERINE HYDROXYMETHYLTRANSFERASE user 7 3 # 7 A 57 GLU D 136 GLU~? 8.82 C5 EPE D 146 A 226 THR C 139 THR^? -4.20 O2S EPE A 145s A 229 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 9.66 102.78 70.07 9.79 101.18 71.42 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 7.24 97.46 49.60 8.11 95.69 48.80 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 10.53 97.56 43.71 9.33 93.71 47.17 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1dfo_c04 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 7 hits 1dfo_c04 naa= 3 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 B 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 226 THR A 139 THR^? -4.08 O1S EPE A 145s B 229 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 20.74 95.78 68.68 19.29 96.84 69.83 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 22.32 101.61 71.64 17.89 98.63 71.55 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 B 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 226 THR A 139 THR^? -4.08 O1S EPE A 145s B 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 20.74 95.78 68.68 19.29 96.84 69.83 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 22.32 101.61 71.64 17.89 98.63 71.55 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 3 3 # 3 B 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 226 THR A 140 THR^? -4.46 O3S EPE A 145s B 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 20.74 95.78 68.68 19.29 96.84 69.83 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 22.32 101.61 71.64 17.89 98.63 71.55 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 4 3 # 4 B 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 B 226 THR B 139 THR^? -4.10 O3S EPE A 145s B 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 20.74 95.78 68.68 19.29 96.84 69.83 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 22.32 101.61 71.64 17.89 98.63 71.55 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 5 3 # 5 B 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 B 226 THR B 140 THR^? -4.33 O2S EPE A 145s B 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 20.74 95.78 68.68 19.29 96.84 69.83 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 22.32 101.61 71.64 17.89 98.63 71.55 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 6 3 # 6 B 57 GLU D 109 GLU~? 11.50 CL CL D 145 B 226 THR D 17 THR~? 16.46 CL CL D 144 B 229 LYS D 20 LYS~? 10.12 CL CL D 144 coo 15.90 87.61 49.61 13.92 86.96 49.36 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 coo 20.74 95.78 68.68 19.29 96.84 69.83 1.11 -9.25 -50.49 1.81 -7.39 -51.27 coo 22.32 101.61 71.64 17.89 98.63 71.55 3.77 -7.84 -45.94 1.16 -2.20 -46.49 ULMN 3 1dfo_c05 SERINE HYDROXYMETHYLTRANSFERASE user 7 3 # 7 B 57 GLU D 136 GLU~? 8.82 C5 EPE D 146 B 226 THR C 139 THR^? -4.20 O2S EPE A 145s B 229 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 15.90 87.61 49.61 13.92 86.96 49.36 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 20.74 95.78 68.68 19.29 96.84 69.83 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 22.32 101.61 71.64 17.89 98.63 71.55 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1dfo_c05 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 7 hits 1dfo_c05 naa= 3 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 C 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 226 THR A 139 THR^? -4.08 O1S EPE A 145s C 229 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 22.16 45.88 73.63 23.23 47.70 73.25 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 28.90 45.91 73.55 25.22 49.72 72.97 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 C 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 226 THR A 139 THR^? -4.08 O1S EPE A 145s C 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 22.16 45.88 73.63 23.23 47.70 73.25 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 28.90 45.91 73.55 25.22 49.72 72.97 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 3 3 # 3 C 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 226 THR A 140 THR^? -4.46 O3S EPE A 145s C 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 22.16 45.88 73.63 23.23 47.70 73.25 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 28.90 45.91 73.55 25.22 49.72 72.97 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 4 3 # 4 C 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 C 226 THR B 139 THR^? -4.10 O3S EPE A 145s C 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 22.16 45.88 73.63 23.23 47.70 73.25 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 28.90 45.91 73.55 25.22 49.72 72.97 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 5 3 # 5 C 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 C 226 THR B 140 THR^? -4.33 O2S EPE A 145s C 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 22.16 45.88 73.63 23.23 47.70 73.25 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 28.90 45.91 73.55 25.22 49.72 72.97 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 6 3 # 6 C 57 GLU D 109 GLU~? 11.50 CL CL D 145 C 226 THR D 17 THR~? 16.46 CL CL D 144 C 229 LYS D 20 LYS~? 10.12 CL CL D 144 coo 5.43 40.40 61.63 4.27 41.99 60.90 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 coo 22.16 45.88 73.63 23.23 47.70 73.25 1.11 -9.25 -50.49 1.81 -7.39 -51.27 coo 28.90 45.91 73.55 25.22 49.72 72.97 3.77 -7.84 -45.94 1.16 -2.20 -46.49 ULMN 3 1dfo_c06 SERINE HYDROXYMETHYLTRANSFERASE user 7 3 # 7 C 57 GLU D 136 GLU~? 8.82 C5 EPE D 146 C 226 THR C 139 THR^? -4.20 O2S EPE A 145s C 229 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 5.43 40.40 61.63 4.27 41.99 60.90 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 22.16 45.88 73.63 23.23 47.70 73.25 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 28.90 45.91 73.55 25.22 49.72 72.97 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1dfo_c06 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 7 hits 1dfo_c06 naa= 3 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 D 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 226 THR A 139 THR^? -4.08 O1S EPE A 145s D 229 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 11.79 47.62 52.67 10.10 46.51 53.39 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 10.05 41.79 49.80 7.94 44.71 53.76 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 D 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 226 THR A 139 THR^? -4.08 O1S EPE A 145s D 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 11.79 47.62 52.67 10.10 46.51 53.39 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 10.05 41.79 49.80 7.94 44.71 53.76 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 3 3 # 3 D 57 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 226 THR A 140 THR^? -4.46 O3S EPE A 145s D 229 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 11.79 47.62 52.67 10.10 46.51 53.39 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 10.05 41.79 49.80 7.94 44.71 53.76 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 4 3 # 4 D 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 D 226 THR B 139 THR^? -4.10 O3S EPE A 145s D 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 11.79 47.62 52.67 10.10 46.51 53.39 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 10.05 41.79 49.80 7.94 44.71 53.76 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 5 3 # 5 D 57 GLU C 98 GLU^? 18.25 O8 EPE A 145 D 226 THR B 140 THR^? -4.33 O2S EPE A 145s D 229 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 11.79 47.62 52.67 10.10 46.51 53.39 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 10.05 41.79 49.80 7.94 44.71 53.76 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 6 3 # 6 D 57 GLU D 109 GLU~? 11.50 CL CL D 145 D 226 THR D 17 THR~? 16.46 CL CL D 144 D 229 LYS D 20 LYS~? 10.12 CL CL D 144 coo 26.07 55.89 66.14 25.33 56.50 68.01 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 coo 11.79 47.62 52.67 10.10 46.51 53.39 1.11 -9.25 -50.49 1.81 -7.39 -51.27 coo 10.05 41.79 49.80 7.94 44.71 53.76 3.77 -7.84 -45.94 1.16 -2.20 -46.49 ULMN 3 1dfo_c07 SERINE HYDROXYMETHYLTRANSFERASE user 7 3 # 7 D 57 GLU D 136 GLU~? 8.82 C5 EPE D 146 D 226 THR C 139 THR^? -4.20 O2S EPE A 145s D 229 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 26.07 55.89 66.14 25.33 56.50 68.01 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 11.79 47.62 52.67 10.10 46.51 53.39 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 10.05 41.79 49.80 7.94 44.71 53.76 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1dfo_c07 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 7 hits 1dfo_c07 naa= 3 ULMN 3 1dfo_c12 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 A 123 HIS A 87 HIS.? 23.42 CL CL A 144 A 200 ASP A 19 ASP~? 15.97 CL CL A 144 A 229 LYS B 65 LYS~? 24.78 CL CL A 144 coo 1.13 77.49 40.64 0.62 75.57 39.98 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 0.84 91.24 49.01 2.91 91.61 49.23 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 10.53 97.56 43.71 9.33 93.71 47.17 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1dfo_c12 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 A 123 HIS C 87 HIS.? 23.40 CL CL A 144 A 200 ASP C 19 ASP~? 15.67 CL CL A 144 A 229 LYS A 65 LYS~? 24.48 CL CL A 144 coo 1.13 77.49 40.64 0.62 75.57 39.98 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 0.84 91.24 49.01 2.91 91.61 49.23 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 10.53 97.56 43.71 9.33 93.71 47.17 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1dfo_c12 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c12 naa= 3 ULMN 3 1dfo_c13 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 B 123 HIS A 87 HIS.? 23.42 CL CL A 144 B 200 ASP A 19 ASP~? 15.97 CL CL A 144 B 229 LYS B 65 LYS~? 24.78 CL CL A 144 coo 9.24 94.26 88.22 8.02 94.07 89.92 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 17.54 90.31 75.01 17.17 92.01 73.80 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 22.32 101.61 71.64 17.89 98.63 71.55 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1dfo_c13 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 B 123 HIS C 87 HIS.? 23.40 CL CL A 144 B 200 ASP C 19 ASP~? 15.67 CL CL A 144 B 229 LYS A 65 LYS~? 24.48 CL CL A 144 coo 9.24 94.26 88.22 8.02 94.07 89.92 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 17.54 90.31 75.01 17.17 92.01 73.80 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 22.32 101.61 71.64 17.89 98.63 71.55 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1dfo_c13 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c13 naa= 3 ULMN 3 1dfo_c14 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 C 123 HIS A 87 HIS.? 23.42 CL CL A 144 C 200 ASP A 19 ASP~? 15.97 CL CL A 144 C 229 LYS B 65 LYS~? 24.78 CL CL A 144 coo 26.77 65.84 83.49 27.06 67.76 84.27 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 19.52 52.01 79.59 20.28 51.65 77.65 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 28.90 45.91 73.55 25.22 49.72 72.97 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1dfo_c14 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 C 123 HIS C 87 HIS.? 23.40 CL CL A 144 C 200 ASP C 19 ASP~? 15.67 CL CL A 144 C 229 LYS A 65 LYS~? 24.48 CL CL A 144 coo 26.77 65.84 83.49 27.06 67.76 84.27 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 19.52 52.01 79.59 20.28 51.65 77.65 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 28.90 45.91 73.55 25.22 49.72 72.97 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1dfo_c14 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c14 naa= 3 ULMN 3 1dfo_c15 SERINE HYDROXYMETHYLTRANSFERASE user 1 3 # 1 D 123 HIS A 87 HIS.? 23.42 CL CL A 144 D 200 ASP A 19 ASP~? 15.97 CL CL A 144 D 229 LYS B 65 LYS~? 24.78 CL CL A 144 coo -10.90 48.74 53.41 -12.98 48.90 53.67 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 4.60 52.95 52.50 5.57 51.29 53.40 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 10.05 41.79 49.80 7.94 44.71 53.76 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1dfo_c15 SERINE HYDROXYMETHYLTRANSFERASE user 2 3 # 2 D 123 HIS C 87 HIS.? 23.40 CL CL A 144 D 200 ASP C 19 ASP~? 15.67 CL CL A 144 D 229 LYS A 65 LYS~? 24.48 CL CL A 144 coo -10.90 48.74 53.41 -12.98 48.90 53.67 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 4.60 52.95 52.50 5.57 51.29 53.40 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 10.05 41.79 49.80 7.94 44.71 53.76 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1dfo_c15 source 1dfo SERINE HYDROXYMETHYLTRANSFERASE : 2 hits 1dfo_c15 naa= 3 ULMN 3 1dhp_c00 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 A 133 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 138 ARG D 134 ARG~? 13.66 CL CL D 145 A 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 29.03 88.95 86.80 28.09 90.57 84.75 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 23.31 93.18 82.88 23.00 93.71 79.86 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 33.83 91.15 88.62 31.07 91.06 83.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 1dhp_c00 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 1 hits 1dhp_c00 naa= 3 ULMN 3 1dhp_c01 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 B 133 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 138 ARG D 134 ARG~? 13.66 CL CL D 145 B 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 4.62 122.69 99.88 5.46 122.82 97.24 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 10.44 122.27 94.08 11.02 123.87 91.53 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -0.17 119.75 99.65 2.51 123.83 95.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 1dhp_c01 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 1 hits 1dhp_c01 naa= 3 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 A 44 THR A 106 THR~? 9.35 CL CL D 145 A 45 THR A 107 THR~? 14.10 CL CL D 145 A 161 LYS B 20 LYS~? 9.95 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo 27.73 89.90 76.08 29.24 91.46 75.95 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 33.83 91.15 88.62 31.07 91.06 83.02 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 2 3 # 2 A 44 THR A 106 THR~? 9.35 CL CL D 145 A 45 THR A 107 THR~? 14.10 CL CL D 145 A 161 LYS B 82 LYS.? 24.10 CL CL D 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo 27.73 89.90 76.08 29.24 91.46 75.95 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 33.83 91.15 88.62 31.07 91.06 83.02 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 3 3 # 3 A 44 THR A 107 THR~? 14.10 CL CL D 145 A 45 THR A 106 THR~? 9.35 CL CL D 145 A 161 LYS B 20 LYS~? 9.95 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo 33.83 91.15 88.62 31.07 91.06 83.02 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 4 3 # 4 A 44 THR A 139 THR^? -4.08 O1S EPE A 145s A 45 THR A 140 THR^? -4.46 O3S EPE A 145s A 161 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 33.83 91.15 88.62 31.07 91.06 83.02 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 5 3 # 5 A 44 THR A 139 THR^? -4.08 O1S EPE A 145s A 45 THR A 140 THR^? -4.46 O3S EPE A 145s A 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 33.83 91.15 88.62 31.07 91.06 83.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 6 3 # 6 A 44 THR A 139 THR^? -4.08 O1S EPE A 145s A 45 THR A 140 THR^? -4.46 O3S EPE A 145s A 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 33.83 91.15 88.62 31.07 91.06 83.02 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 7 3 # 7 A 44 THR A 140 THR^? -4.46 O3S EPE A 145s A 45 THR A 139 THR^? -4.08 O1S EPE A 145s A 161 LYS A 100 LYS^? 18.99 CL CL D 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 33.83 91.15 88.62 31.07 91.06 83.02 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 8 3 # 8 A 44 THR A 140 THR^? -4.46 O3S EPE A 145s A 45 THR A 139 THR^? -4.08 O1S EPE A 145s A 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 27.73 89.90 76.08 29.24 91.46 75.95 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 33.83 91.15 88.62 31.07 91.06 83.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 9 3 # 9 A 44 THR B 106 THR~? 19.39 CL CL A 144 A 45 THR B 107 THR~? 17.49 CL CL A 144 A 161 LYS C 20 LYS~? 9.96 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 27.73 89.90 76.08 29.24 91.46 75.95 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 33.83 91.15 88.62 31.07 91.06 83.02 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 10 3 # 10 A 44 THR B 106 THR~? 19.39 CL CL A 144 A 45 THR B 107 THR~? 17.49 CL CL A 144 A 161 LYS C 82 LYS.? 35.24 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 27.73 89.90 76.08 29.24 91.46 75.95 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 33.83 91.15 88.62 31.07 91.06 83.02 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 11 3 # 11 A 44 THR B 107 THR~? 17.49 CL CL A 144 A 45 THR B 106 THR~? 19.39 CL CL A 144 A 161 LYS C 20 LYS~? 9.96 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 27.73 89.90 76.08 29.24 91.46 75.95 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 33.83 91.15 88.62 31.07 91.06 83.02 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 12 3 # 12 A 44 THR B 107 THR~? 17.49 CL CL A 144 A 45 THR B 106 THR~? 19.39 CL CL A 144 A 161 LYS C 82 LYS.? 35.24 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 27.73 89.90 76.08 29.24 91.46 75.95 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 33.83 91.15 88.62 31.07 91.06 83.02 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 13 3 # 13 A 44 THR B 139 THR^? -4.10 O3S EPE A 145s A 45 THR B 140 THR^? -4.33 O2S EPE A 145s A 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 27.73 89.90 76.08 29.24 91.46 75.95 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 33.83 91.15 88.62 31.07 91.06 83.02 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 14 3 # 14 A 44 THR B 139 THR^? -4.10 O3S EPE A 145s A 45 THR B 140 THR^? -4.33 O2S EPE A 145s A 161 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 26.16 88.25 79.16 25.22 89.47 80.71 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 27.73 89.90 76.08 29.24 91.46 75.95 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 33.83 91.15 88.62 31.07 91.06 83.02 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 15 3 # 15 A 44 THR B 139 THR^? -4.10 O3S EPE A 145s A 45 THR B 140 THR^? -4.33 O2S EPE A 145s A 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 27.73 89.90 76.08 29.24 91.46 75.95 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 33.83 91.15 88.62 31.07 91.06 83.02 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 16 3 # 16 A 44 THR B 140 THR^? -4.33 O2S EPE A 145s A 45 THR B 139 THR^? -4.10 O3S EPE A 145s A 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 27.73 89.90 76.08 29.24 91.46 75.95 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 33.83 91.15 88.62 31.07 91.06 83.02 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 17 3 # 17 A 44 THR B 140 THR^? -4.33 O2S EPE A 145s A 45 THR B 139 THR^? -4.10 O3S EPE A 145s A 161 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 27.73 89.90 76.08 29.24 91.46 75.95 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 33.83 91.15 88.62 31.07 91.06 83.02 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 18 3 # 18 A 44 THR B 140 THR^? -4.33 O2S EPE A 145s A 45 THR B 139 THR^? -4.10 O3S EPE A 145s A 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 27.73 89.90 76.08 29.24 91.46 75.95 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 33.83 91.15 88.62 31.07 91.06 83.02 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 19 3 # 19 A 44 THR C 106 THR~? 19.51 CL CL A 144 A 45 THR C 107 THR~? 17.51 CL CL A 144 A 161 LYS A 20 LYS~? 9.88 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 27.73 89.90 76.08 29.24 91.46 75.95 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 33.83 91.15 88.62 31.07 91.06 83.02 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 20 3 # 20 A 44 THR C 106 THR~? 19.51 CL CL A 144 A 45 THR C 107 THR~? 17.51 CL CL A 144 A 161 LYS A 82 LYS.? 35.27 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 27.73 89.90 76.08 29.24 91.46 75.95 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 33.83 91.15 88.62 31.07 91.06 83.02 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 21 3 # 21 A 44 THR C 107 THR~? 17.51 CL CL A 144 A 45 THR C 106 THR~? 19.51 CL CL A 144 A 161 LYS A 20 LYS~? 9.88 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 27.73 89.90 76.08 29.24 91.46 75.95 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 33.83 91.15 88.62 31.07 91.06 83.02 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 22 3 # 22 A 44 THR C 107 THR~? 17.51 CL CL A 144 A 45 THR C 106 THR~? 19.51 CL CL A 144 A 161 LYS A 82 LYS.? 35.27 CL CL A 144 coo 26.16 88.25 79.16 25.22 89.47 80.71 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 27.73 89.90 76.08 29.24 91.46 75.95 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 33.83 91.15 88.62 31.07 91.06 83.02 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 23 3 # 23 A 44 THR C 139 THR^? -4.20 O2S EPE A 145s A 45 THR C 140 THR^? -4.37 O1S EPE A 145s A 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 27.73 89.90 76.08 29.24 91.46 75.95 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 33.83 91.15 88.62 31.07 91.06 83.02 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 24 3 # 24 A 44 THR C 139 THR^? -4.20 O2S EPE A 145s A 45 THR C 140 THR^? -4.37 O1S EPE A 145s A 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 27.73 89.90 76.08 29.24 91.46 75.95 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 33.83 91.15 88.62 31.07 91.06 83.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 25 3 # 25 A 44 THR C 140 THR^? -4.37 O1S EPE A 145s A 45 THR C 139 THR^? -4.20 O2S EPE A 145s A 161 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 27.73 89.90 76.08 29.24 91.46 75.95 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 33.83 91.15 88.62 31.07 91.06 83.02 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 26 3 # 26 A 44 THR C 140 THR^? -4.37 O1S EPE A 145s A 45 THR C 139 THR^? -4.20 O2S EPE A 145s A 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 27.73 89.90 76.08 29.24 91.46 75.95 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 33.83 91.15 88.62 31.07 91.06 83.02 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 27 3 # 27 A 44 THR C 140 THR^? -4.37 O1S EPE A 145s A 45 THR C 139 THR^? -4.20 O2S EPE A 145s A 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 27.73 89.90 76.08 29.24 91.46 75.95 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 33.83 91.15 88.62 31.07 91.06 83.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 28 3 # 28 A 44 THR C 140 THR^? -4.37 O1S EPE A 145s A 45 THR C 139 THR^? -4.20 O2S EPE A 145s A 161 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 27.73 89.90 76.08 29.24 91.46 75.95 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 33.83 91.15 88.62 31.07 91.06 83.02 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 29 3 # 29 A 44 THR D 139 THR^? -4.08 O3S EPE D 146s A 45 THR D 140 THR^? -4.35 O2S EPE D 146s A 161 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo 26.16 88.25 79.16 25.22 89.47 80.71 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 27.73 89.90 76.08 29.24 91.46 75.95 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 33.83 91.15 88.62 31.07 91.06 83.02 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1dhp_c02 DIHYDRODIPICOLINATE SYNTHASE user 30 3 # 30 A 44 THR D 140 THR^? -4.35 O2S EPE D 146s A 45 THR D 139 THR^? -4.08 O3S EPE D 146s A 161 LYS D 100 LYS^? 18.85 CL CL D 145 coo 26.16 88.25 79.16 25.22 89.47 80.71 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 27.73 89.90 76.08 29.24 91.46 75.95 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 33.83 91.15 88.62 31.07 91.06 83.02 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1dhp_c02 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 30 hits 1dhp_c02 naa= 3 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 1 3 # 1 B 44 THR A 106 THR~? 9.35 CL CL D 145 B 45 THR A 107 THR~? 14.10 CL CL D 145 B 161 LYS B 20 LYS~? 9.95 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo 5.75 129.25 91.25 4.29 128.16 90.07 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo -0.17 119.75 99.65 2.51 123.83 95.70 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 2 3 # 2 B 44 THR A 106 THR~? 9.35 CL CL D 145 B 45 THR A 107 THR~? 14.10 CL CL D 145 B 161 LYS B 82 LYS.? 24.10 CL CL D 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo 5.75 129.25 91.25 4.29 128.16 90.07 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo -0.17 119.75 99.65 2.51 123.83 95.70 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 3 3 # 3 B 44 THR A 107 THR~? 14.10 CL CL D 145 B 45 THR A 106 THR~? 9.35 CL CL D 145 B 161 LYS B 20 LYS~? 9.95 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -29.67 -14.57 -33.80 -30.99 -14.18 -32.08 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.98 -14.07 -34.49 -24.57 -15.36 -33.50 coo -0.17 119.75 99.65 2.51 123.83 95.70 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 4 3 # 4 B 44 THR A 139 THR^? -4.08 O1S EPE A 145s B 45 THR A 140 THR^? -4.46 O3S EPE A 145s B 161 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -0.17 119.75 99.65 2.51 123.83 95.70 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 5 3 # 5 B 44 THR A 139 THR^? -4.08 O1S EPE A 145s B 45 THR A 140 THR^? -4.46 O3S EPE A 145s B 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -0.17 119.75 99.65 2.51 123.83 95.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 6 3 # 6 B 44 THR A 139 THR^? -4.08 O1S EPE A 145s B 45 THR A 140 THR^? -4.46 O3S EPE A 145s B 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -0.17 119.75 99.65 2.51 123.83 95.70 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 7 3 # 7 B 44 THR A 140 THR^? -4.46 O3S EPE A 145s B 45 THR A 139 THR^? -4.08 O1S EPE A 145s B 161 LYS A 100 LYS^? 18.99 CL CL D 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo -0.17 119.75 99.65 2.51 123.83 95.70 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 8 3 # 8 B 44 THR A 140 THR^? -4.46 O3S EPE A 145s B 45 THR A 139 THR^? -4.08 O1S EPE A 145s B 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 5.75 129.25 91.25 4.29 128.16 90.07 -25.04 -5.41 -12.78 -26.45 -5.29 -11.22 coo -0.17 119.75 99.65 2.51 123.83 95.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 9 3 # 9 B 44 THR B 106 THR~? 19.39 CL CL A 144 B 45 THR B 107 THR~? 17.49 CL CL A 144 B 161 LYS C 20 LYS~? 9.96 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 5.75 129.25 91.25 4.29 128.16 90.07 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo -0.17 119.75 99.65 2.51 123.83 95.70 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 10 3 # 10 B 44 THR B 106 THR~? 19.39 CL CL A 144 B 45 THR B 107 THR~? 17.49 CL CL A 144 B 161 LYS C 82 LYS.? 35.24 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo 5.75 129.25 91.25 4.29 128.16 90.07 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo -0.17 119.75 99.65 2.51 123.83 95.70 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 11 3 # 11 B 44 THR B 107 THR~? 17.49 CL CL A 144 B 45 THR B 106 THR~? 19.39 CL CL A 144 B 161 LYS C 20 LYS~? 9.96 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 5.75 129.25 91.25 4.29 128.16 90.07 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo -0.17 119.75 99.65 2.51 123.83 95.70 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 12 3 # 12 B 44 THR B 107 THR~? 17.49 CL CL A 144 B 45 THR B 106 THR~? 19.39 CL CL A 144 B 161 LYS C 82 LYS.? 35.24 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -28.22 -31.86 -8.33 -28.56 -30.63 -10.08 coo 5.75 129.25 91.25 4.29 128.16 90.07 -26.38 -31.28 -5.06 -27.22 -29.75 -3.79 coo -0.17 119.75 99.65 2.51 123.83 95.70 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 13 3 # 13 B 44 THR B 139 THR^? -4.10 O3S EPE A 145s B 45 THR B 140 THR^? -4.33 O2S EPE A 145s B 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 5.75 129.25 91.25 4.29 128.16 90.07 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -0.17 119.75 99.65 2.51 123.83 95.70 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 14 3 # 14 B 44 THR B 139 THR^? -4.10 O3S EPE A 145s B 45 THR B 140 THR^? -4.33 O2S EPE A 145s B 161 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 7.39 128.28 94.56 8.34 126.36 94.79 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 5.75 129.25 91.25 4.29 128.16 90.07 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -0.17 119.75 99.65 2.51 123.83 95.70 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 15 3 # 15 B 44 THR B 139 THR^? -4.10 O3S EPE A 145s B 45 THR B 140 THR^? -4.33 O2S EPE A 145s B 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 5.75 129.25 91.25 4.29 128.16 90.07 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -0.17 119.75 99.65 2.51 123.83 95.70 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 16 3 # 16 B 44 THR B 140 THR^? -4.33 O2S EPE A 145s B 45 THR B 139 THR^? -4.10 O3S EPE A 145s B 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 5.75 129.25 91.25 4.29 128.16 90.07 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo -0.17 119.75 99.65 2.51 123.83 95.70 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 17 3 # 17 B 44 THR B 140 THR^? -4.33 O2S EPE A 145s B 45 THR B 139 THR^? -4.10 O3S EPE A 145s B 161 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 5.75 129.25 91.25 4.29 128.16 90.07 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo -0.17 119.75 99.65 2.51 123.83 95.70 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 18 3 # 18 B 44 THR B 140 THR^? -4.33 O2S EPE A 145s B 45 THR B 139 THR^? -4.10 O3S EPE A 145s B 161 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 5.75 129.25 91.25 4.29 128.16 90.07 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo -0.17 119.75 99.65 2.51 123.83 95.70 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 19 3 # 19 B 44 THR C 106 THR~? 19.51 CL CL A 144 B 45 THR C 107 THR~? 17.51 CL CL A 144 B 161 LYS A 20 LYS~? 9.88 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 5.75 129.25 91.25 4.29 128.16 90.07 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo -0.17 119.75 99.65 2.51 123.83 95.70 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 20 3 # 20 B 44 THR C 106 THR~? 19.51 CL CL A 144 B 45 THR C 107 THR~? 17.51 CL CL A 144 B 161 LYS A 82 LYS.? 35.27 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo 5.75 129.25 91.25 4.29 128.16 90.07 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo -0.17 119.75 99.65 2.51 123.83 95.70 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 21 3 # 21 B 44 THR C 107 THR~? 17.51 CL CL A 144 B 45 THR C 106 THR~? 19.51 CL CL A 144 B 161 LYS A 20 LYS~? 9.88 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 5.75 129.25 91.25 4.29 128.16 90.07 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo -0.17 119.75 99.65 2.51 123.83 95.70 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 22 3 # 22 B 44 THR C 107 THR~? 17.51 CL CL A 144 B 45 THR C 106 THR~? 19.51 CL CL A 144 B 161 LYS A 82 LYS.? 35.27 CL CL A 144 coo 7.39 128.28 94.56 8.34 126.36 94.79 -46.05 -6.81 -8.96 -44.37 -8.11 -8.69 coo 5.75 129.25 91.25 4.29 128.16 90.07 -45.04 -3.18 -8.60 -44.18 -2.39 -10.41 coo -0.17 119.75 99.65 2.51 123.83 95.70 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 23 3 # 23 B 44 THR C 139 THR^? -4.20 O2S EPE A 145s B 45 THR C 140 THR^? -4.37 O1S EPE A 145s B 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 5.75 129.25 91.25 4.29 128.16 90.07 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo -0.17 119.75 99.65 2.51 123.83 95.70 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 24 3 # 24 B 44 THR C 139 THR^? -4.20 O2S EPE A 145s B 45 THR C 140 THR^? -4.37 O1S EPE A 145s B 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo 5.75 129.25 91.25 4.29 128.16 90.07 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo -0.17 119.75 99.65 2.51 123.83 95.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 25 3 # 25 B 44 THR C 140 THR^? -4.37 O1S EPE A 145s B 45 THR C 139 THR^? -4.20 O2S EPE A 145s B 161 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 5.75 129.25 91.25 4.29 128.16 90.07 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo -0.17 119.75 99.65 2.51 123.83 95.70 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 26 3 # 26 B 44 THR C 140 THR^? -4.37 O1S EPE A 145s B 45 THR C 139 THR^? -4.20 O2S EPE A 145s B 161 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 5.75 129.25 91.25 4.29 128.16 90.07 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo -0.17 119.75 99.65 2.51 123.83 95.70 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 27 3 # 27 B 44 THR C 140 THR^? -4.37 O1S EPE A 145s B 45 THR C 139 THR^? -4.20 O2S EPE A 145s B 161 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 5.75 129.25 91.25 4.29 128.16 90.07 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo -0.17 119.75 99.65 2.51 123.83 95.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 28 3 # 28 B 44 THR C 140 THR^? -4.37 O1S EPE A 145s B 45 THR C 139 THR^? -4.20 O2S EPE A 145s B 161 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -26.53 -10.66 -9.09 -27.39 -8.68 -8.89 coo 5.75 129.25 91.25 4.29 128.16 90.07 -23.01 -11.13 -7.76 -22.15 -13.06 -7.97 coo -0.17 119.75 99.65 2.51 123.83 95.70 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 29 3 # 29 B 44 THR D 139 THR^? -4.08 O3S EPE D 146s B 45 THR D 140 THR^? -4.35 O2S EPE D 146s B 161 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo 7.39 128.28 94.56 8.34 126.36 94.79 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 5.75 129.25 91.25 4.29 128.16 90.07 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo -0.17 119.75 99.65 2.51 123.83 95.70 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1dhp_c03 DIHYDRODIPICOLINATE SYNTHASE user 30 3 # 30 B 44 THR D 140 THR^? -4.35 O2S EPE D 146s B 45 THR D 139 THR^? -4.08 O3S EPE D 146s B 161 LYS D 100 LYS^? 18.85 CL CL D 145 coo 7.39 128.28 94.56 8.34 126.36 94.79 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 5.75 129.25 91.25 4.29 128.16 90.07 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo -0.17 119.75 99.65 2.51 123.83 95.70 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1dhp_c03 source 1dhp DIHYDRODIPICOLINATE SYNTHASE : 30 hits 1dhp_c03 naa= 3 ULMN 3 1dhr_c00 DIHYDROPTERIDINE REDUCTASE (DHPR) (Euser 1 3 # 1 146 TYR B 36 TYR.? 11.13 O3S EPE A 145 150 LYS B 8 LYS^? 8.74 C3 EPE A 145 186 ASN D 39 ASN^? 12.69 O3S EPE D 146 coo 32.88 50.55 24.33 31.89 51.78 26.65 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 27.04 52.42 22.30 26.88 49.99 27.00 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 36.98 50.30 37.29 35.85 50.29 35.50 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 1dhr_c00 source 1dhr DIHYDROPTERIDINE REDUCTASE (DHPR) (E.C.1.6.99.: 1 hits 1dhr_c00 naa= 3 ULMN 3 1do8_c00 MALIC ENZYME user 1 3 # 1 A 112 TYR A 67 TYR~? 16.80 CL CL A 144 A 183 LYS A 65 LYS~? 24.48 CL CL A 144 A 278 ASP B 64 ASP~? 15.96 CL CL A 144 coo 19.43 18.53 42.32 17.66 18.80 40.15 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 21.92 15.80 36.19 17.64 19.44 36.35 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 15.46 19.03 31.40 15.01 18.25 33.31 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1do8_c00 MALIC ENZYME user 2 3 # 2 A 112 TYR B 67 TYR~? 16.82 CL CL A 144 A 183 LYS B 65 LYS~? 24.78 CL CL A 144 A 278 ASP C 64 ASP~? 15.91 CL CL A 144 coo 19.43 18.53 42.32 17.66 18.80 40.15 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 21.92 15.80 36.19 17.64 19.44 36.35 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 15.46 19.03 31.40 15.01 18.25 33.31 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1do8_c00 source 1do8 MALIC ENZYME : 2 hits 1do8_c00 naa= 3 ULMN 3 1do8_c01 MALIC ENZYME user 1 3 # 1 B 112 TYR A 67 TYR~? 16.80 CL CL A 144 B 183 LYS A 65 LYS~? 24.48 CL CL A 144 B 278 ASP B 64 ASP~? 15.96 CL CL A 144 coo 58.62 15.99 58.34 60.98 14.60 58.93 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 60.11 10.60 53.63 62.59 10.74 58.67 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 66.50 7.32 58.45 66.26 9.42 58.23 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1do8_c01 MALIC ENZYME user 2 3 # 2 B 112 TYR B 67 TYR~? 16.82 CL CL A 144 B 183 LYS B 65 LYS~? 24.78 CL CL A 144 B 278 ASP C 64 ASP~? 15.91 CL CL A 144 coo 58.62 15.99 58.34 60.98 14.60 58.93 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 60.11 10.60 53.63 62.59 10.74 58.67 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 66.50 7.32 58.45 66.26 9.42 58.23 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1do8_c01 source 1do8 MALIC ENZYME : 2 hits 1do8_c01 naa= 3 ULMN 3 1do8_c02 MALIC ENZYME user 1 3 # 1 C 112 TYR A 67 TYR~? 16.80 CL CL A 144 C 183 LYS A 65 LYS~? 24.48 CL CL A 144 C 278 ASP B 64 ASP~? 15.96 CL CL A 144 coo 76.02 -16.57 8.89 78.24 -15.17 9.87 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 74.18 -11.17 13.22 79.08 -11.19 10.47 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 82.27 -7.93 13.54 81.93 -10.04 13.72 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1do8_c02 MALIC ENZYME user 2 3 # 2 C 112 TYR B 67 TYR~? 16.82 CL CL A 144 C 183 LYS B 65 LYS~? 24.78 CL CL A 144 C 278 ASP C 64 ASP~? 15.91 CL CL A 144 coo 76.02 -16.57 8.89 78.24 -15.17 9.87 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 74.18 -11.17 13.22 79.08 -11.19 10.47 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 82.27 -7.93 13.54 81.93 -10.04 13.72 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1do8_c02 source 1do8 MALIC ENZYME : 2 hits 1do8_c02 naa= 3 ULMN 3 1do8_c03 MALIC ENZYME user 1 3 # 1 D 112 TYR A 67 TYR~? 16.80 CL CL A 144 D 183 LYS A 65 LYS~? 24.48 CL CL A 144 D 278 ASP B 64 ASP~? 15.96 CL CL A 144 coo 35.64 -19.32 -3.24 32.92 -19.55 -2.64 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 33.51 -16.63 3.10 30.11 -20.23 0.26 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 25.62 -19.94 2.86 26.44 -19.16 1.09 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1do8_c03 MALIC ENZYME user 2 3 # 2 D 112 TYR B 67 TYR~? 16.82 CL CL A 144 D 183 LYS B 65 LYS~? 24.78 CL CL A 144 D 278 ASP C 64 ASP~? 15.91 CL CL A 144 coo 35.64 -19.32 -3.24 32.92 -19.55 -2.64 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 33.51 -16.63 3.10 30.11 -20.23 0.26 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 25.62 -19.94 2.86 26.44 -19.16 1.09 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1do8_c03 source 1do8 MALIC ENZYME : 2 hits 1do8_c03 naa= 3 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 1 3 # 1 A 131 LYS A 6 LYS.? 17.07 C5 EPE A 145 A 215 LYS A 100 LYS^? 18.99 CL CL D 145 A 277 LYS A 94 LYS.? 20.29 CL CL D 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 13.06 30.79 51.73 11.40 35.76 53.48 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 13.04 31.88 60.72 10.57 35.34 57.49 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 2 3 # 2 A 131 LYS A 7 LYS.? 11.74 O8 EPE A 145 A 215 LYS A 100 LYS^? 18.99 CL CL D 145 A 277 LYS A 94 LYS.? 20.29 CL CL D 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 -24.35 2.90 -12.02 -25.19 4.34 -6.86 coo 13.06 30.79 51.73 11.40 35.76 53.48 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 13.04 31.88 60.72 10.57 35.34 57.49 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 3 3 # 3 A 131 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 215 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 277 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 13.06 30.79 51.73 11.40 35.76 53.48 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 13.04 31.88 60.72 10.57 35.34 57.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 4 3 # 4 A 131 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 215 LYS D 100 LYS^? 18.85 CL CL D 145 A 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 13.06 30.79 51.73 11.40 35.76 53.48 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 13.04 31.88 60.72 10.57 35.34 57.49 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 5 3 # 5 A 131 LYS C 20 LYS~? 9.96 CL CL A 144 A 215 LYS A 65 LYS~? 24.48 CL CL A 144 A 277 LYS B 65 LYS~? 24.78 CL CL A 144 coo 0.50 24.09 51.68 1.51 29.34 52.35 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 coo 13.06 30.79 51.73 11.40 35.76 53.48 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 13.04 31.88 60.72 10.57 35.34 57.49 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 6 3 # 6 A 131 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 215 LYS D 100 LYS^? 18.85 CL CL D 145 A 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 13.06 30.79 51.73 11.40 35.76 53.48 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 13.04 31.88 60.72 10.57 35.34 57.49 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1e19_c00 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 7 3 # 7 A 131 LYS D 7 LYS.? 12.04 O8 EPE D 146 A 215 LYS D 100 LYS^? 18.85 CL CL D 145 A 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 0.50 24.09 51.68 1.51 29.34 52.35 4.11 -10.06 -22.93 10.31 -9.82 -22.91 coo 13.06 30.79 51.73 11.40 35.76 53.48 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 13.04 31.88 60.72 10.57 35.34 57.49 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1e19_c00 source 1e19 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPHATE SYNTH: 7 hits 1e19_c00 naa= 3 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 1 3 # 1 B 131 LYS A 6 LYS.? 17.07 C5 EPE A 145 B 215 LYS A 100 LYS^? 18.99 CL CL D 145 B 277 LYS A 94 LYS.? 20.29 CL CL D 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 17.88 38.77 19.81 16.38 34.23 17.24 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 20.33 37.78 11.20 16.77 34.53 13.47 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 2 3 # 2 B 131 LYS A 7 LYS.? 11.74 O8 EPE A 145 B 215 LYS A 100 LYS^? 18.99 CL CL D 145 B 277 LYS A 94 LYS.? 20.29 CL CL D 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 -24.35 2.90 -12.02 -25.19 4.34 -6.86 coo 17.88 38.77 19.81 16.38 34.23 17.24 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 20.33 37.78 11.20 16.77 34.53 13.47 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 3 3 # 3 B 131 LYS A 20 LYS~? 9.88 CL CL A 144 B 215 LYS A 65 LYS~? 24.48 CL CL A 144 B 277 LYS B 65 LYS~? 24.78 CL CL A 144 coo 6.78 45.91 16.15 7.82 40.81 15.84 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 coo 17.88 38.77 19.81 16.38 34.23 17.24 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 20.33 37.78 11.20 16.77 34.53 13.47 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 4 3 # 4 B 131 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 215 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 277 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 17.88 38.77 19.81 16.38 34.23 17.24 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 20.33 37.78 11.20 16.77 34.53 13.47 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 5 3 # 5 B 131 LYS B 20 LYS~? 9.95 CL CL A 144 B 215 LYS B 65 LYS~? 24.78 CL CL A 144 B 277 LYS A 65 LYS~? 24.48 CL CL A 144 coo 6.78 45.91 16.15 7.82 40.81 15.84 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 coo 17.88 38.77 19.81 16.38 34.23 17.24 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 20.33 37.78 11.20 16.77 34.53 13.47 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 6 3 # 6 B 131 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 215 LYS D 100 LYS^? 18.85 CL CL D 145 B 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 17.88 38.77 19.81 16.38 34.23 17.24 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 20.33 37.78 11.20 16.77 34.53 13.47 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 7 3 # 7 B 131 LYS C 20 LYS~? 9.96 CL CL A 144 B 215 LYS A 65 LYS~? 24.48 CL CL A 144 B 277 LYS B 65 LYS~? 24.78 CL CL A 144 coo 6.78 45.91 16.15 7.82 40.81 15.84 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 coo 17.88 38.77 19.81 16.38 34.23 17.24 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 20.33 37.78 11.20 16.77 34.53 13.47 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 8 3 # 8 B 131 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 215 LYS D 100 LYS^? 18.85 CL CL D 145 B 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 17.88 38.77 19.81 16.38 34.23 17.24 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 20.33 37.78 11.20 16.77 34.53 13.47 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1e19_c01 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPuser 9 3 # 9 B 131 LYS D 7 LYS.? 12.04 O8 EPE D 146 B 215 LYS D 100 LYS^? 18.85 CL CL D 145 B 277 LYS D 94 LYS.? 20.13 CL CL D 145 coo 6.78 45.91 16.15 7.82 40.81 15.84 4.11 -10.06 -22.93 10.31 -9.82 -22.91 coo 17.88 38.77 19.81 16.38 34.23 17.24 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 20.33 37.78 11.20 16.77 34.53 13.47 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1e19_c01 source 1e19 CARBAMATE KINASE-LIKE CARBAMOYLPHOSPHATE SYNTH: 9 hits 1e19_c01 naa= 3 ULMN 3 1e7q_c01 GDP-FUCOSE SYNTHETASE user 1 3 # 1 A 107 ALA A 32 ALA~? 17.32 O1S EPE A 145 A 136 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 140 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 55.90 7.49 23.83 56.71 8.23 22.76 -33.13 4.85 -15.97 -33.81 4.83 -17.34 coo 59.38 10.02 17.51 59.95 9.89 20.21 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 59.52 3.69 18.67 62.31 6.19 22.58 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1e7q_c01 GDP-FUCOSE SYNTHETASE user 2 3 # 2 A 107 ALA C 32 ALA~? 17.53 O2S EPE A 145 A 136 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 140 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 55.90 7.49 23.83 56.71 8.23 22.76 -25.29 -17.55 3.87 -26.69 -17.66 4.44 coo 59.38 10.02 17.51 59.95 9.89 20.21 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 59.52 3.69 18.67 62.31 6.19 22.58 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1e7q_c01 source 1e7q GDP-FUCOSE SYNTHETASE : 2 hits 1e7q_c01 naa= 3 ULMN 3 1eag_c04 PEPTIDE INHIBITOR user 1 3 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 218 ASP A 133 ASP~? 7.97 CL CL D 145 coo 47.22 22.34 8.57 45.16 22.02 9.13 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 43.58 20.85 5.15 44.62 23.01 5.76 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 44.05 16.99 12.67 44.05 18.89 11.74 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1eag_c04 source 1eag PEPTIDE INHIBITOR : 1 hits 1eag_c04 naa= 3 ULMN 3 1ec9_c04 GLUCARATE DEHYDRATASE user 1 3 # 1 A 205 LYS A 65 LYS~? 24.48 CL CL A 144 A 207 LYS B 65 LYS~? 24.78 CL CL A 144 A 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo -15.19 -26.42 1.17 -15.94 -21.72 -3.01 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -20.91 -23.36 1.14 -20.26 -20.07 -2.33 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -13.66 -24.10 -6.32 -13.27 -22.99 -4.55 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1ec9_c04 GLUCARATE DEHYDRATASE user 2 3 # 2 A 205 LYS B 65 LYS~? 24.78 CL CL A 144 A 207 LYS A 65 LYS~? 24.48 CL CL A 144 A 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo -15.19 -26.42 1.17 -15.94 -21.72 -3.01 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -20.91 -23.36 1.14 -20.26 -20.07 -2.33 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -13.66 -24.10 -6.32 -13.27 -22.99 -4.55 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1ec9_c04 source 1ec9 GLUCARATE DEHYDRATASE : 2 hits 1ec9_c04 naa= 3 ULMN 3 1ec9_c05 GLUCARATE DEHYDRATASE user 1 3 # 1 B 205 LYS A 65 LYS~? 24.48 CL CL A 144 B 207 LYS B 65 LYS~? 24.78 CL CL A 144 B 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo -11.45 28.09 -2.93 -13.20 23.63 1.17 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -17.50 25.66 -3.58 -17.49 22.55 -0.15 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -11.13 25.71 4.86 -10.82 24.43 3.24 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1ec9_c05 GLUCARATE DEHYDRATASE user 2 3 # 2 B 205 LYS B 65 LYS~? 24.78 CL CL A 144 B 207 LYS A 65 LYS~? 24.48 CL CL A 144 B 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo -11.45 28.09 -2.93 -13.20 23.63 1.17 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -17.50 25.66 -3.58 -17.49 22.55 -0.15 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -11.13 25.71 4.86 -10.82 24.43 3.24 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1ec9_c05 source 1ec9 GLUCARATE DEHYDRATASE : 2 hits 1ec9_c05 naa= 3 ULMN 3 1ec9_c06 GLUCARATE DEHYDRATASE user 1 3 # 1 C 205 LYS A 65 LYS~? 24.48 CL CL A 144 C 207 LYS B 65 LYS~? 24.78 CL CL A 144 C 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo 15.57 11.65 -23.50 16.31 5.98 -20.68 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 21.27 10.43 -20.58 20.77 6.00 -18.91 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 14.28 3.88 -24.50 13.85 4.89 -22.78 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1ec9_c06 GLUCARATE DEHYDRATASE user 2 3 # 2 C 205 LYS B 65 LYS~? 24.78 CL CL A 144 C 207 LYS A 65 LYS~? 24.48 CL CL A 144 C 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo 15.57 11.65 -23.50 16.31 5.98 -20.68 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 21.27 10.43 -20.58 20.77 6.00 -18.91 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 14.28 3.88 -24.50 13.85 4.89 -22.78 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1ec9_c06 source 1ec9 GLUCARATE DEHYDRATASE : 2 hits 1ec9_c06 naa= 3 ULMN 3 1ec9_c07 GLUCARATE DEHYDRATASE user 1 3 # 1 D 205 LYS A 65 LYS~? 24.48 CL CL A 144 D 207 LYS B 65 LYS~? 24.78 CL CL A 144 D 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo 11.00 -13.38 25.10 13.14 -7.87 22.68 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 17.14 -12.99 22.96 17.50 -8.64 21.08 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 10.74 -5.36 25.95 10.35 -6.43 24.20 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1ec9_c07 GLUCARATE DEHYDRATASE user 2 3 # 2 D 205 LYS B 65 LYS~? 24.78 CL CL A 144 D 207 LYS A 65 LYS~? 24.48 CL CL A 144 D 366 ASP C 64 ASP~? 15.91 CL CL A 144 coo 11.00 -13.38 25.10 13.14 -7.87 22.68 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 17.14 -12.99 22.96 17.50 -8.64 21.08 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 10.74 -5.36 25.95 10.35 -6.43 24.20 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 1ec9_c07 source 1ec9 GLUCARATE DEHYDRATASE : 2 hits 1ec9_c07 naa= 3 ULMN 3 1eed_c04 ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLuser 1 3 # 1 P 32 ASP D 133 ASP~? 7.85 CL CL D 145 P 35 SER B 34 SER~? 6.65 CL CL D 145 P 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 10.15 33.41 11.98 7.98 33.66 12.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 7.57 37.60 10.00 8.86 37.02 12.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 4.04 29.97 8.82 4.78 31.15 10.46 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1eed_c04 source 1eed ENDOTHIAPEPSIN (E.C.3.4.23.22) COMPLEX WITH TH: 1 hits 1eed_c04 naa= 3 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 1 3 # 1 A 229 ALA B 31 ALA~? 10.75 CL CL D 145 A 257 ALA B 32 ALA~? 12.87 CL CL D 145 A 328 ASP D 124 ASP^? 11.01 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo 43.22 26.73 5.37 41.81 27.09 5.79 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 38.17 34.10 6.67 37.72 32.06 6.84 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 2 3 # 2 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 31 ALA~? 10.75 CL CL D 145 A 328 ASP D 124 ASP^? 11.01 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo 38.17 34.10 6.67 37.72 32.06 6.84 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 3 3 # 3 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 31 ALA~? 10.75 CL CL D 145 A 328 ASP D 133 ASP~? 7.85 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo 38.17 34.10 6.67 37.72 32.06 6.84 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 4 3 # 4 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 33 ALA~? 8.85 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 5 3 # 5 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 33 ALA~? 8.85 CL CL D 145 A 328 ASP D 133 ASP~? 7.85 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 38.17 34.10 6.67 37.72 32.06 6.84 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 6 3 # 6 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 93 ALA.? 14.90 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -13.41 -22.89 -26.14 -14.63 -22.36 -25.43 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 7 3 # 7 A 229 ALA B 32 ALA~? 12.87 CL CL D 145 A 257 ALA B 93 ALA.? 14.90 CL CL D 145 A 328 ASP D 124 ASP^? 11.01 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 43.22 26.73 5.37 41.81 27.09 5.79 -13.41 -22.89 -26.14 -14.63 -22.36 -25.43 coo 38.17 34.10 6.67 37.72 32.06 6.84 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 8 3 # 8 A 229 ALA B 33 ALA~? 8.85 CL CL D 145 A 257 ALA B 32 ALA~? 12.87 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 43.22 26.73 5.37 41.81 27.09 5.79 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 9 3 # 9 A 229 ALA B 33 ALA~? 8.85 CL CL D 145 A 257 ALA B 93 ALA.? 14.90 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 43.22 26.73 5.37 41.81 27.09 5.79 -13.41 -22.89 -26.14 -14.63 -22.36 -25.43 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 10 3 # 10 A 229 ALA B 93 ALA.? 14.90 CL CL D 145 A 257 ALA B 32 ALA~? 12.87 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -13.41 -22.89 -26.14 -14.63 -22.36 -25.43 coo 43.22 26.73 5.37 41.81 27.09 5.79 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 ULMN 3 1eo7_c00 CYCLODEXTRIN GLYCOSYLTRANSFERASE user 11 3 # 11 A 229 ALA B 93 ALA.? 14.90 CL CL D 145 A 257 ALA B 33 ALA~? 8.85 CL CL D 145 A 328 ASP D 123 ASP.? 17.57 CL CL D 145 coo 39.84 24.12 8.44 38.50 24.23 9.11 -13.41 -22.89 -26.14 -14.63 -22.36 -25.43 coo 43.22 26.73 5.37 41.81 27.09 5.79 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 38.17 34.10 6.67 37.72 32.06 6.84 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 1eo7_c00 source 1eo7 CYCLODEXTRIN GLYCOSYLTRANSFERASE : 11 hits 1eo7_c00 naa= 3 ULMN 3 1eq2_c00 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMEuser 1 3 # 1 A 116 SER A 10 SER^? 8.69 O1S EPE A 145 A 140 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 144 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 34.67 35.79 48.83 33.57 37.88 49.47 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 29.60 38.99 53.89 30.10 37.88 51.36 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 32.73 32.94 54.42 29.29 32.83 50.35 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1eq2_c00 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMEuser 2 3 # 2 A 116 SER C 10 SER^? 8.67 O1S EPE A 145 A 140 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 144 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 34.67 35.79 48.83 33.57 37.88 49.47 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 29.60 38.99 53.89 30.10 37.88 51.36 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 32.73 32.94 54.42 29.29 32.83 50.35 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1eq2_c00 source 1eq2 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMERASE : 2 hits 1eq2_c00 naa= 3 ULMN 3 1eq2_c08 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMEuser 1 3 # 1 I 116 SER A 10 SER^? 8.69 O1S EPE A 145 I 140 TYR A 36 TYR.? 11.29 O1S EPE A 145 I 144 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 11.78 90.82 7.18 12.84 88.72 7.93 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 16.78 87.76 12.19 16.39 88.69 9.59 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 13.67 93.83 12.65 17.08 93.94 8.58 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1eq2_c08 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMEuser 2 3 # 2 I 116 SER C 10 SER^? 8.67 O1S EPE A 145 I 140 TYR C 36 TYR.? 11.46 O2S EPE A 145 I 144 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 11.78 90.82 7.18 12.84 88.72 7.93 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 16.78 87.76 12.19 16.39 88.69 9.59 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 13.67 93.83 12.65 17.08 93.94 8.58 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 1eq2_c08 source 1eq2 ADP-L-GLYCERO-D-MANNOHEPTOSE 6-EPIMERASE : 2 hits 1eq2_c08 naa= 3 ULMN 3 1et0_c00 4-AMINO-4-DEOXYCHORISMATE LYASE user 1 3 # 1 A 159 LYS A 94 LYS.? 20.29 CL CL D 145 A 193 GLU A 37 GLU^? 12.50 C6 EPE A 145 A 217 VAL A 99 VAL^? 17.20 O1S EPE A 145 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 0.07 12.29 66.53 -0.24 11.95 64.38 -30.64 3.61 -22.44 -32.61 2.86 -21.79 ULMN 3 1et0_c00 4-AMINO-4-DEOXYCHORISMATE LYASE user 2 3 # 2 A 159 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 193 GLU B 37 GLU^? 13.18 C3 EPE A 145 A 217 VAL B 99 VAL^? 17.15 O3S EPE A 145 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 0.07 12.29 66.53 -0.24 11.95 64.38 -12.64 -22.44 -19.60 -14.08 -22.36 -21.24 ULMN 3 1et0_c00 4-AMINO-4-DEOXYCHORISMATE LYASE user 3 3 # 3 A 159 LYS C 94 LYS.? 22.53 O2S EPE A 145 A 193 GLU C 37 GLU^? 12.70 O8 EPE A 145 A 217 VAL C 99 VAL^? 17.22 O2S EPE A 145 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 0.07 12.29 66.53 -0.24 11.95 64.38 -30.28 -12.68 4.42 -30.67 -14.72 3.73 ULMN 3 1et0_c00 4-AMINO-4-DEOXYCHORISMATE LYASE user 4 3 # 4 A 159 LYS D 94 LYS.? 20.13 CL CL D 145 A 193 GLU D 37 GLU^? 11.78 O8 EPE D 146 A 217 VAL D 99 VAL^? 17.23 O3S EPE D 146 coo 2.10 10.68 61.44 -2.14 13.16 60.61 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 0.07 12.29 66.53 -0.24 11.95 64.38 0.04 -18.32 -30.94 1.48 -18.00 -32.56 1et0_c00 source 1et0 4-AMINO-4-DEOXYCHORISMATE LYASE : 4 hits 1et0_c00 naa= 3 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 1 3 # 1 A 38 THR B 139 THR^? -4.10 O3S EPE A 145s A 159 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 193 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo -2.58 16.31 54.79 -4.02 14.93 55.64 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 2 3 # 2 A 38 THR B 139 THR^? -4.10 O3S EPE A 145s A 159 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 193 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo -2.58 16.31 54.79 -4.02 14.93 55.64 -19.88 -11.02 -14.94 -20.47 -10.13 -16.77 coo 2.10 10.68 61.44 -2.14 13.16 60.61 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 3 3 # 3 A 38 THR D 139 THR^? -4.08 O3S EPE D 146s A 159 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 193 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo -2.58 16.31 54.79 -4.02 14.93 55.64 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 2.10 10.68 61.44 -2.14 13.16 60.61 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 4 3 # 4 A 38 THR D 139 THR^? -4.08 O3S EPE D 146s A 159 LYS D 7 LYS.? 12.04 O8 EPE D 146 A 193 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo -2.58 16.31 54.79 -4.02 14.93 55.64 1.72 -4.29 -28.47 3.80 -4.01 -28.91 coo 2.10 10.68 61.44 -2.14 13.16 60.61 4.11 -10.06 -22.93 10.31 -9.82 -22.91 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1et0_c02 4-AMINO-4-DEOXYCHORISMATE LYASE user 5 3 # 5 A 38 THR D 140 THR^? -4.35 O2S EPE D 146s A 159 LYS D 7 LYS.? 12.04 O8 EPE D 146 A 193 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo -2.58 16.31 54.79 -4.02 14.93 55.64 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 2.10 10.68 61.44 -2.14 13.16 60.61 4.11 -10.06 -22.93 10.31 -9.82 -22.91 coo -5.33 11.71 69.72 -4.62 11.92 67.73 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 1et0_c02 source 1et0 4-AMINO-4-DEOXYCHORISMATE LYASE : 5 hits 1et0_c02 naa= 3 ULMN 3 1euu_c00 SIALIDASE user 1 3 # 1 92 ASP A 64 ASP~? 16.08 CL CL A 144 260 GLU B 68 GLU~? 25.19 CL CL A 144 370 TYR B 67 TYR~? 16.82 CL CL A 144 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1euu_c00 SIALIDASE user 2 3 # 2 92 ASP B 64 ASP~? 15.96 CL CL A 144 260 GLU C 68 GLU~? 25.33 CL CL A 144 370 TYR C 67 TYR~? 16.92 CL CL A 144 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 ULMN 3 1euu_c00 SIALIDASE user 3 3 # 3 92 ASP C 64 ASP~? 15.91 CL CL A 144 260 GLU A 68 GLU~? 25.44 CL CL A 144 370 TYR A 67 TYR~? 16.80 CL CL A 144 coo 8.60 -17.93 28.38 7.67 -19.04 26.88 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 0.12 -12.06 25.14 1.33 -13.03 23.72 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 4.66 -12.77 19.52 3.70 -14.16 21.71 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 1euu_c00 source 1euu SIALIDASE : 3 hits 1euu_c00 naa= 3 ULMN 3 1euy_c00 GLUTAMINYL-TRNA SYNTHETASE user 1 3 # 1 A 34 GLU A 136 GLU~? 8.92 C6 EPE A 145 A 260 ARG D 134 ARG~? 13.66 CL CL D 145 A 270 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 50.99 29.43 12.86 52.11 29.45 14.65 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 39.80 27.50 22.98 42.20 26.56 21.34 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 48.83 21.70 19.50 47.44 24.99 15.25 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1euy_c00 GLUTAMINYL-TRNA SYNTHETASE user 2 3 # 2 A 34 GLU B 37 GLU^? 13.18 C3 EPE A 145 A 260 ARG D 134 ARG~? 13.66 CL CL D 145 A 270 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 50.99 29.43 12.86 52.11 29.45 14.65 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 39.80 27.50 22.98 42.20 26.56 21.34 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 48.83 21.70 19.50 47.44 24.99 15.25 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 1euy_c00 source 1euy GLUTAMINYL-TRNA SYNTHETASE : 2 hits 1euy_c00 naa= 3 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 1 3 # 1 A 112 PHE A 41 PHE^? 11.09 CL CL D 145 A 210 ASP A 124 ASP^? 10.83 CL CL D 145 A 244 LYS A 94 LYS.? 20.29 CL CL D 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 10.51 37.86 19.71 9.07 39.38 20.04 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -1.20 42.34 17.67 3.19 45.13 19.06 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 2 3 # 2 A 112 PHE A 41 PHE^? 11.09 CL CL D 145 A 210 ASP A 133 ASP~? 7.97 CL CL D 145 A 244 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 10.51 37.86 19.71 9.07 39.38 20.04 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -1.20 42.34 17.67 3.19 45.13 19.06 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 3 3 # 3 A 112 PHE A 42 PHE^? 15.34 CL CL A 144 A 210 ASP A 124 ASP^? 10.83 CL CL D 145 A 244 LYS A 94 LYS.? 20.29 CL CL D 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 10.51 37.86 19.71 9.07 39.38 20.04 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -1.20 42.34 17.67 3.19 45.13 19.06 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 4 3 # 4 A 112 PHE A 44 PHE~? 15.48 CL CL A 144 A 210 ASP B 64 ASP~? 15.96 CL CL A 144 A 244 LYS A 20 LYS~? 9.88 CL CL A 144 coo 9.23 46.77 25.11 11.48 48.39 24.76 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 10.51 37.86 19.71 9.07 39.38 20.04 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -1.20 42.34 17.67 3.19 45.13 19.06 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 5 3 # 5 A 112 PHE A 102 PHE^? 11.63 CL CL D 145 A 210 ASP A 133 ASP~? 7.97 CL CL D 145 A 244 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 10.51 37.86 19.71 9.07 39.38 20.04 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -1.20 42.34 17.67 3.19 45.13 19.06 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 6 3 # 6 A 112 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 210 ASP D 133 ASP~? 7.85 CL CL D 145 A 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 10.51 37.86 19.71 9.07 39.38 20.04 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -1.20 42.34 17.67 3.19 45.13 19.06 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 7 3 # 7 A 112 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 210 ASP B 124 ASP^? 22.45 O2S EPE A 145 A 244 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 10.51 37.86 19.71 9.07 39.38 20.04 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -1.20 42.34 17.67 3.19 45.13 19.06 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 8 3 # 8 A 112 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 210 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 10.51 37.86 19.71 9.07 39.38 20.04 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -1.20 42.34 17.67 3.19 45.13 19.06 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 9 3 # 9 A 112 PHE B 42 PHE^? 15.32 CL CL A 144 A 210 ASP B 124 ASP^? 22.45 O2S EPE A 145 A 244 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 10.51 37.86 19.71 9.07 39.38 20.04 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -1.20 42.34 17.67 3.19 45.13 19.06 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 10 3 # 10 A 112 PHE B 44 PHE~? 15.63 CL CL A 144 A 210 ASP C 64 ASP~? 15.91 CL CL A 144 A 244 LYS B 20 LYS~? 9.95 CL CL A 144 coo 9.23 46.77 25.11 11.48 48.39 24.76 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 10.51 37.86 19.71 9.07 39.38 20.04 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -1.20 42.34 17.67 3.19 45.13 19.06 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 11 3 # 11 A 112 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 210 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 10.51 37.86 19.71 9.07 39.38 20.04 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -1.20 42.34 17.67 3.19 45.13 19.06 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 12 3 # 12 A 112 PHE C 41 PHE^? 13.95 CL CL A 144 A 210 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 244 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 10.51 37.86 19.71 9.07 39.38 20.04 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -1.20 42.34 17.67 3.19 45.13 19.06 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 13 3 # 13 A 112 PHE C 42 PHE^? 15.30 CL CL A 144 A 210 ASP C 124 ASP^? 22.63 O1S EPE A 145 A 244 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 10.51 37.86 19.71 9.07 39.38 20.04 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo -1.20 42.34 17.67 3.19 45.13 19.06 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 14 3 # 14 A 112 PHE C 44 PHE~? 15.66 CL CL A 144 A 210 ASP A 64 ASP~? 16.08 CL CL A 144 A 244 LYS C 20 LYS~? 9.96 CL CL A 144 coo 9.23 46.77 25.11 11.48 48.39 24.76 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 10.51 37.86 19.71 9.07 39.38 20.04 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -1.20 42.34 17.67 3.19 45.13 19.06 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 15 3 # 15 A 112 PHE C 102 PHE^? 16.65 O1S EPE A 145 A 210 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 244 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 10.51 37.86 19.71 9.07 39.38 20.04 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -1.20 42.34 17.67 3.19 45.13 19.06 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 16 3 # 16 A 112 PHE D 41 PHE^? 10.83 CL CL D 145 A 210 ASP D 124 ASP^? 11.01 CL CL D 145 A 244 LYS D 94 LYS.? 20.13 CL CL D 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 10.51 37.86 19.71 9.07 39.38 20.04 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -1.20 42.34 17.67 3.19 45.13 19.06 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 17 3 # 17 A 112 PHE D 41 PHE^? 10.83 CL CL D 145 A 210 ASP D 133 ASP~? 7.85 CL CL D 145 A 244 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 9.23 46.77 25.11 11.48 48.39 24.76 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 10.51 37.86 19.71 9.07 39.38 20.04 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -1.20 42.34 17.67 3.19 45.13 19.06 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 18 3 # 18 A 112 PHE D 42 PHE^? 15.36 CL CL D 144 A 210 ASP D 124 ASP^? 11.01 CL CL D 145 A 244 LYS D 94 LYS.? 20.13 CL CL D 145 coo 9.23 46.77 25.11 11.48 48.39 24.76 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 10.51 37.86 19.71 9.07 39.38 20.04 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -1.20 42.34 17.67 3.19 45.13 19.06 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1fc4_c02 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 19 3 # 19 A 112 PHE D 102 PHE^? 11.51 CL CL D 145 A 210 ASP D 133 ASP~? 7.85 CL CL D 145 A 244 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 9.23 46.77 25.11 11.48 48.39 24.76 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 10.51 37.86 19.71 9.07 39.38 20.04 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -1.20 42.34 17.67 3.19 45.13 19.06 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1fc4_c02 source 1fc4 2-AMINO-3-KETOBUTYRATE CONENZYME A LIGASE : 19 hits 1fc4_c02 naa= 3 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 1 3 # 1 B 112 PHE A 41 PHE^? 11.09 CL CL D 145 B 210 ASP A 124 ASP^? 10.83 CL CL D 145 B 244 LYS A 94 LYS.? 20.29 CL CL D 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 9.06 56.85 40.30 7.71 55.27 39.90 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -2.38 51.82 41.62 2.07 49.19 40.42 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 2 3 # 2 B 112 PHE A 41 PHE^? 11.09 CL CL D 145 B 210 ASP A 133 ASP~? 7.97 CL CL D 145 B 244 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 9.06 56.85 40.30 7.71 55.27 39.90 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -2.38 51.82 41.62 2.07 49.19 40.42 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 3 3 # 3 B 112 PHE A 42 PHE^? 15.34 CL CL A 144 B 210 ASP A 124 ASP^? 10.83 CL CL D 145 B 244 LYS A 94 LYS.? 20.29 CL CL D 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 9.06 56.85 40.30 7.71 55.27 39.90 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -2.38 51.82 41.62 2.07 49.19 40.42 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 4 3 # 4 B 112 PHE A 44 PHE~? 15.48 CL CL A 144 B 210 ASP B 64 ASP~? 15.96 CL CL A 144 B 244 LYS A 20 LYS~? 9.88 CL CL A 144 coo 8.76 47.85 34.91 11.08 46.36 35.41 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 9.06 56.85 40.30 7.71 55.27 39.90 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -2.38 51.82 41.62 2.07 49.19 40.42 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 5 3 # 5 B 112 PHE A 102 PHE^? 11.63 CL CL D 145 B 210 ASP A 133 ASP~? 7.97 CL CL D 145 B 244 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 9.06 56.85 40.30 7.71 55.27 39.90 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -2.38 51.82 41.62 2.07 49.19 40.42 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 6 3 # 6 B 112 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 210 ASP D 133 ASP~? 7.85 CL CL D 145 B 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 9.06 56.85 40.30 7.71 55.27 39.90 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -2.38 51.82 41.62 2.07 49.19 40.42 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 7 3 # 7 B 112 PHE B 41 PHE^? 12.26 O2S EPE A 145 B 210 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 244 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 9.06 56.85 40.30 7.71 55.27 39.90 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -2.38 51.82 41.62 2.07 49.19 40.42 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 8 3 # 8 B 112 PHE B 41 PHE^? 12.26 O2S EPE A 145 B 210 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 9.06 56.85 40.30 7.71 55.27 39.90 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -2.38 51.82 41.62 2.07 49.19 40.42 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 9 3 # 9 B 112 PHE B 42 PHE^? 15.32 CL CL A 144 B 210 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 244 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 9.06 56.85 40.30 7.71 55.27 39.90 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -2.38 51.82 41.62 2.07 49.19 40.42 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 10 3 # 10 B 112 PHE B 44 PHE~? 15.63 CL CL A 144 B 210 ASP C 64 ASP~? 15.91 CL CL A 144 B 244 LYS B 20 LYS~? 9.95 CL CL A 144 coo 8.76 47.85 34.91 11.08 46.36 35.41 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 9.06 56.85 40.30 7.71 55.27 39.90 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -2.38 51.82 41.62 2.07 49.19 40.42 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 11 3 # 11 B 112 PHE B 102 PHE^? 16.45 O2S EPE A 145 B 210 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 244 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 9.06 56.85 40.30 7.71 55.27 39.90 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -2.38 51.82 41.62 2.07 49.19 40.42 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 12 3 # 12 B 112 PHE C 41 PHE^? 13.95 CL CL A 144 B 210 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 244 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 9.06 56.85 40.30 7.71 55.27 39.90 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -2.38 51.82 41.62 2.07 49.19 40.42 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 13 3 # 13 B 112 PHE C 42 PHE^? 15.30 CL CL A 144 B 210 ASP C 124 ASP^? 22.63 O1S EPE A 145 B 244 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 9.06 56.85 40.30 7.71 55.27 39.90 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo -2.38 51.82 41.62 2.07 49.19 40.42 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 14 3 # 14 B 112 PHE C 44 PHE~? 15.66 CL CL A 144 B 210 ASP A 64 ASP~? 16.08 CL CL A 144 B 244 LYS C 20 LYS~? 9.96 CL CL A 144 coo 8.76 47.85 34.91 11.08 46.36 35.41 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 9.06 56.85 40.30 7.71 55.27 39.90 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -2.38 51.82 41.62 2.07 49.19 40.42 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 15 3 # 15 B 112 PHE C 102 PHE^? 16.65 O1S EPE A 145 B 210 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 244 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 9.06 56.85 40.30 7.71 55.27 39.90 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -2.38 51.82 41.62 2.07 49.19 40.42 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 16 3 # 16 B 112 PHE D 41 PHE^? 10.83 CL CL D 145 B 210 ASP D 124 ASP^? 11.01 CL CL D 145 B 244 LYS D 94 LYS.? 20.13 CL CL D 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 9.06 56.85 40.30 7.71 55.27 39.90 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -2.38 51.82 41.62 2.07 49.19 40.42 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 17 3 # 17 B 112 PHE D 41 PHE^? 10.83 CL CL D 145 B 210 ASP D 133 ASP~? 7.85 CL CL D 145 B 244 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 8.76 47.85 34.91 11.08 46.36 35.41 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 9.06 56.85 40.30 7.71 55.27 39.90 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -2.38 51.82 41.62 2.07 49.19 40.42 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 18 3 # 18 B 112 PHE D 42 PHE^? 15.36 CL CL D 144 B 210 ASP D 124 ASP^? 11.01 CL CL D 145 B 244 LYS D 94 LYS.? 20.13 CL CL D 145 coo 8.76 47.85 34.91 11.08 46.36 35.41 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 9.06 56.85 40.30 7.71 55.27 39.90 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -2.38 51.82 41.62 2.07 49.19 40.42 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1fc4_c03 2-AMINO-3-KETOBUTYRATE CONENZYME A Luser 19 3 # 19 B 112 PHE D 102 PHE^? 11.51 CL CL D 145 B 210 ASP D 133 ASP~? 7.85 CL CL D 145 B 244 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 8.76 47.85 34.91 11.08 46.36 35.41 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 9.06 56.85 40.30 7.71 55.27 39.90 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -2.38 51.82 41.62 2.07 49.19 40.42 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1fc4_c03 source 1fc4 2-AMINO-3-KETOBUTYRATE CONENZYME A LIGASE : 19 hits 1fc4_c03 naa= 3 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 A 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 142 LEU A 27 LEU~? 10.97 CL CL A 144 A 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 A 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 142 LEU A 27 LEU~? 10.97 CL CL A 144 A 165 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 A 137 TYR A 83 TYR.? 22.53 CL CL A 144 A 142 LEU A 89 LEU.? 20.18 CL CL A 144 A 165 LYS A 82 LYS.? 35.27 CL CL A 144 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -48.44 -0.89 -15.75 -46.04 -0.50 -14.38 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -41.64 0.64 -19.90 -43.12 0.52 -18.28 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 A 137 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 142 LEU B 27 LEU~? 10.97 CL CL A 144 A 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -21.99 -16.73 -23.59 -23.43 -15.19 -23.20 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 A 137 TYR B 83 TYR.? 13.54 CL CL D 145 A 142 LEU B 89 LEU.? 14.49 CL CL D 145 A 165 LYS B 82 LYS.? 24.10 CL CL D 145 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 A 137 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 142 LEU C 27 LEU~? 10.90 CL CL A 144 A 165 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -28.26 -19.77 -4.57 -27.49 -19.79 -6.61 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 A 137 TYR C 83 TYR.? 22.25 CL CL A 144 A 142 LEU C 89 LEU.? 20.13 CL CL A 144 A 165 LYS C 82 LYS.? 35.24 CL CL A 144 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 A 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 142 LEU D 27 LEU~? 11.02 CL CL D 144 A 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 A 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 142 LEU D 27 LEU~? 11.02 CL CL D 144 A 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c00 N-ACETYLNEURAMINATE LYASE user 10 3 # 10 A 137 TYR D 83 TYR.? 22.27 CL CL D 144 A 142 LEU D 89 LEU.? 20.01 CL CL D 144 A 165 LYS D 82 LYS.? 35.01 CL CL D 144 coo -38.10 -88.84 -25.29 -37.86 -86.12 -24.64 13.86 -16.92 -44.50 13.57 -15.58 -42.06 coo -32.09 -82.74 -22.70 -32.91 -80.79 -22.33 7.30 -18.17 -40.08 9.28 -17.51 -40.58 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 15.95 -21.66 -47.76 18.36 -27.22 -48.84 1fdy_c00 source 1fdy N-ACETYLNEURAMINATE LYASE : 10 hits 1fdy_c00 naa= 3 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 B 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 B 142 LEU A 27 LEU~? 10.97 CL CL A 144 B 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 B 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 B 142 LEU A 27 LEU~? 10.97 CL CL A 144 B 165 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 B 137 TYR A 83 TYR.? 22.53 CL CL A 144 B 142 LEU A 89 LEU.? 20.18 CL CL A 144 B 165 LYS A 82 LYS.? 35.27 CL CL A 144 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -48.44 -0.89 -15.75 -46.04 -0.50 -14.38 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -41.64 0.64 -19.90 -43.12 0.52 -18.28 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 B 137 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 142 LEU B 27 LEU~? 10.97 CL CL A 144 B 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -21.99 -16.73 -23.59 -23.43 -15.19 -23.20 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 B 137 TYR B 83 TYR.? 13.54 CL CL D 145 B 142 LEU B 89 LEU.? 14.49 CL CL D 145 B 165 LYS B 82 LYS.? 24.10 CL CL D 145 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 B 137 TYR C 36 TYR.? 11.46 O2S EPE A 145 B 142 LEU C 27 LEU~? 10.90 CL CL A 144 B 165 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -28.26 -19.77 -4.57 -27.49 -19.79 -6.61 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 B 137 TYR C 83 TYR.? 22.25 CL CL A 144 B 142 LEU C 89 LEU.? 20.13 CL CL A 144 B 165 LYS C 82 LYS.? 35.24 CL CL A 144 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 B 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 B 142 LEU D 27 LEU~? 11.02 CL CL D 144 B 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 B 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 B 142 LEU D 27 LEU~? 11.02 CL CL D 144 B 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c01 N-ACETYLNEURAMINATE LYASE user 10 3 # 10 B 137 TYR D 83 TYR.? 22.27 CL CL D 144 B 142 LEU D 89 LEU.? 20.01 CL CL D 144 B 165 LYS D 82 LYS.? 35.01 CL CL D 144 coo 1.63 -78.98 -34.99 0.64 -76.54 -34.02 13.86 -16.92 -44.50 13.57 -15.58 -42.06 coo -5.98 -74.54 -33.87 -5.92 -72.62 -32.92 7.30 -18.17 -40.08 9.28 -17.51 -40.58 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 15.95 -21.66 -47.76 18.36 -27.22 -48.84 1fdy_c01 source 1fdy N-ACETYLNEURAMINATE LYASE : 10 hits 1fdy_c01 naa= 3 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 C 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 C 142 LEU A 27 LEU~? 10.97 CL CL A 144 C 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 C 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 C 142 LEU A 27 LEU~? 10.97 CL CL A 144 C 165 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 C 137 TYR A 83 TYR.? 22.53 CL CL A 144 C 142 LEU A 89 LEU.? 20.18 CL CL A 144 C 165 LYS A 82 LYS.? 35.27 CL CL A 144 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -48.44 -0.89 -15.75 -46.04 -0.50 -14.38 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -41.64 0.64 -19.90 -43.12 0.52 -18.28 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 C 137 TYR B 36 TYR.? 11.13 O3S EPE A 145 C 142 LEU B 27 LEU~? 10.97 CL CL A 144 C 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -21.99 -16.73 -23.59 -23.43 -15.19 -23.20 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 C 137 TYR B 83 TYR.? 13.54 CL CL D 145 C 142 LEU B 89 LEU.? 14.49 CL CL D 145 C 165 LYS B 82 LYS.? 24.10 CL CL D 145 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 C 137 TYR C 36 TYR.? 11.46 O2S EPE A 145 C 142 LEU C 27 LEU~? 10.90 CL CL A 144 C 165 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -28.26 -19.77 -4.57 -27.49 -19.79 -6.61 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 C 137 TYR C 83 TYR.? 22.25 CL CL A 144 C 142 LEU C 89 LEU.? 20.13 CL CL A 144 C 165 LYS C 82 LYS.? 35.24 CL CL A 144 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 C 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 C 142 LEU D 27 LEU~? 11.02 CL CL D 144 C 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 C 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 C 142 LEU D 27 LEU~? 11.02 CL CL D 144 C 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c02 N-ACETYLNEURAMINATE LYASE user 10 3 # 10 C 137 TYR D 83 TYR.? 22.27 CL CL D 144 C 142 LEU D 89 LEU.? 20.01 CL CL D 144 C 165 LYS D 82 LYS.? 35.01 CL CL D 144 coo -19.42 -69.79 -47.15 -19.24 -72.58 -47.52 13.86 -16.92 -44.50 13.57 -15.58 -42.06 coo -15.96 -76.69 -42.83 -16.62 -78.73 -42.99 7.30 -18.17 -40.08 9.28 -17.51 -40.58 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 15.95 -21.66 -47.76 18.36 -27.22 -48.84 1fdy_c02 source 1fdy N-ACETYLNEURAMINATE LYASE : 10 hits 1fdy_c02 naa= 3 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 D 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 D 142 LEU A 27 LEU~? 10.97 CL CL A 144 D 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 D 137 TYR A 36 TYR.? 11.29 O1S EPE A 145 D 142 LEU A 27 LEU~? 10.97 CL CL A 144 D 165 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -35.47 -3.94 -15.06 -34.90 -5.58 -13.81 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 D 137 TYR A 83 TYR.? 22.53 CL CL A 144 D 142 LEU A 89 LEU.? 20.18 CL CL A 144 D 165 LYS A 82 LYS.? 35.27 CL CL A 144 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -48.44 -0.89 -15.75 -46.04 -0.50 -14.38 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -41.64 0.64 -19.90 -43.12 0.52 -18.28 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -53.53 1.50 -17.93 -57.95 5.97 -17.84 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 D 137 TYR B 36 TYR.? 11.13 O3S EPE A 145 D 142 LEU B 27 LEU~? 10.97 CL CL A 144 D 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -21.99 -16.73 -23.59 -23.43 -15.19 -23.20 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 D 137 TYR B 83 TYR.? 13.54 CL CL D 145 D 142 LEU B 89 LEU.? 14.49 CL CL D 145 D 165 LYS B 82 LYS.? 24.10 CL CL D 145 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 D 137 TYR C 36 TYR.? 11.46 O2S EPE A 145 D 142 LEU C 27 LEU~? 10.90 CL CL A 144 D 165 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -28.26 -19.77 -4.57 -27.49 -19.79 -6.61 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 D 137 TYR C 83 TYR.? 22.25 CL CL A 144 D 142 LEU C 89 LEU.? 20.13 CL CL A 144 D 165 LYS C 82 LYS.? 35.24 CL CL A 144 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 -33.26 -23.74 2.02 -32.41 -25.69 1.57 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -35.75 -35.45 3.45 -36.29 -39.60 8.17 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 D 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 D 142 LEU D 27 LEU~? 11.02 CL CL D 144 D 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 D 137 TYR D 36 TYR.? 11.19 O3S EPE D 146 D 142 LEU D 27 LEU~? 11.02 CL CL D 144 D 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 6.31 -9.99 -36.18 6.64 -7.83 -36.31 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c03 N-ACETYLNEURAMINATE LYASE user 10 3 # 10 D 137 TYR D 83 TYR.? 22.27 CL CL D 144 D 142 LEU D 89 LEU.? 20.01 CL CL D 144 D 165 LYS D 82 LYS.? 35.01 CL CL D 144 coo -19.43 -82.92 -7.62 -19.06 -85.28 -9.04 13.86 -16.92 -44.50 13.57 -15.58 -42.06 coo -21.22 -86.47 -15.56 -20.39 -88.44 -15.62 7.30 -18.17 -40.08 9.28 -17.51 -40.58 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 15.95 -21.66 -47.76 18.36 -27.22 -48.84 1fdy_c03 source 1fdy N-ACETYLNEURAMINATE LYASE : 10 hits 1fdy_c03 naa= 3 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 A 47 SER A 10 SER^? 8.69 O1S EPE A 145 A 48 THR A 140 THR^? -4.46 O3S EPE A 145s A 165 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 A 47 SER A 29 SER~? 20.16 O1S EPE A 145 A 48 THR A 28 THR~? 15.27 CL CL A 144 A 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -37.74 2.28 -16.63 -39.96 3.28 -16.58 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 A 47 SER B 10 SER^? 8.49 O2S EPE A 145 A 48 THR B 140 THR^? -4.33 O2S EPE A 145s A 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 A 47 SER B 34 SER~? 6.65 CL CL D 145 A 48 THR D 130 THR~? 5.00 CL CL D 145 A 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 A 47 SER B 34 SER~? 6.65 CL CL D 145 A 48 THR D 130 THR~? 5.00 CL CL D 145 A 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 A 47 SER B 34 SER~? 6.65 CL CL D 145 A 48 THR D 130 THR~? 5.00 CL CL D 145 A 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 A 47 SER B 34 SER~? 6.65 CL CL D 145 A 48 THR D 130 THR~? 5.00 CL CL D 145 A 165 LYS D 100 LYS^? 18.85 CL CL D 145 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 A 47 SER D 10 SER^? 8.71 O3S EPE D 146 A 48 THR D 140 THR^? -4.35 O2S EPE D 146s A 165 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1fdy_c04 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 A 47 SER D 29 SER~? 20.03 O3S EPE D 146 A 48 THR D 28 THR~? 15.29 CL CL D 144 A 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -39.09 -83.21 -19.79 -37.33 -83.94 -21.38 8.08 -16.49 -34.93 9.82 -17.78 -36.00 coo -41.85 -80.60 -20.11 -42.94 -79.78 -21.77 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo -39.97 -88.99 -30.53 -40.75 -85.40 -25.70 4.11 -10.06 -22.93 10.31 -9.82 -22.91 1fdy_c04 source 1fdy N-ACETYLNEURAMINATE LYASE : 9 hits 1fdy_c04 naa= 3 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 B 47 SER A 10 SER^? 8.69 O1S EPE A 145 B 48 THR A 140 THR^? -4.46 O3S EPE A 145s B 165 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 B 47 SER A 29 SER~? 20.16 O1S EPE A 145 B 48 THR A 28 THR~? 15.27 CL CL A 144 B 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -37.74 2.28 -16.63 -39.96 3.28 -16.58 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 B 47 SER B 10 SER^? 8.49 O2S EPE A 145 B 48 THR B 140 THR^? -4.33 O2S EPE A 145s B 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 B 47 SER B 34 SER~? 6.65 CL CL D 145 B 48 THR D 130 THR~? 5.00 CL CL D 145 B 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 B 47 SER B 34 SER~? 6.65 CL CL D 145 B 48 THR D 130 THR~? 5.00 CL CL D 145 B 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 B 47 SER B 34 SER~? 6.65 CL CL D 145 B 48 THR D 130 THR~? 5.00 CL CL D 145 B 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 B 47 SER B 34 SER~? 6.65 CL CL D 145 B 48 THR D 130 THR~? 5.00 CL CL D 145 B 165 LYS D 100 LYS^? 18.85 CL CL D 145 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 B 47 SER D 10 SER^? 8.71 O3S EPE D 146 B 48 THR D 140 THR^? -4.35 O2S EPE D 146s B 165 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1fdy_c05 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 B 47 SER D 29 SER~? 20.03 O3S EPE D 146 B 48 THR D 28 THR~? 15.29 CL CL D 144 B 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo 0.74 -71.26 -35.87 -0.36 -73.34 -35.30 8.08 -16.49 -34.93 9.82 -17.78 -36.00 coo 2.65 -68.72 -33.78 3.66 -68.93 -31.87 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo 4.26 -81.75 -30.55 3.40 -75.83 -32.08 4.11 -10.06 -22.93 10.31 -9.82 -22.91 1fdy_c05 source 1fdy N-ACETYLNEURAMINATE LYASE : 9 hits 1fdy_c05 naa= 3 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 C 47 SER A 10 SER^? 8.69 O1S EPE A 145 C 48 THR A 140 THR^? -4.46 O3S EPE A 145s C 165 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 C 47 SER A 10 SER^? 8.69 O1S EPE A 145 C 48 THR A 140 THR^? -4.46 O3S EPE A 145s C 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 C 47 SER A 29 SER~? 20.16 O1S EPE A 145 C 48 THR A 28 THR~? 15.27 CL CL A 144 C 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -37.74 2.28 -16.63 -39.96 3.28 -16.58 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 C 47 SER B 10 SER^? 8.49 O2S EPE A 145 C 48 THR B 140 THR^? -4.33 O2S EPE A 145s C 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 C 47 SER B 34 SER~? 6.65 CL CL D 145 C 48 THR D 130 THR~? 5.00 CL CL D 145 C 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 C 47 SER B 34 SER~? 6.65 CL CL D 145 C 48 THR D 130 THR~? 5.00 CL CL D 145 C 165 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 C 47 SER B 34 SER~? 6.65 CL CL D 145 C 48 THR D 130 THR~? 5.00 CL CL D 145 C 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 C 47 SER B 34 SER~? 6.65 CL CL D 145 C 48 THR D 130 THR~? 5.00 CL CL D 145 C 165 LYS D 100 LYS^? 18.85 CL CL D 145 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 9 3 # 9 C 47 SER D 10 SER^? 8.71 O3S EPE D 146 C 48 THR D 140 THR^? -4.35 O2S EPE D 146s C 165 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 10 3 # 10 C 47 SER D 10 SER^? 8.71 O3S EPE D 146 C 48 THR D 140 THR^? -4.35 O2S EPE D 146s C 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 4.11 -10.06 -22.93 10.31 -9.82 -22.91 ULMN 3 1fdy_c06 N-ACETYLNEURAMINATE LYASE user 11 3 # 11 C 47 SER D 29 SER~? 20.03 O3S EPE D 146 C 48 THR D 28 THR~? 15.29 CL CL D 144 C 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -15.18 -75.37 -50.42 -16.12 -74.55 -48.34 8.08 -16.49 -34.93 9.82 -17.78 -36.00 coo -16.57 -77.65 -53.15 -18.61 -78.18 -53.63 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo -25.12 -68.79 -47.79 -21.06 -72.76 -50.30 4.11 -10.06 -22.93 10.31 -9.82 -22.91 1fdy_c06 source 1fdy N-ACETYLNEURAMINATE LYASE : 11 hits 1fdy_c06 naa= 3 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 1 3 # 1 D 47 SER A 10 SER^? 8.69 O1S EPE A 145 D 48 THR A 140 THR^? -4.46 O3S EPE A 145s D 165 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -25.84 -7.90 -15.56 -24.35 -8.12 -17.13 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 2 3 # 2 D 47 SER A 29 SER~? 20.16 O1S EPE A 145 D 48 THR A 28 THR~? 15.27 CL CL A 144 D 165 LYS A 7 LYS.? 11.74 O8 EPE A 145 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -37.74 2.28 -16.63 -39.96 3.28 -16.58 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -35.28 -0.43 -17.60 -35.00 -0.71 -19.69 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -24.35 2.90 -12.02 -25.19 4.34 -6.86 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 3 3 # 3 D 47 SER B 10 SER^? 8.49 O2S EPE A 145 D 48 THR B 140 THR^? -4.33 O2S EPE A 145s D 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -22.29 -13.72 -13.75 -21.71 -14.67 -11.88 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 4 3 # 4 D 47 SER B 34 SER~? 6.65 CL CL D 145 D 48 THR D 130 THR~? 5.00 CL CL D 145 D 165 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 5 3 # 5 D 47 SER B 34 SER~? 6.65 CL CL D 145 D 48 THR D 130 THR~? 5.00 CL CL D 145 D 165 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 6 3 # 6 D 47 SER B 34 SER~? 6.65 CL CL D 145 D 48 THR D 130 THR~? 5.00 CL CL D 145 D 165 LYS D 100 LYS^? 18.85 CL CL D 145 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 7 3 # 7 D 47 SER D 10 SER^? 8.71 O3S EPE D 146 D 48 THR D 140 THR^? -4.35 O2S EPE D 146s D 165 LYS D 6 LYS.? 14.92 O8 EPE D 146 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 -0.72 -4.04 -31.39 -2.84 -4.20 -30.87 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 3.13 -11.94 -19.77 2.68 -17.66 -22.71 ULMN 3 1fdy_c07 N-ACETYLNEURAMINATE LYASE user 8 3 # 8 D 47 SER D 29 SER~? 20.03 O3S EPE D 146 D 48 THR D 28 THR~? 15.29 CL CL D 144 D 165 LYS D 7 LYS.? 12.04 O8 EPE D 146 coo -21.69 -90.39 -8.89 -21.07 -88.29 -10.03 8.08 -16.49 -34.93 9.82 -17.78 -36.00 coo -19.38 -93.32 -7.98 -17.24 -93.31 -7.67 5.21 -14.04 -34.95 3.36 -14.88 -35.73 coo -14.17 -80.73 -6.25 -16.63 -86.38 -7.08 4.11 -10.06 -22.93 10.31 -9.82 -22.91 1fdy_c07 source 1fdy N-ACETYLNEURAMINATE LYASE : 8 hits 1fdy_c07 naa= 3 ULMN 3 1fob_c00 BETA-1,4-GALACTANASE user 1 3 # 1 A 45 ARG D 134 ARG~? 13.66 CL CL D 145 A 136 GLU D 98 GLU^? 15.40 O8 EPE D 146 A 246 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 13.94 29.84 106.80 11.67 30.40 108.79 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 9.52 31.97 115.23 8.45 33.74 114.72 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 11.92 33.82 109.35 10.10 33.50 110.39 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 1fob_c00 source 1fob BETA-1,4-GALACTANASE : 1 hits 1fob_c00 naa= 3 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 1 3 # 1 A 317 GLU A 136 GLU~? 8.92 C6 EPE A 145 A 319 ASP A 133 ASP~? 7.97 CL CL D 145 A 359 ARG A 134 ARG~? 13.60 CL CL D 145 coo 14.41 12.40 16.42 12.92 13.74 15.71 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 12.25 13.04 23.85 11.56 15.02 23.93 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 10.89 14.95 28.28 12.39 12.53 29.31 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 2 3 # 2 A 317 GLU B 136 GLU~? 6.67 C2 EPE A 145 A 319 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 359 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 14.41 12.40 16.42 12.92 13.74 15.71 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 12.25 13.04 23.85 11.56 15.02 23.93 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 10.89 14.95 28.28 12.39 12.53 29.31 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 3 3 # 3 A 317 GLU C 136 GLU~? 8.02 O8 EPE A 145 A 319 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 359 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 14.41 12.40 16.42 12.92 13.74 15.71 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 12.25 13.04 23.85 11.56 15.02 23.93 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 10.89 14.95 28.28 12.39 12.53 29.31 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1fr8_c00 BETA 1,4 GALACTOSYLTRANSFERASE user 4 3 # 4 A 317 GLU D 136 GLU~? 8.82 C5 EPE D 146 A 319 ASP D 133 ASP~? 7.85 CL CL D 145 A 359 ARG D 134 ARG~? 13.66 CL CL D 145 coo 14.41 12.40 16.42 12.92 13.74 15.71 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 coo 12.25 13.04 23.85 11.56 15.02 23.93 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 10.89 14.95 28.28 12.39 12.53 29.31 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1fr8_c00 source 1fr8 BETA 1,4 GALACTOSYLTRANSFERASE : 4 hits 1fr8_c00 naa= 3 ULMN 3 1ga8_c00 GALACTOSYL TRANSFERASE LGTC user 1 3 # 1 A 130 ASP A 64 ASP~? 16.08 CL CL A 144 A 153 ASN B 66 ASN~? 17.83 CL CL A 144 A 189 GLN A 62 GLN.? 20.20 CL CL A 144 coo 27.45 53.97 73.24 26.29 54.34 71.54 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 29.93 52.22 70.56 29.34 51.93 68.54 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 coo 26.19 47.96 71.25 25.92 49.81 70.24 -45.83 -15.14 -26.74 -44.25 -16.47 -27.42 1ga8_c00 source 1ga8 GALACTOSYL TRANSFERASE LGTC : 1 hits 1ga8_c00 naa= 3 ULMN 3 1geq_c02 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 1 3 # 1 A 36 GLU A 68 GLU~? 25.44 CL CL A 144 A 47 ASP B 64 ASP~? 15.96 CL CL A 144 A 161 TYR A 67 TYR~? 16.80 CL CL A 144 coo 37.12 18.35 73.76 37.09 16.69 72.44 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 29.81 8.06 73.13 30.21 10.11 72.95 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 37.29 15.56 67.90 37.37 13.79 70.08 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1geq_c02 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 2 3 # 2 A 36 GLU B 68 GLU~? 25.19 CL CL A 144 A 47 ASP C 64 ASP~? 15.91 CL CL A 144 A 161 TYR B 67 TYR~? 16.82 CL CL A 144 coo 37.12 18.35 73.76 37.09 16.69 72.44 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 29.81 8.06 73.13 30.21 10.11 72.95 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 37.29 15.56 67.90 37.37 13.79 70.08 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1geq_c02 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 3 3 # 3 A 36 GLU C 68 GLU~? 25.33 CL CL A 144 A 47 ASP A 64 ASP~? 16.08 CL CL A 144 A 161 TYR C 67 TYR~? 16.92 CL CL A 144 coo 37.12 18.35 73.76 37.09 16.69 72.44 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 29.81 8.06 73.13 30.21 10.11 72.95 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 37.29 15.56 67.90 37.37 13.79 70.08 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 1geq_c02 source 1geq TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT : 3 hits 1geq_c02 naa= 3 ULMN 3 1geq_c03 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 1 3 # 1 B 36 GLU A 68 GLU~? 25.44 CL CL A 144 B 47 ASP B 64 ASP~? 15.96 CL CL A 144 B 161 TYR A 67 TYR~? 16.80 CL CL A 144 coo 53.87 35.49 53.22 55.44 35.72 54.61 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 63.47 43.65 53.95 61.45 43.07 54.06 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 56.38 35.81 59.19 58.25 35.77 57.10 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1geq_c03 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 2 3 # 2 B 36 GLU B 68 GLU~? 25.19 CL CL A 144 B 47 ASP C 64 ASP~? 15.91 CL CL A 144 B 161 TYR B 67 TYR~? 16.82 CL CL A 144 coo 53.87 35.49 53.22 55.44 35.72 54.61 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 63.47 43.65 53.95 61.45 43.07 54.06 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 56.38 35.81 59.19 58.25 35.77 57.10 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1geq_c03 TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT user 3 3 # 3 B 36 GLU C 68 GLU~? 25.33 CL CL A 144 B 47 ASP A 64 ASP~? 16.08 CL CL A 144 B 161 TYR C 67 TYR~? 16.92 CL CL A 144 coo 53.87 35.49 53.22 55.44 35.72 54.61 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 63.47 43.65 53.95 61.45 43.07 54.06 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 56.38 35.81 59.19 58.25 35.77 57.10 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 1geq_c03 source 1geq TRYPTOPHAN SYNTHASE ALPHA-SUBUNIT : 3 hits 1geq_c03 naa= 3 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 1 3 # 1 A 189 PHE A 41 PHE^? 11.09 CL CL D 145 A 298 ASP A 133 ASP~? 7.97 CL CL D 145 A 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 2.59 0.29 25.55 4.65 0.18 25.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 2 3 # 2 A 189 PHE A 42 PHE^? 15.34 CL CL A 144 A 298 ASP A 123 ASP.? 17.71 CL CL D 145 A 329 LYS A 94 LYS.? 20.29 CL CL D 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 2.59 0.29 25.55 4.65 0.18 25.07 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 12.42 6.10 23.27 9.95 1.57 20.16 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 3 3 # 3 A 189 PHE A 44 PHE~? 15.48 CL CL A 144 A 298 ASP B 64 ASP~? 15.96 CL CL A 144 A 329 LYS A 20 LYS~? 9.88 CL CL A 144 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 2.59 0.29 25.55 4.65 0.18 25.07 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 12.42 6.10 23.27 9.95 1.57 20.16 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 4 3 # 4 A 189 PHE A 102 PHE^? 11.63 CL CL D 145 A 298 ASP A 133 ASP~? 7.97 CL CL D 145 A 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 2.59 0.29 25.55 4.65 0.18 25.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 5 3 # 5 A 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 298 ASP A 133 ASP~? 7.97 CL CL D 145 A 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 2.59 0.29 25.55 4.65 0.18 25.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 6 3 # 6 A 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 298 ASP A 133 ASP~? 7.97 CL CL D 145 A 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 2.59 0.29 25.55 4.65 0.18 25.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 7 3 # 7 A 189 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 2.59 0.29 25.55 4.65 0.18 25.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.42 6.10 23.27 9.95 1.57 20.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 8 3 # 8 A 189 PHE B 42 PHE^? 15.32 CL CL A 144 A 298 ASP B 123 ASP.? 21.73 O3S EPE A 145 A 329 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 2.59 0.29 25.55 4.65 0.18 25.07 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 12.42 6.10 23.27 9.95 1.57 20.16 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 9 3 # 9 A 189 PHE B 44 PHE~? 15.63 CL CL A 144 A 298 ASP C 64 ASP~? 15.91 CL CL A 144 A 329 LYS B 20 LYS~? 9.95 CL CL A 144 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 2.59 0.29 25.55 4.65 0.18 25.07 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 12.42 6.10 23.27 9.95 1.57 20.16 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 10 3 # 10 A 189 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 2.59 0.29 25.55 4.65 0.18 25.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.42 6.10 23.27 9.95 1.57 20.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 11 3 # 11 A 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 2.59 0.29 25.55 4.65 0.18 25.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.42 6.10 23.27 9.95 1.57 20.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 12 3 # 12 A 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 2.59 0.29 25.55 4.65 0.18 25.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.42 6.10 23.27 9.95 1.57 20.16 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 13 3 # 13 A 189 PHE C 42 PHE^? 15.30 CL CL A 144 A 298 ASP C 123 ASP.? 21.65 O2S EPE A 145 A 329 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 2.59 0.29 25.55 4.65 0.18 25.07 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 12.42 6.10 23.27 9.95 1.57 20.16 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 14 3 # 14 A 189 PHE C 44 PHE~? 15.66 CL CL A 144 A 298 ASP A 64 ASP~? 16.08 CL CL A 144 A 329 LYS C 20 LYS~? 9.96 CL CL A 144 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 2.59 0.29 25.55 4.65 0.18 25.07 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 12.42 6.10 23.27 9.95 1.57 20.16 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 15 3 # 15 A 189 PHE C 102 PHE^? 16.65 O1S EPE A 145 A 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 2.59 0.29 25.55 4.65 0.18 25.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 16 3 # 16 A 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 2.59 0.29 25.55 4.65 0.18 25.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 17 3 # 17 A 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 2.59 0.29 25.55 4.65 0.18 25.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.42 6.10 23.27 9.95 1.57 20.16 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 18 3 # 18 A 189 PHE D 41 PHE^? 10.83 CL CL D 145 A 298 ASP D 133 ASP~? 7.85 CL CL D 145 A 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 2.59 0.29 25.55 4.65 0.18 25.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.42 6.10 23.27 9.95 1.57 20.16 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 19 3 # 19 A 189 PHE D 42 PHE^? 15.36 CL CL D 144 A 298 ASP D 123 ASP.? 17.57 CL CL D 145 A 329 LYS D 94 LYS.? 20.13 CL CL D 145 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 2.59 0.29 25.55 4.65 0.18 25.07 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 12.42 6.10 23.27 9.95 1.57 20.16 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 20 3 # 20 A 189 PHE D 102 PHE^? 11.51 CL CL D 145 A 298 ASP D 133 ASP~? 7.85 CL CL D 145 A 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 2.59 0.29 25.55 4.65 0.18 25.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.42 6.10 23.27 9.95 1.57 20.16 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c00 4-AMINOBUTYRATE AMINOTRANSFERASE user 21 3 # 21 A 189 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 298 ASP D 133 ASP~? 7.85 CL CL D 145 A 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 6.56 -4.17 18.88 9.26 -4.62 19.48 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 2.59 0.29 25.55 4.65 0.18 25.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.42 6.10 23.27 9.95 1.57 20.16 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gtx_c00 source 1gtx 4-AMINOBUTYRATE AMINOTRANSFERASE : 21 hits 1gtx_c00 naa= 3 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 1 3 # 1 B 189 PHE A 41 PHE^? 11.09 CL CL D 145 B 298 ASP A 133 ASP~? 7.97 CL CL D 145 B 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 2 3 # 2 B 189 PHE A 42 PHE^? 15.34 CL CL A 144 B 298 ASP A 123 ASP.? 17.71 CL CL D 145 B 329 LYS A 94 LYS.? 20.29 CL CL D 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 3 3 # 3 B 189 PHE A 44 PHE~? 15.48 CL CL A 144 B 298 ASP B 64 ASP~? 15.96 CL CL A 144 B 329 LYS A 20 LYS~? 9.88 CL CL A 144 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 4 3 # 4 B 189 PHE A 102 PHE^? 11.63 CL CL D 145 B 298 ASP A 133 ASP~? 7.97 CL CL D 145 B 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 5 3 # 5 B 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 298 ASP A 133 ASP~? 7.97 CL CL D 145 B 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 6 3 # 6 B 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 298 ASP A 133 ASP~? 7.97 CL CL D 145 B 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 7 3 # 7 B 189 PHE B 41 PHE^? 12.26 O2S EPE A 145 B 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 8 3 # 8 B 189 PHE B 42 PHE^? 15.32 CL CL A 144 B 298 ASP B 123 ASP.? 21.73 O3S EPE A 145 B 329 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 9 3 # 9 B 189 PHE B 44 PHE~? 15.63 CL CL A 144 B 298 ASP C 64 ASP~? 15.91 CL CL A 144 B 329 LYS B 20 LYS~? 9.95 CL CL A 144 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 10 3 # 10 B 189 PHE B 102 PHE^? 16.45 O2S EPE A 145 B 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 11 3 # 11 B 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 B 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 12 3 # 12 B 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 B 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 13 3 # 13 B 189 PHE C 42 PHE^? 15.30 CL CL A 144 B 298 ASP C 123 ASP.? 21.65 O2S EPE A 145 B 329 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 14 3 # 14 B 189 PHE C 44 PHE~? 15.66 CL CL A 144 B 298 ASP A 64 ASP~? 16.08 CL CL A 144 B 329 LYS C 20 LYS~? 9.96 CL CL A 144 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 15 3 # 15 B 189 PHE C 102 PHE^? 16.65 O1S EPE A 145 B 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 16 3 # 16 B 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 B 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 17 3 # 17 B 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 B 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 18 3 # 18 B 189 PHE D 41 PHE^? 10.83 CL CL D 145 B 298 ASP D 133 ASP~? 7.85 CL CL D 145 B 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 19 3 # 19 B 189 PHE D 42 PHE^? 15.36 CL CL D 144 B 298 ASP D 123 ASP.? 17.57 CL CL D 145 B 329 LYS D 94 LYS.? 20.13 CL CL D 145 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 20 3 # 20 B 189 PHE D 102 PHE^? 11.51 CL CL D 145 B 298 ASP D 133 ASP~? 7.85 CL CL D 145 B 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c01 4-AMINOBUTYRATE AMINOTRANSFERASE user 21 3 # 21 B 189 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 298 ASP D 133 ASP~? 7.85 CL CL D 145 B 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 20.14 -12.51 41.29 18.81 -10.14 40.57 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 25.22 -15.42 34.53 24.48 -13.46 34.89 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.68 -4.10 35.68 24.39 -7.59 39.32 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gtx_c01 source 1gtx 4-AMINOBUTYRATE AMINOTRANSFERASE : 21 hits 1gtx_c01 naa= 3 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 1 3 # 1 C 189 PHE A 41 PHE^? 11.09 CL CL D 145 C 298 ASP A 133 ASP~? 7.97 CL CL D 145 C 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 24.10 66.43 63.33 24.18 64.30 63.40 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 2 3 # 2 C 189 PHE A 42 PHE^? 15.34 CL CL A 144 C 298 ASP A 123 ASP.? 17.71 CL CL D 145 C 329 LYS A 94 LYS.? 20.29 CL CL D 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 24.10 66.43 63.33 24.18 64.30 63.40 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 27.64 56.61 58.17 22.18 57.92 60.36 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 3 3 # 3 C 189 PHE A 44 PHE~? 15.48 CL CL A 144 C 298 ASP B 64 ASP~? 15.96 CL CL A 144 C 329 LYS A 20 LYS~? 9.88 CL CL A 144 coo 17.41 60.57 64.39 18.40 58.12 65.34 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 24.10 66.43 63.33 24.18 64.30 63.40 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 27.64 56.61 58.17 22.18 57.92 60.36 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 4 3 # 4 C 189 PHE A 102 PHE^? 11.63 CL CL D 145 C 298 ASP A 133 ASP~? 7.97 CL CL D 145 C 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 24.10 66.43 63.33 24.18 64.30 63.40 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 5 3 # 5 C 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 C 298 ASP A 133 ASP~? 7.97 CL CL D 145 C 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 24.10 66.43 63.33 24.18 64.30 63.40 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 6 3 # 6 C 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 C 298 ASP A 133 ASP~? 7.97 CL CL D 145 C 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 24.10 66.43 63.33 24.18 64.30 63.40 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 7 3 # 7 C 189 PHE B 41 PHE^? 12.26 O2S EPE A 145 C 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 24.10 66.43 63.33 24.18 64.30 63.40 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.64 56.61 58.17 22.18 57.92 60.36 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 8 3 # 8 C 189 PHE B 42 PHE^? 15.32 CL CL A 144 C 298 ASP B 123 ASP.? 21.73 O3S EPE A 145 C 329 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 24.10 66.43 63.33 24.18 64.30 63.40 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 27.64 56.61 58.17 22.18 57.92 60.36 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 9 3 # 9 C 189 PHE B 44 PHE~? 15.63 CL CL A 144 C 298 ASP C 64 ASP~? 15.91 CL CL A 144 C 329 LYS B 20 LYS~? 9.95 CL CL A 144 coo 17.41 60.57 64.39 18.40 58.12 65.34 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 24.10 66.43 63.33 24.18 64.30 63.40 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 27.64 56.61 58.17 22.18 57.92 60.36 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 10 3 # 10 C 189 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 24.10 66.43 63.33 24.18 64.30 63.40 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.64 56.61 58.17 22.18 57.92 60.36 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 11 3 # 11 C 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 C 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 24.10 66.43 63.33 24.18 64.30 63.40 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.64 56.61 58.17 22.18 57.92 60.36 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 12 3 # 12 C 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 C 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 24.10 66.43 63.33 24.18 64.30 63.40 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 27.64 56.61 58.17 22.18 57.92 60.36 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 13 3 # 13 C 189 PHE C 42 PHE^? 15.30 CL CL A 144 C 298 ASP C 123 ASP.? 21.65 O2S EPE A 145 C 329 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 24.10 66.43 63.33 24.18 64.30 63.40 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 27.64 56.61 58.17 22.18 57.92 60.36 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 14 3 # 14 C 189 PHE C 44 PHE~? 15.66 CL CL A 144 C 298 ASP A 64 ASP~? 16.08 CL CL A 144 C 329 LYS C 20 LYS~? 9.96 CL CL A 144 coo 17.41 60.57 64.39 18.40 58.12 65.34 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 24.10 66.43 63.33 24.18 64.30 63.40 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 27.64 56.61 58.17 22.18 57.92 60.36 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 15 3 # 15 C 189 PHE C 102 PHE^? 16.65 O1S EPE A 145 C 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 24.10 66.43 63.33 24.18 64.30 63.40 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 16 3 # 16 C 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 C 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 24.10 66.43 63.33 24.18 64.30 63.40 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 17 3 # 17 C 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 C 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 24.10 66.43 63.33 24.18 64.30 63.40 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.64 56.61 58.17 22.18 57.92 60.36 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 18 3 # 18 C 189 PHE D 41 PHE^? 10.83 CL CL D 145 C 298 ASP D 133 ASP~? 7.85 CL CL D 145 C 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 17.41 60.57 64.39 18.40 58.12 65.34 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 24.10 66.43 63.33 24.18 64.30 63.40 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.64 56.61 58.17 22.18 57.92 60.36 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 19 3 # 19 C 189 PHE D 42 PHE^? 15.36 CL CL D 144 C 298 ASP D 123 ASP.? 17.57 CL CL D 145 C 329 LYS D 94 LYS.? 20.13 CL CL D 145 coo 17.41 60.57 64.39 18.40 58.12 65.34 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 24.10 66.43 63.33 24.18 64.30 63.40 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 27.64 56.61 58.17 22.18 57.92 60.36 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 20 3 # 20 C 189 PHE D 102 PHE^? 11.51 CL CL D 145 C 298 ASP D 133 ASP~? 7.85 CL CL D 145 C 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 17.41 60.57 64.39 18.40 58.12 65.34 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 24.10 66.43 63.33 24.18 64.30 63.40 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.64 56.61 58.17 22.18 57.92 60.36 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c02 4-AMINOBUTYRATE AMINOTRANSFERASE user 21 3 # 21 C 189 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 298 ASP D 133 ASP~? 7.85 CL CL D 145 C 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 17.41 60.57 64.39 18.40 58.12 65.34 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 24.10 66.43 63.33 24.18 64.30 63.40 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.64 56.61 58.17 22.18 57.92 60.36 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gtx_c02 source 1gtx 4-AMINOBUTYRATE AMINOTRANSFERASE : 21 hits 1gtx_c02 naa= 3 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 1 3 # 1 D 189 PHE A 41 PHE^? 11.09 CL CL D 145 D 298 ASP A 133 ASP~? 7.97 CL CL D 145 D 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 29.72 46.46 83.60 30.79 47.36 81.99 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 2 3 # 2 D 189 PHE A 42 PHE^? 15.34 CL CL A 144 D 298 ASP A 123 ASP.? 17.71 CL CL D 145 D 329 LYS A 94 LYS.? 20.29 CL CL D 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 29.72 46.46 83.60 30.79 47.36 81.99 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 36.89 44.91 74.55 37.33 48.94 79.01 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 3 3 # 3 D 189 PHE A 44 PHE~? 15.48 CL CL A 144 D 298 ASP B 64 ASP~? 15.96 CL CL A 144 D 329 LYS A 20 LYS~? 9.88 CL CL A 144 coo 35.44 53.35 83.81 35.65 54.53 81.28 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 29.72 46.46 83.60 30.79 47.36 81.99 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 36.89 44.91 74.55 37.33 48.94 79.01 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 4 3 # 4 D 189 PHE A 102 PHE^? 11.63 CL CL D 145 D 298 ASP A 133 ASP~? 7.97 CL CL D 145 D 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 29.72 46.46 83.60 30.79 47.36 81.99 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 5 3 # 5 D 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 D 298 ASP A 133 ASP~? 7.97 CL CL D 145 D 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 29.72 46.46 83.60 30.79 47.36 81.99 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 6 3 # 6 D 189 PHE A 131 PHE~? 8.85 O3S EPE A 145 D 298 ASP A 133 ASP~? 7.97 CL CL D 145 D 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 29.72 46.46 83.60 30.79 47.36 81.99 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 7 3 # 7 D 189 PHE B 41 PHE^? 12.26 O2S EPE A 145 D 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 D 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 29.72 46.46 83.60 30.79 47.36 81.99 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 36.89 44.91 74.55 37.33 48.94 79.01 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 8 3 # 8 D 189 PHE B 42 PHE^? 15.32 CL CL A 144 D 298 ASP B 123 ASP.? 21.73 O3S EPE A 145 D 329 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo 29.72 46.46 83.60 30.79 47.36 81.99 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 36.89 44.91 74.55 37.33 48.94 79.01 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 9 3 # 9 D 189 PHE B 44 PHE~? 15.63 CL CL A 144 D 298 ASP C 64 ASP~? 15.91 CL CL A 144 D 329 LYS B 20 LYS~? 9.95 CL CL A 144 coo 35.44 53.35 83.81 35.65 54.53 81.28 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 29.72 46.46 83.60 30.79 47.36 81.99 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 36.89 44.91 74.55 37.33 48.94 79.01 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 10 3 # 10 D 189 PHE B 102 PHE^? 16.45 O2S EPE A 145 D 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 D 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 29.72 46.46 83.60 30.79 47.36 81.99 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 36.89 44.91 74.55 37.33 48.94 79.01 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 11 3 # 11 D 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 D 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 D 329 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 29.72 46.46 83.60 30.79 47.36 81.99 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 36.89 44.91 74.55 37.33 48.94 79.01 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 12 3 # 12 D 189 PHE B 131 PHE~? 9.25 O2S EPE A 145 D 298 ASP B 133 ASP~? 13.85 C2 EPE A 145 D 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 29.72 46.46 83.60 30.79 47.36 81.99 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 36.89 44.91 74.55 37.33 48.94 79.01 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 13 3 # 13 D 189 PHE C 42 PHE^? 15.30 CL CL A 144 D 298 ASP C 123 ASP.? 21.65 O2S EPE A 145 D 329 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 29.72 46.46 83.60 30.79 47.36 81.99 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 36.89 44.91 74.55 37.33 48.94 79.01 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 14 3 # 14 D 189 PHE C 44 PHE~? 15.66 CL CL A 144 D 298 ASP A 64 ASP~? 16.08 CL CL A 144 D 329 LYS C 20 LYS~? 9.96 CL CL A 144 coo 35.44 53.35 83.81 35.65 54.53 81.28 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 29.72 46.46 83.60 30.79 47.36 81.99 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 36.89 44.91 74.55 37.33 48.94 79.01 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 15 3 # 15 D 189 PHE C 102 PHE^? 16.65 O1S EPE A 145 D 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 D 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 29.72 46.46 83.60 30.79 47.36 81.99 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 16 3 # 16 D 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 D 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 D 329 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 29.72 46.46 83.60 30.79 47.36 81.99 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 17 3 # 17 D 189 PHE C 131 PHE~? 11.28 O1S EPE A 145 D 298 ASP C 133 ASP~? 13.97 O1S EPE A 145 D 329 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 29.72 46.46 83.60 30.79 47.36 81.99 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 36.89 44.91 74.55 37.33 48.94 79.01 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 18 3 # 18 D 189 PHE D 41 PHE^? 10.83 CL CL D 145 D 298 ASP D 133 ASP~? 7.85 CL CL D 145 D 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 35.44 53.35 83.81 35.65 54.53 81.28 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 29.72 46.46 83.60 30.79 47.36 81.99 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 36.89 44.91 74.55 37.33 48.94 79.01 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 19 3 # 19 D 189 PHE D 42 PHE^? 15.36 CL CL D 144 D 298 ASP D 123 ASP.? 17.57 CL CL D 145 D 329 LYS D 94 LYS.? 20.13 CL CL D 145 coo 35.44 53.35 83.81 35.65 54.53 81.28 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 29.72 46.46 83.60 30.79 47.36 81.99 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 36.89 44.91 74.55 37.33 48.94 79.01 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 20 3 # 20 D 189 PHE D 102 PHE^? 11.51 CL CL D 145 D 298 ASP D 133 ASP~? 7.85 CL CL D 145 D 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 35.44 53.35 83.81 35.65 54.53 81.28 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 29.72 46.46 83.60 30.79 47.36 81.99 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 36.89 44.91 74.55 37.33 48.94 79.01 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1gtx_c03 4-AMINOBUTYRATE AMINOTRANSFERASE user 21 3 # 21 D 189 PHE D 131 PHE~? 8.86 O2S EPE D 146 D 298 ASP D 133 ASP~? 7.85 CL CL D 145 D 329 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 35.44 53.35 83.81 35.65 54.53 81.28 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 29.72 46.46 83.60 30.79 47.36 81.99 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 36.89 44.91 74.55 37.33 48.94 79.01 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gtx_c03 source 1gtx 4-AMINOBUTYRATE AMINOTRANSFERASE : 21 hits 1gtx_c03 naa= 3 ULMN 3 1gz6_c00 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 1 3 # 1 A 151 SER A 10 SER^? 8.69 O1S EPE A 145 A 164 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 168 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 32.37 52.40 49.35 31.32 53.88 47.74 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 29.69 55.04 42.83 31.98 53.56 43.49 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 26.96 50.99 47.03 31.03 48.83 44.33 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gz6_c00 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 2 3 # 2 A 151 SER B 10 SER^? 8.49 O2S EPE A 145 A 164 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 168 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 32.37 52.40 49.35 31.32 53.88 47.74 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 29.69 55.04 42.83 31.98 53.56 43.49 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 26.96 50.99 47.03 31.03 48.83 44.33 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gz6_c00 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 3 3 # 3 A 151 SER C 10 SER^? 8.67 O1S EPE A 145 A 164 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 168 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 32.37 52.40 49.35 31.32 53.88 47.74 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 29.69 55.04 42.83 31.98 53.56 43.49 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 26.96 50.99 47.03 31.03 48.83 44.33 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gz6_c00 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 4 3 # 4 A 151 SER D 10 SER^? 8.71 O3S EPE D 146 A 164 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 168 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 32.37 52.40 49.35 31.32 53.88 47.74 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 29.69 55.04 42.83 31.98 53.56 43.49 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 26.96 50.99 47.03 31.03 48.83 44.33 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gz6_c00 source 1gz6 ESTRADIOL 17 BETA-DEHYDROGENASE 4 : 4 hits 1gz6_c00 naa= 3 ULMN 3 1gz6_c01 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 1 3 # 1 B 151 SER A 10 SER^? 8.69 O1S EPE A 145 B 164 TYR A 36 TYR.? 11.29 O1S EPE A 145 B 168 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 13.08 50.93 56.67 13.12 48.99 55.27 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 11.52 46.03 51.32 10.06 47.90 52.76 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 15.72 50.86 51.22 10.77 52.35 51.39 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gz6_c01 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 2 3 # 2 B 151 SER B 10 SER^? 8.49 O2S EPE A 145 B 164 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 168 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 13.08 50.93 56.67 13.12 48.99 55.27 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 11.52 46.03 51.32 10.06 47.90 52.76 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 15.72 50.86 51.22 10.77 52.35 51.39 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gz6_c01 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 3 3 # 3 B 151 SER C 10 SER^? 8.67 O1S EPE A 145 B 164 TYR C 36 TYR.? 11.46 O2S EPE A 145 B 168 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 13.08 50.93 56.67 13.12 48.99 55.27 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 11.52 46.03 51.32 10.06 47.90 52.76 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 15.72 50.86 51.22 10.77 52.35 51.39 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gz6_c01 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 4 3 # 4 B 151 SER D 10 SER^? 8.71 O3S EPE D 146 B 164 TYR D 36 TYR.? 11.19 O3S EPE D 146 B 168 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 13.08 50.93 56.67 13.12 48.99 55.27 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 11.52 46.03 51.32 10.06 47.90 52.76 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 15.72 50.86 51.22 10.77 52.35 51.39 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gz6_c01 source 1gz6 ESTRADIOL 17 BETA-DEHYDROGENASE 4 : 4 hits 1gz6_c01 naa= 3 ULMN 3 1gz6_c02 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 1 3 # 1 C 151 SER A 10 SER^? 8.69 O1S EPE A 145 C 164 TYR A 36 TYR.? 11.29 O1S EPE A 145 C 168 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 11.22 34.38 82.32 11.07 36.29 83.78 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 8.83 39.27 87.38 7.60 37.43 85.69 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 12.98 34.46 88.14 8.11 32.96 87.14 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gz6_c02 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 2 3 # 2 C 151 SER B 10 SER^? 8.49 O2S EPE A 145 C 164 TYR B 36 TYR.? 11.13 O3S EPE A 145 C 168 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 11.22 34.38 82.32 11.07 36.29 83.78 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 8.83 39.27 87.38 7.60 37.43 85.69 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 12.98 34.46 88.14 8.11 32.96 87.14 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gz6_c02 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 3 3 # 3 C 151 SER C 10 SER^? 8.67 O1S EPE A 145 C 164 TYR C 36 TYR.? 11.46 O2S EPE A 145 C 168 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 11.22 34.38 82.32 11.07 36.29 83.78 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 8.83 39.27 87.38 7.60 37.43 85.69 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 12.98 34.46 88.14 8.11 32.96 87.14 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gz6_c02 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 4 3 # 4 C 151 SER D 10 SER^? 8.71 O3S EPE D 146 C 164 TYR D 36 TYR.? 11.19 O3S EPE D 146 C 168 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 11.22 34.38 82.32 11.07 36.29 83.78 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 8.83 39.27 87.38 7.60 37.43 85.69 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 12.98 34.46 88.14 8.11 32.96 87.14 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gz6_c02 source 1gz6 ESTRADIOL 17 BETA-DEHYDROGENASE 4 : 4 hits 1gz6_c02 naa= 3 ULMN 3 1gz6_c03 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 1 3 # 1 D 151 SER A 10 SER^? 8.69 O1S EPE A 145 D 164 TYR A 36 TYR.? 11.29 O1S EPE A 145 D 168 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 29.15 32.90 92.57 27.86 31.44 94.02 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 25.49 30.28 98.59 27.88 31.73 98.26 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 23.46 34.31 94.02 27.08 36.46 97.29 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1gz6_c03 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 2 3 # 2 D 151 SER B 10 SER^? 8.49 O2S EPE A 145 D 164 TYR B 36 TYR.? 11.13 O3S EPE A 145 D 168 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 29.15 32.90 92.57 27.86 31.44 94.02 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 25.49 30.28 98.59 27.88 31.73 98.26 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 23.46 34.31 94.02 27.08 36.46 97.29 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1gz6_c03 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 3 3 # 3 D 151 SER C 10 SER^? 8.67 O1S EPE A 145 D 164 TYR C 36 TYR.? 11.46 O2S EPE A 145 D 168 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 29.15 32.90 92.57 27.86 31.44 94.02 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 25.49 30.28 98.59 27.88 31.73 98.26 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 23.46 34.31 94.02 27.08 36.46 97.29 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1gz6_c03 ESTRADIOL 17 BETA-DEHYDROGENASE 4 user 4 3 # 4 D 151 SER D 10 SER^? 8.71 O3S EPE D 146 D 164 TYR D 36 TYR.? 11.19 O3S EPE D 146 D 168 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 29.15 32.90 92.57 27.86 31.44 94.02 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 25.49 30.28 98.59 27.88 31.73 98.26 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 23.46 34.31 94.02 27.08 36.46 97.29 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1gz6_c03 source 1gz6 ESTRADIOL 17 BETA-DEHYDROGENASE 4 : 4 hits 1gz6_c03 naa= 3 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 1 3 # 1 A 271 GLN B 76 GLN.? 25.52 CL CL D 145 A 296 GLU B 80 GLU.? 23.04 CL CL D 145 A 383 TYR B 83 TYR.? 13.54 CL CL D 145 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 -34.34 -26.19 -42.31 -33.37 -25.21 -43.95 coo 40.93 4.45 2.36 38.91 3.75 2.26 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 coo 30.54 7.22 6.23 31.38 5.79 3.97 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 2 3 # 2 A 271 GLN B 79 GLN.? 26.31 CL CL D 145 A 296 GLU B 80 GLU.? 23.04 CL CL D 145 A 383 TYR B 83 TYR.? 13.54 CL CL D 145 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 -29.81 -28.14 -40.65 -30.64 -29.88 -41.55 coo 40.93 4.45 2.36 38.91 3.75 2.26 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 coo 30.54 7.22 6.23 31.38 5.79 3.97 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 3 3 # 3 A 271 GLN C 76 GLN.? 31.44 CL CL A 144 A 296 GLU C 80 GLU.? 32.79 CL CL A 144 A 383 TYR C 83 TYR.? 22.25 CL CL A 144 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 -39.70 -41.16 -5.47 -37.95 -42.38 -5.32 coo 40.93 4.45 2.36 38.91 3.75 2.26 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 coo 30.54 7.22 6.23 31.38 5.79 3.97 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 4 3 # 4 A 271 GLN C 79 GLN.? 31.20 CL CL A 144 A 296 GLU C 80 GLU.? 32.79 CL CL A 144 A 383 TYR C 83 TYR.? 22.25 CL CL A 144 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 -40.20 -37.98 -1.32 -42.24 -38.65 -1.37 coo 40.93 4.45 2.36 38.91 3.75 2.26 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 coo 30.54 7.22 6.23 31.38 5.79 3.97 -32.88 -31.45 -0.17 -30.65 -29.81 -0.64 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 5 3 # 5 A 271 GLN D 76 GLN.? 31.34 CL CL D 144 A 296 GLU D 80 GLU.? 32.24 CL CL D 144 A 383 TYR D 83 TYR.? 22.27 CL CL D 144 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 17.72 -15.42 -56.74 19.34 -16.00 -55.44 coo 40.93 4.45 2.36 38.91 3.75 2.26 21.10 -18.28 -52.10 22.14 -16.74 -53.08 coo 30.54 7.22 6.23 31.38 5.79 3.97 13.86 -16.92 -44.50 13.57 -15.58 -42.06 ULMN 3 1h19_c00 LEUKOTRIENE A-4 HYDROLASE user 6 3 # 6 A 271 GLN D 79 GLN.? 30.90 CL CL D 144 A 296 GLU D 80 GLU.? 32.24 CL CL D 144 A 383 TYR D 83 TYR.? 22.27 CL CL D 144 coo 38.07 -1.37 3.28 36.21 -0.34 2.92 15.05 -18.90 -54.11 14.25 -19.43 -56.03 coo 40.93 4.45 2.36 38.91 3.75 2.26 21.10 -18.28 -52.10 22.14 -16.74 -53.08 coo 30.54 7.22 6.23 31.38 5.79 3.97 13.86 -16.92 -44.50 13.57 -15.58 -42.06 1h19_c00 source 1h19 LEUKOTRIENE A-4 HYDROLASE : 6 hits 1h19_c00 naa= 3 ULMN 3 1i29_c03 CSDB user 1 3 # 1 A 128 VAL A 13 VAL^? 10.99 CL CL A 144 A 200 ASP B 19 ASP~? 15.75 CL CL A 144 A 226 LYS B 77 LYS.? 21.17 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -33.25 -10.16 -23.25 -34.65 -8.46 -23.33 coo 24.51 43.28 11.18 25.17 44.50 9.58 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1i29_c03 CSDB user 2 3 # 2 A 128 VAL A 24 VAL~? 12.19 CL CL A 144 A 200 ASP A 19 ASP~? 15.97 CL CL A 144 A 226 LYS B 65 LYS~? 24.78 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -37.46 -5.88 -18.82 -36.56 -6.63 -20.66 coo 24.51 43.28 11.18 25.17 44.50 9.58 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 34.47 51.09 7.19 28.58 51.18 7.53 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1i29_c03 CSDB user 3 3 # 3 A 128 VAL A 24 VAL~? 12.19 CL CL A 144 A 200 ASP A 19 ASP~? 15.97 CL CL A 144 A 226 LYS C 20 LYS~? 9.96 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -37.46 -5.88 -18.82 -36.56 -6.63 -20.66 coo 24.51 43.28 11.18 25.17 44.50 9.58 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 34.47 51.09 7.19 28.58 51.18 7.53 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1i29_c03 CSDB user 4 3 # 4 A 128 VAL A 24 VAL~? 12.19 CL CL A 144 A 200 ASP A 64 ASP~? 16.08 CL CL A 144 A 226 LYS C 20 LYS~? 9.96 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -37.46 -5.88 -18.82 -36.56 -6.63 -20.66 coo 24.51 43.28 11.18 25.17 44.50 9.58 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 34.47 51.09 7.19 28.58 51.18 7.53 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1i29_c03 CSDB user 5 3 # 5 A 128 VAL A 38 VAL^? 12.70 O1S EPE A 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -29.02 0.75 -19.10 -31.03 0.33 -18.28 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1i29_c03 CSDB user 6 3 # 6 A 128 VAL A 125 VAL^? 10.58 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -26.56 -4.60 -34.18 -27.41 -5.73 -35.87 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1i29_c03 CSDB user 7 3 # 7 A 128 VAL A 126 VAL^? 7.02 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -23.68 -6.19 -32.32 -23.90 -4.81 -30.61 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1i29_c03 CSDB user 8 3 # 8 A 128 VAL A 126 VAL^? 7.02 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -23.68 -6.19 -32.32 -23.90 -4.81 -30.61 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1i29_c03 CSDB user 9 3 # 9 A 128 VAL A 128 VAL~? 6.20 CL CL D 145 A 200 ASP A 124 ASP^? 10.83 CL CL D 145 A 226 LYS A 94 LYS.? 20.29 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -21.50 -11.04 -27.85 -21.25 -13.10 -27.02 coo 24.51 43.28 11.18 25.17 44.50 9.58 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 34.47 51.09 7.19 28.58 51.18 7.53 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 1i29_c03 CSDB user 10 3 # 10 A 128 VAL A 128 VAL~? 6.20 CL CL D 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS B 82 LYS.? 24.10 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -21.50 -11.04 -27.85 -21.25 -13.10 -27.02 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1i29_c03 CSDB user 11 3 # 11 A 128 VAL A 128 VAL~? 6.20 CL CL D 145 A 200 ASP D 133 ASP~? 7.85 CL CL D 145 A 226 LYS D 100 LYS^? 18.85 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -21.50 -11.04 -27.85 -21.25 -13.10 -27.02 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 34.47 51.09 7.19 28.58 51.18 7.53 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 ULMN 3 1i29_c03 CSDB user 12 3 # 12 A 128 VAL B 13 VAL^? 10.89 CL CL A 144 A 200 ASP B 19 ASP~? 15.75 CL CL A 144 A 226 LYS A 65 LYS~? 24.48 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -26.29 -23.43 -16.65 -25.20 -24.08 -18.40 coo 24.51 43.28 11.18 25.17 44.50 9.58 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1i29_c03 CSDB user 13 3 # 13 A 128 VAL B 13 VAL^? 10.89 CL CL A 144 A 200 ASP C 19 ASP~? 15.67 CL CL A 144 A 226 LYS A 65 LYS~? 24.48 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -26.29 -23.43 -16.65 -25.20 -24.08 -18.40 coo 24.51 43.28 11.18 25.17 44.50 9.58 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1i29_c03 CSDB user 14 3 # 14 A 128 VAL B 24 VAL~? 11.93 CL CL A 144 A 200 ASP B 19 ASP~? 15.75 CL CL A 144 A 226 LYS A 20 LYS~? 9.88 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -24.18 -20.87 -23.30 -24.55 -22.20 -21.56 coo 24.51 43.28 11.18 25.17 44.50 9.58 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1i29_c03 CSDB user 15 3 # 15 A 128 VAL B 38 VAL^? 12.75 O3S EPE A 145 A 200 ASP D 133 ASP~? 7.85 CL CL D 145 A 226 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -14.97 -18.66 -18.27 -16.09 -18.62 -20.15 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 34.47 51.09 7.19 28.58 51.18 7.53 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1i29_c03 CSDB user 16 3 # 16 A 128 VAL B 90 VAL.? 17.95 CL CL D 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS D 94 LYS.? 20.13 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -17.68 -25.38 -25.13 -18.83 -25.68 -23.29 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1i29_c03 CSDB user 17 3 # 17 A 128 VAL B 99 VAL^? 17.15 O3S EPE A 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS D 94 LYS.? 20.13 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -12.64 -22.44 -19.60 -14.08 -22.36 -21.24 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 1i29_c03 CSDB user 18 3 # 18 A 128 VAL B 125 VAL^? 22.24 CL CL A 144 A 200 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 226 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -17.78 -31.54 -9.14 -18.85 -33.45 -8.90 coo 24.51 43.28 11.18 25.17 44.50 9.58 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1i29_c03 CSDB user 19 3 # 19 A 128 VAL B 126 VAL^? 18.52 O2S EPE A 145 A 200 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 226 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -18.42 -28.70 -6.68 -17.28 -27.14 -7.75 coo 24.51 43.28 11.18 25.17 44.50 9.58 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1i29_c03 CSDB user 20 3 # 20 A 128 VAL B 128 VAL~? 14.35 O2S EPE A 145 A 200 ASP B 124 ASP^? 22.45 O2S EPE A 145 A 226 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -22.58 -23.62 -4.60 -24.54 -22.76 -3.92 coo 24.51 43.28 11.18 25.17 44.50 9.58 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 34.47 51.09 7.19 28.58 51.18 7.53 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1i29_c03 CSDB user 21 3 # 21 A 128 VAL C 13 VAL^? 10.91 CL CL A 144 A 200 ASP A 19 ASP~? 15.97 CL CL A 144 A 226 LYS B 65 LYS~? 24.78 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -36.71 -14.33 -7.96 -36.66 -15.56 -6.17 coo 24.51 43.28 11.18 25.17 44.50 9.58 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 34.47 51.09 7.19 28.58 51.18 7.53 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1i29_c03 CSDB user 22 3 # 22 A 128 VAL C 13 VAL^? 10.91 CL CL A 144 A 200 ASP C 19 ASP~? 15.67 CL CL A 144 A 226 LYS B 65 LYS~? 24.78 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -36.71 -14.33 -7.96 -36.66 -15.56 -6.17 coo 24.51 43.28 11.18 25.17 44.50 9.58 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1i29_c03 CSDB user 23 3 # 23 A 128 VAL C 24 VAL~? 12.06 CL CL A 144 A 200 ASP C 19 ASP~? 15.67 CL CL A 144 A 226 LYS A 65 LYS~? 24.48 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -32.93 -20.07 -4.90 -34.41 -18.49 -5.13 coo 24.51 43.28 11.18 25.17 44.50 9.58 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1i29_c03 CSDB user 24 3 # 24 A 128 VAL C 24 VAL~? 12.06 CL CL A 144 A 200 ASP C 19 ASP~? 15.67 CL CL A 144 A 226 LYS B 20 LYS~? 9.95 CL CL A 144 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -32.93 -20.07 -4.90 -34.41 -18.49 -5.13 coo 24.51 43.28 11.18 25.17 44.50 9.58 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 34.47 51.09 7.19 28.58 51.18 7.53 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1i29_c03 CSDB user 25 3 # 25 A 128 VAL C 125 VAL^? 22.27 CL CL A 144 A 200 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 226 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -41.63 -4.13 0.18 -43.79 -4.29 -0.12 coo 24.51 43.28 11.18 25.17 44.50 9.58 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1i29_c03 CSDB user 26 3 # 26 A 128 VAL C 126 VAL^? 18.62 O1S EPE A 145 A 200 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 226 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -39.58 -2.05 -2.22 -37.61 -2.68 -1.44 coo 24.51 43.28 11.18 25.17 44.50 9.58 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 1i29_c03 CSDB user 27 3 # 27 A 128 VAL C 128 VAL~? 14.05 O1S EPE A 145 A 200 ASP C 124 ASP^? 22.63 O1S EPE A 145 A 226 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -36.70 -2.07 -8.37 -36.61 -2.71 -10.46 coo 24.51 43.28 11.18 25.17 44.50 9.58 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 34.47 51.09 7.19 28.58 51.18 7.53 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 1i29_c03 CSDB user 28 3 # 28 A 128 VAL D 125 VAL^? 10.60 CL CL D 145 A 200 ASP D 133 ASP~? 7.85 CL CL D 145 A 226 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.66 -16.98 -36.59 -14.77 -17.44 -38.44 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 34.47 51.09 7.19 28.58 51.18 7.53 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1i29_c03 CSDB user 29 3 # 29 A 128 VAL D 126 VAL^? 6.89 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -14.39 -13.80 -34.63 -12.58 -14.09 -33.41 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1i29_c03 CSDB user 30 3 # 30 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS A 100 LYS^? 18.99 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1i29_c03 CSDB user 31 3 # 31 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 1i29_c03 CSDB user 32 3 # 32 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP A 133 ASP~? 7.97 CL CL D 145 A 226 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.47 51.09 7.19 28.58 51.18 7.53 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1i29_c03 CSDB user 33 3 # 33 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS B 82 LYS.? 24.10 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 ULMN 3 1i29_c03 CSDB user 34 3 # 34 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 1i29_c03 CSDB user 35 3 # 35 A 128 VAL D 128 VAL~? 6.09 CL CL D 145 A 200 ASP D 124 ASP^? 11.01 CL CL D 145 A 226 LYS D 94 LYS.? 20.13 CL CL D 145 coo 19.13 38.05 1.41 19.72 38.80 -0.53 -13.59 -6.93 -34.19 -13.68 -4.78 -34.88 coo 24.51 43.28 11.18 25.17 44.50 9.58 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 34.47 51.09 7.19 28.58 51.18 7.53 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 1i29_c03 source 1i29 CSDB : 35 hits 1i29_c03 naa= 3 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 1 3 # 1 A 14 LYS A 94 LYS.? 20.29 CL CL D 145 A 74 LYS A 100 LYS^? 18.99 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 2 3 # 2 A 14 LYS A 100 LYS^? 18.99 CL CL D 145 A 74 LYS A 94 LYS.? 20.29 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 3 3 # 3 A 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 4 3 # 4 A 14 LYS B 77 LYS.? 21.17 CL CL D 145 A 74 LYS B 82 LYS.? 24.10 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 5 3 # 5 A 14 LYS B 82 LYS.? 24.10 CL CL D 145 A 74 LYS B 77 LYS.? 21.17 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 6 3 # 6 A 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 7 3 # 7 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 8 3 # 8 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1idt_c00 MINOR FMN-DEPENDENT NITROREDUCTASE user 9 3 # 9 A 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 25.34 -34.49 45.28 21.58 -36.23 48.72 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 27.69 -28.18 47.27 24.45 -33.01 49.69 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 15.58 -28.67 55.46 14.00 -29.94 56.12 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1idt_c00 source 1idt MINOR FMN-DEPENDENT NITROREDUCTASE : 9 hits 1idt_c00 naa= 3 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 1 3 # 1 B 14 LYS A 94 LYS.? 20.29 CL CL D 145 B 74 LYS A 100 LYS^? 18.99 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 2 3 # 2 B 14 LYS A 100 LYS^? 18.99 CL CL D 145 B 74 LYS A 94 LYS.? 20.29 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 3 3 # 3 B 14 LYS B 77 LYS.? 21.17 CL CL D 145 B 74 LYS B 82 LYS.? 24.10 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 4 3 # 4 B 14 LYS B 82 LYS.? 24.10 CL CL D 145 B 74 LYS B 77 LYS.? 21.17 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 5 3 # 5 B 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 6 3 # 6 B 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 7 3 # 7 B 14 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 74 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1idt_c01 MINOR FMN-DEPENDENT NITROREDUCTASE user 8 3 # 8 B 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo -11.70 -18.16 41.28 -8.37 -16.95 44.27 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo -14.25 -24.10 43.55 -12.53 -18.94 44.42 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -3.83 -22.11 54.11 -2.14 -20.82 54.20 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1idt_c01 source 1idt MINOR FMN-DEPENDENT NITROREDUCTASE : 8 hits 1idt_c01 naa= 3 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 1 3 # 1 A 55 ASP A 19 ASP~? 15.97 CL CL A 144 A 58 ASP A 64 ASP~? 16.08 CL CL A 144 A 424 GLU A 68 GLU~? 25.44 CL CL A 144 coo 58.42 47.76 20.67 58.01 49.10 19.12 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 58.59 41.80 18.81 58.94 43.89 18.94 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 52.85 46.34 13.34 54.09 44.97 14.42 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 2 3 # 2 A 55 ASP B 19 ASP~? 15.75 CL CL A 144 A 58 ASP B 64 ASP~? 15.96 CL CL A 144 A 424 GLU B 68 GLU~? 25.19 CL CL A 144 coo 58.42 47.76 20.67 58.01 49.10 19.12 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 58.59 41.80 18.81 58.94 43.89 18.94 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 52.85 46.34 13.34 54.09 44.97 14.42 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 3 3 # 3 A 55 ASP C 19 ASP~? 15.67 CL CL A 144 A 58 ASP C 64 ASP~? 15.91 CL CL A 144 A 424 GLU C 68 GLU~? 25.33 CL CL A 144 coo 58.42 47.76 20.67 58.01 49.10 19.12 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 58.59 41.80 18.81 58.94 43.89 18.94 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 52.85 46.34 13.34 54.09 44.97 14.42 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1js4_c00 ENDO-EXOCELLULASE E4 user 4 3 # 4 A 55 ASP D 19 ASP~? 15.85 CL CL D 144 A 58 ASP D 64 ASP~? 16.02 CL CL D 144 A 424 GLU D 68 GLU~? 25.13 CL CL D 144 coo 58.42 47.76 20.67 58.01 49.10 19.12 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 58.59 41.80 18.81 58.94 43.89 18.94 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo 52.85 46.34 13.34 54.09 44.97 14.42 5.74 -4.39 -59.25 4.71 -3.85 -61.06 1js4_c00 source 1js4 ENDO-EXOCELLULASE E4 : 4 hits 1js4_c00 naa= 3 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 1 3 # 1 B 55 ASP A 19 ASP~? 15.97 CL CL A 144 B 58 ASP A 64 ASP~? 16.08 CL CL A 144 B 424 GLU A 68 GLU~? 25.44 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 117.85 63.62 21.08 115.96 63.25 20.18 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 118.47 57.23 15.57 119.32 58.77 16.73 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 2 3 # 2 B 55 ASP A 64 ASP~? 16.08 CL CL A 144 B 58 ASP A 19 ASP~? 15.97 CL CL A 144 B 424 GLU A 68 GLU~? 25.44 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 117.85 63.62 21.08 115.96 63.25 20.18 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 118.47 57.23 15.57 119.32 58.77 16.73 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 3 3 # 3 B 55 ASP A 133 ASP~? 7.97 CL CL D 145 B 58 ASP D 133 ASP~? 7.85 CL CL D 145 B 424 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 112.10 61.46 19.99 111.82 60.65 18.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 117.85 63.62 21.08 115.96 63.25 20.18 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 118.47 57.23 15.57 119.32 58.77 16.73 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 4 3 # 4 B 55 ASP A 133 ASP~? 7.97 CL CL D 145 B 58 ASP D 133 ASP~? 7.85 CL CL D 145 B 424 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo 112.10 61.46 19.99 111.82 60.65 18.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 117.85 63.62 21.08 115.96 63.25 20.18 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 118.47 57.23 15.57 119.32 58.77 16.73 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 5 3 # 5 B 55 ASP B 19 ASP~? 15.75 CL CL A 144 B 58 ASP B 64 ASP~? 15.96 CL CL A 144 B 424 GLU B 68 GLU~? 25.19 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 117.85 63.62 21.08 115.96 63.25 20.18 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 118.47 57.23 15.57 119.32 58.77 16.73 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 6 3 # 6 B 55 ASP B 64 ASP~? 15.96 CL CL A 144 B 58 ASP B 19 ASP~? 15.75 CL CL A 144 B 424 GLU B 68 GLU~? 25.19 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 117.85 63.62 21.08 115.96 63.25 20.18 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 118.47 57.23 15.57 119.32 58.77 16.73 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 7 3 # 7 B 55 ASP C 19 ASP~? 15.67 CL CL A 144 B 58 ASP C 64 ASP~? 15.91 CL CL A 144 B 424 GLU C 68 GLU~? 25.33 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 117.85 63.62 21.08 115.96 63.25 20.18 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 118.47 57.23 15.57 119.32 58.77 16.73 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 8 3 # 8 B 55 ASP C 64 ASP~? 15.91 CL CL A 144 B 58 ASP C 19 ASP~? 15.67 CL CL A 144 B 424 GLU C 68 GLU~? 25.33 CL CL A 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 117.85 63.62 21.08 115.96 63.25 20.18 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 118.47 57.23 15.57 119.32 58.77 16.73 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 9 3 # 9 B 55 ASP D 19 ASP~? 15.85 CL CL D 144 B 58 ASP D 64 ASP~? 16.02 CL CL D 144 B 424 GLU D 68 GLU~? 25.13 CL CL D 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 117.85 63.62 21.08 115.96 63.25 20.18 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo 118.47 57.23 15.57 119.32 58.77 16.73 5.74 -4.39 -59.25 4.71 -3.85 -61.06 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 10 3 # 10 B 55 ASP D 64 ASP~? 16.02 CL CL D 144 B 58 ASP D 19 ASP~? 15.85 CL CL D 144 B 424 GLU D 68 GLU~? 25.13 CL CL D 144 coo 112.10 61.46 19.99 111.82 60.65 18.07 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo 117.85 63.62 21.08 115.96 63.25 20.18 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 118.47 57.23 15.57 119.32 58.77 16.73 5.74 -4.39 -59.25 4.71 -3.85 -61.06 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 11 3 # 11 B 55 ASP D 133 ASP~? 7.85 CL CL D 145 B 58 ASP A 133 ASP~? 7.97 CL CL D 145 B 424 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 112.10 61.46 19.99 111.82 60.65 18.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 117.85 63.62 21.08 115.96 63.25 20.18 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 118.47 57.23 15.57 119.32 58.77 16.73 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1js4_c01 ENDO-EXOCELLULASE E4 user 12 3 # 12 B 55 ASP D 133 ASP~? 7.85 CL CL D 145 B 58 ASP A 133 ASP~? 7.97 CL CL D 145 B 424 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo 112.10 61.46 19.99 111.82 60.65 18.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 117.85 63.62 21.08 115.96 63.25 20.18 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 118.47 57.23 15.57 119.32 58.77 16.73 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 1js4_c01 source 1js4 ENDO-EXOCELLULASE E4 : 12 hits 1js4_c01 naa= 3 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 A 2 GLU A 136 GLU~? 8.92 C6 EPE A 145 A 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 258 ARG A 134 ARG~? 13.60 CL CL D 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 A 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 56 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 A 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 A 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 56 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 A 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 A 56 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 A 2 GLU B 136 GLU~? 6.67 C2 EPE A 145 A 56 LYS C 8 LYS^? 8.33 O8 EPE A 145 A 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 A 2 GLU C 98 GLU^? 18.25 O8 EPE A 145 A 56 LYS C 94 LYS.? 22.53 O2S EPE A 145 A 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 A 2 GLU C 136 GLU~? 8.02 O8 EPE A 145 A 56 LYS A 8 LYS^? 8.24 C6 EPE A 145 A 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 38.45 -0.44 19.89 37.36 0.90 25.90 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c00 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 A 2 GLU D 98 GLU^? 15.40 O8 EPE D 146 A 56 LYS D 94 LYS.? 20.13 CL CL D 145 A 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 42.33 1.56 26.99 42.38 2.91 28.66 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 38.45 -0.44 19.89 37.36 0.90 25.90 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 36.54 -1.79 35.54 37.68 -1.44 32.69 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1k82_c00 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c00 naa= 3 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 B 2 GLU A 136 GLU~? 8.92 C6 EPE A 145 B 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 258 ARG A 134 ARG~? 13.60 CL CL D 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 2.64 1.83 34.81 1.56 1.13 32.02 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 B 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 56 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 2.64 1.83 34.81 1.56 1.13 32.02 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 B 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 2.64 1.83 34.81 1.56 1.13 32.02 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 B 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 56 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 2.64 1.83 34.81 1.56 1.13 32.02 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 B 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 B 56 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 2.64 1.83 34.81 1.56 1.13 32.02 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 B 2 GLU B 136 GLU~? 6.67 C2 EPE A 145 B 56 LYS C 8 LYS^? 8.33 O8 EPE A 145 B 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 2.64 1.83 34.81 1.56 1.13 32.02 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 B 2 GLU C 98 GLU^? 18.25 O8 EPE A 145 B 56 LYS C 94 LYS.? 22.53 O2S EPE A 145 B 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 2.64 1.83 34.81 1.56 1.13 32.02 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 B 2 GLU C 136 GLU~? 8.02 O8 EPE A 145 B 56 LYS A 8 LYS^? 8.24 C6 EPE A 145 B 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 2.64 1.83 34.81 1.56 1.13 32.02 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c01 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 B 2 GLU D 98 GLU^? 15.40 O8 EPE D 146 B 56 LYS D 94 LYS.? 20.13 CL CL D 145 B 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.88 -2.27 26.18 -2.94 -3.40 27.96 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 1.37 -0.44 19.19 2.21 -1.48 25.26 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 2.64 1.83 34.81 1.56 1.13 32.02 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1k82_c01 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c01 naa= 3 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 C 2 GLU A 136 GLU~? 8.92 C6 EPE A 145 C 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 C 258 ARG A 134 ARG~? 13.60 CL CL D 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 C 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 56 LYS B 6 LYS.? 15.05 O8 EPE D 146 C 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 C 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 C 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 C 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 56 LYS B 94 LYS.? 22.75 O3S EPE A 145 C 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 C 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 C 56 LYS B 100 LYS^? 21.03 O3S EPE A 145 C 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 C 2 GLU B 136 GLU~? 6.67 C2 EPE A 145 C 56 LYS C 8 LYS^? 8.33 O8 EPE A 145 C 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 C 2 GLU C 98 GLU^? 18.25 O8 EPE A 145 C 56 LYS C 94 LYS.? 22.53 O2S EPE A 145 C 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 C 2 GLU C 136 GLU~? 8.02 O8 EPE A 145 C 56 LYS A 8 LYS^? 8.24 C6 EPE A 145 C 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c02 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 C 2 GLU D 98 GLU^? 15.40 O8 EPE D 146 C 56 LYS D 94 LYS.? 20.13 CL CL D 145 C 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo 43.38 -1.09 -22.48 43.25 -2.24 -24.24 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 39.00 0.70 -15.53 38.30 -0.73 -21.58 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 37.62 2.54 -31.11 38.78 1.93 -28.33 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1k82_c02 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c02 naa= 3 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 1 3 # 1 D 2 GLU A 136 GLU~? 8.92 C6 EPE A 145 D 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 D 258 ARG A 134 ARG~? 13.60 CL CL D 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 2 3 # 2 D 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 56 LYS B 6 LYS.? 15.05 O8 EPE D 146 D 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 3 3 # 3 D 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 56 LYS B 8 LYS^? 8.74 C3 EPE A 145 D 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 4 3 # 4 D 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 56 LYS B 94 LYS.? 22.75 O3S EPE A 145 D 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 5 3 # 5 D 2 GLU B 98 GLU^? 17.25 C3 EPE A 145 D 56 LYS B 100 LYS^? 21.03 O3S EPE A 145 D 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 6 3 # 6 D 2 GLU B 136 GLU~? 6.67 C2 EPE A 145 D 56 LYS C 8 LYS^? 8.33 O8 EPE A 145 D 258 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 7 3 # 7 D 2 GLU C 98 GLU^? 18.25 O8 EPE A 145 D 56 LYS C 94 LYS.? 22.53 O2S EPE A 145 D 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 8 3 # 8 D 2 GLU C 136 GLU~? 8.02 O8 EPE A 145 D 56 LYS A 8 LYS^? 8.24 C6 EPE A 145 D 258 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1k82_c03 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE user 9 3 # 9 D 2 GLU D 98 GLU^? 15.40 O8 EPE D 146 D 56 LYS D 94 LYS.? 20.13 CL CL D 145 D 258 ARG D 134 ARG~? 13.66 CL CL D 145 coo -2.14 0.68 -23.29 -2.02 1.93 -25.00 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 coo 2.02 -1.43 -16.27 3.11 0.23 -22.16 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 4.06 -2.42 -31.79 2.79 -2.18 -28.99 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1k82_c03 source 1k82 FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE : 9 hits 1k82_c03 naa= 3 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 A 14 LYS A 94 LYS.? 20.29 CL CL D 145 A 74 LYS A 100 LYS^? 18.99 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 19.46 3.44 61.93 23.95 1.12 60.13 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 A 14 LYS A 100 LYS^? 18.99 CL CL D 145 A 74 LYS A 94 LYS.? 20.29 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 19.46 3.44 61.93 23.95 1.12 60.13 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 A 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 24.97 5.82 58.78 26.79 1.97 55.46 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 19.46 3.44 61.93 23.95 1.12 60.13 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 A 14 LYS B 77 LYS.? 21.17 CL CL D 145 A 74 LYS B 82 LYS.? 24.10 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 19.46 3.44 61.93 23.95 1.12 60.13 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 A 14 LYS B 82 LYS.? 24.10 CL CL D 145 A 74 LYS B 77 LYS.? 21.17 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 19.46 3.44 61.93 23.95 1.12 60.13 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 A 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 24.97 5.82 58.78 26.79 1.97 55.46 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 19.46 3.44 61.93 23.95 1.12 60.13 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 24.97 5.82 58.78 26.79 1.97 55.46 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 19.46 3.44 61.93 23.95 1.12 60.13 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 8 3 # 8 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 24.97 5.82 58.78 26.79 1.97 55.46 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 19.46 3.44 61.93 23.95 1.12 60.13 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 9 3 # 9 A 14 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 74 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 19.46 3.44 61.93 23.95 1.12 60.13 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1kqc_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 10 3 # 10 A 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 24.97 5.82 58.78 26.79 1.97 55.46 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 19.46 3.44 61.93 23.95 1.12 60.13 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 19.32 -6.09 50.65 20.51 -6.62 48.98 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1kqc_c00 source 1kqc OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 10 hits 1kqc_c00 naa= 3 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 B 14 LYS A 94 LYS.? 20.29 CL CL D 145 B 74 LYS A 100 LYS^? 18.99 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 10.43 2.88 20.75 5.72 0.41 23.95 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 B 14 LYS A 100 LYS^? 18.99 CL CL D 145 B 74 LYS A 94 LYS.? 20.29 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 10.43 2.88 20.75 5.72 0.41 23.95 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 B 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 4.84 5.09 23.75 3.30 1.39 27.48 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 10.43 2.88 20.75 5.72 0.41 23.95 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 B 14 LYS B 77 LYS.? 21.17 CL CL D 145 B 74 LYS B 82 LYS.? 24.10 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 10.43 2.88 20.75 5.72 0.41 23.95 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 B 14 LYS B 82 LYS.? 24.10 CL CL D 145 B 74 LYS B 77 LYS.? 21.17 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 10.43 2.88 20.75 5.72 0.41 23.95 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 B 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 4.84 5.09 23.75 3.30 1.39 27.48 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 10.43 2.88 20.75 5.72 0.41 23.95 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 B 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 4.84 5.09 23.75 3.30 1.39 27.48 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 10.43 2.88 20.75 5.72 0.41 23.95 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 8 3 # 8 B 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 4.84 5.09 23.75 3.30 1.39 27.48 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 10.43 2.88 20.75 5.72 0.41 23.95 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 9 3 # 9 B 14 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 74 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 10.43 2.88 20.75 5.72 0.41 23.95 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1kqc_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 10 3 # 10 B 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 4.84 5.09 23.75 3.30 1.39 27.48 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 10.43 2.88 20.75 5.72 0.41 23.95 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 10.70 -6.39 32.24 9.53 -6.89 33.94 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1kqc_c01 source 1kqc OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 10 hits 1kqc_c01 naa= 3 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 C 14 LYS A 94 LYS.? 20.29 CL CL D 145 C 74 LYS A 100 LYS^? 18.99 CL CL D 145 C 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 17.59 37.25 25.80 19.64 34.15 21.60 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 12.29 34.52 28.11 16.84 32.47 25.43 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 12.06 27.10 15.56 13.23 27.02 13.80 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 C 14 LYS A 100 LYS^? 18.99 CL CL D 145 C 74 LYS A 94 LYS.? 20.29 CL CL D 145 C 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 17.59 37.25 25.80 19.64 34.15 21.60 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 12.29 34.52 28.11 16.84 32.47 25.43 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 12.06 27.10 15.56 13.23 27.02 13.80 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 C 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 C 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 C 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 17.59 37.25 25.80 19.64 34.15 21.60 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 12.29 34.52 28.11 16.84 32.47 25.43 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 12.06 27.10 15.56 13.23 27.02 13.80 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 C 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 C 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 C 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 17.59 37.25 25.80 19.64 34.15 21.60 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 12.29 34.52 28.11 16.84 32.47 25.43 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 12.06 27.10 15.56 13.23 27.02 13.80 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 C 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 C 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 C 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 17.59 37.25 25.80 19.64 34.15 21.60 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 12.29 34.52 28.11 16.84 32.47 25.43 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 12.06 27.10 15.56 13.23 27.02 13.80 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 C 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 C 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 C 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 17.59 37.25 25.80 19.64 34.15 21.60 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 12.29 34.52 28.11 16.84 32.47 25.43 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 12.06 27.10 15.56 13.23 27.02 13.80 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1kqc_c02 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 C 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 C 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 C 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 17.59 37.25 25.80 19.64 34.15 21.60 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 12.29 34.52 28.11 16.84 32.47 25.43 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 12.06 27.10 15.56 13.23 27.02 13.80 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1kqc_c02 source 1kqc OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 7 hits 1kqc_c02 naa= 3 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 D 14 LYS A 94 LYS.? 20.29 CL CL D 145 D 74 LYS A 100 LYS^? 18.99 CL CL D 145 D 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 D 14 LYS A 100 LYS^? 18.99 CL CL D 145 D 74 LYS A 94 LYS.? 20.29 CL CL D 145 D 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 D 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 D 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 D 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 D 14 LYS B 77 LYS.? 21.17 CL CL D 145 D 74 LYS B 82 LYS.? 24.10 CL CL D 145 D 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 D 14 LYS B 82 LYS.? 24.10 CL CL D 145 D 74 LYS B 77 LYS.? 21.17 CL CL D 145 D 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 D 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 D 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 D 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 D 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 D 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 D 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 8 3 # 8 D 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 D 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 D 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 9 3 # 9 D 14 LYS D 6 LYS.? 14.92 O8 EPE D 146 D 74 LYS D 8 LYS^? 8.17 O8 EPE D 146 D 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1kqc_c03 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 10 3 # 10 D 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 D 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 D 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo -2.23 43.20 -8.84 -3.98 39.03 -6.02 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 3.33 41.47 -12.31 -1.15 38.64 -10.07 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 3.51 30.30 -2.73 2.31 29.63 -1.11 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1kqc_c03 source 1kqc OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 10 hits 1kqc_c03 naa= 3 ULMN 3 1lij_c01 ADENOSINE KINASE user 1 3 # 1 A 316 ALA B 33 ALA~? 8.85 CL CL D 145 A 317 GLY B 35 GLY.? 12.52 CL CL D 145 A 318 ASP D 133 ASP~? 7.85 CL CL D 145 coo 144.15 17.54 -4.21 144.96 16.79 -5.26 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 145.79 20.97 -4.38 145.13 20.72 -3.93 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 141.70 22.54 -2.23 141.09 23.62 -3.92 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 1lij_c01 source 1lij ADENOSINE KINASE : 1 hits 1lij_c01 naa= 3 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 1 3 # 1 164 LYS A 8 LYS^? 8.24 C6 EPE A 145 166 LYS A 6 LYS.? 17.07 C5 EPE A 145 324 SER B 34 SER~? 6.65 CL CL D 145 coo 25.93 8.11 25.51 26.40 7.80 19.66 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 27.27 1.43 25.09 29.18 5.25 22.89 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 46.32 14.55 19.93 45.95 12.72 21.27 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 2 3 # 2 164 LYS A 8 LYS^? 8.24 C6 EPE A 145 166 LYS A 6 LYS.? 17.07 C5 EPE A 145 324 SER C 105 SER~? 20.92 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 27.27 1.43 25.09 29.18 5.25 22.89 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 46.32 14.55 19.93 45.95 12.72 21.27 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 3 3 # 3 164 LYS A 94 LYS.? 20.29 CL CL D 145 166 LYS A 100 LYS^? 18.99 CL CL D 145 324 SER A 57 SER~? 28.57 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 27.27 1.43 25.09 29.18 5.25 22.89 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 46.32 14.55 19.93 45.95 12.72 21.27 -49.08 -7.91 -34.54 -49.39 -10.25 -34.18 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 4 3 # 4 164 LYS A 100 LYS^? 18.99 CL CL D 145 166 LYS A 94 LYS.? 20.29 CL CL D 145 324 SER A 57 SER~? 28.57 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 27.27 1.43 25.09 29.18 5.25 22.89 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 46.32 14.55 19.93 45.95 12.72 21.27 -49.08 -7.91 -34.54 -49.39 -10.25 -34.18 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 5 3 # 5 164 LYS B 8 LYS^? 8.74 C3 EPE A 145 166 LYS B 6 LYS.? 15.05 O8 EPE D 146 324 SER C 34 SER~? 16.74 O2S EPE A 145 coo 25.93 8.11 25.51 26.40 7.80 19.66 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 27.27 1.43 25.09 29.18 5.25 22.89 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 46.32 14.55 19.93 45.95 12.72 21.27 -20.19 -19.13 3.46 -19.76 -20.67 1.72 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 6 3 # 6 164 LYS B 8 LYS^? 8.74 C3 EPE A 145 166 LYS B 6 LYS.? 15.05 O8 EPE D 146 324 SER D 105 SER~? 6.83 CL CL D 145 coo 25.93 8.11 25.51 26.40 7.80 19.66 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 27.27 1.43 25.09 29.18 5.25 22.89 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 46.32 14.55 19.93 45.95 12.72 21.27 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 7 3 # 7 164 LYS B 77 LYS.? 21.17 CL CL D 145 166 LYS B 82 LYS.? 24.10 CL CL D 145 324 SER B 15 SER.? 10.55 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 27.27 1.43 25.09 29.18 5.25 22.89 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 46.32 14.55 19.93 45.95 12.72 21.27 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 8 3 # 8 164 LYS B 82 LYS.? 24.10 CL CL D 145 166 LYS B 77 LYS.? 21.17 CL CL D 145 324 SER B 15 SER.? 10.55 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 27.27 1.43 25.09 29.18 5.25 22.89 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 46.32 14.55 19.93 45.95 12.72 21.27 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 9 3 # 9 164 LYS B 82 LYS.? 24.10 CL CL D 145 166 LYS B 77 LYS.? 21.17 CL CL D 145 324 SER B 54 SER~? 22.69 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 27.27 1.43 25.09 29.18 5.25 22.89 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 46.32 14.55 19.93 45.95 12.72 21.27 -27.89 -37.22 -22.85 -28.75 -34.99 -22.56 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 10 3 # 10 164 LYS B 94 LYS.? 22.75 O3S EPE A 145 166 LYS B 100 LYS^? 21.03 O3S EPE A 145 324 SER B 57 SER~? 28.12 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 27.27 1.43 25.09 29.18 5.25 22.89 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 46.32 14.55 19.93 45.95 12.72 21.27 -28.93 -39.57 -27.29 -31.24 -38.94 -26.86 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 11 3 # 11 164 LYS B 94 LYS.? 22.75 O3S EPE A 145 166 LYS B 100 LYS^? 21.03 O3S EPE A 145 324 SER D 10 SER^? 8.71 O3S EPE D 146 coo 25.93 8.11 25.51 26.40 7.80 19.66 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 27.27 1.43 25.09 29.18 5.25 22.89 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 46.32 14.55 19.93 45.95 12.72 21.27 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 12 3 # 12 164 LYS B 100 LYS^? 21.03 O3S EPE A 145 166 LYS B 94 LYS.? 22.75 O3S EPE A 145 324 SER B 57 SER~? 28.12 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 27.27 1.43 25.09 29.18 5.25 22.89 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 46.32 14.55 19.93 45.95 12.72 21.27 -28.93 -39.57 -27.29 -31.24 -38.94 -26.86 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 13 3 # 13 164 LYS C 94 LYS.? 22.53 O2S EPE A 145 166 LYS C 100 LYS^? 20.71 O2S EPE A 145 324 SER C 57 SER~? 28.33 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 27.27 1.43 25.09 29.18 5.25 22.89 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 46.32 14.55 19.93 45.95 12.72 21.27 -51.53 -24.60 -0.40 -52.06 -24.91 -2.73 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 14 3 # 14 164 LYS C 100 LYS^? 20.71 O2S EPE A 145 166 LYS C 94 LYS.? 22.53 O2S EPE A 145 324 SER C 57 SER~? 28.33 CL CL A 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 27.27 1.43 25.09 29.18 5.25 22.89 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 46.32 14.55 19.93 45.95 12.72 21.27 -51.53 -24.60 -0.40 -52.06 -24.91 -2.73 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 15 3 # 15 164 LYS D 6 LYS.? 14.92 O8 EPE D 146 166 LYS D 8 LYS^? 8.17 O8 EPE D 146 324 SER B 10 SER^? 8.49 O2S EPE A 145 coo 25.93 8.11 25.51 26.40 7.80 19.66 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 27.27 1.43 25.09 29.18 5.25 22.89 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 46.32 14.55 19.93 45.95 12.72 21.27 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 16 3 # 16 164 LYS D 8 LYS^? 8.17 O8 EPE D 146 166 LYS D 6 LYS.? 14.92 O8 EPE D 146 324 SER B 29 SER~? 11.10 CL CL D 145 coo 25.93 8.11 25.51 26.40 7.80 19.66 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 27.27 1.43 25.09 29.18 5.25 22.89 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 46.32 14.55 19.93 45.95 12.72 21.27 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 17 3 # 17 164 LYS D 94 LYS.? 20.13 CL CL D 145 166 LYS D 100 LYS^? 18.85 CL CL D 145 324 SER D 57 SER~? 28.27 CL CL D 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 27.27 1.43 25.09 29.18 5.25 22.89 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 46.32 14.55 19.93 45.95 12.72 21.27 -2.00 -21.84 -55.44 -2.14 -19.80 -56.74 ULMN 3 1mdr_c01 MANDELATE RACEMASE (E.C.5.1.2.2) user 18 3 # 18 164 LYS D 100 LYS^? 18.85 CL CL D 145 166 LYS D 94 LYS.? 20.13 CL CL D 145 324 SER D 57 SER~? 28.27 CL CL D 144 coo 25.93 8.11 25.51 26.40 7.80 19.66 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 27.27 1.43 25.09 29.18 5.25 22.89 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 46.32 14.55 19.93 45.95 12.72 21.27 -2.00 -21.84 -55.44 -2.14 -19.80 -56.74 1mdr_c01 source 1mdr MANDELATE RACEMASE (E.C.5.1.2.2) : 18 hits 1mdr_c01 naa= 3 ULMN 3 1mpp_c04 PEPSIN (RENIN) (E.C.3.4.23.23) user 1 3 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 20.97 14.47 32.28 19.66 15.96 31.62 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 16.04 14.72 33.82 17.27 13.71 31.95 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 20.65 22.00 33.80 20.06 20.56 32.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1mpp_c04 source 1mpp PEPSIN (RENIN) (E.C.3.4.23.23) : 1 hits 1mpp_c04 naa= 3 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 1 3 # 1 A 465 GLY A 25 GLY~? 16.04 CL CL A 144 A 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -39.61 -2.76 -19.24 -39.33 -3.08 -18.55 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 2 3 # 2 A 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 A 501 ASP A 124 ASP^? 10.83 CL CL D 145 B 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 3 3 # 3 A 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 A 501 ASP C 123 ASP.? 21.65 O2S EPE A 145 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 4 3 # 4 A 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 A 501 ASP C 123 ASP.? 21.65 O2S EPE A 145 B 367 TYR B 67 TYR~? 16.82 CL CL A 144 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 5 3 # 5 A 465 GLY A 35 GLY.? 16.89 C5 EPE A 145 A 501 ASP A 124 ASP^? 10.83 CL CL D 145 B 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 6 3 # 6 A 465 GLY A 35 GLY.? 16.89 C5 EPE A 145 A 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 7 3 # 7 A 465 GLY B 25 GLY~? 14.76 CL CL D 145 A 501 ASP A 124 ASP^? 10.83 CL CL D 145 B 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -21.98 -22.22 -26.09 -22.26 -21.44 -25.98 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 8 3 # 8 A 465 GLY B 30 GLY~? 7.61 CL CL D 145 A 501 ASP A 123 ASP.? 17.71 CL CL D 145 B 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 9 3 # 9 A 465 GLY B 30 GLY~? 7.61 CL CL D 145 A 501 ASP A 123 ASP.? 17.71 CL CL D 145 B 367 TYR C 67 TYR~? 16.92 CL CL A 144 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 10 3 # 10 A 465 GLY B 30 GLY~? 7.61 CL CL D 145 A 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 11 3 # 11 A 465 GLY B 35 GLY.? 12.52 CL CL D 145 A 501 ASP A 124 ASP^? 10.83 CL CL D 145 B 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 12 3 # 12 A 465 GLY B 35 GLY.? 12.52 CL CL D 145 A 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 13 3 # 13 A 465 GLY C 25 GLY~? 15.93 CL CL A 144 A 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -33.04 -21.93 -1.59 -32.46 -21.96 -2.16 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 14 3 # 14 A 465 GLY C 30 GLY~? 16.61 O2S EPE A 145 A 501 ASP B 123 ASP.? 21.73 O3S EPE A 145 B 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 15 3 # 15 A 465 GLY C 30 GLY~? 16.61 O2S EPE A 145 A 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 16 3 # 16 A 465 GLY C 35 GLY.? 16.82 C2 EPE A 145 A 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 B 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -20.52 -15.68 4.99 -20.85 -15.81 4.28 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 17 3 # 17 A 465 GLY C 35 GLY.? 16.82 C2 EPE A 145 A 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -20.52 -15.68 4.99 -20.85 -15.81 4.28 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 18 3 # 18 A 465 GLY C 138 GLY.? -4.86 C2 EPE A 145s A 501 ASP D 133 ASP~? 7.85 CL CL D 145 B 367 TYR A 67 TYR~? 16.80 CL CL A 144 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 -21.96 -8.16 -5.68 -22.21 -7.83 -6.43 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1mro_c00 METHYL-COENZYME M REDUCTASE user 19 3 # 19 A 465 GLY D 30 GLY~? 16.53 O3S EPE D 146 A 501 ASP D 64 ASP~? 16.02 CL CL D 144 B 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 4.40 25.46 -23.33 5.00 25.87 -23.68 10.38 -14.18 -33.00 9.58 -14.37 -32.83 coo 13.82 6.17 -29.83 11.78 5.87 -29.33 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo 27.05 35.80 -12.24 28.72 34.05 -10.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 1mro_c00 source 1mro METHYL-COENZYME M REDUCTASE : 19 hits 1mro_c00 naa= 3 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 1 3 # 1 D 465 GLY A 25 GLY~? 16.04 CL CL A 144 D 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -39.61 -2.76 -19.24 -39.33 -3.08 -18.55 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 2 3 # 2 D 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 D 501 ASP A 124 ASP^? 10.83 CL CL D 145 E 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 3 3 # 3 D 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 D 501 ASP C 123 ASP.? 21.65 O2S EPE A 145 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 4 3 # 4 D 465 GLY A 30 GLY~? 16.60 O1S EPE A 145 D 501 ASP C 123 ASP.? 21.65 O2S EPE A 145 E 367 TYR B 67 TYR~? 16.82 CL CL A 144 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -36.92 2.15 -12.92 -36.38 2.17 -13.55 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 5 3 # 5 D 465 GLY A 35 GLY.? 16.89 C5 EPE A 145 D 501 ASP A 124 ASP^? 10.83 CL CL D 145 E 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 6 3 # 6 D 465 GLY A 35 GLY.? 16.89 C5 EPE A 145 D 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -29.80 7.53 -12.97 -29.98 6.77 -13.01 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 7 3 # 7 D 465 GLY B 25 GLY~? 14.76 CL CL D 145 D 501 ASP A 124 ASP^? 10.83 CL CL D 145 E 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -21.98 -22.22 -26.09 -22.26 -21.44 -25.98 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 8 3 # 8 D 465 GLY B 30 GLY~? 7.61 CL CL D 145 D 501 ASP A 123 ASP.? 17.71 CL CL D 145 E 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 9 3 # 9 D 465 GLY B 30 GLY~? 7.61 CL CL D 145 D 501 ASP A 123 ASP.? 17.71 CL CL D 145 E 367 TYR C 67 TYR~? 16.92 CL CL A 144 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 10 3 # 10 D 465 GLY B 30 GLY~? 7.61 CL CL D 145 D 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 E 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -16.89 -15.62 -27.66 -16.65 -16.05 -26.98 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 11 3 # 11 D 465 GLY B 35 GLY.? 12.52 CL CL D 145 D 501 ASP A 124 ASP^? 10.83 CL CL D 145 E 367 TYR C 36 TYR.? 11.46 O2S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 12 3 # 12 D 465 GLY B 35 GLY.? 12.52 CL CL D 145 D 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 E 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 13 3 # 13 D 465 GLY C 25 GLY~? 15.93 CL CL A 144 D 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 E 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -33.04 -21.93 -1.59 -32.46 -21.96 -2.16 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 14 3 # 14 D 465 GLY C 30 GLY~? 16.61 O2S EPE A 145 D 501 ASP B 123 ASP.? 21.73 O3S EPE A 145 E 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 15 3 # 15 D 465 GLY C 30 GLY~? 16.61 O2S EPE A 145 D 501 ASP B 123 ASP.? 21.73 O3S EPE A 145 E 367 TYR A 67 TYR~? 16.80 CL CL A 144 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 16 3 # 16 D 465 GLY C 30 GLY~? 16.61 O2S EPE A 145 D 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -24.90 -22.06 0.72 -25.26 -21.33 0.87 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 17 3 # 17 D 465 GLY C 35 GLY.? 16.82 C2 EPE A 145 D 501 ASP B 124 ASP^? 22.45 O2S EPE A 145 E 367 TYR A 36 TYR.? 11.29 O1S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -20.52 -15.68 4.99 -20.85 -15.81 4.28 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -29.01 2.19 -12.61 -28.81 1.03 -10.05 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 18 3 # 18 D 465 GLY C 35 GLY.? 16.82 C2 EPE A 145 D 501 ASP C 124 ASP^? 22.63 O1S EPE A 145 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -20.52 -15.68 4.99 -20.85 -15.81 4.28 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 19 3 # 19 D 465 GLY C 138 GLY.? -4.86 C2 EPE A 145s D 501 ASP D 133 ASP~? 7.85 CL CL D 145 E 367 TYR A 67 TYR~? 16.80 CL CL A 144 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 -21.96 -8.16 -5.68 -22.21 -7.83 -6.43 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 ULMN 3 1mro_c01 METHYL-COENZYME M REDUCTASE user 20 3 # 20 D 465 GLY D 30 GLY~? 16.53 O3S EPE D 146 D 501 ASP D 64 ASP~? 16.02 CL CL D 144 E 367 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 21.60 60.44 -42.77 21.61 59.72 -42.40 10.38 -14.18 -33.00 9.58 -14.37 -32.83 coo 42.23 65.30 -35.49 41.21 67.05 -36.13 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo 28.27 36.08 -52.91 30.75 35.88 -54.18 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 1mro_c01 source 1mro METHYL-COENZYME M REDUCTASE : 20 hits 1mro_c01 naa= 3 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 1 3 # 1 A 50 ASP A 19 ASP~? 15.97 CL CL A 144 A 55 TYR A 67 TYR~? 16.80 CL CL A 144 A 84 LYS A 65 LYS~? 24.48 CL CL A 144 coo 11.09 42.89 24.44 11.32 42.06 22.49 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 4.60 40.33 20.42 7.25 39.50 20.05 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 9.71 44.83 15.47 10.13 41.43 19.93 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 2 3 # 2 A 50 ASP A 64 ASP~? 16.08 CL CL A 144 A 55 TYR B 67 TYR~? 16.82 CL CL A 144 A 84 LYS B 65 LYS~? 24.78 CL CL A 144 coo 11.09 42.89 24.44 11.32 42.06 22.49 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 4.60 40.33 20.42 7.25 39.50 20.05 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 9.71 44.83 15.47 10.13 41.43 19.93 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 3 3 # 3 A 50 ASP B 19 ASP~? 15.75 CL CL A 144 A 55 TYR B 67 TYR~? 16.82 CL CL A 144 A 84 LYS B 65 LYS~? 24.78 CL CL A 144 coo 11.09 42.89 24.44 11.32 42.06 22.49 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 4.60 40.33 20.42 7.25 39.50 20.05 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 9.71 44.83 15.47 10.13 41.43 19.93 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 4 3 # 4 A 50 ASP C 64 ASP~? 15.91 CL CL A 144 A 55 TYR A 67 TYR~? 16.80 CL CL A 144 A 84 LYS A 65 LYS~? 24.48 CL CL A 144 coo 11.09 42.89 24.44 11.32 42.06 22.49 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 4.60 40.33 20.42 7.25 39.50 20.05 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 9.71 44.83 15.47 10.13 41.43 19.93 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 5 3 # 5 A 50 ASP D 19 ASP~? 15.85 CL CL D 144 A 55 TYR D 67 TYR~? 16.83 CL CL D 144 A 84 LYS D 65 LYS~? 24.46 CL CL D 144 coo 11.09 42.89 24.44 11.32 42.06 22.49 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 4.60 40.33 20.42 7.25 39.50 20.05 8.02 -1.60 -52.64 7.08 0.27 -50.76 coo 9.71 44.83 15.47 10.13 41.43 19.93 3.33 -3.03 -56.97 -1.82 -3.51 -60.81 ULMN 3 1mrq_c02 ALDO-KETO REDUCTASE FAMILY 1 MEMBER user 6 3 # 6 A 50 ASP D 133 ASP~? 7.85 CL CL D 145 A 55 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 84 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 11.09 42.89 24.44 11.32 42.06 22.49 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 4.60 40.33 20.42 7.25 39.50 20.05 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 9.71 44.83 15.47 10.13 41.43 19.93 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 1mrq_c02 source 1mrq ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1 : 6 hits 1mrq_c02 naa= 3 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 1 3 # 1 A 167 LYS A 65 LYS~? 24.48 CL CL A 144 A 169 LYS B 65 LYS~? 24.78 CL CL A 144 A 327 GLU C 68 GLU~? 25.33 CL CL A 144 coo 20.73 15.53 25.54 22.09 15.64 19.40 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 24.31 10.25 23.71 29.02 12.05 20.75 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 21.86 20.40 18.59 22.12 18.33 18.33 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 2 3 # 2 A 167 LYS A 100 LYS^? 18.99 CL CL D 145 A 169 LYS A 94 LYS.? 20.29 CL CL D 145 A 327 GLU A 37 GLU^? 12.50 C6 EPE A 145 coo 20.73 15.53 25.54 22.09 15.64 19.40 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 24.31 10.25 23.71 29.02 12.05 20.75 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 21.86 20.40 18.59 22.12 18.33 18.33 -25.10 3.21 -19.35 -23.00 2.86 -19.59 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 3 3 # 3 A 167 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 169 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 327 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 20.73 15.53 25.54 22.09 15.64 19.40 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 24.31 10.25 23.71 29.02 12.05 20.75 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 21.86 20.40 18.59 22.12 18.33 18.33 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 4 3 # 4 A 167 LYS B 65 LYS~? 24.78 CL CL A 144 A 169 LYS A 65 LYS~? 24.48 CL CL A 144 A 327 GLU C 68 GLU~? 25.33 CL CL A 144 coo 20.73 15.53 25.54 22.09 15.64 19.40 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 24.31 10.25 23.71 29.02 12.05 20.75 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 21.86 20.40 18.59 22.12 18.33 18.33 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 5 3 # 5 A 167 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 169 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 327 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo 20.73 15.53 25.54 22.09 15.64 19.40 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 24.31 10.25 23.71 29.02 12.05 20.75 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 21.86 20.40 18.59 22.12 18.33 18.33 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 6 3 # 6 A 167 LYS C 100 LYS^? 20.71 O2S EPE A 145 A 169 LYS C 94 LYS.? 22.53 O2S EPE A 145 A 327 GLU C 37 GLU^? 12.70 O8 EPE A 145 coo 20.73 15.53 25.54 22.09 15.64 19.40 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 24.31 10.25 23.71 29.02 12.05 20.75 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 21.86 20.40 18.59 22.12 18.33 18.33 -25.71 -8.80 2.61 -25.32 -6.70 2.31 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 7 3 # 7 A 167 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 169 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 327 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 20.73 15.53 25.54 22.09 15.64 19.40 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 24.31 10.25 23.71 29.02 12.05 20.75 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 21.86 20.40 18.59 22.12 18.33 18.33 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1muc_c00 MUCONATE LACTONIZING ENZYME user 8 3 # 8 A 167 LYS D 100 LYS^? 18.85 CL CL D 145 A 169 LYS D 94 LYS.? 20.13 CL CL D 145 A 327 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 20.73 15.53 25.54 22.09 15.64 19.40 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 24.31 10.25 23.71 29.02 12.05 20.75 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 21.86 20.40 18.59 22.12 18.33 18.33 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 1muc_c00 source 1muc MUCONATE LACTONIZING ENZYME : 8 hits 1muc_c00 naa= 3 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 1 3 # 1 B 167 LYS A 65 LYS~? 24.48 CL CL A 144 B 169 LYS B 65 LYS~? 24.78 CL CL A 144 B 327 GLU C 68 GLU~? 25.33 CL CL A 144 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 2 3 # 2 B 167 LYS A 100 LYS^? 18.99 CL CL D 145 B 169 LYS A 94 LYS.? 20.29 CL CL D 145 B 327 GLU A 37 GLU^? 12.50 C6 EPE A 145 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -25.10 3.21 -19.35 -23.00 2.86 -19.59 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 3 3 # 3 B 167 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 169 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 327 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 4 3 # 4 B 167 LYS B 65 LYS~? 24.78 CL CL A 144 B 169 LYS A 65 LYS~? 24.48 CL CL A 144 B 327 GLU C 68 GLU~? 25.33 CL CL A 144 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 5 3 # 5 B 167 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 169 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 327 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 6 3 # 6 B 167 LYS C 100 LYS^? 20.71 O2S EPE A 145 B 169 LYS C 94 LYS.? 22.53 O2S EPE A 145 B 327 GLU C 37 GLU^? 12.70 O8 EPE A 145 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 -31.80 -15.89 7.76 -36.59 -12.49 6.80 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -25.71 -8.80 2.61 -25.32 -6.70 2.31 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 7 3 # 7 B 167 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 169 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 327 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1muc_c01 MUCONATE LACTONIZING ENZYME user 8 3 # 8 B 167 LYS D 100 LYS^? 18.85 CL CL D 145 B 169 LYS D 94 LYS.? 20.13 CL CL D 145 B 327 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 25.79 1.90 -25.69 27.00 2.59 -19.56 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 25.18 8.17 -23.75 30.94 6.65 -21.59 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 coo 29.96 -1.07 -18.59 28.74 0.63 -18.32 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 1muc_c01 source 1muc MUCONATE LACTONIZING ENZYME : 8 hits 1muc_c01 naa= 3 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 1 3 # 1 549 LYS A 8 LYS^? 8.24 C6 EPE A 145 631 LYS C 100 LYS^? 20.71 O2S EPE A 145 708 LYS A 100 LYS^? 18.99 CL CL D 145 coo 8.61 33.06 11.15 10.12 29.19 8.82 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 18.16 32.86 9.85 16.06 28.20 13.56 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 2 3 # 2 549 LYS B 8 LYS^? 8.74 C3 EPE A 145 631 LYS A 6 LYS.? 17.07 C5 EPE A 145 708 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 8.61 33.06 11.15 10.12 29.19 8.82 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 18.16 32.86 9.85 16.06 28.20 13.56 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 3 3 # 3 549 LYS B 8 LYS^? 8.74 C3 EPE A 145 631 LYS A 100 LYS^? 18.99 CL CL D 145 708 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 8.61 33.06 11.15 10.12 29.19 8.82 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 18.16 32.86 9.85 16.06 28.20 13.56 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 4 3 # 4 549 LYS C 8 LYS^? 8.33 O8 EPE A 145 631 LYS B 6 LYS.? 15.05 O8 EPE D 146 708 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 8.61 33.06 11.15 10.12 29.19 8.82 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 18.16 32.86 9.85 16.06 28.20 13.56 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 5 3 # 5 549 LYS C 8 LYS^? 8.33 O8 EPE A 145 631 LYS B 100 LYS^? 21.03 O3S EPE A 145 708 LYS C 100 LYS^? 20.71 O2S EPE A 145 coo 8.61 33.06 11.15 10.12 29.19 8.82 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 18.16 32.86 9.85 16.06 28.20 13.56 -32.91 -10.09 3.52 -31.08 -8.45 7.79 ULMN 3 1nsf_c00 N-ETHYLMALEIMIDE SENSITIVE FACTOR user 6 3 # 6 549 LYS D 100 LYS^? 18.85 CL CL D 145 631 LYS B 82 LYS.? 24.10 CL CL D 145 708 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 8.61 33.06 11.15 10.12 29.19 8.82 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo -11.99 27.40 17.14 -13.60 24.52 11.71 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 18.16 32.86 9.85 16.06 28.20 13.56 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1nsf_c00 source 1nsf N-ETHYLMALEIMIDE SENSITIVE FACTOR : 6 hits 1nsf_c00 naa= 3 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 1 3 # 1 A 62 SER A 10 SER^? 8.69 O1S EPE A 145 A 154 ASP A 123 ASP.? 17.71 CL CL D 145 A 261 ARG A 134 ARG~? 13.60 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 16.07 84.71 8.14 15.20 82.81 8.14 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 10.59 77.85 4.81 13.09 76.36 5.76 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 2 3 # 2 A 62 SER B 10 SER^? 8.49 O2S EPE A 145 A 154 ASP B 123 ASP.? 21.73 O3S EPE A 145 A 261 ARG B 134 ARG~? 16.21 C3 EPE A 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 16.07 84.71 8.14 15.20 82.81 8.14 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo 10.59 77.85 4.81 13.09 76.36 5.76 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 3 3 # 3 A 62 SER B 34 SER~? 6.65 CL CL D 145 A 154 ASP D 123 ASP.? 17.57 CL CL D 145 A 261 ARG D 134 ARG~? 13.66 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 16.07 84.71 8.14 15.20 82.81 8.14 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 10.59 77.85 4.81 13.09 76.36 5.76 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 4 3 # 4 A 62 SER C 10 SER^? 8.67 O1S EPE A 145 A 154 ASP C 123 ASP.? 21.65 O2S EPE A 145 A 261 ARG C 134 ARG~? 16.35 O1S EPE A 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 16.07 84.71 8.14 15.20 82.81 8.14 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 10.59 77.85 4.81 13.09 76.36 5.76 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 5 3 # 5 A 62 SER D 10 SER^? 8.71 O3S EPE D 146 A 154 ASP D 123 ASP.? 17.57 CL CL D 145 A 261 ARG D 134 ARG~? 13.66 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 16.07 84.71 8.14 15.20 82.81 8.14 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 10.59 77.85 4.81 13.09 76.36 5.76 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 6 3 # 6 A 62 SER D 105 SER~? 6.83 CL CL D 145 A 154 ASP D 117 ASP~? 21.71 CL CL D 145 A 261 ARG D 115 ARG~? 12.45 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo 16.07 84.71 8.14 15.20 82.81 8.14 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo 10.59 77.85 4.81 13.09 76.36 5.76 -16.99 -21.67 -39.03 -18.83 -20.42 -36.87 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 7 3 # 7 A 62 SER D 105 SER~? 6.83 CL CL D 145 A 154 ASP D 123 ASP.? 17.57 CL CL D 145 A 261 ARG D 115 ARG~? 12.45 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo 16.07 84.71 8.14 15.20 82.81 8.14 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 10.59 77.85 4.81 13.09 76.36 5.76 -16.99 -21.67 -39.03 -18.83 -20.42 -36.87 ULMN 3 1o98_c00 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT user 8 3 # 8 A 62 SER D 105 SER~? 6.83 CL CL D 145 A 154 ASP D 124 ASP^? 11.01 CL CL D 145 A 261 ARG D 115 ARG~? 12.45 CL CL D 145 coo 16.10 74.10 3.11 17.18 73.52 5.20 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo 16.07 84.71 8.14 15.20 82.81 8.14 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 10.59 77.85 4.81 13.09 76.36 5.76 -16.99 -21.67 -39.03 -18.83 -20.42 -36.87 1o98_c00 source 1o98 2,3-BISPHOSPHOGLYCERATE-INDEPENDENT PHOSPHOGLY: 8 hits 1o98_c00 naa= 3 ULMN 3 1ofd_c02 FERREDOXIN-DEPENDENT GLUTAMATE SYNTHuser 1 3 # 1 A 1 CYH C 104 CYH^? 16.50 CL CL A 144 A 903 GLU C 68 GLU~? 25.33 CL CL A 144 A 972 LYS B 65 LYS~? 24.78 CL CL A 144 coo 88.42 112.53 24.94 87.72 110.88 27.11 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 coo 61.58 117.15 13.99 62.31 115.51 15.12 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 60.18 107.64 21.53 58.13 110.55 17.14 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 1ofd_c02 source 1ofd FERREDOXIN-DEPENDENT GLUTAMATE SYNTHASE 2 : 1 hits 1ofd_c02 naa= 3 ULMN 3 1ok4_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 A 24 ASP B 19 ASP~? 15.75 CL CL A 144 A 146 TYR B 83 TYR.? 13.54 CL CL D 145 A 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -3.50 124.89 25.05 -2.25 124.77 23.26 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 1.87 119.38 16.45 1.41 122.11 16.84 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -2.59 124.07 12.67 -0.91 126.17 18.42 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c00 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 A 24 ASP C 19 ASP~? 15.67 CL CL A 144 A 146 TYR A 67 TYR~? 16.80 CL CL A 144 A 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -3.50 124.89 25.05 -2.25 124.77 23.26 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 1.87 119.38 16.45 1.41 122.11 16.84 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -2.59 124.07 12.67 -0.91 126.17 18.42 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c00 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c00 naa= 3 ULMN 3 1ok4_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 B 24 ASP B 19 ASP~? 15.75 CL CL A 144 B 146 TYR B 83 TYR.? 13.54 CL CL D 145 B 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -7.43 109.06 51.23 -5.84 110.54 50.86 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 0.22 114.56 44.62 -0.76 115.18 47.18 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -4.18 120.17 46.85 -4.02 115.31 51.00 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c01 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 B 24 ASP C 19 ASP~? 15.67 CL CL A 144 B 146 TYR A 67 TYR~? 16.80 CL CL A 144 B 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -7.43 109.06 51.23 -5.84 110.54 50.86 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 0.22 114.56 44.62 -0.76 115.18 47.18 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -4.18 120.17 46.85 -4.02 115.31 51.00 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c01 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c01 naa= 3 ULMN 3 1ok4_c02 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 C 24 ASP B 19 ASP~? 15.75 CL CL A 144 C 146 TYR B 83 TYR.? 13.54 CL CL D 145 C 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -13.49 79.65 43.90 -12.13 80.29 45.45 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -5.65 86.78 48.49 -7.16 84.72 49.65 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -11.22 87.18 53.49 -10.94 81.64 50.31 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c02 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 C 24 ASP C 19 ASP~? 15.67 CL CL A 144 C 146 TYR A 67 TYR~? 16.80 CL CL A 144 C 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -13.49 79.65 43.90 -12.13 80.29 45.45 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -5.65 86.78 48.49 -7.16 84.72 49.65 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -11.22 87.18 53.49 -10.94 81.64 50.31 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c02 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c02 naa= 3 ULMN 3 1ok4_c03 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 D 24 ASP B 19 ASP~? 15.75 CL CL A 144 D 146 TYR B 83 TYR.? 13.54 CL CL D 145 D 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -13.44 77.36 13.12 -12.53 75.97 14.48 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -7.85 74.44 22.75 -9.22 72.86 20.89 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -14.24 70.61 23.48 -12.55 71.73 17.42 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c03 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 D 24 ASP C 19 ASP~? 15.67 CL CL A 144 D 146 TYR A 67 TYR~? 16.80 CL CL A 144 D 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -13.44 77.36 13.12 -12.53 75.97 14.48 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -7.85 74.44 22.75 -9.22 72.86 20.89 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -14.24 70.61 23.48 -12.55 71.73 17.42 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c03 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c03 naa= 3 ULMN 3 1ok4_c04 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 E 24 ASP B 19 ASP~? 15.75 CL CL A 144 E 146 TYR B 83 TYR.? 13.54 CL CL D 145 E 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -7.12 105.25 1.43 -6.30 103.34 0.77 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -3.11 94.55 3.01 -3.83 95.92 0.66 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -8.77 93.34 -1.70 -6.28 99.15 -2.21 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c04 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 E 24 ASP C 19 ASP~? 15.67 CL CL A 144 E 146 TYR A 67 TYR~? 16.80 CL CL A 144 E 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -7.12 105.25 1.43 -6.30 103.34 0.77 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -3.11 94.55 3.01 -3.83 95.92 0.66 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -8.77 93.34 -1.70 -6.28 99.15 -2.21 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c04 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c04 naa= 3 ULMN 3 1ok4_c05 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 F 24 ASP B 19 ASP~? 15.75 CL CL A 144 F 146 TYR B 83 TYR.? 13.54 CL CL D 145 F 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -44.75 128.15 10.28 -45.68 129.67 11.55 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -50.43 131.90 19.60 -49.04 133.31 17.60 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -44.10 135.86 19.99 -45.67 134.21 14.07 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c05 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 F 24 ASP C 19 ASP~? 15.67 CL CL A 144 F 146 TYR A 67 TYR~? 16.80 CL CL A 144 F 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -44.75 128.15 10.28 -45.68 129.67 11.55 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -50.43 131.90 19.60 -49.04 133.31 17.60 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -44.10 135.86 19.99 -45.67 134.21 14.07 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c05 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c05 naa= 3 ULMN 3 1ok4_c06 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 G 24 ASP B 19 ASP~? 15.75 CL CL A 144 G 146 TYR B 83 TYR.? 13.54 CL CL D 145 G 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -44.97 128.78 41.20 -46.32 128.26 42.83 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -52.83 122.13 46.42 -51.31 124.30 47.39 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -47.30 122.24 51.49 -47.46 127.44 47.81 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c06 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 G 24 ASP C 19 ASP~? 15.67 CL CL A 144 G 146 TYR A 67 TYR~? 16.80 CL CL A 144 G 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -44.97 128.78 41.20 -46.32 128.26 42.83 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -52.83 122.13 46.42 -51.31 124.30 47.39 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -47.30 122.24 51.49 -47.46 127.44 47.81 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c06 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c06 naa= 3 ULMN 3 1ok4_c07 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 H 24 ASP B 19 ASP~? 15.75 CL CL A 144 H 146 TYR B 83 TYR.? 13.54 CL CL D 145 H 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -51.11 100.30 51.41 -52.67 98.82 51.12 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -58.70 94.17 45.32 -57.76 93.82 47.92 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -54.32 88.79 48.13 -54.61 94.04 51.74 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c07 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 H 24 ASP C 19 ASP~? 15.67 CL CL A 144 H 146 TYR A 67 TYR~? 16.80 CL CL A 144 H 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -51.11 100.30 51.41 -52.67 98.82 51.12 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -58.70 94.17 45.32 -57.76 93.82 47.92 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -54.32 88.79 48.13 -54.61 94.04 51.74 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c07 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c07 naa= 3 ULMN 3 1ok4_c08 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 I 24 ASP B 19 ASP~? 15.75 CL CL A 144 I 146 TYR B 83 TYR.? 13.54 CL CL D 145 I 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -54.65 81.97 26.87 -55.88 81.89 25.07 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -59.92 86.62 17.74 -59.42 83.94 18.40 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -55.38 81.61 14.50 -57.11 80.05 20.41 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c08 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 I 24 ASP C 19 ASP~? 15.67 CL CL A 144 I 146 TYR A 67 TYR~? 16.80 CL CL A 144 I 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -54.65 81.97 26.87 -55.88 81.89 25.07 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -59.92 86.62 17.74 -59.42 83.94 18.40 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -55.38 81.61 14.50 -57.11 80.05 20.41 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c08 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c08 naa= 3 ULMN 3 1ok4_c09 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 1 3 # 1 J 24 ASP B 19 ASP~? 15.75 CL CL A 144 J 146 TYR B 83 TYR.? 13.54 CL CL D 145 J 177 LYS B 77 LYS.? 21.17 CL CL D 145 coo -50.64 99.08 1.52 -51.52 100.83 0.67 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -54.74 109.84 1.86 -54.04 108.22 -0.34 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo -49.01 110.53 -2.89 -51.59 104.72 -2.78 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 1ok4_c09 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASSuser 2 3 # 2 J 24 ASP C 19 ASP~? 15.67 CL CL A 144 J 146 TYR A 67 TYR~? 16.80 CL CL A 144 J 177 LYS A 65 LYS~? 24.48 CL CL A 144 coo -50.64 99.08 1.52 -51.52 100.83 0.67 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -54.74 109.84 1.86 -54.04 108.22 -0.34 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -49.01 110.53 -2.89 -51.59 104.72 -2.78 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 1ok4_c09 source 1ok4 FRUCTOSE-BISPHOSPHATE ALDOLASE CLASS I : 2 hits 1ok4_c09 naa= 3 ULMN 3 1onr_c00 TRANSALDOLASE B user 1 3 # 1 A 17 ASP A 133 ASP~? 7.97 CL CL D 145 A 96 GLU A 37 GLU^? 12.50 C6 EPE A 145 A 132 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 31.23 12.29 16.44 30.82 11.56 18.39 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 26.82 3.20 24.36 27.99 4.86 24.98 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 29.99 0.62 22.18 30.38 6.69 20.81 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1onr_c00 TRANSALDOLASE B user 2 3 # 2 A 17 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 96 GLU B 37 GLU^? 13.18 C3 EPE A 145 A 132 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 31.23 12.29 16.44 30.82 11.56 18.39 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 26.82 3.20 24.36 27.99 4.86 24.98 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 29.99 0.62 22.18 30.38 6.69 20.81 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1onr_c00 TRANSALDOLASE B user 3 3 # 3 A 17 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 96 GLU C 37 GLU^? 12.70 O8 EPE A 145 A 132 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 31.23 12.29 16.44 30.82 11.56 18.39 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 26.82 3.20 24.36 27.99 4.86 24.98 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 29.99 0.62 22.18 30.38 6.69 20.81 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1onr_c00 TRANSALDOLASE B user 4 3 # 4 A 17 ASP D 133 ASP~? 7.85 CL CL D 145 A 96 GLU B 37 GLU^? 13.18 C3 EPE A 145 A 132 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 31.23 12.29 16.44 30.82 11.56 18.39 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 26.82 3.20 24.36 27.99 4.86 24.98 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 29.99 0.62 22.18 30.38 6.69 20.81 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1onr_c00 TRANSALDOLASE B user 5 3 # 5 A 17 ASP D 133 ASP~? 7.85 CL CL D 145 A 96 GLU D 37 GLU^? 11.78 O8 EPE D 146 A 132 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 31.23 12.29 16.44 30.82 11.56 18.39 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 26.82 3.20 24.36 27.99 4.86 24.98 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 29.99 0.62 22.18 30.38 6.69 20.81 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1onr_c00 source 1onr TRANSALDOLASE B : 5 hits 1onr_c00 naa= 3 ULMN 3 1onr_c01 TRANSALDOLASE B user 1 3 # 1 B 17 ASP A 133 ASP~? 7.97 CL CL D 145 B 96 GLU A 37 GLU^? 12.50 C6 EPE A 145 B 132 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 31.16 57.31 -0.94 30.73 56.64 1.01 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 26.69 48.45 7.18 27.85 50.13 7.74 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 29.82 45.80 5.07 30.26 51.81 3.56 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1onr_c01 TRANSALDOLASE B user 2 3 # 2 B 17 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 96 GLU B 37 GLU^? 13.18 C3 EPE A 145 B 132 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 31.16 57.31 -0.94 30.73 56.64 1.01 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 26.69 48.45 7.18 27.85 50.13 7.74 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 29.82 45.80 5.07 30.26 51.81 3.56 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1onr_c01 TRANSALDOLASE B user 3 3 # 3 B 17 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 96 GLU C 37 GLU^? 12.70 O8 EPE A 145 B 132 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 31.16 57.31 -0.94 30.73 56.64 1.01 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 26.69 48.45 7.18 27.85 50.13 7.74 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 29.82 45.80 5.07 30.26 51.81 3.56 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1onr_c01 TRANSALDOLASE B user 4 3 # 4 B 17 ASP D 133 ASP~? 7.85 CL CL D 145 B 96 GLU B 37 GLU^? 13.18 C3 EPE A 145 B 132 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 31.16 57.31 -0.94 30.73 56.64 1.01 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 26.69 48.45 7.18 27.85 50.13 7.74 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 29.82 45.80 5.07 30.26 51.81 3.56 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1onr_c01 TRANSALDOLASE B user 5 3 # 5 B 17 ASP D 133 ASP~? 7.85 CL CL D 145 B 96 GLU D 37 GLU^? 11.78 O8 EPE D 146 B 132 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 31.16 57.31 -0.94 30.73 56.64 1.01 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 26.69 48.45 7.18 27.85 50.13 7.74 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 coo 29.82 45.80 5.07 30.26 51.81 3.56 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1onr_c01 source 1onr TRANSALDOLASE B : 5 hits 1onr_c01 naa= 3 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 1 3 # 1 A 170 SER A 10 SER^? 8.69 O1S EPE A 145 A 239 VAL A 38 VAL^? 12.70 O1S EPE A 145 A 413 ASN A 39 ASN^? 12.67 O1S EPE A 145 coo 80.14 40.76 52.28 77.73 40.59 51.94 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 75.67 35.37 52.30 76.00 35.96 50.23 -29.02 0.75 -19.10 -31.03 0.33 -18.28 coo 81.75 35.21 52.13 80.92 37.12 51.69 -26.45 -1.95 -22.01 -25.11 -0.41 -21.60 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 2 3 # 2 A 170 SER B 10 SER^? 8.49 O2S EPE A 145 A 239 VAL B 38 VAL^? 12.75 O3S EPE A 145 A 413 ASN B 39 ASN^? 12.62 O2S EPE A 145 coo 80.14 40.76 52.28 77.73 40.59 51.94 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 75.67 35.37 52.30 76.00 35.96 50.23 -14.97 -18.66 -18.27 -16.09 -18.62 -20.15 coo 81.75 35.21 52.13 80.92 37.12 51.69 -16.43 -20.24 -14.07 -14.54 -19.54 -13.47 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 3 3 # 3 A 170 SER C 10 SER^? 8.67 O1S EPE A 145 A 239 VAL C 38 VAL^? 12.77 O2S EPE A 145 A 413 ASN C 39 ASN^? 12.71 O1S EPE A 145 coo 80.14 40.76 52.28 77.73 40.59 51.94 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 75.67 35.37 52.30 76.00 35.96 50.23 -27.80 -12.35 0.50 -28.10 -14.51 0.09 coo 81.75 35.21 52.13 80.92 37.12 51.69 -30.23 -8.85 -1.51 -29.05 -7.61 -0.29 ULMN 3 1oqz_c00 GLUTARYL ACYLASE user 4 3 # 4 A 170 SER D 10 SER^? 8.71 O3S EPE D 146 A 239 VAL D 38 VAL^? 12.83 O3S EPE D 146 A 413 ASN D 39 ASN^? 12.69 O3S EPE D 146 coo 80.14 40.76 52.28 77.73 40.59 51.94 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 75.67 35.37 52.30 76.00 35.96 50.23 0.77 -13.85 -30.11 2.45 -13.81 -31.51 coo 81.75 35.21 52.13 80.92 37.12 51.69 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 1oqz_c00 source 1oqz GLUTARYL ACYLASE : 4 hits 1oqz_c00 naa= 3 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 1 3 # 1 B 170 SER A 10 SER^? 8.69 O1S EPE A 145 B 239 VAL A 38 VAL^? 12.70 O1S EPE A 145 B 413 ASN A 39 ASN^? 12.67 O1S EPE A 145 coo 25.22 6.41 2.90 27.67 6.33 3.11 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 29.71 1.00 2.66 29.43 1.57 4.74 -29.02 0.75 -19.10 -31.03 0.33 -18.28 coo 23.72 0.88 2.95 24.56 2.79 3.34 -26.45 -1.95 -22.01 -25.11 -0.41 -21.60 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 2 3 # 2 B 170 SER B 10 SER^? 8.49 O2S EPE A 145 B 239 VAL B 38 VAL^? 12.75 O3S EPE A 145 B 413 ASN B 39 ASN^? 12.62 O2S EPE A 145 coo 25.22 6.41 2.90 27.67 6.33 3.11 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 29.71 1.00 2.66 29.43 1.57 4.74 -14.97 -18.66 -18.27 -16.09 -18.62 -20.15 coo 23.72 0.88 2.95 24.56 2.79 3.34 -16.43 -20.24 -14.07 -14.54 -19.54 -13.47 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 3 3 # 3 B 170 SER C 10 SER^? 8.67 O1S EPE A 145 B 239 VAL C 38 VAL^? 12.77 O2S EPE A 145 B 413 ASN C 39 ASN^? 12.71 O1S EPE A 145 coo 25.22 6.41 2.90 27.67 6.33 3.11 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 29.71 1.00 2.66 29.43 1.57 4.74 -27.80 -12.35 0.50 -28.10 -14.51 0.09 coo 23.72 0.88 2.95 24.56 2.79 3.34 -30.23 -8.85 -1.51 -29.05 -7.61 -0.29 ULMN 3 1oqz_c01 GLUTARYL ACYLASE user 4 3 # 4 B 170 SER D 10 SER^? 8.71 O3S EPE D 146 B 239 VAL D 38 VAL^? 12.83 O3S EPE D 146 B 413 ASN D 39 ASN^? 12.69 O3S EPE D 146 coo 25.22 6.41 2.90 27.67 6.33 3.11 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 29.71 1.00 2.66 29.43 1.57 4.74 0.77 -13.85 -30.11 2.45 -13.81 -31.51 coo 23.72 0.88 2.95 24.56 2.79 3.34 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 1oqz_c01 source 1oqz GLUTARYL ACYLASE : 4 hits 1oqz_c01 naa= 3 ULMN 3 1oyg_c00 LEVANSUCRASE user 1 3 # 1 A 86 ASP A 133 ASP~? 7.97 CL CL D 145 A 247 ASP D 133 ASP~? 7.85 CL CL D 145 A 342 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo 44.36 35.68 9.71 43.29 36.20 11.51 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 41.40 28.81 12.91 40.82 30.90 12.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 40.37 33.11 18.06 39.99 34.93 17.06 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 ULMN 3 1oyg_c00 LEVANSUCRASE user 2 3 # 2 A 86 ASP D 133 ASP~? 7.85 CL CL D 145 A 247 ASP A 133 ASP~? 7.97 CL CL D 145 A 342 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 44.36 35.68 9.71 43.29 36.20 11.51 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 41.40 28.81 12.91 40.82 30.90 12.97 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 40.37 33.11 18.06 39.99 34.93 17.06 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 1oyg_c00 source 1oyg LEVANSUCRASE : 2 hits 1oyg_c00 naa= 3 ULMN 3 1p1x_c00 DEOXYRIBOSE-PHOSPHATE ALDOLASE user 1 3 # 1 A 102 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 167 LYS A 7 LYS.? 11.74 O8 EPE A 145 A 201 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.53 8.31 20.37 28.45 8.41 19.40 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 24.92 6.08 13.38 27.75 4.33 18.83 -24.35 2.90 -12.02 -25.19 4.34 -6.86 coo 29.08 5.53 11.69 30.46 5.61 17.93 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 1p1x_c00 source 1p1x DEOXYRIBOSE-PHOSPHATE ALDOLASE : 1 hits 1p1x_c00 naa= 3 ULMN 3 1p1x_c01 DEOXYRIBOSE-PHOSPHATE ALDOLASE user 1 3 # 1 B1102 ASP C 133 ASP~? 13.97 O1S EPE A 145 B1167 LYS A 7 LYS.? 11.74 O8 EPE A 145 B1201 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 26.10 12.11 49.61 24.19 12.48 50.51 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 27.70 11.69 56.92 24.82 8.55 52.12 -24.35 2.90 -12.02 -25.19 4.34 -6.86 coo 23.50 11.64 58.67 22.19 10.19 52.59 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 1p1x_c01 source 1p1x DEOXYRIBOSE-PHOSPHATE ALDOLASE : 1 hits 1p1x_c01 naa= 3 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 1 3 # 1 A 70 ALA A 31 ALA~? 12.58 O1S EPE A 145 A 126 LEU A 9 LEU^? 8.44 O1S EPE A 145 A 158 GLU A 37 GLU^? 12.50 C6 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -28.91 -2.02 -15.21 -30.40 -3.54 -14.72 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -25.10 3.21 -19.35 -23.00 2.86 -19.59 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 2 3 # 2 A 70 ALA A 31 ALA~? 12.58 O1S EPE A 145 A 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 A 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 3 3 # 3 A 70 ALA A 129 ALA~? 3.92 CL CL D 145 A 126 LEU A 132 LEU~? 8.84 CL CL D 145 A 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -18.16 -9.62 -27.03 -16.85 -9.69 -27.84 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 4 3 # 4 A 70 ALA B 31 ALA~? 10.75 CL CL D 145 A 126 LEU A 132 LEU~? 8.84 CL CL D 145 A 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 5 3 # 5 A 70 ALA B 31 ALA~? 10.75 CL CL D 145 A 126 LEU B 9 LEU^? 8.47 O3S EPE A 145 A 158 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -17.89 -14.84 -18.61 -19.87 -14.81 -19.52 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 6 3 # 6 A 70 ALA B 129 ALA~? 15.74 O2S EPE A 145 A 126 LEU B 132 LEU~? 10.18 O2S EPE A 145 A 158 GLU B 136 GLU~? 6.67 C2 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -20.16 -21.74 -2.40 -19.83 -22.10 -0.98 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -20.43 -18.00 -4.54 -22.59 -18.03 -4.29 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 7 3 # 7 A 70 ALA C 129 ALA~? 15.24 O1S EPE A 145 A 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 A 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -34.15 0.77 -8.09 -34.39 2.21 -8.42 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 8 3 # 8 A 70 ALA D 31 ALA~? 12.56 O3S EPE D 146 A 126 LEU D 9 LEU^? 8.47 O3S EPE D 146 A 158 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo -2.29 37.66 144.73 -1.46 37.12 145.87 7.72 -13.14 -30.48 6.43 -12.32 -30.75 coo -4.62 32.83 147.14 -5.50 32.85 149.12 2.98 -9.46 -30.28 3.72 -8.56 -32.09 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1pjh_c00 ENOYL-COA ISOMERASE; ECI1P user 9 3 # 9 A 70 ALA D 129 ALA~? -3.66 CL CL D 145s A 126 LEU D 132 LEU~? 8.53 CL CL D 145 A 158 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo -2.29 37.66 144.73 -1.46 37.12 145.87 -14.52 -6.51 -30.58 -15.90 -6.50 -30.00 coo -4.62 32.83 147.14 -5.50 32.85 149.12 -10.90 -4.61 -29.31 -11.77 -3.12 -30.70 coo -0.83 29.57 149.77 -0.39 31.47 148.95 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 1pjh_c00 source 1pjh ENOYL-COA ISOMERASE; ECI1P : 9 hits 1pjh_c00 naa= 3 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 1 3 # 1 B 70 ALA A 31 ALA~? 12.58 O1S EPE A 145 B 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 B 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 2 3 # 2 B 70 ALA A 129 ALA~? 3.92 CL CL D 145 B 126 LEU A 132 LEU~? 8.84 CL CL D 145 B 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -18.16 -9.62 -27.03 -16.85 -9.69 -27.84 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 3 3 # 3 B 70 ALA B 31 ALA~? 10.75 CL CL D 145 B 126 LEU A 132 LEU~? 8.84 CL CL D 145 B 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 4 3 # 4 B 70 ALA B 31 ALA~? 10.75 CL CL D 145 B 126 LEU B 9 LEU^? 8.47 O3S EPE A 145 B 158 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -17.89 -14.84 -18.61 -19.87 -14.81 -19.52 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 5 3 # 5 B 70 ALA B 129 ALA~? 15.74 O2S EPE A 145 B 126 LEU B 132 LEU~? 10.18 O2S EPE A 145 B 158 GLU B 136 GLU~? 6.67 C2 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -20.16 -21.74 -2.40 -19.83 -22.10 -0.98 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -20.43 -18.00 -4.54 -22.59 -18.03 -4.29 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 6 3 # 6 B 70 ALA C 129 ALA~? 15.24 O1S EPE A 145 B 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 B 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -34.15 0.77 -8.09 -34.39 2.21 -8.42 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 7 3 # 7 B 70 ALA D 31 ALA~? 12.56 O3S EPE D 146 B 126 LEU D 9 LEU^? 8.47 O3S EPE D 146 B 158 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo -39.79 4.61 147.27 -39.61 5.56 148.47 7.72 -13.14 -30.48 6.43 -12.32 -30.75 coo -34.22 5.06 149.25 -33.65 4.24 151.15 2.98 -9.46 -30.28 3.72 -8.56 -32.09 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1pjh_c01 ENOYL-COA ISOMERASE; ECI1P user 8 3 # 8 B 70 ALA D 129 ALA~? -3.66 CL CL D 145s B 126 LEU D 132 LEU~? 8.53 CL CL D 145 B 158 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo -39.79 4.61 147.27 -39.61 5.56 148.47 -14.52 -6.51 -30.58 -15.90 -6.50 -30.00 coo -34.22 5.06 149.25 -33.65 4.24 151.15 -10.90 -4.61 -29.31 -11.77 -3.12 -30.70 coo -33.03 9.93 151.71 -34.98 9.38 151.11 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 1pjh_c01 source 1pjh ENOYL-COA ISOMERASE; ECI1P : 8 hits 1pjh_c01 naa= 3 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 1 3 # 1 C 70 ALA A 31 ALA~? 12.58 O1S EPE A 145 C 126 LEU A 9 LEU^? 8.44 O1S EPE A 145 C 158 GLU A 37 GLU^? 12.50 C6 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -28.91 -2.02 -15.21 -30.40 -3.54 -14.72 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -25.10 3.21 -19.35 -23.00 2.86 -19.59 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 2 3 # 2 C 70 ALA A 31 ALA~? 12.58 O1S EPE A 145 C 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 C 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -33.15 2.02 -13.40 -32.37 0.82 -14.04 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 3 3 # 3 C 70 ALA A 129 ALA~? 3.92 CL CL D 145 C 126 LEU A 132 LEU~? 8.84 CL CL D 145 C 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -18.16 -9.62 -27.03 -16.85 -9.69 -27.84 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 4 3 # 4 C 70 ALA B 31 ALA~? 10.75 CL CL D 145 C 126 LEU A 132 LEU~? 8.84 CL CL D 145 C 158 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -18.72 -9.37 -22.79 -19.00 -11.51 -23.05 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 5 3 # 5 C 70 ALA B 31 ALA~? 10.75 CL CL D 145 C 126 LEU B 9 LEU^? 8.47 O3S EPE A 145 C 158 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -15.67 -14.91 -24.16 -16.39 -15.23 -22.83 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -17.89 -14.84 -18.61 -19.87 -14.81 -19.52 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 6 3 # 6 C 70 ALA B 129 ALA~? 15.74 O2S EPE A 145 C 126 LEU B 132 LEU~? 10.18 O2S EPE A 145 C 158 GLU B 136 GLU~? 6.67 C2 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -20.16 -21.74 -2.40 -19.83 -22.10 -0.98 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -20.43 -18.00 -4.54 -22.59 -18.03 -4.29 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 7 3 # 7 C 70 ALA C 31 ALA~? 12.76 O2S EPE A 145 C 126 LEU C 9 LEU^? 8.62 O2S EPE A 145 C 158 GLU C 37 GLU^? 12.70 O8 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -24.09 -18.38 0.32 -24.85 -17.40 -0.54 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -25.39 -13.82 -3.34 -26.17 -15.36 -4.67 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -25.71 -8.80 2.61 -25.32 -6.70 2.31 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 8 3 # 8 C 70 ALA C 129 ALA~? 15.24 O1S EPE A 145 C 126 LEU C 132 LEU~? 9.43 O1S EPE A 145 C 158 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -34.15 0.77 -8.09 -34.39 2.21 -8.42 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -30.81 -1.95 -9.00 -31.52 -3.08 -10.75 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 9 3 # 9 C 70 ALA D 31 ALA~? 12.56 O3S EPE D 146 C 126 LEU D 9 LEU^? 8.47 O3S EPE D 146 C 158 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 7.72 -13.14 -30.48 6.43 -12.32 -30.75 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 2.98 -9.46 -30.28 3.72 -8.56 -32.09 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1pjh_c02 ENOYL-COA ISOMERASE; ECI1P user 10 3 # 10 C 70 ALA D 129 ALA~? -3.66 CL CL D 145s C 126 LEU D 132 LEU~? 8.53 CL CL D 145 C 158 GLU D 136 GLU~? 8.82 C5 EPE D 146 coo 7.77 -11.41 146.15 6.88 -11.77 147.32 -14.52 -6.51 -30.58 -15.90 -6.50 -30.00 coo 4.88 -6.81 148.13 5.33 -5.89 150.06 -10.90 -4.61 -29.31 -11.77 -3.12 -30.70 coo 0.03 -8.25 150.96 1.55 -9.64 150.41 -7.17 -3.74 -23.12 -9.02 -3.88 -22.01 1pjh_c02 source 1pjh ENOYL-COA ISOMERASE; ECI1P : 10 hits 1pjh_c02 naa= 3 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 1 3 # 1 A 248 ASP A 64 ASP~? 16.08 CL CL A 144 A 270 LYS A 20 LYS~? 9.88 CL CL A 144 A 382 MET B 70 MET?? 24.22 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -40.20 -21.36 -34.10 -40.65 -18.51 -35.23 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 2 3 # 2 A 248 ASP A 124 ASP^? 10.83 CL CL D 145 A 270 LYS A 100 LYS^? 18.99 CL CL D 145 A 382 MET A 108 MET?? 12.87 CL CL D 145 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -30.49 -12.32 -36.76 -29.82 -8.26 -36.14 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 3 3 # 3 A 248 ASP B 64 ASP~? 15.96 CL CL A 144 A 270 LYS A 65 LYS~? 24.48 CL CL A 144 A 382 MET C 70 MET?? 23.49 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -38.45 -35.60 -15.07 -35.31 -36.22 -16.82 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 4 3 # 4 A 248 ASP B 64 ASP~? 15.96 CL CL A 144 A 270 LYS B 20 LYS~? 9.95 CL CL A 144 A 382 MET C 70 MET?? 23.49 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -38.45 -35.60 -15.07 -35.31 -36.22 -16.82 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 5 3 # 5 A 248 ASP B 124 ASP^? 22.45 O2S EPE A 145 A 270 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 382 MET B 108 MET?? 22.26 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -26.15 -35.01 -8.82 -22.13 -34.43 -9.91 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 6 3 # 6 A 248 ASP C 64 ASP~? 15.91 CL CL A 144 A 270 LYS B 65 LYS~? 24.78 CL CL A 144 A 382 MET A 70 MET?? 24.17 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -52.64 -16.84 -14.14 -52.56 -16.85 -10.86 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 7 3 # 7 A 248 ASP C 64 ASP~? 15.91 CL CL A 144 A 270 LYS C 20 LYS~? 9.96 CL CL A 144 A 382 MET A 70 MET?? 24.17 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -52.64 -16.84 -14.14 -52.56 -16.85 -10.86 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 8 3 # 8 A 248 ASP C 124 ASP^? 22.63 O1S EPE A 145 A 270 LYS C 100 LYS^? 20.71 O2S EPE A 145 A 382 MET C 108 MET?? 22.43 CL CL A 144 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -48.05 -6.45 -5.72 -45.99 -6.36 -2.12 ULMN 3 1pjq_c02 SIROHEME SYNTHASE user 9 3 # 9 A 248 ASP D 124 ASP^? 11.01 CL CL D 145 A 270 LYS D 100 LYS^? 18.85 CL CL D 145 A 382 MET D 108 MET?? 12.93 CL CL D 145 coo -27.63 121.99 45.48 -26.66 123.86 45.68 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -32.20 115.91 49.56 -31.37 121.03 53.12 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo -23.75 127.89 58.42 -26.02 128.79 55.12 -15.66 -13.69 -44.73 -14.37 -16.36 -41.79 1pjq_c02 source 1pjq SIROHEME SYNTHASE : 9 hits 1pjq_c02 naa= 3 ULMN 3 1pjq_c03 SIROHEME SYNTHASE user 1 3 # 1 B 248 ASP A 64 ASP~? 16.08 CL CL A 144 B 270 LYS A 20 LYS~? 9.88 CL CL A 144 B 382 MET A 75 MET?? 23.11 CL CL A 144 coo -11.82 154.51 43.38 -12.86 152.74 43.79 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -5.09 158.39 43.41 -0.74 158.80 47.15 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 coo -2.79 145.52 50.38 -5.75 148.14 51.66 -53.45 -8.86 -18.34 -50.95 -9.68 -20.12 ULMN 3 1pjq_c03 SIROHEME SYNTHASE user 2 3 # 2 B 248 ASP B 64 ASP~? 15.96 CL CL A 144 B 270 LYS B 20 LYS~? 9.95 CL CL A 144 B 382 MET B 75 MET?? 23.15 CL CL D 145 coo -11.82 154.51 43.38 -12.86 152.74 43.79 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -5.09 158.39 43.41 -0.74 158.80 47.15 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 coo -2.79 145.52 50.38 -5.75 148.14 51.66 -32.72 -25.98 -36.33 -32.53 -26.98 -33.28 ULMN 3 1pjq_c03 SIROHEME SYNTHASE user 3 3 # 3 B 248 ASP C 64 ASP~? 15.91 CL CL A 144 B 270 LYS C 20 LYS~? 9.96 CL CL A 144 B 382 MET C 75 MET?? 23.18 CL CL A 144 coo -11.82 154.51 43.38 -12.86 152.74 43.79 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -5.09 158.39 43.41 -0.74 158.80 47.15 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 coo -2.79 145.52 50.38 -5.75 148.14 51.66 -39.66 -34.96 -6.08 -40.73 -32.05 -6.73 ULMN 3 1pjq_c03 SIROHEME SYNTHASE user 4 3 # 4 B 248 ASP D 64 ASP~? 16.02 CL CL D 144 B 270 LYS D 20 LYS~? 10.12 CL CL D 144 B 382 MET D 75 MET?? 23.07 CL CL D 144 coo -11.82 154.51 43.38 -12.86 152.74 43.79 3.77 -3.98 -52.36 2.81 -2.05 -52.32 coo -5.09 158.39 43.41 -0.74 158.80 47.15 3.77 -7.84 -45.94 1.16 -2.20 -46.49 coo -2.79 145.52 50.38 -5.75 148.14 51.66 12.55 -13.86 -53.61 9.25 -13.35 -53.06 1pjq_c03 source 1pjq SIROHEME SYNTHASE : 4 hits 1pjq_c03 naa= 3 ULMN 3 1pnl_c00 PENICILLIN AMIDOHYDROLASE user 1 3 # 1 B 1 SER A 10 SER^? 8.69 O1S EPE A 145 B 69 ALA A 135 ALA~? 7.09 O3S EPE A 145 B 241 ASN A 39 ASN^? 12.67 O1S EPE A 145 coo 13.24 41.94 33.13 13.08 39.54 33.17 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 9.15 37.89 36.69 10.55 37.76 37.22 -21.74 -4.83 -19.35 -22.31 -6.22 -19.41 coo 10.91 43.03 38.47 11.81 41.82 36.93 -26.45 -1.95 -22.01 -25.11 -0.41 -21.60 ULMN 3 1pnl_c00 PENICILLIN AMIDOHYDROLASE user 2 3 # 2 B 1 SER B 10 SER^? 8.49 O2S EPE A 145 B 69 ALA B 135 ALA~? 7.14 O2S EPE A 145 B 241 ASN B 39 ASN^? 12.62 O2S EPE A 145 coo 13.24 41.94 33.13 13.08 39.54 33.17 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 9.15 37.89 36.69 10.55 37.76 37.22 -17.57 -16.05 -9.94 -19.08 -16.31 -9.93 coo 10.91 43.03 38.47 11.81 41.82 36.93 -16.43 -20.24 -14.07 -14.54 -19.54 -13.47 ULMN 3 1pnl_c00 PENICILLIN AMIDOHYDROLASE user 3 3 # 3 B 1 SER C 10 SER^? 8.67 O1S EPE A 145 B 69 ALA C 135 ALA~? 7.15 O1S EPE A 145 B 241 ASN C 39 ASN^? 12.71 O1S EPE A 145 coo 13.24 41.94 33.13 13.08 39.54 33.17 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 9.15 37.89 36.69 10.55 37.76 37.22 -27.20 -5.52 -5.36 -28.06 -6.03 -6.53 coo 10.91 43.03 38.47 11.81 41.82 36.93 -30.23 -8.85 -1.51 -29.05 -7.61 -0.29 ULMN 3 1pnl_c00 PENICILLIN AMIDOHYDROLASE user 4 3 # 4 B 1 SER D 10 SER^? 8.71 O3S EPE D 146 B 69 ALA D 135 ALA~? 7.33 O2S EPE D 146 B 241 ASN D 39 ASN^? 12.69 O3S EPE D 146 coo 13.24 41.94 33.13 13.08 39.54 33.17 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 9.15 37.89 36.69 10.55 37.76 37.22 -5.15 -7.14 -27.91 -5.30 -6.27 -29.15 coo 10.91 43.03 38.47 11.81 41.82 36.93 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 1pnl_c00 source 1pnl PENICILLIN AMIDOHYDROLASE : 4 hits 1pnl_c00 naa= 3 ULMN 3 1qgn_c16 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 110 ARG D 134 ARG~? 13.66 CL CL D 145 C 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 C 236 ASP A 133 ASP~? 7.97 CL CL D 145 coo 39.01 29.77 22.02 37.48 31.30 19.84 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 39.51 34.34 13.63 37.63 32.61 14.79 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 45.78 31.11 9.51 44.25 30.06 10.53 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1qgn_c16 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c16 naa= 3 ULMN 3 1qgn_c17 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 110 ARG D 134 ARG~? 13.66 CL CL D 145 D 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 D 236 ASP A 133 ASP~? 7.97 CL CL D 145 coo 23.05 -7.35 32.81 21.30 -7.38 35.33 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 21.28 -11.43 41.42 21.14 -8.83 40.39 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 28.41 -14.31 44.14 27.98 -12.36 43.41 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1qgn_c17 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c17 naa= 3 ULMN 3 1qgn_c18 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 A 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 236 ASP A 133 ASP~? 7.97 CL CL D 145 C 110 ARG D 134 ARG~? 13.66 CL CL D 145 coo 55.48 26.51 40.65 55.39 23.99 39.43 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 48.87 29.19 44.63 49.10 27.34 43.63 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 52.39 23.42 32.10 54.51 23.27 34.29 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1qgn_c18 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c18 naa= 3 ULMN 3 1qgn_c19 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 B 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 236 ASP A 133 ASP~? 7.97 CL CL D 145 D 110 ARG D 134 ARG~? 13.66 CL CL D 145 coo 32.99 -16.32 11.66 35.01 -14.70 12.72 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 26.18 -12.82 8.91 27.87 -11.87 9.77 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 34.79 -12.60 20.34 35.97 -13.92 17.84 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1qgn_c19 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c19 naa= 3 ULMN 3 1qgn_c20 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 E 110 ARG D 134 ARG~? 13.66 CL CL D 145 G 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 G 236 ASP A 133 ASP~? 7.97 CL CL D 145 coo 60.40 -9.85 -55.76 62.00 -8.48 -58.01 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 64.84 -10.79 -64.16 63.27 -8.78 -63.00 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 61.22 -16.97 -68.13 60.30 -15.38 -67.08 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1qgn_c20 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c20 naa= 3 ULMN 3 1qgn_c21 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 F 110 ARG D 134 ARG~? 13.66 CL CL D 145 H 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 H 236 ASP A 133 ASP~? 7.97 CL CL D 145 coo 24.62 8.71 -44.89 24.77 10.53 -42.42 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 20.90 10.83 -36.23 23.51 10.75 -37.23 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 17.57 3.99 -33.38 19.51 4.24 -34.16 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1qgn_c21 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c21 naa= 3 ULMN 3 1qgn_c22 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 E 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 E 236 ASP A 133 ASP~? 7.97 CL CL D 145 G 110 ARG D 134 ARG~? 13.66 CL CL D 145 coo 56.39 -25.68 -36.91 53.88 -25.46 -38.13 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 59.54 -19.27 -32.99 57.70 -19.44 -33.97 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 53.35 -22.70 -45.35 52.95 -24.81 -43.16 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1qgn_c22 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c22 naa= 3 ULMN 3 1qgn_c23 CYSTATHIONINE GAMMA-SYNTHASE user 1 3 # 1 F 163 TYR B 36 TYR.? 11.13 O3S EPE A 145 F 236 ASP A 133 ASP~? 7.97 CL CL D 145 H 110 ARG D 134 ARG~? 13.66 CL CL D 145 coo 14.88 -1.19 -65.80 16.37 -3.30 -64.72 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 18.75 5.49 -68.65 19.58 3.75 -67.80 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 18.56 -3.01 -57.11 17.14 -4.14 -59.58 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 1qgn_c23 source 1qgn CYSTATHIONINE GAMMA-SYNTHASE : 1 hits 1qgn_c23 naa= 3 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 1 3 # 1 A 49 ASP A 19 ASP~? 15.97 CL CL A 144 A 147 THR A 17 THR~? 16.13 CL CL A 144 A 294 ASP B 64 ASP~? 15.96 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 2 3 # 2 A 49 ASP A 64 ASP~? 16.08 CL CL A 144 A 147 THR A 17 THR~? 16.13 CL CL A 144 A 294 ASP B 19 ASP~? 15.75 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 3 3 # 3 A 49 ASP B 19 ASP~? 15.75 CL CL A 144 A 147 THR B 17 THR~? 16.02 CL CL A 144 A 294 ASP C 64 ASP~? 15.91 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 4 3 # 4 A 49 ASP B 64 ASP~? 15.96 CL CL A 144 A 147 THR B 17 THR~? 16.02 CL CL A 144 A 294 ASP C 19 ASP~? 15.67 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 5 3 # 5 A 49 ASP C 19 ASP~? 15.67 CL CL A 144 A 147 THR C 17 THR~? 16.03 CL CL A 144 A 294 ASP A 64 ASP~? 16.08 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1qgx_c02 3',5'-ADENOSINE BISPHOSPHATASE user 6 3 # 6 A 49 ASP C 64 ASP~? 15.91 CL CL A 144 A 147 THR C 17 THR~? 16.03 CL CL A 144 A 294 ASP A 19 ASP~? 15.97 CL CL A 144 coo 1.13 15.67 -24.51 2.35 14.34 -25.71 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 6.09 11.55 -27.32 4.75 13.20 -27.33 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 coo 14.48 16.57 -21.30 13.03 16.83 -22.81 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 1qgx_c02 source 1qgx 3',5'-ADENOSINE BISPHOSPHATASE : 6 hits 1qgx_c02 naa= 3 ULMN 3 1qz9_c02 KYNURENINASE user 1 3 # 1 A 129 PHE A 14 PHE.? 11.46 CL CL A 144 A 201 ASP B 19 ASP~? 15.75 CL CL A 144 A 227 LYS A 20 LYS~? 9.88 CL CL A 144 coo 23.39 49.81 32.16 21.33 51.68 32.26 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 25.52 45.12 37.98 23.98 46.65 37.85 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 12.68 46.83 36.69 18.26 48.67 34.51 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1qz9_c02 KYNURENINASE user 2 3 # 2 A 129 PHE A 14 PHE.? 11.46 CL CL A 144 A 201 ASP B 64 ASP~? 15.96 CL CL A 144 A 227 LYS A 20 LYS~? 9.88 CL CL A 144 coo 23.39 49.81 32.16 21.33 51.68 32.26 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 25.52 45.12 37.98 23.98 46.65 37.85 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 12.68 46.83 36.69 18.26 48.67 34.51 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 1qz9_c02 KYNURENINASE user 3 3 # 3 A 129 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 201 ASP A 133 ASP~? 7.97 CL CL D 145 A 227 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 25.52 45.12 37.98 23.98 46.65 37.85 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.68 46.83 36.69 18.26 48.67 34.51 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1qz9_c02 KYNURENINASE user 4 3 # 4 A 129 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 201 ASP A 133 ASP~? 7.97 CL CL D 145 A 227 LYS A 100 LYS^? 18.99 CL CL D 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 25.52 45.12 37.98 23.98 46.65 37.85 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.68 46.83 36.69 18.26 48.67 34.51 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 1qz9_c02 KYNURENINASE user 5 3 # 5 A 129 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 201 ASP A 133 ASP~? 7.97 CL CL D 145 A 227 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 25.52 45.12 37.98 23.98 46.65 37.85 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.68 46.83 36.69 18.26 48.67 34.51 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1qz9_c02 KYNURENINASE user 6 3 # 6 A 129 PHE B 14 PHE.? 11.43 CL CL A 144 A 201 ASP C 64 ASP~? 15.91 CL CL A 144 A 227 LYS B 20 LYS~? 9.95 CL CL A 144 coo 23.39 49.81 32.16 21.33 51.68 32.26 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 coo 25.52 45.12 37.98 23.98 46.65 37.85 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 12.68 46.83 36.69 18.26 48.67 34.51 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 1qz9_c02 KYNURENINASE user 7 3 # 7 A 129 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 201 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 227 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 25.52 45.12 37.98 23.98 46.65 37.85 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.68 46.83 36.69 18.26 48.67 34.51 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1qz9_c02 KYNURENINASE user 8 3 # 8 A 129 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 201 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 227 LYS B 100 LYS^? 21.03 O3S EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 25.52 45.12 37.98 23.98 46.65 37.85 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.68 46.83 36.69 18.26 48.67 34.51 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 ULMN 3 1qz9_c02 KYNURENINASE user 9 3 # 9 A 129 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 201 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 227 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 25.52 45.12 37.98 23.98 46.65 37.85 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.68 46.83 36.69 18.26 48.67 34.51 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1qz9_c02 KYNURENINASE user 10 3 # 10 A 129 PHE C 14 PHE.? 11.62 CL CL A 144 A 201 ASP A 19 ASP~? 15.97 CL CL A 144 A 227 LYS C 20 LYS~? 9.96 CL CL A 144 coo 23.39 49.81 32.16 21.33 51.68 32.26 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 coo 25.52 45.12 37.98 23.98 46.65 37.85 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 12.68 46.83 36.69 18.26 48.67 34.51 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1qz9_c02 KYNURENINASE user 11 3 # 11 A 129 PHE C 14 PHE.? 11.62 CL CL A 144 A 201 ASP A 64 ASP~? 16.08 CL CL A 144 A 227 LYS C 20 LYS~? 9.96 CL CL A 144 coo 23.39 49.81 32.16 21.33 51.68 32.26 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 coo 25.52 45.12 37.98 23.98 46.65 37.85 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 12.68 46.83 36.69 18.26 48.67 34.51 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 1qz9_c02 KYNURENINASE user 12 3 # 12 A 129 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 201 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 227 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 25.52 45.12 37.98 23.98 46.65 37.85 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.68 46.83 36.69 18.26 48.67 34.51 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1qz9_c02 KYNURENINASE user 13 3 # 13 A 129 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 201 ASP D 133 ASP~? 7.85 CL CL D 145 A 227 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 23.39 49.81 32.16 21.33 51.68 32.26 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 25.52 45.12 37.98 23.98 46.65 37.85 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.68 46.83 36.69 18.26 48.67 34.51 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 1qz9_c02 KYNURENINASE user 14 3 # 14 A 129 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 201 ASP D 133 ASP~? 7.85 CL CL D 145 A 227 LYS D 100 LYS^? 18.85 CL CL D 145 coo 23.39 49.81 32.16 21.33 51.68 32.26 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 25.52 45.12 37.98 23.98 46.65 37.85 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.68 46.83 36.69 18.26 48.67 34.51 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 1qz9_c02 source 1qz9 KYNURENINASE : 14 hits 1qz9_c02 naa= 3 ULMN 3 1rne_c04 RENIN (ACTIVATED, GLYCOSYLATED, INHIuser 1 3 # 1 32 ASP D 133 ASP~? 7.85 CL CL D 145 35 SER B 34 SER~? 6.65 CL CL D 145 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo 11.85 17.24 72.81 11.09 15.37 72.36 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.20 12.71 75.45 13.69 13.84 74.03 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 5.22 15.03 71.43 7.19 14.88 70.83 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1rne_c04 source 1rne RENIN (ACTIVATED, GLYCOSYLATED, INHIBITED) (E.: 1 hits 1rne_c04 naa= 3 ULMN 3 1roz_c00 DEOXYHYPUSINE SYNTHASE user 1 3 # 1 A 137 GLU B 109 GLU~? 24.97 CL CL A 144 A 288 HIS C 87 HIS.? 23.40 CL CL A 144 A 329 LYS C 52 LYS~? 30.57 CL CL A 144 coo 29.27 18.78 14.99 27.16 18.62 14.76 -26.03 -35.79 -3.78 -25.87 -35.00 -1.85 coo 49.52 10.06 10.36 50.99 9.65 8.92 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 57.80 12.92 13.83 53.77 8.42 12.15 -49.26 -17.15 2.71 -49.73 -13.44 7.75 1roz_c00 source 1roz DEOXYHYPUSINE SYNTHASE : 1 hits 1roz_c00 naa= 3 ULMN 3 1roz_c01 DEOXYHYPUSINE SYNTHASE user 1 3 # 1 B 137 GLU B 109 GLU~? 24.97 CL CL A 144 B 288 HIS C 87 HIS.? 23.40 CL CL A 144 B 329 LYS C 52 LYS~? 30.57 CL CL A 144 coo 51.99 -1.20 48.77 51.89 -0.93 46.67 -26.03 -35.79 -3.78 -25.87 -35.00 -1.85 coo 31.44 -9.36 43.35 29.98 -10.83 43.65 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 23.19 -4.89 44.25 27.28 -8.41 40.97 -49.26 -17.15 2.71 -49.73 -13.44 7.75 1roz_c01 source 1roz DEOXYHYPUSINE SYNTHASE : 1 hits 1roz_c01 naa= 3 ULMN 3 1sll_c00 SIALIDASE L user 1 3 # 1 318 ASP A 64 ASP~? 16.08 CL CL A 144 595 GLU B 68 GLU~? 25.19 CL CL A 144 713 TYR B 67 TYR~? 16.82 CL CL A 144 coo 5.64 2.82 38.49 4.59 4.19 37.25 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 4.35 13.73 37.63 3.39 12.18 36.55 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 3.76 10.25 31.38 3.16 9.87 34.10 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 ULMN 3 1sll_c00 SIALIDASE L user 2 3 # 2 318 ASP B 64 ASP~? 15.96 CL CL A 144 595 GLU C 68 GLU~? 25.33 CL CL A 144 713 TYR C 67 TYR~? 16.92 CL CL A 144 coo 5.64 2.82 38.49 4.59 4.19 37.25 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 4.35 13.73 37.63 3.39 12.18 36.55 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 3.76 10.25 31.38 3.16 9.87 34.10 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 ULMN 3 1sll_c00 SIALIDASE L user 3 3 # 3 318 ASP C 64 ASP~? 15.91 CL CL A 144 595 GLU A 68 GLU~? 25.44 CL CL A 144 713 TYR A 67 TYR~? 16.80 CL CL A 144 coo 5.64 2.82 38.49 4.59 4.19 37.25 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 4.35 13.73 37.63 3.39 12.18 36.55 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 3.76 10.25 31.38 3.16 9.87 34.10 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 1sll_c00 source 1sll SIALIDASE L : 3 hits 1sll_c00 naa= 3 ULMN 3 1sme_c04 PLASMEPSIN II user 1 3 # 1 A 34 ASP D 133 ASP~? 7.85 CL CL D 145 A 37 SER B 34 SER~? 6.65 CL CL D 145 A 214 ASP A 133 ASP~? 7.97 CL CL D 145 coo 51.75 60.57 19.10 52.05 60.90 21.19 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 51.10 65.11 20.73 52.62 63.74 19.42 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 48.59 58.89 25.78 50.13 59.74 24.61 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1sme_c04 source 1sme PLASMEPSIN II : 1 hits 1sme_c04 naa= 3 ULMN 3 1sme_c05 PLASMEPSIN II user 1 3 # 1 B 34 ASP D 133 ASP~? 7.85 CL CL D 145 B 37 SER B 34 SER~? 6.65 CL CL D 145 B 214 ASP A 133 ASP~? 7.97 CL CL D 145 coo 17.69 97.58 52.73 17.33 97.19 54.77 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 20.67 100.44 55.84 20.21 98.51 54.45 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 12.41 98.71 58.47 14.37 98.17 58.05 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 1sme_c05 source 1sme PLASMEPSIN II : 1 hits 1sme_c05 naa= 3 ULMN 3 1stc_c02 CAMP-DEPENDENT PROTEIN KINASE user 1 3 # 1 E 166 ASP D 19 ASP~? 15.85 CL CL D 144 E 168 LYS D 65 LYS~? 24.46 CL CL D 144 E 201 THR D 17 THR~? 16.46 CL CL D 144 coo 5.36 16.20 22.10 3.88 17.00 23.31 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 5.06 22.32 18.11 1.02 22.08 22.74 3.33 -3.03 -56.97 -1.82 -3.51 -60.81 coo -1.79 18.29 19.05 -1.19 20.28 19.71 1.11 -9.25 -50.49 1.81 -7.39 -51.27 1stc_c02 source 1stc CAMP-DEPENDENT PROTEIN KINASE : 1 hits 1stc_c02 naa= 3 ULMN 3 1tz3_c02 PUTATIVE SUGAR KINASE user 1 3 # 1 A 250 ALA B 33 ALA~? 8.85 CL CL D 145 A 251 GLY B 35 GLY.? 12.52 CL CL D 145 A 252 ASP D 133 ASP~? 7.85 CL CL D 145 coo 27.46 -16.39 -4.13 28.50 -15.30 -4.20 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 24.64 -14.61 -2.31 24.63 -15.34 -2.63 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 21.52 -17.78 -4.15 20.67 -16.16 -5.23 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 1tz3_c02 source 1tz3 PUTATIVE SUGAR KINASE : 1 hits 1tz3_c02 naa= 3 ULMN 3 1tz3_c03 PUTATIVE SUGAR KINASE user 1 3 # 1 B 250 ALA B 33 ALA~? 8.85 CL CL D 145 B 251 GLY B 35 GLY.? 12.52 CL CL D 145 B 252 ASP D 133 ASP~? 7.85 CL CL D 145 coo 16.60 -23.26 -48.35 15.78 -24.48 -48.70 -11.81 -16.00 -27.86 -12.67 -15.95 -29.14 coo 14.17 -20.48 -49.26 14.89 -20.41 -48.91 -9.37 -13.72 -23.55 -10.13 -13.72 -23.39 coo 16.67 -17.59 -46.30 15.00 -17.34 -45.02 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 1tz3_c03 source 1tz3 PUTATIVE SUGAR KINASE : 1 hits 1tz3_c03 naa= 3 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 1 3 # 1 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU A 136 GLU~? 8.92 C6 EPE A 145 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 2 3 # 2 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU B 37 GLU^? 13.18 C3 EPE A 145 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 3 3 # 3 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU B 37 GLU^? 13.18 C3 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 4 3 # 4 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU B 136 GLU~? 6.67 C2 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 5 3 # 5 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU C 37 GLU^? 12.70 O8 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 6 3 # 6 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU C 80 GLU.? 32.79 CL CL A 144 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 7 3 # 7 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU C 95 GLU.? 27.59 O2S EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 8 3 # 8 199 ASP A 64 ASP~? 16.08 CL CL A 144 218 GLU C 98 GLU^? 18.25 O8 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 70.09 11.71 8.46 70.56 12.89 6.77 -26.60 -9.58 6.05 -28.04 -8.33 6.98 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 9 3 # 9 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU A 80 GLU.? 32.70 CL CL A 144 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -58.68 -2.10 -13.66 -59.90 -3.56 -12.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 10 3 # 10 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU A 95 GLU.? 27.70 O1S EPE A 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 11 3 # 11 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU B 136 GLU~? 6.67 C2 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 12 3 # 12 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU C 37 GLU^? 12.70 O8 EPE A 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 13 3 # 13 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU C 37 GLU^? 12.70 O8 EPE A 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -25.71 -8.80 2.61 -25.32 -6.70 2.31 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 14 3 # 14 199 ASP B 64 ASP~? 15.96 CL CL A 144 218 GLU C 136 GLU~? 8.02 O8 EPE A 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 70.09 11.71 8.46 70.56 12.89 6.77 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 15 3 # 15 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU A 37 GLU^? 12.50 C6 EPE A 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 16 3 # 16 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU A 37 GLU^? 12.50 C6 EPE A 145 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -25.10 3.21 -19.35 -23.00 2.86 -19.59 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 17 3 # 17 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU A 136 GLU~? 8.92 C6 EPE A 145 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 18 3 # 18 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU B 80 GLU.? 23.04 CL CL D 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 19 3 # 19 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU B 98 GLU^? 17.25 C3 EPE A 145 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 20 3 # 20 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU C 116 GLU~? 31.54 CL CL A 144 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -52.13 -7.01 5.97 -52.83 -5.84 4.34 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c04 OLIGO-1,6-GLUCOSIDASE user 21 3 # 21 199 ASP C 64 ASP~? 15.91 CL CL A 144 218 GLU C 136 GLU~? 8.02 O8 EPE A 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 70.09 11.71 8.46 70.56 12.89 6.77 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 1uok_c04 source 1uok OLIGO-1,6-GLUCOSIDASE : 21 hits 1uok_c04 naa= 3 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 1 3 # 1 199 ASP A 64 ASP~? 16.08 CL CL A 144 242 GLU A 80 GLU.? 32.70 CL CL A 144 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 30.42 34.74 5.00 29.09 35.09 3.38 -58.68 -2.10 -13.66 -59.90 -3.56 -12.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 2 3 # 2 199 ASP A 64 ASP~? 16.08 CL CL A 144 242 GLU A 80 GLU.? 32.70 CL CL A 144 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 30.42 34.74 5.00 29.09 35.09 3.38 -58.68 -2.10 -13.66 -59.90 -3.56 -12.69 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 3 3 # 3 199 ASP B 64 ASP~? 15.96 CL CL A 144 242 GLU B 80 GLU.? 23.04 CL CL D 145 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 30.42 34.74 5.00 29.09 35.09 3.38 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 4 3 # 4 199 ASP B 64 ASP~? 15.96 CL CL A 144 242 GLU B 80 GLU.? 23.04 CL CL D 145 329 ASP C 64 ASP~? 15.91 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 30.42 34.74 5.00 29.09 35.09 3.38 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 coo 59.16 37.82 13.95 57.63 37.03 15.12 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 5 3 # 5 199 ASP C 64 ASP~? 15.91 CL CL A 144 242 GLU B 109 GLU~? 24.97 CL CL A 144 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 30.42 34.74 5.00 29.09 35.09 3.38 -26.03 -35.79 -3.78 -25.87 -35.00 -1.85 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 6 3 # 6 199 ASP C 64 ASP~? 15.91 CL CL A 144 242 GLU C 80 GLU.? 32.79 CL CL A 144 329 ASP A 64 ASP~? 16.08 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 30.42 34.74 5.00 29.09 35.09 3.38 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 coo 59.16 37.82 13.95 57.63 37.03 15.12 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 1uok_c05 OLIGO-1,6-GLUCOSIDASE user 7 3 # 7 199 ASP C 64 ASP~? 15.91 CL CL A 144 242 GLU C 80 GLU.? 32.79 CL CL A 144 329 ASP B 64 ASP~? 15.96 CL CL A 144 coo 49.16 35.16 15.19 51.08 34.43 15.65 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 30.42 34.74 5.00 29.09 35.09 3.38 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 coo 59.16 37.82 13.95 57.63 37.03 15.12 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 1uok_c05 source 1uok OLIGO-1,6-GLUCOSIDASE : 7 hits 1uok_c05 naa= 3 ULMN 3 1vom_c00 MYOSIN user 1 3 # 1 233 ASN A 66 ASN~? 17.58 CL CL A 144 457 GLY A 71 GLY.? 23.70 CL CL A 144 459 GLU A 68 GLU~? 25.44 CL CL A 144 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -52.38 -14.94 -17.47 -52.97 -14.90 -16.94 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 ULMN 3 1vom_c00 MYOSIN user 2 3 # 2 233 ASN B 66 ASN~? 17.83 CL CL A 144 457 GLY B 71 GLY.? 23.54 CL CL A 144 459 GLU B 68 GLU~? 25.19 CL CL A 144 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -38.06 -24.44 -33.46 -38.29 -24.16 -34.16 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 ULMN 3 1vom_c00 MYOSIN user 3 3 # 3 233 ASN C 66 ASN~? 17.61 CL CL A 144 457 GLY C 71 GLY.? 23.56 CL CL A 144 459 GLU C 68 GLU~? 25.33 CL CL A 144 coo 59.14 42.15 -25.87 60.93 42.86 -24.97 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 coo 63.27 35.38 -30.38 62.82 35.87 -30.84 -40.54 -34.08 -12.23 -40.32 -34.83 -12.31 coo 57.92 36.85 -33.37 58.28 38.94 -33.63 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 1vom_c00 source 1vom MYOSIN : 3 hits 1vom_c00 naa= 3 ULMN 3 1vzz_c00 STEROID DELTA-ISOMERASE user 1 3 # 1 A 16 TYR B 83 TYR.? 13.54 CL CL D 145 A 40 ASP D 124 ASP^? 11.01 CL CL D 145 A 103 LEU B 89 LEU.? 14.49 CL CL D 145 coo 12.09 16.13 10.57 11.28 18.80 10.73 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo 7.55 25.51 14.34 9.65 25.73 14.24 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 11.83 18.73 16.99 10.99 19.71 15.26 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 1vzz_c00 source 1vzz STEROID DELTA-ISOMERASE : 1 hits 1vzz_c00 naa= 3 ULMN 3 1vzz_c01 STEROID DELTA-ISOMERASE user 1 3 # 1 B 16 TYR B 83 TYR.? 13.54 CL CL D 145 B 40 ASP D 124 ASP^? 11.01 CL CL D 145 B 103 LEU B 89 LEU.? 14.49 CL CL D 145 coo 14.25 20.09 37.35 13.48 17.40 37.38 -23.78 -22.19 -35.58 -22.78 -20.09 -34.07 coo 9.39 10.77 34.53 11.50 10.63 34.41 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo 12.89 17.60 31.13 12.34 16.51 32.90 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 1vzz_c01 source 1vzz STEROID DELTA-ISOMERASE : 1 hits 1vzz_c01 naa= 3 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 1 3 # 1 A 183 GLY A 16 GLY.? 15.74 CL CL A 144 B 419 GLY A 46 GLY~? 14.99 CL CL A 144 B 420 ALA A 49 ALA~? 18.23 CL CL A 144 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -40.03 -13.36 -25.72 -40.28 -13.76 -25.07 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -36.29 -11.34 -27.41 -36.11 -11.63 -28.19 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -40.09 -9.47 -29.99 -39.97 -9.63 -28.47 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 2 3 # 2 A 183 GLY B 16 GLY.? 15.61 CL CL A 144 B 419 GLY B 46 GLY~? 14.88 CL CL A 144 B 420 ALA B 49 ALA~? 18.15 CL CL A 144 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -31.54 -27.94 -20.51 -32.04 -27.41 -20.81 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -28.15 -28.34 -17.39 -28.30 -29.00 -16.89 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -27.56 -32.18 -20.49 -27.81 -30.73 -20.89 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 3 3 # 3 A 183 GLY C 16 GLY.? 15.72 CL CL A 144 B 419 GLY C 46 GLY~? 15.01 CL CL A 144 B 420 ALA C 49 ALA~? 18.21 CL CL A 144 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -42.53 -19.56 -9.41 -42.18 -20.02 -9.95 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -41.88 -15.54 -7.30 -42.58 -15.06 -7.34 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -44.86 -18.05 -4.31 -43.58 -18.58 -5.01 ULMN 3 1xny_c00 PROPIONYL-COA CARBOXYLASE COMPLEX B user 4 3 # 4 A 183 GLY D 16 GLY.? 15.70 CL CL D 144 B 419 GLY D 46 GLY~? 14.94 CL CL D 144 B 420 ALA D 49 ALA~? 18.27 CL CL D 144 coo 26.12 -67.67-130.71 26.18 -67.32-131.45 -2.08 -10.01 -48.59 -1.56 -9.45 -48.80 coo 25.10 -66.82-126.88 25.40 -66.55-126.17 -4.92 -11.21 -45.24 -5.67 -11.37 -45.57 coo 26.37 -68.04-123.51 27.50 -67.42-122.72 -4.16 -15.33 -47.99 -3.09 -14.36 -47.53 1xny_c00 source 1xny PROPIONYL-COA CARBOXYLASE COMPLEX B SUBUNIT : 4 hits 1xny_c00 naa= 3 ULMN 3 1xs1_c07 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 B 124 ALA B 32 ALA~? 12.87 CL CL D 145 B 126 ARG D 134 ARG~? 13.66 CL CL D 145 B 138 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo 2.11 4.00 19.31 3.14 4.86 19.99 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 2.45 5.53 11.28 3.59 7.56 13.29 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 6.10 2.00 25.24 6.12 1.84 23.13 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 1xs1_c07 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 1 hits 1xs1_c07 naa= 3 ULMN 3 1xs1_c08 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 C 124 ALA B 32 ALA~? 12.87 CL CL D 145 C 126 ARG D 134 ARG~? 13.66 CL CL D 145 C 138 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo -4.54 -7.50 19.94 -4.33 -8.73 20.82 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo -3.14 -9.40 12.05 -1.75 -11.23 14.08 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -8.56 -9.50 25.72 -8.77 -9.47 23.62 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 1xs1_c08 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 1 hits 1xs1_c08 naa= 3 ULMN 3 1xs1_c09 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 D 124 ALA B 32 ALA~? 12.87 CL CL D 145 D 126 ARG D 134 ARG~? 13.66 CL CL D 145 D 138 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo 2.08 -1.49 62.94 3.12 -2.39 62.28 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo 2.52 -3.11 70.84 3.63 -5.24 68.92 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 6.23 0.50 57.10 5.93 0.72 59.19 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 1xs1_c09 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 1 hits 1xs1_c09 naa= 3 ULMN 3 1xs1_c10 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 E 124 ALA B 32 ALA~? 12.87 CL CL D 145 E 126 ARG D 134 ARG~? 13.66 CL CL D 145 E 138 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo -4.56 10.03 62.36 -4.38 11.31 61.55 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo -3.02 12.00 70.07 -1.94 13.84 67.82 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -8.67 12.22 56.54 -8.68 12.09 58.65 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 1xs1_c10 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 1 hits 1xs1_c10 naa= 3 ULMN 3 1xs1_c11 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASEuser 1 3 # 1 F 124 ALA B 32 ALA~? 12.87 CL CL D 145 F 126 ARG D 134 ARG~? 13.66 CL CL D 145 F 138 GLU B 37 GLU^? 13.18 C3 EPE A 145 coo -11.15 -1.53 62.85 -12.44 -2.03 62.23 -12.85 -17.44 -24.50 -12.99 -18.93 -24.73 coo -13.16 -0.52 70.77 -15.41 -0.40 68.66 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -11.26 -6.31 57.37 -11.02 -6.31 59.47 -11.58 -17.61 -15.54 -10.83 -17.36 -13.54 1xs1_c11 source 1xs1 DEOXYCYTIDINE TRIPHOSPHATE DEAMINASE : 1 hits 1xs1_c11 naa= 3 ULMN 3 1xva_c03 GLYCINE N-METHYLTRANSFERASE user 1 3 # 1 B 137 GLY B 97 GLY.? 16.18 CL CL D 145 B 175 ARG D 134 ARG~? 13.66 CL CL D 145 B 242 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 99.45 58.28 3.33 99.57 58.61 4.10 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo 106.37 63.53 0.89 108.02 63.40 -1.62 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 100.93 69.04 4.38 99.52 68.48 2.09 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 1xva_c03 source 1xva GLYCINE N-METHYLTRANSFERASE : 1 hits 1xva_c03 naa= 3 ULMN 3 1ybv_c00 TRIHYDROXYNAPHTHALENE REDUCTASE user 1 3 # 1 A 164 SER A 10 SER^? 8.69 O1S EPE A 145 A 178 TYR A 36 TYR.? 11.29 O1S EPE A 145 A 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 81.46 10.53 21.66 82.20 10.82 19.39 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 87.67 8.69 17.10 86.62 10.83 18.52 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 85.30 6.17 22.83 87.26 11.02 23.50 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1ybv_c00 TRIHYDROXYNAPHTHALENE REDUCTASE user 2 3 # 2 A 164 SER B 10 SER^? 8.49 O2S EPE A 145 A 178 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 81.46 10.53 21.66 82.20 10.82 19.39 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 87.67 8.69 17.10 86.62 10.83 18.52 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 85.30 6.17 22.83 87.26 11.02 23.50 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ybv_c00 TRIHYDROXYNAPHTHALENE REDUCTASE user 3 3 # 3 A 164 SER C 10 SER^? 8.67 O1S EPE A 145 A 178 TYR C 36 TYR.? 11.46 O2S EPE A 145 A 182 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 81.46 10.53 21.66 82.20 10.82 19.39 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 87.67 8.69 17.10 86.62 10.83 18.52 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 85.30 6.17 22.83 87.26 11.02 23.50 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ybv_c00 TRIHYDROXYNAPHTHALENE REDUCTASE user 4 3 # 4 A 164 SER D 10 SER^? 8.71 O3S EPE D 146 A 178 TYR D 36 TYR.? 11.19 O3S EPE D 146 A 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 81.46 10.53 21.66 82.20 10.82 19.39 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 87.67 8.69 17.10 86.62 10.83 18.52 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 85.30 6.17 22.83 87.26 11.02 23.50 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1ybv_c00 source 1ybv TRIHYDROXYNAPHTHALENE REDUCTASE : 4 hits 1ybv_c00 naa= 3 ULMN 3 1ybv_c01 TRIHYDROXYNAPHTHALENE REDUCTASE user 1 3 # 1 B 164 SER A 10 SER^? 8.69 O1S EPE A 145 B 178 TYR A 36 TYR.? 11.29 O1S EPE A 145 B 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 61.22 3.61 34.51 60.46 1.86 35.98 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo 54.99 -1.20 35.40 56.04 1.15 36.44 -29.01 2.19 -12.61 -28.81 1.03 -10.05 coo 57.40 2.23 30.19 55.43 5.44 33.87 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 1ybv_c01 TRIHYDROXYNAPHTHALENE REDUCTASE user 2 3 # 2 B 164 SER B 10 SER^? 8.49 O2S EPE A 145 B 178 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 61.22 3.61 34.51 60.46 1.86 35.98 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo 54.99 -1.20 35.40 56.04 1.15 36.44 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 57.40 2.23 30.19 55.43 5.44 33.87 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 1ybv_c01 TRIHYDROXYNAPHTHALENE REDUCTASE user 3 3 # 3 B 164 SER C 10 SER^? 8.67 O1S EPE A 145 B 178 TYR C 36 TYR.? 11.46 O2S EPE A 145 B 182 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 61.22 3.61 34.51 60.46 1.86 35.98 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo 54.99 -1.20 35.40 56.04 1.15 36.44 -21.57 -14.90 -0.19 -19.53 -15.50 -1.96 coo 57.40 2.23 30.19 55.43 5.44 33.87 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 1ybv_c01 TRIHYDROXYNAPHTHALENE REDUCTASE user 4 3 # 4 B 164 SER D 10 SER^? 8.71 O3S EPE D 146 B 178 TYR D 36 TYR.? 11.19 O3S EPE D 146 B 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 61.22 3.61 34.51 60.46 1.86 35.98 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo 54.99 -1.20 35.40 56.04 1.15 36.44 5.96 -11.60 -26.95 7.30 -9.17 -26.45 coo 57.40 2.23 30.19 55.43 5.44 33.87 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 1ybv_c01 source 1ybv TRIHYDROXYNAPHTHALENE REDUCTASE : 4 hits 1ybv_c01 naa= 3 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 A 14 LYS A 94 LYS.? 20.29 CL CL D 145 A 74 LYS A 100 LYS^? 18.99 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 18.28 7.83 36.39 22.82 8.75 39.52 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 14.16 13.09 37.03 20.00 12.44 37.49 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 22.22 16.06 48.76 23.94 15.33 49.78 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 A 14 LYS A 100 LYS^? 18.99 CL CL D 145 A 74 LYS A 94 LYS.? 20.29 CL CL D 145 A 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 18.28 7.83 36.39 22.82 8.75 39.52 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 14.16 13.09 37.03 20.00 12.44 37.49 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 22.22 16.06 48.76 23.94 15.33 49.78 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 A 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 18.28 7.83 36.39 22.82 8.75 39.52 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 14.16 13.09 37.03 20.00 12.44 37.49 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 22.22 16.06 48.76 23.94 15.33 49.78 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 A 14 LYS B 77 LYS.? 21.17 CL CL D 145 A 74 LYS B 82 LYS.? 24.10 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 18.28 7.83 36.39 22.82 8.75 39.52 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 14.16 13.09 37.03 20.00 12.44 37.49 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 22.22 16.06 48.76 23.94 15.33 49.78 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 A 14 LYS B 82 LYS.? 24.10 CL CL D 145 A 74 LYS B 77 LYS.? 21.17 CL CL D 145 A 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 18.28 7.83 36.39 22.82 8.75 39.52 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 14.16 13.09 37.03 20.00 12.44 37.49 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 22.22 16.06 48.76 23.94 15.33 49.78 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 A 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 18.28 7.83 36.39 22.82 8.75 39.52 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 14.16 13.09 37.03 20.00 12.44 37.49 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 22.22 16.06 48.76 23.94 15.33 49.78 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 18.28 7.83 36.39 22.82 8.75 39.52 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 14.16 13.09 37.03 20.00 12.44 37.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 22.22 16.06 48.76 23.94 15.33 49.78 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 8 3 # 8 A 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 A 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 A 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 18.28 7.83 36.39 22.82 8.75 39.52 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 14.16 13.09 37.03 20.00 12.44 37.49 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 22.22 16.06 48.76 23.94 15.33 49.78 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1ylu_c00 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 9 3 # 9 A 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 18.28 7.83 36.39 22.82 8.75 39.52 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 14.16 13.09 37.03 20.00 12.44 37.49 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 22.22 16.06 48.76 23.94 15.33 49.78 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1ylu_c00 source 1ylu OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 9 hits 1ylu_c00 naa= 3 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 1 3 # 1 B 14 LYS A 94 LYS.? 20.29 CL CL D 145 B 74 LYS A 100 LYS^? 18.99 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 13.51 0.92 76.10 12.98 6.13 74.68 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 21.39 11.56 68.52 20.24 13.13 67.73 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 2 3 # 2 B 14 LYS A 100 LYS^? 18.99 CL CL D 145 B 74 LYS A 94 LYS.? 20.29 CL CL D 145 B 165 GLU A 120 GLU.? 23.98 CL CL D 145 coo 13.51 0.92 76.10 12.98 6.13 74.68 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -34.52 6.28 -23.57 -33.07 3.91 -28.88 coo 21.39 11.56 68.52 20.24 13.13 67.73 -38.38 3.21 -36.38 -37.30 3.13 -38.22 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 3 3 # 3 B 14 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 74 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 165 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 13.51 0.92 76.10 12.98 6.13 74.68 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 21.39 11.56 68.52 20.24 13.13 67.73 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 4 3 # 4 B 14 LYS B 77 LYS.? 21.17 CL CL D 145 B 74 LYS B 82 LYS.? 24.10 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 13.51 0.92 76.10 12.98 6.13 74.68 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 21.39 11.56 68.52 20.24 13.13 67.73 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 5 3 # 5 B 14 LYS B 82 LYS.? 24.10 CL CL D 145 B 74 LYS B 77 LYS.? 21.17 CL CL D 145 B 165 GLU D 109 GLU~? 11.50 CL CL D 145 coo 13.51 0.92 76.10 12.98 6.13 74.68 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 21.39 11.56 68.52 20.24 13.13 67.73 -20.62 -12.50 -43.53 -21.76 -11.35 -42.18 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 6 3 # 6 B 14 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 74 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 13.51 0.92 76.10 12.98 6.13 74.68 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 21.39 11.56 68.52 20.24 13.13 67.73 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 7 3 # 7 B 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 165 GLU B 120 GLU.? 30.33 CL CL A 144 coo 13.51 0.92 76.10 12.98 6.13 74.68 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 21.39 11.56 68.52 20.24 13.13 67.73 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 8 3 # 8 B 14 LYS B 100 LYS^? 21.03 O3S EPE A 145 B 74 LYS B 94 LYS.? 22.75 O3S EPE A 145 B 165 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 13.51 0.92 76.10 12.98 6.13 74.68 -13.57 -24.59 -16.58 -9.34 -25.78 -16.57 coo 19.89 -0.55 76.51 17.10 4.32 77.43 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 coo 21.39 11.56 68.52 20.24 13.13 67.73 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 1ylu_c01 OXYGEN-INSENSITIVE NAD(P)H NITROREDUuser 9 3 # 9 B 14 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 74 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 165 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 13.51 0.92 76.10 12.98 6.13 74.68 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 19.89 -0.55 76.51 17.10 4.32 77.43 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 21.39 11.56 68.52 20.24 13.13 67.73 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 1ylu_c01 source 1ylu OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE : 9 hits 1ylu_c01 naa= 3 ULMN 3 1zrz_c02 PROTEIN KINASE C, IOTA user 1 3 # 1 A 369 ASP A 64 ASP~? 16.08 CL CL A 144 A 371 LYS A 20 LYS~? 9.88 CL CL A 144 A 407 THR A 17 THR~? 16.13 CL CL A 144 coo -5.17 31.09 15.73 -7.07 31.12 16.73 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -4.43 30.92 22.89 -6.61 31.91 19.71 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 coo -8.38 36.02 19.06 -8.83 34.10 19.89 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 ULMN 3 1zrz_c02 PROTEIN KINASE C, IOTA user 2 3 # 2 A 369 ASP B 64 ASP~? 15.96 CL CL A 144 A 371 LYS B 20 LYS~? 9.95 CL CL A 144 A 407 THR B 17 THR~? 16.02 CL CL A 144 coo -5.17 31.09 15.73 -7.07 31.12 16.73 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -4.43 30.92 22.89 -6.61 31.91 19.71 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 coo -8.38 36.02 19.06 -8.83 34.10 19.89 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 ULMN 3 1zrz_c02 PROTEIN KINASE C, IOTA user 3 3 # 3 A 369 ASP C 64 ASP~? 15.91 CL CL A 144 A 371 LYS C 20 LYS~? 9.96 CL CL A 144 A 407 THR C 17 THR~? 16.03 CL CL A 144 coo -5.17 31.09 15.73 -7.07 31.12 16.73 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -4.43 30.92 22.89 -6.61 31.91 19.71 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 coo -8.38 36.02 19.06 -8.83 34.10 19.89 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 1zrz_c02 source 1zrz PROTEIN KINASE C, IOTA : 3 hits 1zrz_c02 naa= 3 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 1 3 # 1 B 29 HIS A 87 HIS.? 23.42 CL CL A 144 B 50 GLU A 95 GLU.? 27.70 O1S EPE A 145 B 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 2 3 # 2 B 29 HIS A 87 HIS.? 23.42 CL CL A 144 B 50 GLU A 120 GLU.? 23.98 CL CL D 145 B 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 3 3 # 3 B 29 HIS B 87 HIS.? 23.18 CL CL D 145 B 50 GLU B 120 GLU.? 30.33 CL CL A 144 B 113 GLN B 88 GLN.? 21.63 CL CL D 145 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -19.43 -30.24 -31.08 -20.08 -30.64 -33.11 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 4 3 # 4 B 29 HIS C 87 HIS.? 23.40 CL CL A 144 B 50 GLU C 95 GLU.? 27.59 O2S EPE A 145 B 113 GLN C 88 GLN.? 26.49 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 2ag0_c04 BENZALDEHYDE LYASE user 5 3 # 5 B 29 HIS D 87 HIS.? 23.22 CL CL D 144 B 50 GLU D 95 GLU.? 27.71 O3S EPE D 146 B 113 GLN D 88 GLN.? 26.72 CL CL D 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 3.99 -26.89 -34.16 4.97 -27.71 -35.94 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 6.01 -23.47 -44.11 7.56 -24.08 -45.47 2ag0_c04 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c04 naa= 3 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 1 3 # 1 B 29 HIS A 87 HIS.? 23.42 CL CL A 144 B 50 GLU A 95 GLU.? 27.70 O1S EPE A 145 B 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 2 3 # 2 B 29 HIS A 87 HIS.? 23.42 CL CL A 144 B 50 GLU A 120 GLU.? 23.98 CL CL D 145 B 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 3 3 # 3 B 29 HIS B 87 HIS.? 23.18 CL CL D 145 B 50 GLU B 120 GLU.? 30.33 CL CL A 144 B 113 GLN B 88 GLN.? 21.63 CL CL D 145 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -19.43 -30.24 -31.08 -20.08 -30.64 -33.11 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 4 3 # 4 B 29 HIS C 87 HIS.? 23.40 CL CL A 144 B 50 GLU C 95 GLU.? 27.59 O2S EPE A 145 B 113 GLN C 88 GLN.? 26.49 CL CL A 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 2ag0_c08 BENZALDEHYDE LYASE user 5 3 # 5 B 29 HIS D 87 HIS.? 23.22 CL CL D 144 B 50 GLU D 95 GLU.? 27.71 O3S EPE D 146 B 113 GLN D 88 GLN.? 26.72 CL CL D 144 coo 37.74 -17.01 11.59 38.11 -17.83 13.49 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 46.64 -18.37 3.41 46.45 -20.27 4.34 3.99 -26.89 -34.16 4.97 -27.71 -35.94 coo 42.38 -20.40 13.90 41.08 -20.72 12.22 6.01 -23.47 -44.11 7.56 -24.08 -45.47 2ag0_c08 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c08 naa= 3 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 1 3 # 1 A 29 HIS A 87 HIS.? 23.42 CL CL A 144 A 50 GLU A 95 GLU.? 27.70 O1S EPE A 145 A 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 2 3 # 2 A 29 HIS A 87 HIS.? 23.42 CL CL A 144 A 50 GLU A 120 GLU.? 23.98 CL CL D 145 A 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 3 3 # 3 A 29 HIS B 87 HIS.? 23.18 CL CL D 145 A 50 GLU B 120 GLU.? 30.33 CL CL A 144 A 113 GLN B 88 GLN.? 21.63 CL CL D 145 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -19.43 -30.24 -31.08 -20.08 -30.64 -33.11 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 4 3 # 4 A 29 HIS C 87 HIS.? 23.40 CL CL A 144 A 50 GLU C 95 GLU.? 27.59 O2S EPE A 145 A 113 GLN C 88 GLN.? 26.49 CL CL A 144 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 2ag0_c09 BENZALDEHYDE LYASE user 5 3 # 5 A 29 HIS D 87 HIS.? 23.22 CL CL D 144 A 50 GLU D 95 GLU.? 27.71 O3S EPE D 146 A 113 GLN D 88 GLN.? 26.72 CL CL D 144 coo 73.37 -13.43 4.64 73.06 -11.77 3.39 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 63.97 -21.08 5.81 64.12 -20.78 3.71 3.99 -26.89 -34.16 4.97 -27.71 -35.94 coo 68.60 -11.76 1.04 69.76 -13.55 1.03 6.01 -23.47 -44.11 7.56 -24.08 -45.47 2ag0_c09 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c09 naa= 3 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 1 3 # 1 C 29 HIS A 87 HIS.? 23.42 CL CL A 144 C 50 GLU A 95 GLU.? 27.70 O1S EPE A 145 C 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 74.92 8.52 28.42 74.88 6.86 29.70 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 65.25 15.95 28.73 65.73 15.63 30.78 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 70.80 6.73 32.72 71.88 8.55 32.53 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 2 3 # 2 C 29 HIS A 87 HIS.? 23.42 CL CL A 144 C 50 GLU A 120 GLU.? 23.98 CL CL D 145 C 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 74.92 8.52 28.42 74.88 6.86 29.70 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 65.25 15.95 28.73 65.73 15.63 30.78 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 70.80 6.73 32.72 71.88 8.55 32.53 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 3 3 # 3 C 29 HIS B 87 HIS.? 23.18 CL CL D 145 C 50 GLU B 120 GLU.? 30.33 CL CL A 144 C 113 GLN B 88 GLN.? 21.63 CL CL D 145 coo 74.92 8.52 28.42 74.88 6.86 29.70 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 65.25 15.95 28.73 65.73 15.63 30.78 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 70.80 6.73 32.72 71.88 8.55 32.53 -19.43 -30.24 -31.08 -20.08 -30.64 -33.11 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 4 3 # 4 C 29 HIS C 87 HIS.? 23.40 CL CL A 144 C 50 GLU C 95 GLU.? 27.59 O2S EPE A 145 C 113 GLN C 88 GLN.? 26.49 CL CL A 144 coo 74.92 8.52 28.42 74.88 6.86 29.70 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 65.25 15.95 28.73 65.73 15.63 30.78 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 70.80 6.73 32.72 71.88 8.55 32.53 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 2ag0_c10 BENZALDEHYDE LYASE user 5 3 # 5 C 29 HIS D 87 HIS.? 23.22 CL CL D 144 C 50 GLU D 95 GLU.? 27.71 O3S EPE D 146 C 113 GLN D 88 GLN.? 26.72 CL CL D 144 coo 74.92 8.52 28.42 74.88 6.86 29.70 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 65.25 15.95 28.73 65.73 15.63 30.78 3.99 -26.89 -34.16 4.97 -27.71 -35.94 coo 70.80 6.73 32.72 71.88 8.55 32.53 6.01 -23.47 -44.11 7.56 -24.08 -45.47 2ag0_c10 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c10 naa= 3 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 1 3 # 1 D 29 HIS A 87 HIS.? 23.42 CL CL A 144 D 50 GLU A 95 GLU.? 27.70 O1S EPE A 145 D 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 38.66 11.31 27.15 38.67 12.13 25.22 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 48.72 12.85 33.83 48.36 14.77 32.95 -38.05 9.59 -25.22 -40.20 9.68 -25.46 coo 42.85 14.77 24.15 41.85 15.11 26.02 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 2 3 # 2 D 29 HIS A 87 HIS.? 23.42 CL CL A 144 D 50 GLU A 120 GLU.? 23.98 CL CL D 145 D 113 GLN A 88 GLN.? 26.71 CL CL A 144 coo 38.66 11.31 27.15 38.67 12.13 25.22 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 48.72 12.85 33.83 48.36 14.77 32.95 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 42.85 14.77 24.15 41.85 15.11 26.02 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 3 3 # 3 D 29 HIS B 87 HIS.? 23.18 CL CL D 145 D 50 GLU B 120 GLU.? 30.33 CL CL A 144 D 113 GLN B 88 GLN.? 21.63 CL CL D 145 coo 38.66 11.31 27.15 38.67 12.13 25.22 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 48.72 12.85 33.83 48.36 14.77 32.95 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 42.85 14.77 24.15 41.85 15.11 26.02 -19.43 -30.24 -31.08 -20.08 -30.64 -33.11 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 4 3 # 4 D 29 HIS C 87 HIS.? 23.40 CL CL A 144 D 50 GLU C 95 GLU.? 27.59 O2S EPE A 145 D 113 GLN C 88 GLN.? 26.49 CL CL A 144 coo 38.66 11.31 27.15 38.67 12.13 25.22 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 48.72 12.85 33.83 48.36 14.77 32.95 -33.39 -18.53 11.57 -34.39 -20.35 12.06 coo 42.85 14.77 24.15 41.85 15.11 26.02 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 2ag0_c11 BENZALDEHYDE LYASE user 5 3 # 5 D 29 HIS D 87 HIS.? 23.22 CL CL D 144 D 50 GLU D 95 GLU.? 27.71 O3S EPE D 146 D 113 GLN D 88 GLN.? 26.72 CL CL D 144 coo 38.66 11.31 27.15 38.67 12.13 25.22 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 48.72 12.85 33.83 48.36 14.77 32.95 3.99 -26.89 -34.16 4.97 -27.71 -35.94 coo 42.85 14.77 24.15 41.85 15.11 26.02 6.01 -23.47 -44.11 7.56 -24.08 -45.47 2ag0_c11 source 2ag0 BENZALDEHYDE LYASE : 5 hits 2ag0_c11 naa= 3 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 1 3 # 1 193 ASP A 64 ASP~? 16.08 CL CL A 144 231 ASP C 117 ASP~? 29.23 CL CL A 144 294 ASP C 64 ASP~? 15.91 CL CL A 144 coo 27.89 102.52 14.98 29.35 101.92 13.57 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -51.47 -11.37 0.99 -53.36 -10.39 1.01 coo 33.16 106.80 7.72 33.34 104.87 6.92 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 2 3 # 2 193 ASP B 64 ASP~? 15.96 CL CL A 144 231 ASP A 117 ASP~? 21.56 CL CL D 145 294 ASP A 64 ASP~? 16.08 CL CL A 144 coo 27.89 102.52 14.98 29.35 101.92 13.57 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -36.85 -7.00 -40.01 -36.64 -7.71 -42.00 coo 33.16 106.80 7.72 33.34 104.87 6.92 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 ULMN 3 2amg_c06 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLAuser 3 3 # 3 193 ASP C 64 ASP~? 15.91 CL CL A 144 231 ASP B 117 ASP~? 29.07 CL CL A 144 294 ASP B 64 ASP~? 15.96 CL CL A 144 coo 27.89 102.52 14.98 29.35 101.92 13.57 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 14.74 93.05 -1.00 14.30 94.22 0.73 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo 33.16 106.80 7.72 33.34 104.87 6.92 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 2amg_c06 source 2amg 1,4-ALPHA-D-GLUCAN MALTOTETRAHYDROLASE : 3 hits 2amg_c06 naa= 3 ULMN 3 2apr_c04 ACID PROTEINASE (RHIZOPUSPEPSIN) (E.user 1 3 # 1 35 ASP D 133 ASP~? 7.85 CL CL D 145 38 SER B 34 SER~? 6.65 CL CL D 145 218 ASP A 133 ASP~? 7.97 CL CL D 145 coo 41.14 58.72 105.19 42.39 59.85 103.92 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 46.04 57.35 103.96 44.97 58.52 105.78 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 41.33 60.20 97.63 42.00 60.96 99.49 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 2apr_c04 source 2apr ACID PROTEINASE (RHIZOPUSPEPSIN) (E.C.3.4.23.6: 1 hits 2apr_c04 naa= 3 ULMN 3 2c7v_c08 PTERIDINE REDUCTASE user 1 3 # 1 A 14 ARG A 134 ARG~? 13.60 CL CL D 145 A 161 ASP D 133 ASP~? 7.85 CL CL D 145 A 174 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 14.43 -13.26 8.40 11.75 -14.25 9.60 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo 3.82 -4.94 15.61 3.37 -6.97 16.02 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 8.61 -7.11 20.41 7.51 -6.92 17.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 2c7v_c08 source 2c7v PTERIDINE REDUCTASE : 1 hits 2c7v_c08 naa= 3 ULMN 3 2c7v_c09 PTERIDINE REDUCTASE user 1 3 # 1 B 14 ARG A 134 ARG~? 13.60 CL CL D 145 B 161 ASP D 133 ASP~? 7.85 CL CL D 145 B 174 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo -18.34 17.48 -4.91 -16.98 18.69 -2.39 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo -14.86 10.19 8.14 -14.82 12.31 8.42 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -21.46 12.70 8.53 -19.04 12.30 7.24 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 2c7v_c09 source 2c7v PTERIDINE REDUCTASE : 1 hits 2c7v_c09 naa= 3 ULMN 3 2c7v_c10 PTERIDINE REDUCTASE user 1 3 # 1 C 14 ARG A 134 ARG~? 13.60 CL CL D 145 C 161 ASP D 133 ASP~? 7.85 CL CL D 145 C 174 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 2.84 19.43 40.34 1.59 20.35 37.65 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo -0.62 11.10 28.05 -0.65 13.15 27.46 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 5.94 13.28 27.17 3.53 13.05 28.58 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 2c7v_c10 source 2c7v PTERIDINE REDUCTASE : 1 hits 2c7v_c10 naa= 3 ULMN 3 2c7v_c11 PTERIDINE REDUCTASE user 1 3 # 1 D 14 ARG A 134 ARG~? 13.60 CL CL D 145 D 161 ASP D 133 ASP~? 7.85 CL CL D 145 D 174 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo -30.56 -11.62 29.88 -27.98 -12.86 28.66 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo -19.83 -4.38 21.99 -19.35 -6.45 21.76 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -24.51 -6.92 17.31 -23.48 -6.50 19.84 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 2c7v_c11 source 2c7v PTERIDINE REDUCTASE : 1 hits 2c7v_c11 naa= 3 ULMN 3 2cnd_c01 NADH-DEPENDENT NITRATE REDUCTASE (CYuser 1 3 # 1 65 THR B 130 THR~? 17.10 O2S EPE A 145 242 CYH B 104 CYH^? 16.50 CL CL A 144 270 PHE B 41 PHE^? 12.26 O2S EPE A 145 coo 12.97 28.35 3.84 11.81 28.07 2.09 -17.23 -22.87 -4.50 -16.07 -24.66 -4.52 coo 8.65 19.49 -2.27 10.50 20.91 -0.59 -23.20 -29.24 -9.27 -25.51 -28.44 -7.91 coo 9.41 24.60 -3.66 7.52 26.57 -4.16 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 ULMN 3 2cnd_c01 NADH-DEPENDENT NITRATE REDUCTASE (CYuser 2 3 # 2 65 THR C 130 THR~? 17.24 O1S EPE A 145 242 CYH C 104 CYH^? 16.50 CL CL A 144 270 PHE C 41 PHE^? 13.95 CL CL A 144 coo 12.97 28.35 3.84 11.81 28.07 2.09 -33.96 0.15 -4.28 -35.19 0.92 -2.69 coo 8.65 19.49 -2.27 10.50 20.91 -0.59 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 coo 9.41 24.60 -3.66 7.52 26.57 -4.16 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 2cnd_c01 source 2cnd NADH-DEPENDENT NITRATE REDUCTASE (CYTOCHROME B: 2 hits 2cnd_c01 naa= 3 ULMN 3 2dbt_c00 CHITINASE C user 1 3 # 1 A 147 GLU B 120 GLU.? 30.33 CL CL A 144 A 156 GLU B 116 GLU~? 31.41 CL CL A 144 A 194 ASN B 56 ASN~? 29.95 CL CL A 144 coo 74.14 15.91 8.55 72.08 15.36 8.63 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 67.47 20.07 1.34 65.99 20.06 2.88 -19.55 -43.74 -13.26 -19.51 -43.52 -11.15 coo 67.44 25.26 13.91 67.54 23.65 15.28 -24.41 -40.76 -26.59 -22.33 -40.56 -26.21 2dbt_c00 source 2dbt CHITINASE C : 1 hits 2dbt_c00 naa= 3 ULMN 3 2dbt_c01 CHITINASE C user 1 3 # 1 B 147 GLU B 116 GLU~? 31.41 CL CL A 144 B 156 GLU B 120 GLU.? 30.33 CL CL A 144 B 194 ASN B 56 ASN~? 29.95 CL CL A 144 coo 45.64 63.11 17.20 47.48 62.43 16.45 -19.55 -43.74 -13.26 -19.51 -43.52 -11.15 coo 54.43 67.89 19.82 55.62 67.90 18.07 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 49.79 70.75 7.78 50.10 68.90 6.86 -24.41 -40.76 -26.59 -22.33 -40.56 -26.21 ULMN 3 2dbt_c01 CHITINASE C user 2 3 # 2 B 147 GLU B 120 GLU.? 30.33 CL CL A 144 B 156 GLU B 116 GLU~? 31.41 CL CL A 144 B 194 ASN B 56 ASN~? 29.95 CL CL A 144 coo 45.64 63.11 17.20 47.48 62.43 16.45 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 54.43 67.89 19.82 55.62 67.90 18.07 -19.55 -43.74 -13.26 -19.51 -43.52 -11.15 coo 49.79 70.75 7.78 50.10 68.90 6.86 -24.41 -40.76 -26.59 -22.33 -40.56 -26.21 2dbt_c01 source 2dbt CHITINASE C : 2 hits 2dbt_c01 naa= 3 ULMN 3 2dbt_c02 CHITINASE C user 1 3 # 1 C 147 GLU B 120 GLU.? 30.33 CL CL A 144 C 156 GLU B 116 GLU~? 31.41 CL CL A 144 C 194 ASN B 56 ASN~? 29.95 CL CL A 144 coo 41.23 29.31 13.28 43.03 29.85 12.29 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 44.75 23.09 5.51 46.77 22.91 6.12 -19.55 -43.74 -13.26 -19.51 -43.52 -11.15 coo 49.75 21.00 18.12 50.45 23.02 18.26 -24.41 -40.76 -26.59 -22.33 -40.56 -26.21 2dbt_c02 source 2dbt CHITINASE C : 1 hits 2dbt_c02 naa= 3 ULMN 3 2dw7_c32 BLL6730 PROTEIN user 1 3 # 1 A 182 LYS A 65 LYS~? 24.48 CL CL A 144 A 184 LYS B 65 LYS~? 24.78 CL CL A 144 A 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 5.98 42.76 7.73 10.19 38.62 9.02 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 2.77 37.17 4.99 6.33 34.76 8.06 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 0.07 40.30 18.65 -0.21 42.34 18.18 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c32 BLL6730 PROTEIN user 2 3 # 2 A 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 5.98 42.76 7.73 10.19 38.62 9.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 2.77 37.17 4.99 6.33 34.76 8.06 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 0.07 40.30 18.65 -0.21 42.34 18.18 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c32 BLL6730 PROTEIN user 3 3 # 3 A 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 A 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 5.98 42.76 7.73 10.19 38.62 9.02 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 2.77 37.17 4.99 6.33 34.76 8.06 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 0.07 40.30 18.65 -0.21 42.34 18.18 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c32 BLL6730 PROTEIN user 4 3 # 4 A 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 A 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 A 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 5.98 42.76 7.73 10.19 38.62 9.02 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 2.77 37.17 4.99 6.33 34.76 8.06 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 0.07 40.30 18.65 -0.21 42.34 18.18 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c32 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c32 naa= 3 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 1 3 # 1 B 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 B 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 B 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 38.76 2.27 4.00 34.00 5.99 4.37 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 40.63 7.13 9.06 35.85 7.36 8.95 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 2 3 # 2 B 182 LYS A 65 LYS~? 24.48 CL CL A 144 B 184 LYS B 65 LYS~? 24.78 CL CL A 144 B 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 38.76 2.27 4.00 34.00 5.99 4.37 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 40.63 7.13 9.06 35.85 7.36 8.95 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 3 3 # 3 B 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 B 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 B 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 38.76 2.27 4.00 34.00 5.99 4.37 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 40.63 7.13 9.06 35.85 7.36 8.95 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 4 3 # 4 B 182 LYS B 65 LYS~? 24.78 CL CL A 144 B 184 LYS A 65 LYS~? 24.48 CL CL A 144 B 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 38.76 2.27 4.00 34.00 5.99 4.37 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 40.63 7.13 9.06 35.85 7.36 8.95 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 5 3 # 5 B 182 LYS B 77 LYS.? 21.17 CL CL D 145 B 184 LYS B 82 LYS.? 24.10 CL CL D 145 B 345 ASP B 19 ASP~? 15.75 CL CL A 144 coo 38.76 2.27 4.00 34.00 5.99 4.37 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 40.63 7.13 9.06 35.85 7.36 8.95 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 ULMN 3 2dw7_c33 BLL6730 PROTEIN user 6 3 # 6 B 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 B 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 B 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 38.76 2.27 4.00 34.00 5.99 4.37 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 40.63 7.13 9.06 35.85 7.36 8.95 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 34.36 -6.33 13.69 36.02 -6.07 12.41 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c33 source 2dw7 BLL6730 PROTEIN : 6 hits 2dw7_c33 naa= 3 ULMN 3 2dw7_c34 BLL6730 PROTEIN user 1 3 # 1 C 182 LYS A 65 LYS~? 24.48 CL CL A 144 C 184 LYS B 65 LYS~? 24.78 CL CL A 144 C 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo -5.66 12.40 71.13 -2.66 9.98 66.50 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 0.95 12.72 73.51 1.58 12.72 68.31 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -4.59 24.28 66.67 -6.26 24.34 67.99 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c34 BLL6730 PROTEIN user 2 3 # 2 C 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 C 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 C 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo -5.66 12.40 71.13 -2.66 9.98 66.50 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 0.95 12.72 73.51 1.58 12.72 68.31 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -4.59 24.28 66.67 -6.26 24.34 67.99 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c34 BLL6730 PROTEIN user 3 3 # 3 C 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 C 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 C 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo -5.66 12.40 71.13 -2.66 9.98 66.50 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 0.95 12.72 73.51 1.58 12.72 68.31 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -4.59 24.28 66.67 -6.26 24.34 67.99 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c34 BLL6730 PROTEIN user 4 3 # 4 C 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 C 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 C 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo -5.66 12.40 71.13 -2.66 9.98 66.50 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 0.95 12.72 73.51 1.58 12.72 68.31 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -4.59 24.28 66.67 -6.26 24.34 67.99 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c34 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c34 naa= 3 ULMN 3 2dw7_c35 BLL6730 PROTEIN user 1 3 # 1 D 182 LYS A 65 LYS~? 24.48 CL CL A 144 D 184 LYS B 65 LYS~? 24.78 CL CL A 144 D 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 29.31 -12.29 40.88 26.50 -8.82 44.94 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 23.25 -10.73 37.68 24.08 -6.91 41.08 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 35.01 -2.71 35.14 36.51 -4.14 34.87 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c35 BLL6730 PROTEIN user 2 3 # 2 D 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 D 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 D 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 29.31 -12.29 40.88 26.50 -8.82 44.94 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 23.25 -10.73 37.68 24.08 -6.91 41.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 35.01 -2.71 35.14 36.51 -4.14 34.87 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c35 BLL6730 PROTEIN user 3 3 # 3 D 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 D 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 D 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 29.31 -12.29 40.88 26.50 -8.82 44.94 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 23.25 -10.73 37.68 24.08 -6.91 41.08 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 35.01 -2.71 35.14 36.51 -4.14 34.87 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c35 BLL6730 PROTEIN user 4 3 # 4 D 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 D 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 D 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 29.31 -12.29 40.88 26.50 -8.82 44.94 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 23.25 -10.73 37.68 24.08 -6.91 41.08 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 35.01 -2.71 35.14 36.51 -4.14 34.87 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c35 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c35 naa= 3 ULMN 3 2dw7_c36 BLL6730 PROTEIN user 1 3 # 1 E 182 LYS A 65 LYS~? 24.48 CL CL A 144 E 184 LYS B 65 LYS~? 24.78 CL CL A 144 E 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo -21.16 62.58 121.86 -16.35 60.33 119.23 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -23.22 55.98 120.74 -18.11 55.31 120.43 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -17.15 59.71 133.33 -17.96 61.54 134.01 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c36 BLL6730 PROTEIN user 2 3 # 2 E 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 E 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 E 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo -21.16 62.58 121.86 -16.35 60.33 119.23 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo -23.22 55.98 120.74 -18.11 55.31 120.43 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -17.15 59.71 133.33 -17.96 61.54 134.01 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c36 BLL6730 PROTEIN user 3 3 # 3 E 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 E 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 E 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo -21.16 62.58 121.86 -16.35 60.33 119.23 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo -23.22 55.98 120.74 -18.11 55.31 120.43 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -17.15 59.71 133.33 -17.96 61.54 134.01 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c36 BLL6730 PROTEIN user 4 3 # 4 E 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 E 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 E 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo -21.16 62.58 121.86 -16.35 60.33 119.23 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo -23.22 55.98 120.74 -18.11 55.31 120.43 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -17.15 59.71 133.33 -17.96 61.54 134.01 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c36 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c36 naa= 3 ULMN 3 2dw7_c37 BLL6730 PROTEIN user 1 3 # 1 F 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 F 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 F 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 10.64 34.02 91.30 6.30 35.60 95.11 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 13.75 39.76 94.12 11.42 37.23 97.89 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 16.35 26.90 99.56 16.81 25.90 97.75 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c37 BLL6730 PROTEIN user 2 3 # 2 F 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 F 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 F 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 10.64 34.02 91.30 6.30 35.60 95.11 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 13.75 39.76 94.12 11.42 37.23 97.89 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 16.35 26.90 99.56 16.81 25.90 97.75 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c37 source 2dw7 BLL6730 PROTEIN : 2 hits 2dw7_c37 naa= 3 ULMN 3 2dw7_c38 BLL6730 PROTEIN user 1 3 # 1 G 182 LYS A 65 LYS~? 24.48 CL CL A 144 G 184 LYS B 65 LYS~? 24.78 CL CL A 144 G 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 39.68 42.04 76.11 43.42 46.43 74.96 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 36.69 47.69 78.93 39.38 50.40 75.35 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 33.43 44.37 65.47 33.10 42.30 65.37 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c38 BLL6730 PROTEIN user 2 3 # 2 G 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 G 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 G 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 39.68 42.04 76.11 43.42 46.43 74.96 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 36.69 47.69 78.93 39.38 50.40 75.35 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 33.43 44.37 65.47 33.10 42.30 65.37 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c38 BLL6730 PROTEIN user 3 3 # 3 G 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 G 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 G 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 39.68 42.04 76.11 43.42 46.43 74.96 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 36.69 47.69 78.93 39.38 50.40 75.35 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 33.43 44.37 65.47 33.10 42.30 65.37 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c38 source 2dw7 BLL6730 PROTEIN : 3 hits 2dw7_c38 naa= 3 ULMN 3 2dw7_c39 BLL6730 PROTEIN user 1 3 # 1 H 182 LYS A 65 LYS~? 24.48 CL CL A 144 H 184 LYS B 65 LYS~? 24.78 CL CL A 144 H 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 71.58 83.18 80.51 66.88 79.77 79.84 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 73.65 78.64 75.66 68.14 79.07 75.04 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 67.43 90.73 71.39 68.27 92.30 72.52 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c39 BLL6730 PROTEIN user 2 3 # 2 H 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 H 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 H 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 71.58 83.18 80.51 66.88 79.77 79.84 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 73.65 78.64 75.66 68.14 79.07 75.04 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 67.43 90.73 71.39 68.27 92.30 72.52 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c39 BLL6730 PROTEIN user 3 3 # 3 H 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 H 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 H 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 71.58 83.18 80.51 66.88 79.77 79.84 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 73.65 78.64 75.66 68.14 79.07 75.04 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 67.43 90.73 71.39 68.27 92.30 72.52 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c39 BLL6730 PROTEIN user 4 3 # 4 H 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 H 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 H 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 71.58 83.18 80.51 66.88 79.77 79.84 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 73.65 78.64 75.66 68.14 79.07 75.04 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 67.43 90.73 71.39 68.27 92.30 72.52 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c39 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c39 naa= 3 ULMN 3 2dw7_c40 BLL6730 PROTEIN user 1 3 # 1 I 182 LYS A 65 LYS~? 24.48 CL CL A 144 I 184 LYS B 65 LYS~? 24.78 CL CL A 144 I 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 60.20 96.92 42.53 57.60 93.13 38.67 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 54.31 95.46 46.01 55.34 91.59 42.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 66.35 87.81 48.53 68.10 89.01 48.77 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c40 BLL6730 PROTEIN user 2 3 # 2 I 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 I 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 I 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 60.20 96.92 42.53 57.60 93.13 38.67 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 54.31 95.46 46.01 55.34 91.59 42.65 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 66.35 87.81 48.53 68.10 89.01 48.77 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c40 BLL6730 PROTEIN user 3 3 # 3 I 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 I 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 I 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 60.20 96.92 42.53 57.60 93.13 38.67 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 54.31 95.46 46.01 55.34 91.59 42.65 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 66.35 87.81 48.53 68.10 89.01 48.77 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c40 BLL6730 PROTEIN user 4 3 # 4 I 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 I 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 I 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 60.20 96.92 42.53 57.60 93.13 38.67 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 54.31 95.46 46.01 55.34 91.59 42.65 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 66.35 87.81 48.53 68.10 89.01 48.77 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c40 source 2dw7 BLL6730 PROTEIN : 4 hits 2dw7_c40 naa= 3 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 1 3 # 1 J 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 J 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 J 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 25.22 70.55 14.03 27.64 73.07 18.65 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 31.73 69.87 11.50 32.73 70.19 16.40 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 25.87 58.42 18.79 23.95 58.54 17.90 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 2 3 # 2 J 182 LYS A 65 LYS~? 24.48 CL CL A 144 J 184 LYS B 65 LYS~? 24.78 CL CL A 144 J 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 25.22 70.55 14.03 27.64 73.07 18.65 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 31.73 69.87 11.50 32.73 70.19 16.40 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 25.87 58.42 18.79 23.95 58.54 17.90 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 3 3 # 3 J 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 J 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 J 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 25.22 70.55 14.03 27.64 73.07 18.65 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 31.73 69.87 11.50 32.73 70.19 16.40 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 25.87 58.42 18.79 23.95 58.54 17.90 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 4 3 # 4 J 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 J 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 J 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 25.22 70.55 14.03 27.64 73.07 18.65 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 31.73 69.87 11.50 32.73 70.19 16.40 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 25.87 58.42 18.79 23.95 58.54 17.90 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 5 3 # 5 J 182 LYS B 65 LYS~? 24.78 CL CL A 144 J 184 LYS A 65 LYS~? 24.48 CL CL A 144 J 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 25.22 70.55 14.03 27.64 73.07 18.65 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 31.73 69.87 11.50 32.73 70.19 16.40 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 25.87 58.42 18.79 23.95 58.54 17.90 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c41 BLL6730 PROTEIN user 6 3 # 6 J 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 J 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 J 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 25.22 70.55 14.03 27.64 73.07 18.65 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 31.73 69.87 11.50 32.73 70.19 16.40 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 25.87 58.42 18.79 23.95 58.54 17.90 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c41 source 2dw7 BLL6730 PROTEIN : 6 hits 2dw7_c41 naa= 3 ULMN 3 2dw7_c42 BLL6730 PROTEIN user 1 3 # 1 K 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 K 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 K 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 51.91 50.98 -7.18 47.83 49.38 -11.15 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 54.95 45.24 -9.88 51.94 46.65 -13.66 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 58.09 58.36 -15.39 58.48 59.93 -14.05 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c42 BLL6730 PROTEIN user 2 3 # 2 K 182 LYS A 65 LYS~? 24.48 CL CL A 144 K 184 LYS B 65 LYS~? 24.78 CL CL A 144 K 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 51.91 50.98 -7.18 47.83 49.38 -11.15 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 54.95 45.24 -9.88 51.94 46.65 -13.66 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 58.09 58.36 -15.39 58.48 59.93 -14.05 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c42 BLL6730 PROTEIN user 3 3 # 3 K 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 K 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 K 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 51.91 50.98 -7.18 47.83 49.38 -11.15 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 54.95 45.24 -9.88 51.94 46.65 -13.66 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 58.09 58.36 -15.39 58.48 59.93 -14.05 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c42 BLL6730 PROTEIN user 4 3 # 4 K 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 K 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 K 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 51.91 50.98 -7.18 47.83 49.38 -11.15 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 54.95 45.24 -9.88 51.94 46.65 -13.66 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 58.09 58.36 -15.39 58.48 59.93 -14.05 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c42 BLL6730 PROTEIN user 5 3 # 5 K 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 K 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 K 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 51.91 50.98 -7.18 47.83 49.38 -11.15 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 54.95 45.24 -9.88 51.94 46.65 -13.66 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 58.09 58.36 -15.39 58.48 59.93 -14.05 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c42 source 2dw7 BLL6730 PROTEIN : 5 hits 2dw7_c42 naa= 3 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 1 3 # 1 L 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 L 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 L 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 2 3 # 2 L 182 LYS A 65 LYS~? 24.48 CL CL A 144 L 184 LYS B 65 LYS~? 24.78 CL CL A 144 L 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 3 3 # 3 L 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 L 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 L 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 4 3 # 4 L 182 LYS B 65 LYS~? 24.78 CL CL A 144 L 184 LYS A 65 LYS~? 24.48 CL CL A 144 L 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 5 3 # 5 L 182 LYS B 77 LYS.? 21.17 CL CL D 145 L 184 LYS B 82 LYS.? 24.10 CL CL D 145 L 345 ASP B 19 ASP~? 15.75 CL CL A 144 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 ULMN 3 2dw7_c43 BLL6730 PROTEIN user 6 3 # 6 L 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 L 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 L 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 20.72 21.86 -37.85 25.46 24.17 -34.95 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 18.47 28.51 -37.00 23.90 28.36 -37.29 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 25.62 23.75 -50.41 24.07 23.21 -49.03 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c43 source 2dw7 BLL6730 PROTEIN : 6 hits 2dw7_c43 naa= 3 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 1 3 # 1 M 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 M 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 M 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 2 3 # 2 M 182 LYS A 65 LYS~? 24.48 CL CL A 144 M 184 LYS B 65 LYS~? 24.78 CL CL A 144 M 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 3 3 # 3 M 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 M 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 M 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 4 3 # 4 M 182 LYS B 65 LYS~? 24.78 CL CL A 144 M 184 LYS A 65 LYS~? 24.48 CL CL A 144 M 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 5 3 # 5 M 182 LYS B 77 LYS.? 21.17 CL CL D 145 M 184 LYS B 82 LYS.? 24.10 CL CL D 145 M 345 ASP B 19 ASP~? 15.75 CL CL A 144 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 ULMN 3 2dw7_c44 BLL6730 PROTEIN user 6 3 # 6 M 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 M 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 M 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo -16.84 -32.78 53.48 -13.51 -32.22 58.34 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo -11.12 -36.54 51.97 -12.06 -36.49 56.95 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo -23.86 -43.59 58.54 -23.60 -42.14 57.00 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c44 source 2dw7 BLL6730 PROTEIN : 6 hits 2dw7_c44 naa= 3 ULMN 3 2dw7_c45 BLL6730 PROTEIN user 1 3 # 1 N 182 LYS B 6 LYS.? 15.05 O8 EPE D 146 N 184 LYS B 8 LYS^? 8.74 C3 EPE A 145 N 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 22.75 -28.13 87.31 18.89 -29.87 83.00 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 16.58 -26.28 90.12 15.40 -29.80 86.61 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 22.32 -38.59 93.74 24.34 -38.41 94.32 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c45 BLL6730 PROTEIN user 2 3 # 2 N 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 N 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 N 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 22.75 -28.13 87.31 18.89 -29.87 83.00 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 16.58 -26.28 90.12 15.40 -29.80 86.61 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 22.32 -38.59 93.74 24.34 -38.41 94.32 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c45 BLL6730 PROTEIN user 3 3 # 3 N 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 N 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 N 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 22.75 -28.13 87.31 18.89 -29.87 83.00 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 16.58 -26.28 90.12 15.40 -29.80 86.61 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 22.32 -38.59 93.74 24.34 -38.41 94.32 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c45 source 2dw7 BLL6730 PROTEIN : 3 hits 2dw7_c45 naa= 3 ULMN 3 2dw7_c46 BLL6730 PROTEIN user 1 3 # 1 O 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 O 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 O 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 54.57 -51.89 -4.22 51.14 -49.62 0.15 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 48.40 -53.90 -6.78 48.57 -49.84 -4.13 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 54.15 -41.12 -10.77 56.24 -41.47 -10.94 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c46 BLL6730 PROTEIN user 2 3 # 2 O 182 LYS A 65 LYS~? 24.48 CL CL A 144 O 184 LYS B 65 LYS~? 24.78 CL CL A 144 O 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 54.57 -51.89 -4.22 51.14 -49.62 0.15 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 48.40 -53.90 -6.78 48.57 -49.84 -4.13 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 54.15 -41.12 -10.77 56.24 -41.47 -10.94 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c46 BLL6730 PROTEIN user 3 3 # 3 O 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 O 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 O 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 54.57 -51.89 -4.22 51.14 -49.62 0.15 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 48.40 -53.90 -6.78 48.57 -49.84 -4.13 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 54.15 -41.12 -10.77 56.24 -41.47 -10.94 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c46 BLL6730 PROTEIN user 4 3 # 4 O 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 O 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 O 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 54.57 -51.89 -4.22 51.14 -49.62 0.15 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 48.40 -53.90 -6.78 48.57 -49.84 -4.13 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 54.15 -41.12 -10.77 56.24 -41.47 -10.94 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c46 BLL6730 PROTEIN user 5 3 # 5 O 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 O 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 O 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 54.57 -51.89 -4.22 51.14 -49.62 0.15 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 48.40 -53.90 -6.78 48.57 -49.84 -4.13 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 54.15 -41.12 -10.77 56.24 -41.47 -10.94 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c46 source 2dw7 BLL6730 PROTEIN : 5 hits 2dw7_c46 naa= 3 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 1 3 # 1 P 182 LYS A 8 LYS^? 8.24 C6 EPE A 145 P 184 LYS A 6 LYS.? 17.07 C5 EPE A 145 P 345 ASP A 133 ASP~? 7.97 CL CL D 145 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 -22.55 6.13 -12.91 -26.50 8.70 -17.21 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 2 3 # 2 P 182 LYS A 65 LYS~? 24.48 CL CL A 144 P 184 LYS B 65 LYS~? 24.78 CL CL A 144 P 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 3 3 # 3 P 182 LYS B 8 LYS^? 8.74 C3 EPE A 145 P 184 LYS B 6 LYS.? 15.05 O8 EPE D 146 P 345 ASP B 133 ASP~? 13.85 C2 EPE A 145 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 4 3 # 4 P 182 LYS B 65 LYS~? 24.78 CL CL A 144 P 184 LYS A 65 LYS~? 24.48 CL CL A 144 P 345 ASP C 19 ASP~? 15.67 CL CL A 144 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 5 3 # 5 P 182 LYS B 77 LYS.? 21.17 CL CL D 145 P 184 LYS B 82 LYS.? 24.10 CL CL D 145 P 345 ASP B 19 ASP~? 15.75 CL CL A 144 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 -23.14 -26.08 -40.21 -21.49 -29.23 -44.46 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 ULMN 3 2dw7_c47 BLL6730 PROTEIN user 6 3 # 6 P 182 LYS D 8 LYS^? 8.17 O8 EPE D 146 P 184 LYS D 6 LYS.? 14.92 O8 EPE D 146 P 345 ASP D 133 ASP~? 7.85 CL CL D 145 coo 14.97 -47.15 29.92 18.26 -47.80 24.89 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 20.57 -43.13 31.26 20.62 -43.22 26.05 3.13 -11.94 -19.77 2.68 -17.66 -22.71 coo 7.60 -36.55 24.79 7.77 -37.99 26.35 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 2dw7_c47 source 2dw7 BLL6730 PROTEIN : 6 hits 2dw7_c47 naa= 3 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 1 3 # 1 A 157 PHE A 14 PHE.? 11.46 CL CL A 144 A 245 ASP B 19 ASP~? 15.75 CL CL A 144 A 273 LYS B 77 LYS.? 21.17 CL CL D 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 2 3 # 2 A 157 PHE A 41 PHE^? 11.09 CL CL D 145 A 245 ASP A 133 ASP~? 7.97 CL CL D 145 A 273 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 3 3 # 3 A 157 PHE A 131 PHE~? 8.85 O3S EPE A 145 A 245 ASP A 133 ASP~? 7.97 CL CL D 145 A 273 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 4 3 # 4 A 157 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 245 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 273 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 5 3 # 5 A 157 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 245 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 273 LYS A 6 LYS.? 17.07 C5 EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -22.55 6.13 -12.91 -26.50 8.70 -17.21 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 6 3 # 6 A 157 PHE D 41 PHE^? 10.83 CL CL D 145 A 245 ASP D 123 ASP.? 17.57 CL CL D 145 A 273 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 7 3 # 7 A 157 PHE D 41 PHE^? 10.83 CL CL D 145 A 245 ASP D 124 ASP^? 11.01 CL CL D 145 A 273 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.65 -18.88 -33.14 -13.54 -19.30 -32.35 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 8 3 # 8 A 157 PHE D 41 PHE^? 10.83 CL CL D 145 A 245 ASP D 133 ASP~? 7.85 CL CL D 145 A 273 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 9 3 # 9 A 157 PHE D 102 PHE^? 11.51 CL CL D 145 A 245 ASP D 133 ASP~? 7.85 CL CL D 145 A 273 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 10 3 # 10 A 157 PHE D 102 PHE^? 11.51 CL CL D 145 A 245 ASP D 133 ASP~? 7.85 CL CL D 145 A 273 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 11 3 # 11 A 157 PHE D 121 PHE.? 21.38 CL CL D 145 A 245 ASP D 123 ASP.? 17.57 CL CL D 145 A 273 LYS B 94 LYS.? 22.75 O3S EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -11.45 -24.99 -23.62 -12.58 -29.27 -19.62 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 12 3 # 12 A 157 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 245 ASP D 133 ASP~? 7.85 CL CL D 145 A 273 LYS B 6 LYS.? 15.05 O8 EPE D 146 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -8.35 -10.46 -16.14 -6.77 -16.05 -18.84 ULMN 3 2gsa_c04 GLUTAMATE SEMIALDEHYDE AMINOTRANSFERuser 13 3 # 13 A 157 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 245 ASP D 133 ASP~? 7.85 CL CL D 145 A 273 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 9.49 9.24 -34.27 7.12 7.86 -33.75 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 1.75 12.92 -36.29 2.66 14.31 -34.97 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -0.09 22.51 -29.56 4.47 22.51 -33.59 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 2gsa_c04 source 2gsa GLUTAMATE SEMIALDEHYDE AMINOTRANSFERASE : 13 hits 2gsa_c04 naa= 3 ULMN 3 2jxr_c04 LIGAND CP-081282 user 1 3 # 1 A 32 ASP D 133 ASP~? 7.85 CL CL D 145 A 35 SER B 34 SER~? 6.65 CL CL D 145 A 215 ASP A 133 ASP~? 7.97 CL CL D 145 coo -14.00 61.45 43.99 -14.19 63.14 42.84 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo -13.21 66.21 45.84 -15.49 65.90 45.84 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo -10.72 64.19 37.77 -12.20 64.43 39.15 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 2jxr_c04 source 2jxr LIGAND CP-081282 : 1 hits 2jxr_c04 naa= 3 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 A 177 PHE A 41 PHE^? 11.09 CL CL D 145 A 263 ASP A 133 ASP~? 7.97 CL CL D 145 A 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 54.43 44.82 23.74 55.21 45.06 21.80 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 2 3 # 2 A 177 PHE A 44 PHE~? 15.48 CL CL A 144 A 263 ASP B 64 ASP~? 15.96 CL CL A 144 A 292 LYS A 20 LYS~? 9.88 CL CL A 144 coo 51.51 50.32 16.39 52.13 49.68 13.75 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 54.43 44.82 23.74 55.21 45.06 21.80 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 63.95 45.30 16.71 59.11 49.15 16.05 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 3 3 # 3 A 177 PHE A 102 PHE^? 11.63 CL CL D 145 A 263 ASP A 133 ASP~? 7.97 CL CL D 145 A 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 54.43 44.82 23.74 55.21 45.06 21.80 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 4 3 # 4 A 177 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 54.43 44.82 23.74 55.21 45.06 21.80 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 63.95 45.30 16.71 59.11 49.15 16.05 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 5 3 # 5 A 177 PHE B 44 PHE~? 15.63 CL CL A 144 A 263 ASP C 64 ASP~? 15.91 CL CL A 144 A 292 LYS B 20 LYS~? 9.95 CL CL A 144 coo 51.51 50.32 16.39 52.13 49.68 13.75 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 54.43 44.82 23.74 55.21 45.06 21.80 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 63.95 45.30 16.71 59.11 49.15 16.05 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 6 3 # 6 A 177 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 54.43 44.82 23.74 55.21 45.06 21.80 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 63.95 45.30 16.71 59.11 49.15 16.05 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 7 3 # 7 A 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 54.43 44.82 23.74 55.21 45.06 21.80 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 63.95 45.30 16.71 59.11 49.15 16.05 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 8 3 # 8 A 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 A 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 A 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 54.43 44.82 23.74 55.21 45.06 21.80 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 63.95 45.30 16.71 59.11 49.15 16.05 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 9 3 # 9 A 177 PHE C 41 PHE^? 13.95 CL CL A 144 A 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 54.43 44.82 23.74 55.21 45.06 21.80 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 10 3 # 10 A 177 PHE C 44 PHE~? 15.66 CL CL A 144 A 263 ASP A 64 ASP~? 16.08 CL CL A 144 A 292 LYS C 20 LYS~? 9.96 CL CL A 144 coo 51.51 50.32 16.39 52.13 49.68 13.75 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 54.43 44.82 23.74 55.21 45.06 21.80 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 63.95 45.30 16.71 59.11 49.15 16.05 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 11 3 # 11 A 177 PHE C 102 PHE^? 16.65 O1S EPE A 145 A 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 54.43 44.82 23.74 55.21 45.06 21.80 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 12 3 # 12 A 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 54.43 44.82 23.74 55.21 45.06 21.80 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 13 3 # 13 A 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 A 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 54.43 44.82 23.74 55.21 45.06 21.80 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 63.95 45.30 16.71 59.11 49.15 16.05 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 14 3 # 14 A 177 PHE D 41 PHE^? 10.83 CL CL D 145 A 263 ASP D 133 ASP~? 7.85 CL CL D 145 A 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 51.51 50.32 16.39 52.13 49.68 13.75 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 54.43 44.82 23.74 55.21 45.06 21.80 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 63.95 45.30 16.71 59.11 49.15 16.05 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 15 3 # 15 A 177 PHE D 102 PHE^? 11.51 CL CL D 145 A 263 ASP D 133 ASP~? 7.85 CL CL D 145 A 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 51.51 50.32 16.39 52.13 49.68 13.75 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 54.43 44.82 23.74 55.21 45.06 21.80 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 63.95 45.30 16.71 59.11 49.15 16.05 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 16 3 # 16 A 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 263 ASP D 133 ASP~? 7.85 CL CL D 145 A 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 51.51 50.32 16.39 52.13 49.68 13.75 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 54.43 44.82 23.74 55.21 45.06 21.80 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 63.95 45.30 16.71 59.11 49.15 16.05 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c03 ORNITHINE AMINOTRANSFERASE user 17 3 # 17 A 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 A 263 ASP D 133 ASP~? 7.85 CL CL D 145 A 292 LYS D 100 LYS^? 18.85 CL CL D 145 coo 51.51 50.32 16.39 52.13 49.68 13.75 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 54.43 44.82 23.74 55.21 45.06 21.80 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 63.95 45.30 16.71 59.11 49.15 16.05 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 2oat_c03 source 2oat ORNITHINE AMINOTRANSFERASE : 17 hits 2oat_c03 naa= 3 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 B 177 PHE A 41 PHE^? 11.09 CL CL D 145 B 263 ASP A 123 ASP.? 17.71 CL CL D 145 B 292 LYS A 94 LYS.? 20.29 CL CL D 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 60.53 31.67 0.97 57.79 27.51 3.63 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 2 3 # 2 B 177 PHE A 41 PHE^? 11.09 CL CL D 145 B 263 ASP A 133 ASP~? 7.97 CL CL D 145 B 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 3 3 # 3 B 177 PHE A 42 PHE^? 15.34 CL CL A 144 B 263 ASP A 123 ASP.? 17.71 CL CL D 145 B 292 LYS A 94 LYS.? 20.29 CL CL D 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo 60.53 31.67 0.97 57.79 27.51 3.63 -34.52 6.28 -23.57 -33.07 3.91 -28.88 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 4 3 # 4 B 177 PHE A 44 PHE~? 15.48 CL CL A 144 B 263 ASP B 64 ASP~? 15.96 CL CL A 144 B 292 LYS A 20 LYS~? 9.88 CL CL A 144 coo 49.99 26.05 6.28 51.46 26.87 8.49 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 60.53 31.67 0.97 57.79 27.51 3.63 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 5 3 # 5 B 177 PHE A 102 PHE^? 11.63 CL CL D 145 B 263 ASP A 133 ASP~? 7.97 CL CL D 145 B 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 6 3 # 6 B 177 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 263 ASP A 133 ASP~? 7.97 CL CL D 145 B 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 7 3 # 7 B 177 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 263 ASP A 133 ASP~? 7.97 CL CL D 145 B 292 LYS A 100 LYS^? 18.99 CL CL D 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 8 3 # 8 B 177 PHE A 131 PHE~? 8.85 O3S EPE A 145 B 263 ASP A 133 ASP~? 7.97 CL CL D 145 B 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 9 3 # 9 B 177 PHE B 41 PHE^? 12.26 O2S EPE A 145 B 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 60.53 31.67 0.97 57.79 27.51 3.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 10 3 # 10 B 177 PHE B 44 PHE~? 15.63 CL CL A 144 B 263 ASP C 64 ASP~? 15.91 CL CL A 144 B 292 LYS B 20 LYS~? 9.95 CL CL A 144 coo 49.99 26.05 6.28 51.46 26.87 8.49 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 60.53 31.67 0.97 57.79 27.51 3.63 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 11 3 # 11 B 177 PHE B 102 PHE^? 16.45 O2S EPE A 145 B 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 60.53 31.67 0.97 57.79 27.51 3.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 12 3 # 12 B 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 B 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 60.53 31.67 0.97 57.79 27.51 3.63 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 13 3 # 13 B 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 B 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 B 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 60.53 31.67 0.97 57.79 27.51 3.63 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 14 3 # 14 B 177 PHE C 41 PHE^? 13.95 CL CL A 144 B 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 15 3 # 15 B 177 PHE C 42 PHE^? 15.30 CL CL A 144 B 263 ASP C 123 ASP.? 21.65 O2S EPE A 145 B 292 LYS C 94 LYS.? 22.53 O2S EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo 60.53 31.67 0.97 57.79 27.51 3.63 -31.80 -15.89 7.76 -36.59 -12.49 6.80 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 16 3 # 16 B 177 PHE C 44 PHE~? 15.66 CL CL A 144 B 263 ASP A 64 ASP~? 16.08 CL CL A 144 B 292 LYS C 20 LYS~? 9.96 CL CL A 144 coo 49.99 26.05 6.28 51.46 26.87 8.49 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 60.53 31.67 0.97 57.79 27.51 3.63 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 17 3 # 17 B 177 PHE C 102 PHE^? 16.65 O1S EPE A 145 B 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 18 3 # 18 B 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 B 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 19 3 # 19 B 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 B 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 B 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 60.53 31.67 0.97 57.79 27.51 3.63 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 20 3 # 20 B 177 PHE D 41 PHE^? 10.83 CL CL D 145 B 263 ASP D 133 ASP~? 7.85 CL CL D 145 B 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 49.99 26.05 6.28 51.46 26.87 8.49 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 60.53 31.67 0.97 57.79 27.51 3.63 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 21 3 # 21 B 177 PHE D 42 PHE^? 15.36 CL CL D 144 B 263 ASP D 123 ASP.? 17.57 CL CL D 145 B 292 LYS D 94 LYS.? 20.13 CL CL D 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -7.43 -20.78 -33.24 -5.47 -21.58 -33.20 coo 60.53 31.67 0.97 57.79 27.51 3.63 2.22 -22.30 -32.78 -3.43 -22.89 -34.83 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 22 3 # 22 B 177 PHE D 102 PHE^? 11.51 CL CL D 145 B 263 ASP D 133 ASP~? 7.85 CL CL D 145 B 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 49.99 26.05 6.28 51.46 26.87 8.49 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 60.53 31.67 0.97 57.79 27.51 3.63 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 23 3 # 23 B 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 263 ASP D 133 ASP~? 7.85 CL CL D 145 B 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 49.99 26.05 6.28 51.46 26.87 8.49 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 60.53 31.67 0.97 57.79 27.51 3.63 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c04 ORNITHINE AMINOTRANSFERASE user 24 3 # 24 B 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 B 263 ASP D 133 ASP~? 7.85 CL CL D 145 B 292 LYS D 100 LYS^? 18.85 CL CL D 145 coo 49.99 26.05 6.28 51.46 26.87 8.49 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 60.53 31.67 0.97 57.79 27.51 3.63 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 2oat_c04 source 2oat ORNITHINE AMINOTRANSFERASE : 24 hits 2oat_c04 naa= 3 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 C 177 PHE A 41 PHE^? 11.09 CL CL D 145 C 263 ASP A 133 ASP~? 7.97 CL CL D 145 C 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo 19.84 12.02 9.33 18.68 11.23 7.75 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 2 3 # 2 C 177 PHE A 44 PHE~? 15.48 CL CL A 144 C 263 ASP B 64 ASP~? 15.96 CL CL A 144 C 292 LYS A 20 LYS~? 9.88 CL CL A 144 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 coo 19.84 12.02 9.33 18.68 11.23 7.75 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo 12.82 3.49 4.98 17.80 5.59 1.90 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 3 3 # 3 C 177 PHE A 102 PHE^? 11.63 CL CL D 145 C 263 ASP A 133 ASP~? 7.97 CL CL D 145 C 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo 19.84 12.02 9.33 18.68 11.23 7.75 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 4 3 # 4 C 177 PHE B 41 PHE^? 12.26 O2S EPE A 145 C 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo 19.84 12.02 9.33 18.68 11.23 7.75 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.82 3.49 4.98 17.80 5.59 1.90 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 5 3 # 5 C 177 PHE B 44 PHE~? 15.63 CL CL A 144 C 263 ASP C 64 ASP~? 15.91 CL CL A 144 C 292 LYS B 20 LYS~? 9.95 CL CL A 144 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 coo 19.84 12.02 9.33 18.68 11.23 7.75 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo 12.82 3.49 4.98 17.80 5.59 1.90 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 6 3 # 6 C 177 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo 19.84 12.02 9.33 18.68 11.23 7.75 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.82 3.49 4.98 17.80 5.59 1.90 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 7 3 # 7 C 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 C 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 292 LYS B 8 LYS^? 8.74 C3 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 19.84 12.02 9.33 18.68 11.23 7.75 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.82 3.49 4.98 17.80 5.59 1.90 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 8 3 # 8 C 177 PHE B 131 PHE~? 9.25 O2S EPE A 145 C 263 ASP B 133 ASP~? 13.85 C2 EPE A 145 C 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 coo 19.84 12.02 9.33 18.68 11.23 7.75 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo 12.82 3.49 4.98 17.80 5.59 1.90 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 9 3 # 9 C 177 PHE C 41 PHE^? 13.95 CL CL A 144 C 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo 19.84 12.02 9.33 18.68 11.23 7.75 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 10 3 # 10 C 177 PHE C 44 PHE~? 15.66 CL CL A 144 C 263 ASP A 64 ASP~? 16.08 CL CL A 144 C 292 LYS C 20 LYS~? 9.96 CL CL A 144 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 coo 19.84 12.02 9.33 18.68 11.23 7.75 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo 12.82 3.49 4.98 17.80 5.59 1.90 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 11 3 # 11 C 177 PHE C 102 PHE^? 16.65 O1S EPE A 145 C 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo 19.84 12.02 9.33 18.68 11.23 7.75 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 12 3 # 12 C 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 C 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 292 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 19.84 12.02 9.33 18.68 11.23 7.75 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 13 3 # 13 C 177 PHE C 131 PHE~? 11.28 O1S EPE A 145 C 263 ASP C 133 ASP~? 13.97 O1S EPE A 145 C 292 LYS C 8 LYS^? 8.33 O8 EPE A 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo 19.84 12.02 9.33 18.68 11.23 7.75 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo 12.82 3.49 4.98 17.80 5.59 1.90 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 14 3 # 14 C 177 PHE D 41 PHE^? 10.83 CL CL D 145 C 263 ASP D 133 ASP~? 7.85 CL CL D 145 C 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo 19.84 12.02 9.33 18.68 11.23 7.75 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.82 3.49 4.98 17.80 5.59 1.90 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 15 3 # 15 C 177 PHE D 102 PHE^? 11.51 CL CL D 145 C 263 ASP D 133 ASP~? 7.85 CL CL D 145 C 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo 19.84 12.02 9.33 18.68 11.23 7.75 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.82 3.49 4.98 17.80 5.59 1.90 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 16 3 # 16 C 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 263 ASP D 133 ASP~? 7.85 CL CL D 145 C 292 LYS D 8 LYS^? 8.17 O8 EPE D 146 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 19.84 12.02 9.33 18.68 11.23 7.75 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.82 3.49 4.98 17.80 5.59 1.90 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 ULMN 3 2oat_c05 ORNITHINE AMINOTRANSFERASE user 17 3 # 17 C 177 PHE D 131 PHE~? 8.86 O2S EPE D 146 C 263 ASP D 133 ASP~? 7.85 CL CL D 145 C 292 LYS D 100 LYS^? 18.85 CL CL D 145 coo 21.96 11.84 -0.03 20.04 11.74 -2.01 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 coo 19.84 12.02 9.33 18.68 11.23 7.75 -11.36 -8.42 -25.83 -13.22 -7.56 -25.44 coo 12.82 3.49 4.98 17.80 5.59 1.90 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 2oat_c05 source 2oat ORNITHINE AMINOTRANSFERASE : 17 hits 2oat_c05 naa= 3 ULMN 3 2oat_c06 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 A 178 TRP A 45 TRP~? 16.76 CL CL A 144 A 263 ASP B 19 ASP~? 15.75 CL CL A 144 A 292 LYS B 77 LYS.? 21.17 CL CL D 145 coo 48.96 45.07 19.49 48.62 41.39 18.16 -36.53 -17.86 -26.77 -37.06 -19.54 -30.28 coo 54.43 44.82 23.74 55.21 45.06 21.80 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 63.95 45.30 16.71 59.11 49.15 16.05 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 2oat_c06 source 2oat ORNITHINE AMINOTRANSFERASE : 1 hits 2oat_c06 naa= 3 ULMN 3 2oat_c07 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 B 178 TRP A 45 TRP~? 16.76 CL CL A 144 B 263 ASP B 19 ASP~? 15.75 CL CL A 144 B 292 LYS B 77 LYS.? 21.17 CL CL D 145 coo 45.83 31.15 4.65 45.88 34.74 6.24 -36.53 -17.86 -26.77 -37.06 -19.54 -30.28 coo 49.07 31.32 -1.50 50.64 31.29 -0.07 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 60.53 31.67 0.97 57.79 27.51 3.63 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 2oat_c07 source 2oat ORNITHINE AMINOTRANSFERASE : 1 hits 2oat_c07 naa= 3 ULMN 3 2oat_c08 ORNITHINE AMINOTRANSFERASE user 1 3 # 1 C 178 TRP A 45 TRP~? 16.76 CL CL A 144 C 263 ASP B 19 ASP~? 15.75 CL CL A 144 C 292 LYS B 77 LYS.? 21.17 CL CL D 145 coo 20.52 16.65 4.15 17.32 18.91 4.39 -36.53 -17.86 -26.77 -37.06 -19.54 -30.28 coo 19.84 12.02 9.33 18.68 11.23 7.75 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 12.82 3.49 4.98 17.80 5.59 1.90 -30.90 -22.61 -40.36 -33.33 -17.81 -43.14 2oat_c08 source 2oat ORNITHINE AMINOTRANSFERASE : 1 hits 2oat_c08 naa= 3 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 1 3 # 1 141 ASP A 123 ASP.? 17.71 CL CL D 145 166 GLY A 137 GLY.? -3.78 C6 EPE A 145s 169 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -28.83 2.05 -30.31 -30.24 3.22 -29.26 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -18.38 -3.49 -14.19 -19.07 -3.76 -14.47 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 2 3 # 2 141 ASP A 124 ASP^? 10.83 CL CL D 145 166 GLY A 112 GLY.? 18.91 CL CL D 145 169 GLU B 80 GLU.? 23.04 CL CL D 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -33.24 -14.40 -41.22 -33.47 -14.08 -40.51 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -28.75 -23.57 -44.78 -30.57 -22.57 -45.34 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 3 3 # 3 141 ASP A 124 ASP^? 10.83 CL CL D 145 166 GLY A 137 GLY.? -3.78 C6 EPE A 145s 169 GLU C 136 GLU~? 8.02 O8 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -25.70 -0.61 -32.58 -24.16 -0.75 -34.05 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -18.38 -3.49 -14.19 -19.07 -3.76 -14.47 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -23.69 -0.96 -7.59 -23.14 1.06 -7.18 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 4 3 # 4 141 ASP B 123 ASP.? 21.73 O3S EPE A 145 166 GLY B 137 GLY.? 3.85 C3 EPE A 145 169 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -12.80 -29.05 -14.92 -12.27 -28.60 -16.96 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -15.65 -10.07 -9.36 -16.12 -10.54 -9.75 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 5 3 # 5 141 ASP B 124 ASP^? 22.45 O2S EPE A 145 166 GLY B 97 GLY.? 16.18 CL CL D 145 169 GLU D 37 GLU^? 11.78 O8 EPE D 146 coo 8.28 6.87 1.62 10.08 5.77 1.34 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -1.17 -14.18 -26.07 -2.75 -13.47 -24.70 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 6 3 # 6 141 ASP B 124 ASP^? 22.45 O2S EPE A 145 166 GLY B 97 GLY.? 16.18 CL CL D 145 169 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 8.28 6.87 1.62 10.08 5.77 1.34 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -8.95 -20.22 -23.77 -9.06 -21.01 -23.69 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 7 3 # 7 141 ASP B 124 ASP^? 22.45 O2S EPE A 145 166 GLY B 112 GLY.? 26.93 CL CL A 144 169 GLU C 80 GLU.? 32.79 CL CL A 144 coo 8.28 6.87 1.62 10.08 5.77 1.34 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -28.71 -40.06 -8.90 -28.57 -39.50 -9.48 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -35.53 -41.95 -0.57 -35.49 -43.35 -2.16 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 8 3 # 8 141 ASP B 124 ASP^? 22.45 O2S EPE A 145 166 GLY B 137 GLY.? 3.85 C3 EPE A 145 169 GLU A 136 GLU~? 8.92 C6 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -13.87 -29.88 -10.42 -13.21 -30.56 -8.48 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -15.65 -10.07 -9.36 -16.12 -10.54 -9.75 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -15.87 -5.54 -17.59 -14.02 -5.13 -18.66 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 9 3 # 9 141 ASP B 133 ASP~? 13.85 C2 EPE A 145 166 GLY C 97 GLY.? 20.31 O2S EPE A 145 169 GLU C 95 GLU.? 27.59 O2S EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -15.34 -18.69 -3.95 -16.08 -18.61 -1.88 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -26.46 -15.38 8.24 -27.23 -15.31 8.39 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -33.39 -18.53 11.57 -34.39 -20.35 12.06 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 10 3 # 10 141 ASP C 123 ASP.? 21.65 O2S EPE A 145 166 GLY C 137 GLY.? 4.19 O8 EPE A 145 169 GLU B 136 GLU~? 6.67 C2 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -36.85 -7.95 5.37 -36.01 -9.72 6.20 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -21.03 -4.52 -6.25 -21.60 -5.04 -6.36 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 11 3 # 11 141 ASP C 124 ASP^? 22.63 O1S EPE A 145 166 GLY C 112 GLY.? 27.03 CL CL A 144 169 GLU A 80 GLU.? 32.70 CL CL A 144 coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -53.62 -7.18 -5.92 -53.00 -7.71 -5.83 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -58.68 -2.10 -13.66 -59.90 -3.56 -12.69 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 12 3 # 12 141 ASP C 124 ASP^? 22.63 O1S EPE A 145 166 GLY C 137 GLY.? 4.19 O8 EPE A 145 169 GLU B 136 GLU~? 6.67 C2 EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -38.62 -3.96 3.32 -39.43 -1.93 3.43 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -21.03 -4.52 -6.25 -21.60 -5.04 -6.36 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -15.76 -12.24 -5.41 -17.52 -11.44 -4.57 ULMN 3 2tdt_c00 TETRAHYDRODIPICOLINATE N-SUCCINYLTRAuser 13 3 # 13 141 ASP C 133 ASP~? 13.97 O1S EPE A 145 166 GLY A 97 GLY.? 20.25 O1S EPE A 145 169 GLU A 95 GLU.? 27.70 O1S EPE A 145 coo 8.28 6.87 1.62 10.08 5.77 1.34 -29.44 0.95 -4.55 -29.98 2.55 -5.94 coo -8.58 13.22 3.21 -8.90 13.15 4.05 -32.13 8.56 -19.27 -32.37 8.45 -20.03 coo -16.67 7.89 2.78 -17.65 6.56 1.49 -38.05 9.59 -25.22 -40.20 9.68 -25.46 2tdt_c00 source 2tdt TETRAHYDRODIPICOLINATE N-SUCCINYLTRANSFERASE : 13 hits 2tdt_c00 naa= 3 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 1 3 # 1 A 122 TYR A 67 TYR~? 16.80 CL CL A 144 A 214 ASP C 64 ASP~? 15.91 CL CL A 144 A 256 LYS B 20 LYS~? 9.95 CL CL A 144 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 2 3 # 2 A 122 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 214 ASP A 133 ASP~? 7.97 CL CL D 145 A 256 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 3 3 # 3 A 122 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 214 ASP A 133 ASP~? 7.97 CL CL D 145 A 256 LYS A 100 LYS^? 18.99 CL CL D 145 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 4 3 # 4 A 122 TYR B 67 TYR~? 16.82 CL CL A 144 A 214 ASP A 64 ASP~? 16.08 CL CL A 144 A 256 LYS C 20 LYS~? 9.96 CL CL A 144 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 2tpl_c04 TYROSINE PHENOL-LYASE user 5 3 # 5 A 122 TYR C 67 TYR~? 16.92 CL CL A 144 A 214 ASP B 64 ASP~? 15.96 CL CL A 144 A 256 LYS A 20 LYS~? 9.88 CL CL A 144 coo -36.51 -15.34 5.35 -36.90 -16.76 7.69 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo -29.95 -11.32 -1.46 -28.83 -11.55 0.31 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -18.13 -8.46 4.26 -20.75 -6.32 9.36 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 2tpl_c04 source 2tpl TYROSINE PHENOL-LYASE : 5 hits 2tpl_c04 naa= 3 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 1 3 # 1 B 122 TYR A 67 TYR~? 16.80 CL CL A 144 B 214 ASP C 64 ASP~? 15.91 CL CL A 144 B 256 LYS B 20 LYS~? 9.95 CL CL A 144 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -40.17 -25.98 -15.74 -39.91 -24.84 -17.53 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -30.77 -22.05 -23.86 -34.88 -19.76 -19.80 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 2 3 # 2 B 122 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 214 ASP A 133 ASP~? 7.97 CL CL D 145 B 256 LYS A 8 LYS^? 8.24 C6 EPE A 145 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -25.01 0.47 -14.85 -20.09 -0.96 -18.04 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 3 3 # 3 B 122 TYR B 36 TYR.? 11.13 O3S EPE A 145 B 214 ASP A 133 ASP~? 7.97 CL CL D 145 B 256 LYS A 100 LYS^? 18.99 CL CL D 145 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -17.09 -4.66 -24.23 -15.31 -5.59 -24.94 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -29.11 1.73 -25.37 -27.34 6.20 -25.84 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 4 3 # 4 B 122 TYR B 67 TYR~? 16.82 CL CL A 144 B 214 ASP A 64 ASP~? 16.08 CL CL A 144 B 256 LYS C 20 LYS~? 9.96 CL CL A 144 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -44.29 -18.35 -19.23 -43.03 -20.05 -18.93 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -36.48 -22.77 -10.00 -36.43 -20.15 -15.71 ULMN 3 2tpl_c05 TYROSINE PHENOL-LYASE user 5 3 # 5 B 122 TYR C 67 TYR~? 16.92 CL CL A 144 B 214 ASP B 64 ASP~? 15.96 CL CL A 144 B 256 LYS A 20 LYS~? 9.88 CL CL A 144 coo -32.67 22.74 10.17 -32.85 23.98 7.70 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo -26.88 17.61 16.89 -26.08 17.11 15.00 -38.28 -23.12 -24.63 -39.40 -22.34 -22.99 coo -16.04 12.06 11.09 -17.97 10.54 5.71 -40.69 -11.75 -19.10 -37.57 -17.10 -17.93 2tpl_c05 source 2tpl TYROSINE PHENOL-LYASE : 5 hits 2tpl_c05 naa= 3 ULMN 3 2tps_c00 THIAMIN PHOSPHATE SYNTHASE user 1 3 # 1 A 59 ARG D 134 ARG~? 13.66 CL CL D 145 A 130 SER B 29 SER~? 11.10 CL CL D 145 A 159 LYS D 100 LYS^? 18.85 CL CL D 145 coo 18.35 45.84 20.99 16.20 47.83 21.89 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 15.14 43.67 10.77 15.61 44.43 13.04 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 coo 11.57 48.49 22.18 13.51 49.99 17.21 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 2tps_c00 source 2tps THIAMIN PHOSPHATE SYNTHASE : 1 hits 2tps_c00 naa= 3 ULMN 3 2tps_c01 THIAMIN PHOSPHATE SYNTHASE user 1 3 # 1 B 59 ARG D 134 ARG~? 13.66 CL CL D 145 B 130 SER B 29 SER~? 11.10 CL CL D 145 B 159 LYS D 100 LYS^? 18.85 CL CL D 145 coo 58.72 31.58 20.45 60.80 29.39 20.94 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 61.66 35.17 10.39 61.29 34.14 12.56 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 coo 65.38 28.77 21.17 63.49 28.03 16.12 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 2tps_c01 source 2tps THIAMIN PHOSPHATE SYNTHASE : 1 hits 2tps_c01 naa= 3 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 1 1 # 1 A 461 ASN A 39 ASN^? 12.67 O1S EPE A 145 coo 5.80 63.03 55.85 5.52 65.03 56.45 -26.45 -1.95 -22.01 -25.11 -0.41 -21.60 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 2 1 # 2 A 461 ASN A 56 ASN~? 29.36 CL CL D 145 coo 5.80 63.03 55.85 5.52 65.03 56.45 -47.19 -3.92 -36.22 -45.94 -2.20 -36.30 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 3 1 # 3 A 461 ASN A 66 ASN~? 17.58 CL CL A 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 4 1 # 4 A 461 ASN B 39 ASN^? 12.62 O2S EPE A 145 coo 5.80 63.03 55.85 5.52 65.03 56.45 -16.43 -20.24 -14.07 -14.54 -19.54 -13.47 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 5 1 # 5 A 461 ASN B 56 ASN~? 29.95 CL CL A 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 -24.41 -40.76 -26.59 -22.33 -40.56 -26.21 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 6 1 # 6 A 461 ASN B 66 ASN~? 17.83 CL CL A 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 7 1 # 7 A 461 ASN C 39 ASN^? 12.71 O1S EPE A 145 coo 5.80 63.03 55.85 5.52 65.03 56.45 -30.23 -8.85 -1.51 -29.05 -7.61 -0.29 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 8 1 # 8 A 461 ASN C 56 ASN~? 29.98 CL CL A 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 -51.05 -22.38 3.65 -50.21 -21.11 5.13 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 9 1 # 9 A 461 ASN C 66 ASN~? 17.61 CL CL A 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 10 1 # 10 A 461 ASN D 39 ASN^? 12.69 O3S EPE D 146 coo 5.80 63.03 55.85 5.52 65.03 56.45 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 11 1 # 11 A 461 ASN D 56 ASN~? 29.38 CL CL D 145 coo 5.80 63.03 55.85 5.52 65.03 56.45 -3.32 -25.21 -52.58 -3.72 -26.33 -50.84 ULMN 1 1kbk_p00 ALPHA-AMYLASE, PANCREATIC user 12 1 # 12 A 461 ASN D 66 ASN~? 17.81 CL CL D 144 coo 5.80 63.03 55.85 5.52 65.03 56.45 4.84 0.60 -54.09 2.98 1.60 -54.16 1kbk_p00 source 1kbk ALPHA-AMYLASE, PANCREATIC : 12 hits 1kbk_p00 naa= 1 ULMN 4 1kqr_p00 VP4 user 1 4 # 1 A 101 ARG D 134 ARG~? 13.66 CL CL D 145 A 187 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 188 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 190 SER B 34 SER~? 6.65 CL CL D 145 coo 10.93 40.49 13.39 9.72 39.25 15.90 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 2.71 31.72 11.75 7.91 29.74 9.11 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 1.39 36.04 13.60 -0.23 35.82 15.85 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 4.80 41.21 15.27 3.05 40.92 16.89 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 1kqr_p00 source 1kqr VP4 : 1 hits 1kqr_p00 naa= 4 ULMN 3 1uy2_p00 ENDO-1,4-BETA-XYLANASE A user 1 3 # 1 A 51 TYR A 67 TYR~? 16.80 CL CL A 144 A 108 ASN C 66 ASN~? 17.61 CL CL A 144 A 135 ASN B 66 ASN~? 17.83 CL CL A 144 coo 17.59 4.66 17.88 15.38 5.96 18.97 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 12.36 16.24 15.27 12.06 14.29 16.05 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 coo 18.05 11.56 12.71 17.57 10.75 14.60 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 ULMN 3 1uy2_p00 ENDO-1,4-BETA-XYLANASE A user 2 3 # 2 A 51 TYR B 67 TYR~? 16.82 CL CL A 144 A 108 ASN A 66 ASN~? 17.58 CL CL A 144 A 135 ASN C 66 ASN~? 17.61 CL CL A 144 coo 17.59 4.66 17.88 15.38 5.96 18.97 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 12.36 16.24 15.27 12.06 14.29 16.05 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 coo 18.05 11.56 12.71 17.57 10.75 14.60 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 ULMN 3 1uy2_p00 ENDO-1,4-BETA-XYLANASE A user 3 3 # 3 A 51 TYR C 67 TYR~? 16.92 CL CL A 144 A 108 ASN B 66 ASN~? 17.83 CL CL A 144 A 135 ASN A 66 ASN~? 17.58 CL CL A 144 coo 17.59 4.66 17.88 15.38 5.96 18.97 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo 12.36 16.24 15.27 12.06 14.29 16.05 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 coo 18.05 11.56 12.71 17.57 10.75 14.60 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 1uy2_p00 source 1uy2 ENDO-1,4-BETA-XYLANASE A : 3 hits 1uy2_p00 naa= 3 ULMN 3 1uy4_p00 ENDO-1,4-BETA-XYLANASE A user 1 3 # 1 A 51 TYR A 67 TYR~? 16.80 CL CL A 144 A 108 ASN C 66 ASN~? 17.61 CL CL A 144 A 135 ASN B 66 ASN~? 17.83 CL CL A 144 coo 17.50 4.57 17.85 15.28 5.88 18.97 -46.12 -18.82 -14.78 -43.51 -19.34 -13.84 coo 12.22 15.98 15.24 11.94 14.05 16.09 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 coo 17.94 11.43 12.65 17.42 10.61 14.53 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 ULMN 3 1uy4_p00 ENDO-1,4-BETA-XYLANASE A user 2 3 # 2 A 51 TYR B 67 TYR~? 16.82 CL CL A 144 A 108 ASN A 66 ASN~? 17.58 CL CL A 144 A 135 ASN C 66 ASN~? 17.61 CL CL A 144 coo 17.50 4.57 17.85 15.28 5.88 18.97 -39.97 -19.52 -27.45 -39.78 -17.75 -25.28 coo 12.22 15.98 15.24 11.94 14.05 16.09 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 coo 17.94 11.43 12.65 17.42 10.61 14.53 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 ULMN 3 1uy4_p00 ENDO-1,4-BETA-XYLANASE A user 3 3 # 3 A 51 TYR C 67 TYR~? 16.92 CL CL A 144 A 108 ASN B 66 ASN~? 17.83 CL CL A 144 A 135 ASN A 66 ASN~? 17.58 CL CL A 144 coo 17.50 4.57 17.85 15.28 5.88 18.97 -37.19 -29.45 -17.63 -35.57 -27.50 -18.75 coo 12.22 15.98 15.24 11.94 14.05 16.09 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 coo 17.94 11.43 12.65 17.42 10.61 14.53 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 1uy4_p00 source 1uy4 ENDO-1,4-BETA-XYLANASE A : 3 hits 1uy4_p00 naa= 3 ULMN 3 2p3i_p00 VP4 user 1 3 # 1 A 101 ARG D 134 ARG~? 13.66 CL CL D 145 A 188 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 190 SER B 34 SER~? 6.65 CL CL D 145 coo 37.69 7.64 13.51 38.82 8.84 16.11 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 47.14 12.10 13.73 48.75 12.33 16.01 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 43.77 6.93 15.46 45.49 7.21 17.11 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 2p3i_p00 source 2p3i VP4 : 1 hits 2p3i_p00 naa= 3 ULMN 4 2p3k_p00 VP4 user 1 4 # 1 A 101 ARG D 134 ARG~? 13.66 CL CL D 145 A 187 LYS B 8 LYS^? 8.74 C3 EPE A 145 A 188 TYR B 36 TYR.? 11.13 O3S EPE A 145 A 190 SER B 34 SER~? 6.65 CL CL D 145 coo 37.00 7.53 13.18 38.22 8.80 15.70 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 45.42 16.25 11.76 45.82 18.39 15.98 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 46.58 11.94 13.55 48.24 12.22 15.76 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 coo 43.09 6.80 15.14 44.84 7.11 16.79 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 2p3k_p00 source 2p3k VP4 : 1 hits 2p3k_p00 naa= 4 ULMN 3 1b01_d00 GENE REGULATION/DNA user 1 3 # 1 B 4 ARG A 134 ARG~? 13.60 CL CL D 145 B 6 THR A 130 THR~? 5.01 CL CL D 145 B 8 THR D 130 THR~? 5.00 CL CL D 145 coo 40.52 16.08 100.90 37.97 16.41 102.60 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo 36.11 13.64 95.03 34.54 14.86 95.91 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 coo 32.72 8.05 92.39 31.25 9.11 91.35 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 ULMN 3 1b01_d00 GENE REGULATION/DNA user 2 3 # 2 B 4 ARG D 134 ARG~? 13.66 CL CL D 145 B 6 THR D 130 THR~? 5.00 CL CL D 145 B 8 THR A 130 THR~? 5.01 CL CL D 145 coo 40.52 16.08 100.90 37.97 16.41 102.60 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 36.11 13.64 95.03 34.54 14.86 95.91 -13.12 -9.89 -29.84 -13.84 -11.84 -30.18 coo 32.72 8.05 92.39 31.25 9.11 91.35 -19.52 -6.17 -27.61 -19.84 -5.13 -29.46 1b01_d00 source 1b01 GENE REGULATION/DNA : 2 hits 1b01_d00 naa= 3 ULMN 3 1hwt_d00 GENE REGULATION/DNA user 1 3 # 1 C 70 ARG A 134 ARG~? 13.60 CL CL D 145 C 71 LYS A 100 LYS^? 18.99 CL CL D 145 C 72 VAL A 101 VAL^? 16.85 CL CL D 145 coo 23.89 33.54 29.21 26.59 34.86 28.68 -22.90 -0.99 -24.49 -22.42 1.94 -25.28 coo 25.82 26.89 29.68 23.33 22.98 25.84 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo 28.86 29.08 30.37 28.04 31.02 29.93 -30.86 -1.03 -27.28 -33.04 -1.05 -27.44 ULMN 3 1hwt_d00 GENE REGULATION/DNA user 2 3 # 2 C 70 ARG C 134 ARG~? 16.35 O1S EPE A 145 C 71 LYS C 100 LYS^? 20.71 O2S EPE A 145 C 72 VAL C 101 VAL^? 18.22 CL CL A 144 coo 23.89 33.54 29.21 26.59 34.86 28.68 -31.39 -3.77 -0.29 -30.40 -4.40 2.52 coo 25.82 26.89 29.68 23.33 22.98 25.84 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo 28.86 29.08 30.37 28.04 31.02 29.93 -36.11 -10.86 1.69 -37.10 -12.75 1.89 ULMN 3 1hwt_d00 GENE REGULATION/DNA user 3 3 # 3 C 70 ARG D 134 ARG~? 13.66 CL CL D 145 C 71 LYS D 100 LYS^? 18.85 CL CL D 145 C 72 VAL D 101 VAL^? 16.68 CL CL D 145 coo 23.89 33.54 29.21 26.59 34.86 28.68 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 25.82 26.89 29.68 23.33 22.98 25.84 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo 28.86 29.08 30.37 28.04 31.02 29.93 -4.88 -17.41 -35.41 -3.77 -18.20 -37.13 1hwt_d00 source 1hwt GENE REGULATION/DNA : 3 hits 1hwt_d00 naa= 3 ULMN 4 1kqq_d00 TRANSCRIPTION/DNA user 1 4 # 1 A 92 THR B 28 THR~? 14.99 CL CL D 145 A 93 SER B 29 SER~? 11.10 CL CL D 145 A 96 LEU B 89 LEU.? 14.49 CL CL D 145 A 131 ARG D 115 ARG~? 12.45 CL CL D 145 coo 3.35 5.93 10.54 2.79 5.49 12.55 -18.46 -19.33 -23.79 -18.52 -21.15 -22.62 coo 3.53 2.76 8.43 3.13 1.02 10.05 -16.84 -19.42 -27.17 -16.59 -20.00 -29.46 coo 5.64 -0.49 6.46 5.57 -2.53 7.21 -19.69 -23.85 -28.81 -20.50 -22.87 -30.58 coo 12.62 -3.51 13.26 13.87 -0.97 14.34 -16.99 -21.67 -39.03 -18.83 -20.42 -36.87 1kqq_d00 source 1kqq TRANSCRIPTION/DNA : 1 hits 1kqq_d00 naa= 4 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 1 3 # 1 A1290 LYS A 65 LYS~? 24.48 CL CL A 144 A1294 ASN A 66 ASN~? 17.58 CL CL A 144 A1297 GLU C 68 GLU~? 25.33 CL CL A 144 coo 39.24 18.84-161.99 36.62 21.47-165.99 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 33.53 17.37-161.81 34.31 17.81-163.76 -44.62 -22.38 -16.58 -43.15 -23.61 -17.42 coo 29.78 23.31-161.30 31.23 23.66-162.84 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 2 3 # 2 A1290 LYS A 65 LYS~? 24.48 CL CL A 144 A1294 ASN B 66 ASN~? 17.83 CL CL A 144 A1297 GLU B 68 GLU~? 25.19 CL CL A 144 coo 39.24 18.84-161.99 36.62 21.47-165.99 -47.16 -21.80 -20.71 -47.31 -24.95 -26.18 coo 33.53 17.37-161.81 34.31 17.81-163.76 -42.50 -20.61 -24.23 -43.28 -20.90 -22.30 coo 29.78 23.31-161.30 31.23 23.66-162.84 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 3 3 # 3 A1290 LYS B 8 LYS^? 8.74 C3 EPE A 145 A1294 ASN B 39 ASN^? 12.62 O2S EPE A 145 A1297 GLU B 98 GLU^? 17.25 C3 EPE A 145 coo 39.24 18.84-161.99 36.62 21.47-165.99 -14.20 -13.24 -16.16 -13.35 -14.38 -10.44 coo 33.53 17.37-161.81 34.31 17.81-163.76 -16.43 -20.24 -14.07 -14.54 -19.54 -13.47 coo 29.78 23.31-161.30 31.23 23.66-162.84 -8.65 -20.03 -17.66 -7.39 -18.77 -16.45 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 4 3 # 4 A1290 LYS B 65 LYS~? 24.78 CL CL A 144 A1294 ASN C 66 ASN~? 17.61 CL CL A 144 A1297 GLU C 68 GLU~? 25.33 CL CL A 144 coo 39.24 18.84-161.99 36.62 21.47-165.99 -42.33 -25.36 -25.32 -44.51 -30.98 -23.14 coo 33.53 17.37-161.81 34.31 17.81-163.76 -39.37 -27.13 -20.44 -39.80 -25.55 -21.78 coo 29.78 23.31-161.30 31.23 23.66-162.84 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 5 3 # 5 A1290 LYS C 8 LYS^? 8.33 O8 EPE A 145 A1294 ASN C 39 ASN^? 12.71 O1S EPE A 145 A1297 GLU C 98 GLU^? 18.25 O8 EPE A 145 coo 39.24 18.84-161.99 36.62 21.47-165.99 -22.71 -10.41 -1.55 -23.88 -4.70 -2.31 coo 33.53 17.37-161.81 34.31 17.81-163.76 -30.23 -8.85 -1.51 -29.05 -7.61 -0.29 coo 29.78 23.31-161.30 31.23 23.66-162.84 -26.60 -9.58 6.05 -28.04 -8.33 6.98 ULMN 3 1xpx_d00 TRANSCRIPTION REGULATION/DNA user 6 3 # 6 A1290 LYS D 8 LYS^? 8.17 O8 EPE D 146 A1294 ASN D 39 ASN^? 12.69 O3S EPE D 146 A1297 GLU D 98 GLU^? 15.40 O8 EPE D 146 coo 39.24 18.84-161.99 36.62 21.47-165.99 1.68 -9.90 -25.83 -3.84 -8.88 -23.92 coo 33.53 17.37-161.81 34.31 17.81-163.76 -3.62 -12.33 -30.72 -3.64 -12.93 -28.70 coo 29.78 23.31-161.30 31.23 23.66-162.84 -0.49 -18.73 -25.88 -0.97 -17.97 -23.90 1xpx_d00 source 1xpx TRANSCRIPTION REGULATION/DNA : 6 hits 1xpx_d00 naa= 3 ULMN 4 2q2t_d00 LIGASE/DNA user 1 4 # 1 A 48 ARG D 134 ARG~? 13.66 CL CL D 145 A 249 THR B 43 THR~? 12.93 CL CL A 144 A 285 ARG B 134 ARG~? 16.21 C3 EPE A 145 A 286 PHE B 102 PHE^? 16.45 O2S EPE A 145 coo -81.95 4.55 64.73 -81.11 4.84 61.78 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo -64.79 -0.51 43.10 -64.46 -1.42 45.04 -26.93 -27.71 -12.36 -27.70 -26.13 -11.10 coo -72.24 -8.41 51.99 -72.03 -9.47 54.89 -13.78 -21.83 -9.74 -11.11 -21.61 -11.28 coo -68.50 -7.10 50.68 -69.42 -6.74 53.31 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 2q2t_d00 source 2q2t LIGASE/DNA : 1 hits 2q2t_d00 naa= 4 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 1 3 # 1 A 101 VAL A 101 VAL^? 16.85 CL CL D 145 A 102 PHE A 121 PHE.? 21.34 CL CL A 144 A 169 CYH A 104 CYH^? 10.13 CL CL D 145 coo -0.48 2.03 12.21 0.64 0.32 12.97 -30.86 -1.03 -27.28 -33.04 -1.05 -27.44 coo 0.51 5.20 15.97 0.26 4.09 18.50 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -27.84 -9.67 -31.52 -27.40 -12.40 -31.03 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 2 3 # 2 A 101 VAL A 122 VAL.? 16.79 CL CL D 145 A 102 PHE A 121 PHE.? 21.34 CL CL A 144 A 169 CYH A 104 CYH^? 10.13 CL CL D 145 coo -0.48 2.03 12.21 0.64 0.32 12.97 -32.69 -0.27 -31.86 -32.58 -2.33 -32.56 coo 0.51 5.20 15.97 0.26 4.09 18.50 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -27.84 -9.67 -31.52 -27.40 -12.40 -31.03 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 3 3 # 3 A 101 VAL B 101 VAL^? 18.17 CL CL A 144 A 102 PHE B 121 PHE.? 21.57 CL CL A 144 A 169 CYH B 104 CYH^? 16.50 CL CL A 144 coo -0.48 2.03 12.21 0.64 0.32 12.97 -16.64 -26.81 -16.50 -17.48 -27.69 -18.27 coo 0.51 5.20 15.97 0.26 4.09 18.50 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -23.20 -29.24 -9.27 -25.51 -28.44 -7.91 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 4 3 # 4 A 101 VAL B 122 VAL.? 21.81 CL CL A 144 A 102 PHE B 121 PHE.? 21.57 CL CL A 144 A 169 CYH B 104 CYH^? 16.50 CL CL A 144 coo -0.48 2.03 12.21 0.64 0.32 12.97 -16.21 -31.81 -16.78 -18.01 -32.26 -15.68 coo 0.51 5.20 15.97 0.26 4.09 18.50 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -23.20 -29.24 -9.27 -25.51 -28.44 -7.91 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 5 3 # 5 A 101 VAL C 101 VAL^? 18.22 CL CL A 144 A 102 PHE C 121 PHE.? 21.26 CL CL A 144 A 169 CYH C 104 CYH^? 16.50 CL CL A 144 coo -0.48 2.03 12.21 0.64 0.32 12.97 -36.11 -10.86 1.69 -37.10 -12.75 1.89 coo 0.51 5.20 15.97 0.26 4.09 18.50 -39.63 -15.47 4.86 -39.83 -16.41 2.24 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 6 3 # 6 A 101 VAL C 122 VAL.? 21.93 CL CL A 144 A 102 PHE C 121 PHE.? 21.26 CL CL A 144 A 169 CYH C 104 CYH^? 16.50 CL CL A 144 coo -0.48 2.03 12.21 0.64 0.32 12.97 -40.52 -10.78 4.14 -41.76 -10.22 2.44 coo 0.51 5.20 15.97 0.26 4.09 18.50 -39.63 -15.47 4.86 -39.83 -16.41 2.24 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -41.69 -6.23 -5.37 -41.91 -5.89 -8.20 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 7 3 # 7 A 101 VAL D 101 VAL^? 16.68 CL CL D 145 A 102 PHE D 121 PHE.? 21.38 CL CL D 145 A 169 CYH D 104 CYH^? 9.92 CL CL D 145 coo -0.48 2.03 12.21 0.64 0.32 12.97 -4.88 -17.41 -35.41 -3.77 -18.20 -37.13 coo 0.51 5.20 15.97 0.26 4.09 18.50 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -12.42 -12.02 -39.45 -13.14 -9.45 -40.35 ULMN 3 3s57_d00 OXIDOREDUCTASE/DNA user 8 3 # 8 A 101 VAL D 122 VAL.? 16.71 CL CL D 145 A 102 PHE D 121 PHE.? 21.38 CL CL D 145 A 169 CYH D 104 CYH^? 9.92 CL CL D 145 coo -0.48 2.03 12.21 0.64 0.32 12.97 -7.11 -21.08 -38.01 -8.33 -19.86 -39.33 coo 0.51 5.20 15.97 0.26 4.09 18.50 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 coo 4.56 -7.03 18.26 5.32 -4.76 16.88 -12.42 -12.02 -39.45 -13.14 -9.45 -40.35 3s57_d00 source 3s57 OXIDOREDUCTASE/DNA : 8 hits 3s57_d00 naa= 3 ULMN 4 3thx_d00 DNA BINDING PROTEIN/DNA user 1 4 # 1 A 41 ASP A 19 ASP~? 15.97 CL CL A 144 A 42 PHE C 14 PHE.? 11.62 CL CL A 144 A 79 VAL C 13 VAL^? 10.91 CL CL A 144 A 81 SER C 15 SER.? 10.60 CL CL A 144 coo -11.49 -6.95 34.02 -12.16 -8.53 35.26 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -8.04 -3.06 33.00 -7.11 -2.18 35.47 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 coo -5.58 1.49 30.28 -6.75 1.22 32.10 -36.71 -14.33 -7.96 -36.66 -15.56 -6.17 coo -10.21 -2.58 27.81 -11.76 -1.58 26.23 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 ULMN 4 3thx_d00 DNA BINDING PROTEIN/DNA user 2 4 # 2 A 41 ASP B 19 ASP~? 15.75 CL CL A 144 A 42 PHE A 14 PHE.? 11.46 CL CL A 144 A 79 VAL A 13 VAL^? 10.99 CL CL A 144 A 81 SER A 15 SER.? 10.59 CL CL A 144 coo -11.49 -6.95 34.02 -12.16 -8.53 35.26 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -8.04 -3.06 33.00 -7.11 -2.18 35.47 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 coo -5.58 1.49 30.28 -6.75 1.22 32.10 -33.25 -10.16 -23.25 -34.65 -8.46 -23.33 coo -10.21 -2.58 27.81 -11.76 -1.58 26.23 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 ULMN 4 3thx_d00 DNA BINDING PROTEIN/DNA user 3 4 # 3 A 41 ASP C 19 ASP~? 15.67 CL CL A 144 A 42 PHE B 14 PHE.? 11.43 CL CL A 144 A 79 VAL B 13 VAL^? 10.89 CL CL A 144 A 81 SER B 15 SER.? 10.55 CL CL A 144 coo -11.49 -6.95 34.02 -12.16 -8.53 35.26 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -8.04 -3.06 33.00 -7.11 -2.18 35.47 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 coo -5.58 1.49 30.28 -6.75 1.22 32.10 -26.29 -23.43 -16.65 -25.20 -24.08 -18.40 coo -10.21 -2.58 27.81 -11.76 -1.58 26.23 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 3thx_d00 source 3thx DNA BINDING PROTEIN/DNA : 3 hits 3thx_d00 naa= 4 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 1 3 # 1 C 61 LYS A 100 LYS^? 18.99 CL CL D 145 C 90 HIS A 87 HIS.? 23.42 CL CL A 144 C 91 GLN A 88 GLN.? 26.71 CL CL A 144 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -29.11 1.73 -25.37 -27.34 6.20 -25.84 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -45.63 1.89 -25.25 -47.71 2.14 -24.93 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 2 3 # 2 C 61 LYS C 100 LYS^? 20.71 O2S EPE A 145 C 90 HIS C 87 HIS.? 23.40 CL CL A 144 C 91 GLN C 88 GLN.? 26.49 CL CL A 144 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -32.91 -10.09 3.52 -31.08 -8.45 7.79 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 -39.02 -25.32 5.34 -39.49 -27.40 5.47 ULMN 3 4hp3_d00 DNA BINDING PROTEIN/DNA user 3 3 # 3 C 61 LYS D 100 LYS^? 18.85 CL CL D 145 C 90 HIS D 87 HIS.? 23.22 CL CL D 144 C 91 GLN D 88 GLN.? 26.72 CL CL D 144 coo -19.62 -7.95 11.61 -14.74 -11.23 10.80 -3.65 -17.98 -31.83 -3.73 -21.18 -28.01 coo -14.60 -21.92 8.98 -13.75 -22.48 7.16 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo -19.27 -22.51 13.20 -20.06 -20.67 12.43 6.01 -23.47 -44.11 7.56 -24.08 -45.47 4hp3_d00 source 4hp3 DNA BINDING PROTEIN/DNA : 3 hits 4hp3_d00 naa= 3 ULMN 3 2odj_o00 PORIN D user 1 3 # 1 A 156 HIS A 87 HIS.? 23.42 CL CL A 144 A 208 ASP A 19 ASP~? 15.97 CL CL A 144 A 296 SER A 34 SER~? 16.02 O1S EPE A 145 coo 12.72 17.48 24.71 12.80 19.37 23.81 -43.34 -1.79 -27.09 -45.33 -1.55 -27.72 coo 18.47 29.19 29.68 19.30 29.17 27.75 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 6.89 17.22 46.63 5.08 16.21 47.91 -32.76 6.30 -10.88 -32.27 4.90 -8.97 ULMN 3 2odj_o00 PORIN D user 2 3 # 2 A 156 HIS B 87 HIS.? 23.18 CL CL D 145 A 208 ASP B 19 ASP~? 15.75 CL CL A 144 A 296 SER B 34 SER~? 6.65 CL CL D 145 coo 12.72 17.48 24.71 12.80 19.37 23.81 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 18.47 29.19 29.68 19.30 29.17 27.75 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 6.89 17.22 46.63 5.08 16.21 47.91 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 2odj_o00 PORIN D user 3 3 # 3 A 156 HIS B 87 HIS.? 23.18 CL CL D 145 A 208 ASP B 19 ASP~? 15.75 CL CL A 144 A 296 SER D 105 SER~? 6.83 CL CL D 145 coo 12.72 17.48 24.71 12.80 19.37 23.81 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo 18.47 29.19 29.68 19.30 29.17 27.75 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 6.89 17.22 46.63 5.08 16.21 47.91 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 ULMN 3 2odj_o00 PORIN D user 4 3 # 4 A 156 HIS C 87 HIS.? 23.40 CL CL A 144 A 208 ASP C 19 ASP~? 15.67 CL CL A 144 A 296 SER C 34 SER~? 16.74 O2S EPE A 145 coo 12.72 17.48 24.71 12.80 19.37 23.81 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 18.47 29.19 29.68 19.30 29.17 27.75 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 6.89 17.22 46.63 5.08 16.21 47.91 -20.19 -19.13 3.46 -19.76 -20.67 1.72 ULMN 3 2odj_o00 PORIN D user 5 3 # 5 A 156 HIS C 87 HIS.? 23.40 CL CL A 144 A 208 ASP C 19 ASP~? 15.67 CL CL A 144 A 296 SER C 105 SER~? 20.92 CL CL A 144 coo 12.72 17.48 24.71 12.80 19.37 23.81 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo 18.47 29.19 29.68 19.30 29.17 27.75 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 6.89 17.22 46.63 5.08 16.21 47.91 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 ULMN 3 2odj_o00 PORIN D user 6 3 # 6 A 156 HIS D 87 HIS.? 23.22 CL CL D 144 A 208 ASP D 19 ASP~? 15.85 CL CL D 144 A 296 SER D 34 SER~? 16.19 O3S EPE D 146 coo 12.72 17.48 24.71 12.80 19.37 23.81 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo 18.47 29.19 29.68 19.30 29.17 27.75 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 6.89 17.22 46.63 5.08 16.21 47.91 10.70 -14.90 -26.85 11.77 -13.07 -27.90 2odj_o00 source 2ODJ PORIN D : 6 hits 2odj_o00 naa= 3 ULMN 3 2odj_o01 PORIN D user 1 3 # 1 B 156 HIS B 87 HIS.? 23.18 CL CL D 145 B 208 ASP B 19 ASP~? 15.75 CL CL A 144 B 296 SER B 34 SER~? 6.65 CL CL D 145 coo -2.35 -7.60 76.02 -1.45 -9.49 76.24 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo -7.90 -19.74 71.88 -5.88 -19.94 71.25 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -24.72 -6.64 81.21 -24.66 -4.26 81.67 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 ULMN 3 2odj_o01 PORIN D user 2 3 # 2 B 156 HIS B 87 HIS.? 23.18 CL CL D 145 B 208 ASP B 19 ASP~? 15.75 CL CL A 144 B 296 SER D 105 SER~? 6.83 CL CL D 145 coo -2.35 -7.60 76.02 -1.45 -9.49 76.24 -22.02 -31.00 -27.17 -22.59 -32.25 -28.75 coo -7.90 -19.74 71.88 -5.88 -19.94 71.25 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -24.72 -6.64 81.21 -24.66 -4.26 81.67 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 ULMN 3 2odj_o01 PORIN D user 3 3 # 3 B 156 HIS C 87 HIS.? 23.40 CL CL A 144 B 208 ASP C 19 ASP~? 15.67 CL CL A 144 B 296 SER C 34 SER~? 16.74 O2S EPE A 145 coo -2.35 -7.60 76.02 -1.45 -9.49 76.24 -40.94 -22.54 2.26 -42.04 -24.19 2.95 coo -7.90 -19.74 71.88 -5.88 -19.94 71.25 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -24.72 -6.64 81.21 -24.66 -4.26 81.67 -20.19 -19.13 3.46 -19.76 -20.67 1.72 ULMN 3 2odj_o01 PORIN D user 4 3 # 4 B 156 HIS D 87 HIS.? 23.22 CL CL D 144 B 208 ASP D 19 ASP~? 15.85 CL CL D 144 B 296 SER D 34 SER~? 16.19 O3S EPE D 146 coo -2.35 -7.60 76.02 -1.45 -9.49 76.24 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo -7.90 -19.74 71.88 -5.88 -19.94 71.25 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo -24.72 -6.64 81.21 -24.66 -4.26 81.67 10.70 -14.90 -26.85 11.77 -13.07 -27.90 ULMN 3 2odj_o01 PORIN D user 5 3 # 5 B 156 HIS D 87 HIS.? 23.22 CL CL D 144 B 208 ASP D 117 ASP~? 21.71 CL CL D 145 B 296 SER B 34 SER~? 6.65 CL CL D 145 coo -2.35 -7.60 76.02 -1.45 -9.49 76.24 2.16 -20.58 -45.32 2.88 -21.47 -47.08 coo -7.90 -19.74 71.88 -5.88 -19.94 71.25 -12.87 -21.66 -47.77 -14.70 -22.12 -48.75 coo -24.72 -6.64 81.21 -24.66 -4.26 81.67 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 2odj_o01 source 2ODJ PORIN D : 5 hits 2odj_o01 naa= 3 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 1 3 # 1 A 130 SER A 10 SER^? 8.69 O1S EPE A 145 A 166 PHE A 42 PHE^? 15.34 CL CL A 144 A 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 2 3 # 2 A 130 SER A 10 SER^? 8.69 O1S EPE A 145 A 166 PHE A 102 PHE^? 11.63 CL CL D 145 A 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 3 3 # 3 A 130 SER A 10 SER^? 8.69 O1S EPE A 145 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 4 3 # 4 A 130 SER A 15 SER.? 10.59 CL CL A 144 A 166 PHE A 42 PHE^? 15.34 CL CL A 144 A 182 PHE A 41 PHE^? 11.09 CL CL D 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 5 3 # 5 A 130 SER A 15 SER.? 10.59 CL CL A 144 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 6 3 # 6 A 130 SER A 15 SER.? 10.59 CL CL A 144 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 7 3 # 7 A 130 SER A 15 SER.? 10.59 CL CL A 144 A 166 PHE C 142 PHE^? -6.66 CL CL A 144s A 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 8 3 # 8 A 130 SER A 15 SER.? 10.59 CL CL A 144 A 166 PHE C 142 PHE^? -6.66 CL CL A 144s A 182 PHE C 44 PHE~? 15.66 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 9 3 # 9 A 130 SER A 54 SER~? 22.83 CL CL A 144 A 166 PHE A 42 PHE^? 15.34 CL CL A 144 A 182 PHE A 121 PHE.? 21.34 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.02 -8.67 -33.86 -43.33 -9.84 -31.84 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 10 3 # 10 A 130 SER A 105 SER~? 6.77 CL CL D 145 A 166 PHE A 41 PHE^? 11.09 CL CL D 145 A 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 11 3 # 11 A 130 SER A 105 SER~? 6.77 CL CL D 145 A 166 PHE A 42 PHE^? 15.34 CL CL A 144 A 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 12 3 # 12 A 130 SER A 105 SER~? 6.77 CL CL D 145 A 166 PHE A 102 PHE^? 11.63 CL CL D 145 A 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 13 3 # 13 A 130 SER A 105 SER~? 6.77 CL CL D 145 A 166 PHE A 102 PHE^? 11.63 CL CL D 145 A 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 14 3 # 14 A 130 SER B 10 SER^? 8.49 O2S EPE A 145 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 15 3 # 15 A 130 SER B 10 SER^? 8.49 O2S EPE A 145 A 166 PHE B 42 PHE^? 15.32 CL CL A 144 A 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 16 3 # 16 A 130 SER B 10 SER^? 8.49 O2S EPE A 145 A 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 17 3 # 17 A 130 SER B 10 SER^? 8.49 O2S EPE A 145 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 18 3 # 18 A 130 SER B 15 SER.? 10.55 CL CL A 144 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE A 44 PHE~? 15.48 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 19 3 # 19 A 130 SER B 15 SER.? 10.55 CL CL A 144 A 166 PHE A 142 PHE^? -6.60 CL CL A 144s A 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 20 3 # 20 A 130 SER B 15 SER.? 10.55 CL CL A 144 A 166 PHE B 42 PHE^? 15.32 CL CL A 144 A 182 PHE B 41 PHE^? 12.26 O2S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 21 3 # 21 A 130 SER B 15 SER.? 10.55 CL CL A 144 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 22 3 # 22 A 130 SER B 15 SER.? 10.55 CL CL A 144 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 23 3 # 23 A 130 SER B 54 SER~? 22.69 CL CL A 144 A 166 PHE B 42 PHE^? 15.32 CL CL A 144 A 182 PHE B 121 PHE.? 21.57 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -27.89 -37.22 -22.85 -28.75 -34.99 -22.56 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 24 3 # 24 A 130 SER B 105 SER~? 20.82 CL CL A 144 A 166 PHE B 41 PHE^? 12.26 O2S EPE A 145 A 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 25 3 # 25 A 130 SER B 105 SER~? 20.82 CL CL A 144 A 166 PHE B 42 PHE^? 15.32 CL CL A 144 A 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 26 3 # 26 A 130 SER B 105 SER~? 20.82 CL CL A 144 A 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 27 3 # 27 A 130 SER B 105 SER~? 20.82 CL CL A 144 A 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 A 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 28 3 # 28 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 29 3 # 29 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE C 41 PHE^? 13.95 CL CL A 144 A 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 30 3 # 30 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE C 41 PHE^? 13.95 CL CL A 144 A 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 31 3 # 31 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE C 42 PHE^? 15.30 CL CL A 144 A 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 32 3 # 32 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE C 102 PHE^? 16.65 O1S EPE A 145 A 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 33 3 # 33 A 130 SER C 10 SER^? 8.67 O1S EPE A 145 A 166 PHE C 142 PHE^? -6.66 CL CL A 144s A 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 34 3 # 34 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 35 3 # 35 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE B 142 PHE^? -6.58 CL CL A 144s A 182 PHE B 44 PHE~? 15.63 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 36 3 # 36 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE C 42 PHE^? 15.30 CL CL A 144 A 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 37 3 # 37 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE C 42 PHE^? 15.30 CL CL A 144 A 182 PHE C 131 PHE~? 11.28 O1S EPE A 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 38 3 # 38 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE C 142 PHE^? -6.66 CL CL A 144s A 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 39 3 # 39 A 130 SER C 15 SER.? 10.60 CL CL A 144 A 166 PHE C 142 PHE^? -6.66 CL CL A 144s A 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 40 3 # 40 A 130 SER C 105 SER~? 20.92 CL CL A 144 A 166 PHE C 41 PHE^? 13.95 CL CL A 144 A 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 41 3 # 41 A 130 SER C 105 SER~? 20.92 CL CL A 144 A 166 PHE C 41 PHE^? 13.95 CL CL A 144 A 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 42 3 # 42 A 130 SER C 105 SER~? 20.92 CL CL A 144 A 166 PHE C 42 PHE^? 15.30 CL CL A 144 A 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 43 3 # 43 A 130 SER C 105 SER~? 20.92 CL CL A 144 A 166 PHE C 102 PHE^? 16.65 O1S EPE A 145 A 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 44 3 # 44 A 130 SER C 105 SER~? 20.92 CL CL A 144 A 166 PHE C 131 PHE~? 11.28 O1S EPE A 145 A 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 45 3 # 45 A 130 SER D 10 SER^? 8.71 O3S EPE D 146 A 166 PHE D 42 PHE^? 15.36 CL CL D 144 A 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 46 3 # 46 A 130 SER D 10 SER^? 8.71 O3S EPE D 146 A 166 PHE D 102 PHE^? 11.51 CL CL D 145 A 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 47 3 # 47 A 130 SER D 15 SER.? 10.54 CL CL D 144 A 166 PHE D 42 PHE^? 15.36 CL CL D 144 A 182 PHE D 41 PHE^? 10.83 CL CL D 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 48 3 # 48 A 130 SER D 15 SER.? 10.54 CL CL D 144 A 166 PHE D 142 PHE^? -6.62 CL CL D 144s A 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -3.96 -2.13 -39.55 -5.77 -2.32 -41.61 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 49 3 # 49 A 130 SER D 54 SER~? 22.73 CL CL D 144 A 166 PHE D 42 PHE^? 15.36 CL CL D 144 A 182 PHE D 121 PHE.? 21.38 CL CL D 145 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -4.63 -19.29 -51.90 -3.66 -17.18 -51.11 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 50 3 # 50 A 130 SER D 105 SER~? 6.83 CL CL D 145 A 166 PHE D 41 PHE^? 10.83 CL CL D 145 A 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 51 3 # 51 A 130 SER D 105 SER~? 6.83 CL CL D 145 A 166 PHE D 42 PHE^? 15.36 CL CL D 144 A 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 52 3 # 52 A 130 SER D 105 SER~? 6.83 CL CL D 145 A 166 PHE D 102 PHE^? 11.51 CL CL D 145 A 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o00 CARBOXYLESTERASE NP user 53 3 # 53 A 130 SER D 105 SER~? 6.83 CL CL D 145 A 166 PHE D 102 PHE^? 11.51 CL CL D 145 A 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -46.28 37.24 81.97 -44.96 39.32 82.40 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -36.62 39.62 84.60 -38.76 41.24 85.25 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -36.55 45.66 79.22 -38.34 43.94 80.53 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 2r11_o00 source 2R11 CARBOXYLESTERASE NP : 53 hits 2r11_o00 naa= 3 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 1 3 # 1 B 130 SER A 10 SER^? 8.69 O1S EPE A 145 B 166 PHE A 42 PHE^? 15.34 CL CL A 144 B 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 2 3 # 2 B 130 SER A 15 SER.? 10.59 CL CL A 144 B 166 PHE A 42 PHE^? 15.34 CL CL A 144 B 182 PHE A 41 PHE^? 11.09 CL CL D 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 3 3 # 3 B 130 SER A 15 SER.? 10.59 CL CL A 144 B 166 PHE A 142 PHE^? -6.60 CL CL A 144s B 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 4 3 # 4 B 130 SER A 15 SER.? 10.59 CL CL A 144 B 166 PHE A 142 PHE^? -6.60 CL CL A 144s B 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 5 3 # 5 B 130 SER A 15 SER.? 10.59 CL CL A 144 B 166 PHE C 142 PHE^? -6.66 CL CL A 144s B 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 6 3 # 6 B 130 SER A 15 SER.? 10.59 CL CL A 144 B 166 PHE C 142 PHE^? -6.66 CL CL A 144s B 182 PHE C 44 PHE~? 15.66 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 7 3 # 7 B 130 SER A 54 SER~? 22.83 CL CL A 144 B 166 PHE A 42 PHE^? 15.34 CL CL A 144 B 182 PHE A 121 PHE.? 21.34 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -44.02 -8.67 -33.86 -43.33 -9.84 -31.84 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 8 3 # 8 B 130 SER A 105 SER~? 6.77 CL CL D 145 B 166 PHE A 42 PHE^? 15.34 CL CL A 144 B 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 9 3 # 9 B 130 SER A 105 SER~? 6.77 CL CL D 145 B 166 PHE A 102 PHE^? 11.63 CL CL D 145 B 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 10 3 # 10 B 130 SER B 10 SER^? 8.49 O2S EPE A 145 B 166 PHE A 142 PHE^? -6.60 CL CL A 144s B 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 11 3 # 11 B 130 SER B 10 SER^? 8.49 O2S EPE A 145 B 166 PHE B 42 PHE^? 15.32 CL CL A 144 B 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 12 3 # 12 B 130 SER B 10 SER^? 8.49 O2S EPE A 145 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 13 3 # 13 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE A 142 PHE^? -6.60 CL CL A 144s B 182 PHE A 44 PHE~? 15.48 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 14 3 # 14 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE A 142 PHE^? -6.60 CL CL A 144s B 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 15 3 # 15 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE B 42 PHE^? 15.32 CL CL A 144 B 182 PHE B 41 PHE^? 12.26 O2S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 16 3 # 16 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE B 111 PHE~? 20.82 CL CL A 144 B 182 PHE B 110 PHE~? 21.03 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 17 3 # 17 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 18 3 # 18 B 130 SER B 15 SER.? 10.55 CL CL A 144 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 19 3 # 19 B 130 SER B 54 SER~? 22.69 CL CL A 144 B 166 PHE B 42 PHE^? 15.32 CL CL A 144 B 182 PHE B 121 PHE.? 21.57 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -27.89 -37.22 -22.85 -28.75 -34.99 -22.56 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 20 3 # 20 B 130 SER B 105 SER~? 20.82 CL CL A 144 B 166 PHE B 42 PHE^? 15.32 CL CL A 144 B 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 21 3 # 21 B 130 SER B 105 SER~? 20.82 CL CL A 144 B 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 B 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 22 3 # 22 B 130 SER C 10 SER^? 8.67 O1S EPE A 145 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 23 3 # 23 B 130 SER C 10 SER^? 8.67 O1S EPE A 145 B 166 PHE C 41 PHE^? 13.95 CL CL A 144 B 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 24 3 # 24 B 130 SER C 10 SER^? 8.67 O1S EPE A 145 B 166 PHE C 42 PHE^? 15.30 CL CL A 144 B 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 25 3 # 25 B 130 SER C 10 SER^? 8.67 O1S EPE A 145 B 166 PHE C 142 PHE^? -6.66 CL CL A 144s B 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 26 3 # 26 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 27 3 # 27 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE B 142 PHE^? -6.58 CL CL A 144s B 182 PHE B 44 PHE~? 15.63 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 28 3 # 28 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE C 42 PHE^? 15.30 CL CL A 144 B 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 29 3 # 29 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE C 42 PHE^? 15.30 CL CL A 144 B 182 PHE C 131 PHE~? 11.28 O1S EPE A 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 30 3 # 30 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE C 142 PHE^? -6.66 CL CL A 144s B 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 31 3 # 31 B 130 SER C 15 SER.? 10.60 CL CL A 144 B 166 PHE C 142 PHE^? -6.66 CL CL A 144s B 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 32 3 # 32 B 130 SER C 105 SER~? 20.92 CL CL A 144 B 166 PHE C 41 PHE^? 13.95 CL CL A 144 B 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 33 3 # 33 B 130 SER C 105 SER~? 20.92 CL CL A 144 B 166 PHE C 42 PHE^? 15.30 CL CL A 144 B 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 34 3 # 34 B 130 SER D 10 SER^? 8.71 O3S EPE D 146 B 166 PHE D 42 PHE^? 15.36 CL CL D 144 B 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 35 3 # 35 B 130 SER D 15 SER.? 10.54 CL CL D 144 B 166 PHE D 42 PHE^? 15.36 CL CL D 144 B 182 PHE D 41 PHE^? 10.83 CL CL D 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 36 3 # 36 B 130 SER D 15 SER.? 10.54 CL CL D 144 B 166 PHE D 142 PHE^? -6.62 CL CL D 144s B 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -3.96 -2.13 -39.55 -5.77 -2.32 -41.61 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 37 3 # 37 B 130 SER D 54 SER~? 22.73 CL CL D 144 B 166 PHE D 42 PHE^? 15.36 CL CL D 144 B 182 PHE D 121 PHE.? 21.38 CL CL D 145 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -4.63 -19.29 -51.90 -3.66 -17.18 -51.11 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 38 3 # 38 B 130 SER D 105 SER~? 6.83 CL CL D 145 B 166 PHE D 42 PHE^? 15.36 CL CL D 144 B 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o01 CARBOXYLESTERASE NP user 39 3 # 39 B 130 SER D 105 SER~? 6.83 CL CL D 145 B 166 PHE D 102 PHE^? 11.51 CL CL D 145 B 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -19.94 46.29 97.83 -22.38 46.56 97.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -29.59 43.40 95.66 -28.22 45.54 94.50 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -32.72 50.15 98.46 -30.32 48.85 97.77 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 2r11_o01 source 2R11 CARBOXYLESTERASE NP : 39 hits 2r11_o01 naa= 3 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 1 3 # 1 C 130 SER A 10 SER^? 8.69 O1S EPE A 145 C 166 PHE A 42 PHE^? 15.34 CL CL A 144 C 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 2 3 # 2 C 130 SER A 10 SER^? 8.69 O1S EPE A 145 C 166 PHE A 102 PHE^? 11.63 CL CL D 145 C 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 3 3 # 3 C 130 SER A 10 SER^? 8.69 O1S EPE A 145 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -27.14 -4.57 -18.63 -24.88 -3.66 -19.12 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 4 3 # 4 C 130 SER A 15 SER.? 10.59 CL CL A 144 C 166 PHE A 42 PHE^? 15.34 CL CL A 144 C 182 PHE A 41 PHE^? 11.09 CL CL D 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 5 3 # 5 C 130 SER A 15 SER.? 10.59 CL CL A 144 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 6 3 # 6 C 130 SER A 15 SER.? 10.59 CL CL A 144 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 7 3 # 7 C 130 SER A 15 SER.? 10.59 CL CL A 144 C 166 PHE C 142 PHE^? -6.66 CL CL A 144s C 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 8 3 # 8 C 130 SER A 15 SER.? 10.59 CL CL A 144 C 166 PHE C 142 PHE^? -6.66 CL CL A 144s C 182 PHE C 44 PHE~? 15.66 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 9 3 # 9 C 130 SER A 54 SER~? 22.83 CL CL A 144 C 166 PHE A 42 PHE^? 15.34 CL CL A 144 C 182 PHE A 121 PHE.? 21.34 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.02 -8.67 -33.86 -43.33 -9.84 -31.84 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 10 3 # 10 C 130 SER A 105 SER~? 6.77 CL CL D 145 C 166 PHE A 41 PHE^? 11.09 CL CL D 145 C 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 11 3 # 11 C 130 SER A 105 SER~? 6.77 CL CL D 145 C 166 PHE A 42 PHE^? 15.34 CL CL A 144 C 182 PHE A 14 PHE.? 11.46 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -32.91 -16.22 -24.10 -33.31 -18.76 -25.05 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 12 3 # 12 C 130 SER A 105 SER~? 6.77 CL CL D 145 C 166 PHE A 102 PHE^? 11.63 CL CL D 145 C 182 PHE A 42 PHE^? 15.34 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 13 3 # 13 C 130 SER A 105 SER~? 6.77 CL CL D 145 C 166 PHE A 102 PHE^? 11.63 CL CL D 145 C 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 14 3 # 14 C 130 SER B 10 SER^? 8.49 O2S EPE A 145 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 15 3 # 15 C 130 SER B 10 SER^? 8.49 O2S EPE A 145 C 166 PHE B 42 PHE^? 15.32 CL CL A 144 C 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 16 3 # 16 C 130 SER B 10 SER^? 8.49 O2S EPE A 145 C 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 17 3 # 17 C 130 SER B 10 SER^? 8.49 O2S EPE A 145 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 18 3 # 18 C 130 SER B 15 SER.? 10.55 CL CL A 144 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE A 44 PHE~? 15.48 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 19 3 # 19 C 130 SER B 15 SER.? 10.55 CL CL A 144 C 166 PHE A 142 PHE^? -6.60 CL CL A 144s C 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 20 3 # 20 C 130 SER B 15 SER.? 10.55 CL CL A 144 C 166 PHE B 42 PHE^? 15.32 CL CL A 144 C 182 PHE B 41 PHE^? 12.26 O2S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 21 3 # 21 C 130 SER B 15 SER.? 10.55 CL CL A 144 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 22 3 # 22 C 130 SER B 15 SER.? 10.55 CL CL A 144 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 23 3 # 23 C 130 SER B 54 SER~? 22.69 CL CL A 144 C 166 PHE B 42 PHE^? 15.32 CL CL A 144 C 182 PHE B 121 PHE.? 21.57 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -27.89 -37.22 -22.85 -28.75 -34.99 -22.56 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 24 3 # 24 C 130 SER B 105 SER~? 20.82 CL CL A 144 C 166 PHE B 41 PHE^? 12.26 O2S EPE A 145 C 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 25 3 # 25 C 130 SER B 105 SER~? 20.82 CL CL A 144 C 166 PHE B 42 PHE^? 15.32 CL CL A 144 C 182 PHE B 14 PHE.? 11.43 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -31.72 -23.92 -13.87 -34.17 -24.82 -13.03 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 26 3 # 26 C 130 SER B 105 SER~? 20.82 CL CL A 144 C 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 182 PHE B 42 PHE^? 15.32 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 27 3 # 27 C 130 SER B 105 SER~? 20.82 CL CL A 144 C 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 C 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 28 3 # 28 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 29 3 # 29 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE C 41 PHE^? 13.95 CL CL A 144 C 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 30 3 # 30 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE C 41 PHE^? 13.95 CL CL A 144 C 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 31 3 # 31 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE C 42 PHE^? 15.30 CL CL A 144 C 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 32 3 # 32 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE C 102 PHE^? 16.65 O1S EPE A 145 C 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 33 3 # 33 C 130 SER C 10 SER^? 8.67 O1S EPE A 145 C 166 PHE C 142 PHE^? -6.66 CL CL A 144s C 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 34 3 # 34 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 35 3 # 35 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE B 142 PHE^? -6.58 CL CL A 144s C 182 PHE B 44 PHE~? 15.63 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -31.86 -28.13 -10.78 -32.58 -28.09 -8.11 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 36 3 # 36 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE C 42 PHE^? 15.30 CL CL A 144 C 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 37 3 # 37 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE C 42 PHE^? 15.30 CL CL A 144 C 182 PHE C 131 PHE~? 11.28 O1S EPE A 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 38 3 # 38 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE C 142 PHE^? -6.66 CL CL A 144s C 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 39 3 # 39 C 130 SER C 15 SER.? 10.60 CL CL A 144 C 166 PHE C 142 PHE^? -6.66 CL CL A 144s C 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 40 3 # 40 C 130 SER C 105 SER~? 20.92 CL CL A 144 C 166 PHE C 41 PHE^? 13.95 CL CL A 144 C 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 41 3 # 41 C 130 SER C 105 SER~? 20.92 CL CL A 144 C 166 PHE C 41 PHE^? 13.95 CL CL A 144 C 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 42 3 # 42 C 130 SER C 105 SER~? 20.92 CL CL A 144 C 166 PHE C 42 PHE^? 15.30 CL CL A 144 C 182 PHE C 14 PHE.? 11.62 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.56 -13.55 -13.39 -41.43 -13.65 -15.42 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 43 3 # 43 C 130 SER C 105 SER~? 20.92 CL CL A 144 C 166 PHE C 102 PHE^? 16.65 O1S EPE A 145 C 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -35.81 -6.60 -0.17 -33.81 -5.63 1.48 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 44 3 # 44 C 130 SER C 105 SER~? 20.92 CL CL A 144 C 166 PHE C 131 PHE~? 11.28 O1S EPE A 145 C 182 PHE C 42 PHE^? 15.30 CL CL A 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -44.14 -3.35 -4.89 -42.92 -1.28 -5.37 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 45 3 # 45 C 130 SER D 10 SER^? 8.71 O3S EPE D 146 C 166 PHE D 42 PHE^? 15.36 CL CL D 144 C 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 46 3 # 46 C 130 SER D 10 SER^? 8.71 O3S EPE D 146 C 166 PHE D 102 PHE^? 11.51 CL CL D 145 C 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -1.45 -8.76 -31.59 -2.81 -8.96 -29.58 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 47 3 # 47 C 130 SER D 15 SER.? 10.54 CL CL D 144 C 166 PHE D 42 PHE^? 15.36 CL CL D 144 C 182 PHE D 41 PHE^? 10.83 CL CL D 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 48 3 # 48 C 130 SER D 15 SER.? 10.54 CL CL D 144 C 166 PHE D 142 PHE^? -6.62 CL CL D 144s C 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -3.96 -2.13 -39.55 -5.77 -2.32 -41.61 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 49 3 # 49 C 130 SER D 54 SER~? 22.73 CL CL D 144 C 166 PHE D 42 PHE^? 15.36 CL CL D 144 C 182 PHE D 121 PHE.? 21.38 CL CL D 145 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -4.63 -19.29 -51.90 -3.66 -17.18 -51.11 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 50 3 # 50 C 130 SER D 105 SER~? 6.83 CL CL D 145 C 166 PHE D 41 PHE^? 10.83 CL CL D 145 C 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 51 3 # 51 C 130 SER D 105 SER~? 6.83 CL CL D 145 C 166 PHE D 42 PHE^? 15.36 CL CL D 144 C 182 PHE D 14 PHE.? 11.55 CL CL D 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -5.77 -4.60 -44.36 -7.08 -3.34 -46.47 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 52 3 # 52 C 130 SER D 105 SER~? 6.83 CL CL D 145 C 166 PHE D 102 PHE^? 11.51 CL CL D 145 C 182 PHE D 42 PHE^? 15.36 CL CL D 144 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 ULMN 3 2r11_o02 CARBOXYLESTERASE NP user 53 3 # 53 C 130 SER D 105 SER~? 6.83 CL CL D 145 C 166 PHE D 102 PHE^? 11.51 CL CL D 145 C 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -2.19 64.27 51.12 -3.34 62.10 50.60 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -11.14 61.91 46.89 -9.88 60.30 48.76 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -7.71 55.92 42.70 -7.18 57.60 44.85 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 2r11_o02 source 2R11 CARBOXYLESTERASE NP : 53 hits 2r11_o02 naa= 3 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 1 3 # 1 D 130 SER A 15 SER.? 10.59 CL CL A 144 D 166 PHE A 42 PHE^? 15.34 CL CL A 144 D 182 PHE A 41 PHE^? 11.09 CL CL D 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -26.75 -6.55 -24.97 -24.69 -4.74 -24.40 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 2 3 # 2 D 130 SER A 15 SER.? 10.59 CL CL A 144 D 166 PHE A 142 PHE^? -6.60 CL CL A 144s D 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 3 3 # 3 D 130 SER A 15 SER.? 10.59 CL CL A 144 D 166 PHE A 142 PHE^? -6.60 CL CL A 144s D 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 4 3 # 4 D 130 SER A 15 SER.? 10.59 CL CL A 144 D 166 PHE C 142 PHE^? -6.66 CL CL A 144s D 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 5 3 # 5 D 130 SER A 15 SER.? 10.59 CL CL A 144 D 166 PHE C 142 PHE^? -6.66 CL CL A 144s D 182 PHE C 44 PHE~? 15.66 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -37.08 -14.45 -23.60 -36.79 -15.47 -21.43 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -43.65 -10.51 -12.73 -44.09 -8.18 -14.19 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 6 3 # 6 D 130 SER A 54 SER~? 22.83 CL CL A 144 D 166 PHE A 42 PHE^? 15.34 CL CL A 144 D 182 PHE A 121 PHE.? 21.34 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -44.02 -8.67 -33.86 -43.33 -9.84 -31.84 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -33.94 -6.93 -27.39 -35.37 -5.18 -25.73 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -36.80 0.91 -29.53 -37.53 -1.54 -28.41 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 7 3 # 7 D 130 SER A 105 SER~? 6.77 CL CL D 145 D 166 PHE A 102 PHE^? 11.63 CL CL D 145 D 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -26.22 -10.25 -34.90 -23.84 -10.17 -34.52 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -26.61 -2.82 -28.07 -25.08 -0.64 -27.33 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 8 3 # 8 D 130 SER B 10 SER^? 8.49 O2S EPE A 145 D 166 PHE A 142 PHE^? -6.60 CL CL A 144s D 182 PHE A 131 PHE~? 8.85 O3S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -23.22 -9.05 -23.48 -23.57 -10.09 -20.88 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 9 3 # 9 D 130 SER B 10 SER^? 8.49 O2S EPE A 145 D 166 PHE B 142 PHE^? -6.58 CL CL A 144s D 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -19.33 -17.30 -14.97 -17.73 -16.83 -13.18 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 10 3 # 10 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE A 142 PHE^? -6.60 CL CL A 144s D 182 PHE A 44 PHE~? 15.48 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -31.75 -17.20 -28.98 -29.62 -18.87 -29.75 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 11 3 # 11 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE A 142 PHE^? -6.60 CL CL A 144s D 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 12 3 # 12 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE B 42 PHE^? 15.32 CL CL A 144 D 182 PHE B 41 PHE^? 12.26 O2S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -20.51 -22.94 -11.78 -18.21 -21.64 -10.88 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 13 3 # 13 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE B 111 PHE~? 20.82 CL CL A 144 D 182 PHE B 110 PHE~? 21.03 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -31.67 -35.16 -11.51 -33.33 -32.92 -11.92 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -31.84 -33.04 -5.84 -32.10 -31.15 -3.77 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 14 3 # 14 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE B 142 PHE^? -6.58 CL CL A 144s D 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 15 3 # 15 D 130 SER B 15 SER.? 10.55 CL CL A 144 D 166 PHE B 142 PHE^? -6.58 CL CL A 144s D 182 PHE C 142 PHE^? -6.66 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -31.66 -24.94 -18.24 -32.80 -22.80 -18.34 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 16 3 # 16 D 130 SER B 54 SER~? 22.69 CL CL A 144 D 166 PHE B 42 PHE^? 15.32 CL CL A 144 D 182 PHE B 121 PHE.? 21.57 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -27.89 -37.22 -22.85 -28.75 -34.99 -22.56 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -23.10 -27.75 -17.00 -22.30 -26.80 -19.51 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -16.81 -31.27 -21.69 -19.52 -30.71 -22.08 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 17 3 # 17 D 130 SER B 105 SER~? 20.82 CL CL A 144 D 166 PHE B 102 PHE^? 16.45 O2S EPE A 145 D 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -22.88 -31.86 -6.52 -22.00 -30.65 -4.58 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -16.80 -25.90 -11.93 -14.40 -24.56 -11.65 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 18 3 # 18 D 130 SER C 10 SER^? 8.67 O1S EPE A 145 D 166 PHE B 142 PHE^? -6.58 CL CL A 144s D 182 PHE B 131 PHE~? 9.25 O2S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -21.30 -20.61 -8.44 -22.83 -18.44 -9.26 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 19 3 # 19 D 130 SER C 10 SER^? 8.67 O1S EPE A 145 D 166 PHE C 142 PHE^? -6.66 CL CL A 144s D 182 PHE B 142 PHE^? -6.58 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -28.52 -10.74 -4.79 -27.70 -8.57 -4.05 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -34.01 -12.30 -13.91 -36.67 -11.93 -14.57 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 20 3 # 20 D 130 SER C 15 SER.? 10.60 CL CL A 144 D 166 PHE B 142 PHE^? -6.58 CL CL A 144s D 182 PHE A 142 PHE^? -6.60 CL CL A 144s coo -32.42 55.27 46.18 -30.51 54.94 47.67 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -29.74 -18.65 -12.94 -31.21 -20.92 -12.11 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -29.58 -14.91 -19.71 -30.17 -16.40 -21.97 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 21 3 # 21 D 130 SER C 15 SER.? 10.60 CL CL A 144 D 166 PHE C 42 PHE^? 15.30 CL CL A 144 D 182 PHE C 41 PHE^? 13.95 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -36.68 -7.66 -5.84 -38.44 -5.69 -6.71 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 22 3 # 22 D 130 SER C 15 SER.? 10.60 CL CL A 144 D 166 PHE C 42 PHE^? 15.30 CL CL A 144 D 182 PHE C 131 PHE~? 11.28 O1S EPE A 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -39.36 -13.49 -3.46 -37.88 -15.46 -2.19 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -33.49 -5.86 -5.07 -32.32 -8.32 -4.62 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 23 3 # 23 D 130 SER C 15 SER.? 10.60 CL CL A 144 D 166 PHE C 111 PHE~? 21.07 CL CL A 144 D 182 PHE C 110 PHE~? 21.09 CL CL A 144 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -39.97 -17.62 -11.45 -38.45 -18.08 -13.19 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -50.06 -10.80 -9.50 -48.81 -11.85 -11.73 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -48.65 -5.68 -12.24 -47.16 -3.89 -13.77 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 24 3 # 24 D 130 SER D 15 SER.? 10.54 CL CL D 144 D 166 PHE D 42 PHE^? 15.36 CL CL D 144 D 182 PHE D 41 PHE^? 10.83 CL CL D 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -7.11 -10.47 -34.64 -7.32 -10.90 -31.87 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 25 3 # 25 D 130 SER D 15 SER.? 10.54 CL CL D 144 D 166 PHE D 111 PHE~? 18.80 CL CL D 145 D 182 PHE D 110 PHE~? 14.54 CL CL D 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -13.55 -11.13 -49.68 -12.29 -8.64 -49.81 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -17.33 -7.60 -46.75 -18.21 -5.55 -45.07 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 26 3 # 26 D 130 SER D 15 SER.? 10.54 CL CL D 144 D 166 PHE D 142 PHE^? -6.62 CL CL D 144s D 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -2.48 -7.02 -46.28 -1.29 -4.94 -45.89 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -3.96 -2.13 -39.55 -5.77 -2.32 -41.61 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 27 3 # 27 D 130 SER D 54 SER~? 22.73 CL CL D 144 D 166 PHE D 42 PHE^? 15.36 CL CL D 144 D 182 PHE D 121 PHE.? 21.38 CL CL D 145 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -4.63 -19.29 -51.90 -3.66 -17.18 -51.11 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -4.87 -13.89 -41.00 -2.30 -14.83 -40.57 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -2.63 -22.13 -39.63 -2.04 -19.88 -41.19 ULMN 3 2r11_o03 CARBOXYLESTERASE NP user 28 3 # 28 D 130 SER D 105 SER~? 6.83 CL CL D 145 D 166 PHE D 102 PHE^? 11.51 CL CL D 145 D 182 PHE D 131 PHE~? 8.86 O2S EPE D 146 coo -32.42 55.27 46.18 -30.51 54.94 47.67 -16.11 -12.90 -39.74 -17.17 -11.87 -37.85 coo -23.62 58.20 50.84 -23.76 56.14 48.96 -8.42 -15.11 -33.45 -8.00 -15.88 -30.83 coo -23.08 51.44 54.96 -24.43 52.71 52.88 -8.64 -6.67 -32.74 -6.73 -4.53 -32.78 2r11_o03 source 2R11 CARBOXYLESTERASE NP : 28 hits 2r11_o03 naa= 3 ULMN 3 3hde_o00 LYSOZYME user 1 3 # 1 A 35 GLU A 68 GLU~? 25.44 CL CL A 144 A 44 ASP A 19 ASP~? 15.97 CL CL A 144 A 50 THR A 17 THR~? 16.13 CL CL A 144 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 ULMN 3 3hde_o00 LYSOZYME user 2 3 # 2 A 35 GLU A 120 GLU.? 23.98 CL CL D 145 A 44 ASP A 117 ASP~? 21.56 CL CL D 145 A 50 THR A 51 THR~? 21.79 CL CL D 145 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 -36.85 -7.00 -40.01 -36.64 -7.71 -42.00 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 -39.12 -6.90 -34.97 -39.27 -9.04 -35.41 ULMN 3 3hde_o00 LYSOZYME user 3 3 # 3 A 35 GLU B 68 GLU~? 25.19 CL CL A 144 A 44 ASP B 19 ASP~? 15.75 CL CL A 144 A 50 THR B 17 THR~? 16.02 CL CL A 144 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 ULMN 3 3hde_o00 LYSOZYME user 4 3 # 4 A 35 GLU B 120 GLU.? 30.33 CL CL A 144 A 44 ASP B 117 ASP~? 29.07 CL CL A 144 A 50 THR B 51 THR~? 23.62 CL CL A 144 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 -24.39 -36.62 -18.92 -26.35 -36.97 -18.08 ULMN 3 3hde_o00 LYSOZYME user 5 3 # 5 A 35 GLU C 68 GLU~? 25.33 CL CL A 144 A 44 ASP C 19 ASP~? 15.67 CL CL A 144 A 50 THR C 17 THR~? 16.03 CL CL A 144 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 ULMN 3 3hde_o00 LYSOZYME user 6 3 # 6 A 35 GLU D 68 GLU~? 25.13 CL CL D 144 A 44 ASP D 19 ASP~? 15.85 CL CL D 144 A 50 THR D 17 THR~? 16.46 CL CL D 144 coo 3.19 -22.62 -21.80 4.26 -21.93 -23.46 5.74 -4.39 -59.25 4.71 -3.85 -61.06 coo -3.28 -18.53 -28.91 -2.33 -19.01 -30.75 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo -4.91 -24.14 -27.53 -3.37 -22.71 -27.06 1.11 -9.25 -50.49 1.81 -7.39 -51.27 3hde_o00 source 3HDE LYSOZYME : 6 hits 3hde_o00 naa= 3 ULMN 3 3hde_o01 LYSOZYME user 1 3 # 1 B 35 GLU A 68 GLU~? 25.44 CL CL A 144 B 44 ASP A 19 ASP~? 15.97 CL CL A 144 B 50 THR A 17 THR~? 16.13 CL CL A 144 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 ULMN 3 3hde_o01 LYSOZYME user 2 3 # 2 B 35 GLU A 120 GLU.? 23.98 CL CL D 145 B 44 ASP A 117 ASP~? 21.56 CL CL D 145 B 50 THR A 51 THR~? 21.79 CL CL D 145 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 -36.85 -7.00 -40.01 -36.64 -7.71 -42.00 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 -39.12 -6.90 -34.97 -39.27 -9.04 -35.41 ULMN 3 3hde_o01 LYSOZYME user 3 3 # 3 B 35 GLU B 68 GLU~? 25.19 CL CL A 144 B 44 ASP B 19 ASP~? 15.75 CL CL A 144 B 50 THR B 17 THR~? 16.02 CL CL A 144 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 ULMN 3 3hde_o01 LYSOZYME user 4 3 # 4 B 35 GLU B 120 GLU.? 30.33 CL CL A 144 B 44 ASP B 117 ASP~? 29.07 CL CL A 144 B 50 THR B 51 THR~? 23.62 CL CL A 144 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 -24.39 -36.62 -18.92 -26.35 -36.97 -18.08 ULMN 3 3hde_o01 LYSOZYME user 5 3 # 5 B 35 GLU C 68 GLU~? 25.33 CL CL A 144 B 44 ASP C 19 ASP~? 15.67 CL CL A 144 B 50 THR C 17 THR~? 16.03 CL CL A 144 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 ULMN 3 3hde_o01 LYSOZYME user 6 3 # 6 B 35 GLU D 68 GLU~? 25.13 CL CL D 144 B 44 ASP D 19 ASP~? 15.85 CL CL D 144 B 50 THR D 17 THR~? 16.46 CL CL D 144 coo -10.34 -10.51 -29.93 -8.23 -10.47 -29.91 5.74 -4.39 -59.25 4.71 -3.85 -61.06 coo -0.99 -14.50 -23.89 0.18 -12.74 -23.86 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo -5.24 -12.06 -20.18 -4.96 -12.24 -22.31 1.11 -9.25 -50.49 1.81 -7.39 -51.27 3hde_o01 source 3HDE LYSOZYME : 6 hits 3hde_o01 naa= 3 ULMN 3 3hde_o02 LYSOZYME user 1 3 # 1 C 35 GLU A 68 GLU~? 25.44 CL CL A 144 C 44 ASP A 19 ASP~? 15.97 CL CL A 144 C 50 THR A 17 THR~? 16.13 CL CL A 144 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 -50.79 -21.32 -20.45 -51.55 -23.03 -21.49 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 -44.93 -13.29 -17.81 -44.26 -15.06 -18.69 coo 25.48 4.87 1.60 23.90 4.95 0.15 -43.10 -14.04 -23.55 -42.77 -15.91 -22.52 ULMN 3 3hde_o02 LYSOZYME user 2 3 # 2 C 35 GLU A 120 GLU.? 23.98 CL CL D 145 C 44 ASP A 117 ASP~? 21.56 CL CL D 145 C 50 THR A 51 THR~? 21.79 CL CL D 145 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 -38.38 3.21 -36.38 -37.30 3.13 -38.22 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 -36.85 -7.00 -40.01 -36.64 -7.71 -42.00 coo 25.48 4.87 1.60 23.90 4.95 0.15 -39.12 -6.90 -34.97 -39.27 -9.04 -35.41 ULMN 3 3hde_o02 LYSOZYME user 3 3 # 3 C 35 GLU B 68 GLU~? 25.19 CL CL A 144 C 44 ASP B 19 ASP~? 15.75 CL CL A 144 C 50 THR B 17 THR~? 16.02 CL CL A 144 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 -43.15 -26.37 -28.72 -44.86 -27.57 -28.33 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 -33.88 -22.19 -27.39 -35.22 -22.73 -25.88 coo 25.48 4.87 1.60 23.90 4.95 0.15 -33.39 -26.92 -23.67 -35.17 -25.75 -23.14 ULMN 3 3hde_o02 LYSOZYME user 4 3 # 4 C 35 GLU B 120 GLU.? 30.33 CL CL A 144 C 44 ASP B 117 ASP~? 29.07 CL CL A 144 C 50 THR B 51 THR~? 23.62 CL CL A 144 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 -14.59 -38.14 -21.57 -14.06 -39.61 -20.16 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 -23.26 -40.57 -15.19 -23.67 -42.33 -14.04 coo 25.48 4.87 1.60 23.90 4.95 0.15 -24.39 -36.62 -18.92 -26.35 -36.97 -18.08 ULMN 3 3hde_o02 LYSOZYME user 5 3 # 5 C 35 GLU C 68 GLU~? 25.33 CL CL A 144 C 44 ASP C 19 ASP~? 15.67 CL CL A 144 C 50 THR C 17 THR~? 16.03 CL CL A 144 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 -44.78 -31.25 -17.36 -46.61 -31.41 -18.48 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 -37.52 -27.12 -11.44 -38.53 -25.96 -12.88 coo 25.48 4.87 1.60 23.90 4.95 0.15 -41.99 -23.21 -10.39 -41.60 -23.28 -12.50 ULMN 3 3hde_o02 LYSOZYME user 6 3 # 6 C 35 GLU D 68 GLU~? 25.13 CL CL D 144 C 44 ASP D 19 ASP~? 15.85 CL CL D 144 C 50 THR D 17 THR~? 16.46 CL CL D 144 coo 15.89 -0.52 0.58 15.91 1.38 -0.35 5.74 -4.39 -59.25 4.71 -3.85 -61.06 coo 24.21 6.79 -4.52 23.75 8.67 -3.70 6.80 -7.28 -49.47 5.20 -6.20 -50.30 coo 25.48 4.87 1.60 23.90 4.95 0.15 1.11 -9.25 -50.49 1.81 -7.39 -51.27 3hde_o02 source 3HDE LYSOZYME : 6 hits 3hde_o02 naa= 3 ULMN 3 4dqk_o00 BIFUNCTIONAL P-450/NADPH-P450 REDUCTuser 1 3 # 1 A 966 SER B 34 SER~? 6.65 CL CL D 145 A 967 ARG D 134 ARG~? 13.66 CL CL D 145 A 975 TYR B 36 TYR.? 11.13 O3S EPE A 145 coo 82.02 40.88 31.11 79.88 41.56 30.18 -11.81 -12.54 -26.23 -13.84 -11.31 -26.72 coo 78.94 44.79 33.75 77.86 47.56 32.82 -7.38 -13.38 -28.19 -7.10 -15.95 -26.51 coo 83.57 40.86 25.45 83.15 43.18 26.91 -14.03 -12.72 -20.86 -15.21 -10.11 -20.77 4dqk_o00 source 4DQK BIFUNCTIONAL P-450/NADPH-P450 REDUCTASE : 1 hits 4dqk_o00 naa= 3